

Chapter 1 – References

1. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. *Nat Med* 2004;10(8):789.
2. Kinzler KW, Vogelstein B. Lessons from hereditary colon cancer. *Cell* 1996;87(2):159.
3. International Human Genome Sequencing Consortium. Finishing the euchromatic sequence of the human genome. *Nature* 2004;431(7011): 931.
4. Stehelin D, Varmus HE, Bishop JM, et al. DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA. *Nature* 1976;260(5547):170.
5. Rous P. Transmission of a malignant new growth by means of a cell-free filtrate. *JAMA* 1911;56:198.
6. International HapMap Consortium. The international HapMap project. *Nature* 2003;426(6968):789.
7. International HapMap Consortium. A haplotype map of the human genome. *Nature* 2005;437(7063):1299.
8. Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. *Proc Natl Acad Sci U S A* 1977;74(12):5463.
9. Pinard R, de Winter A, Sarkis GJ, et al. Assessment of whole genome amplification-induced bias through high-throughput, massively parallel whole genome sequencing. *BMC Genomics* 2006;7:216.
10. Thomas RK, Nickerson E, Simons JF, et al. Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. *Nat Med* 2006;12(7):852.
11. Assie G, LaFramboise T, Platzer P, et al. SNP arrays in heterogeneous tissue: highly accurate collection of both germline and somatic genetic information from unpaired single tumor samples. *Am J Hum Genet* 2008; 82(4):903.
12. Peiffer DA, Le JM, Steemers FJ, et al. High-resolution genomic profiling of chromosomal aberrations using Infinium whole-genome genotyping. *Genome Res* 2006;16(9):1136.
13. Leary RJ, Lin JC, Cummins J, et al. Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers. *Proc Natl Acad Sci U S A* 2008;105(42):16224.
14. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. *Nature* 2002;417(6892): 949.
15. Rajagopalan H, Bardelli A, Lengauer C, et al. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. *Nature* 2002;418(6901):934.
16. Moodie SA, Wolfman A. The 3Rs of life: Ras, Raf and growth regulation. *Trends Genet* 1994;10(2):44.
17. Hafen E, Dickson B, Brunner D, et al. Genetic dissection of signal transduction mediated by the sevenless receptor tyrosine kinase in *Drosophila*. *Prog Neurobiol* 1994; 42(2):287.
18. Bardelli A, Parsons DW, Silliman N, et al. Mutational analysis of the tyrosine kinase in colorectal cancers. *Science* 2003;300(5621):949.
19. Greenman C, Stephens P, Smith R, et al. Patterns of somatic mutation in human cancer genomes. *Nature* 2007;446(7132):153.
20. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. *Science* 2004;304(5670):554.
21. Prickett TD, Agrawal NS, Wei X, et al. Analysis of the tyrosine kinase in melanoma reveals recurrent mutations in ERBB4. *Nat Genet* 2009;41(10): 1127.
22. Sjoblom T, Jones S, Wood LD, et al. The consensus coding sequences of human breast and colorectal cancers. *Science* 2006;314(5797):268.
23. Wang Z, Shen D, Parsons DW, et al. Mutational analysis of the tyrosine phosphatome in colorectal cancers. *Science* 2004;304(5674):1164.
24. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. *Nat Rev Cancer* 2002; 2(7):489.
25. Broderick DK, Di C, Parrett TJ, et al. Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. *Cancer Res* 2004;64(15):5048.
26. Lee JW, Soung YH, Kim SY, et al. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. *Oncogene* 2005;24(8):1477.
27. Bachman KE, Argani P, Samuels Y, et al. The PIK3CA gene is mutated with high frequency in human breast cancers. *Cancer Biol Ther* 2004; 3(8):772.
28. Oda K, Stokoe D, Taketani Y, et al. High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. *Cancer Res* 2005;65(23): 10669.
29. Samuels Y, WT. Oncogenic mutations of PIK3CA in human cancers. In: Rommel C, Vanhaesebroeck B, Vogt PK, eds. *Current topics in microbiology and immunology*. 1st ed. vol. 2. New York: Springer, 2010;2:21.
30. Parsons DW, Wang TL, Samuels Y, et al. Colorectal cancer: mutations in a signalling pathway. *Nature* 2005;436(7052):792.
31. Lopez-Otin C, Overall CM. Protease degradomics: a new challenge for proteomics. *Nat Rev Mol Cell Biol* 2002;3(7):509.
32. Liotta LA, Tryggvason K, Garbisa S, et al. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. *Nature* 1980;284(5751):67.
33. López-Otín C, Hunter T. The regulatory crosstalk between kinases and proteases in cancer. *Nat Rev Cancer* 2010;10(4):278.
34. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. *Nat Rev Cancer* 2002;2(3):161.
35. López-Otín C, Matrisian LM. Emerging roles of proteases in tumour suppression. *Nat Rev Cancer* 2007;7(10):800.
36. Wood LD, Parsons DW, Jones S, et al. The genomic landscapes of human breast and colorectal cancers. *Science* 2007;318(5853):1108.
37. Palavalli LH, Prickett TD, Wunderlich JR, et al. Analysis of the matrix metalloproteinase family reveals that MMP8 is often mutated in melanoma. *Nat Genet* 2009;41(5):518.
38. López-Otín C, Palavalli LH, Samuels Y. Protective roles of matrix metalloproteinases: from mouse models to human cancer. *Cell Cycle* 2009;8(22):3657.
39. Bleeker FE, Lamba S, Rodolfo M, et al. Mutational profiling of cancer candidate genes in glioblastoma, melanoma and pancreatic carcinoma reveals a snapshot of their genomic landscapes. *Hum Mutat* 2009;30(2):E451.
40. Vilorio CG, Obaya AJ, Moncada-Pazos A, et al. Genetic inactivation of ADAMTS15 metalloprotease in human colorectal cancer. *Cancer Res* 2009;69(11):4926.
41. Wei X, Prickett TD, Vilorio CG, et al. Mutational and functional analysis reveals ADAMTS18 metalloproteinase as a novel driver in melanoma. *Mol Cancer Res* 2010;8(11):1513.
42. Wei, X, Moncada-Pazos, A, Cal, S., et al. *Analysis of the disintegrin-metalloproteinases family reveals ADAM29 and ADAM7 are often mutated in melanoma*. Human Mutation, 2011.
43. Hanahan D, Weinberg RA The hallmarks of cancer. *Cell* 2000;100(1): 57.
44. Teitz T, Wei T, Valentine MB, et al. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. *Nat Med* 2000;6(5):529.
45. Mandruzzato S, Brasseur F, Andry G, et al. A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma. *J Exp Med* 1997;186(5):785.
46. Soung YH, Lee JW, Kim SY, et al. CASPASE-8 gene is inactivated by somatic mutations in gastric carcinomas. *Cancer Res* 2005;65(3):815.

47. Soung YH, Lee JW, Kim SY, et al. Somatic mutations of CASP3 gene in human cancers. *Hum Genet* 2004;115(2):112.
48. Offman J, Gascoigne K, Bristow F, et al. Repeated sequences in CASPASE-5 and FANCD2 but not NF1 are targets for mutation in microsatellite-unstable acute leukemia/myelodysplastic syndrome. *Mol Cancer Res* 2005;3(5):251.
49. Lee JW, Kim MR, Soung YH, et al. Mutational analysis of the CASP6 gene in colorectal and gastric carcinomas. *APMIS* 2006;114(9):646.
50. Soung YH, Lee JW, Kim HS, et al. Inactivating mutations of CASPASE-7 gene in human cancers. *Oncogene* 2003;22(39):8048.
51. Soung YH, Jeong EG, Ahn CH, et al. Mutational analysis of caspase 1, 4, and 5 genes in common human cancers. *Hum Pathol* 2008;39(6):895.
52. Shin MS, Kim HS, Kang CS, et al. Inactivating mutations of CASP10 gene in non-Hodgkin lymphomas. *Blood* 2002;99(11):4094.
53. Kim YR, Kim KM, Yoo NJ, et al. Mutational analysis of CASP1, 2, 3, 4, 5, 6, 7, 8, 9, 10, and 14 genes in gastrointestinal stromal tumors. *Hum Pathol* 2009;40(6):868.
54. Ghavami S, Hashemi M, Ande SR, et al. Apoptosis and cancer: mutations within caspase genes. *J Med Genet* 2009;46(8):497.
55. Hoeller D, Hecker CM, Dikic I. Ubiquitin and ubiquitin-like proteins in cancer pathogenesis. *Nat Rev Cancer* 2006;6(10):776.
56. Bignell GR, Warren W, Seal S, et al. Identification of the familial cylindromatosis tumour-suppressor gene. *Nat Genet* 2000;25(2):160.
57. Schmitz R, Hansmann ML, Bohle V, et al. TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma. *J Exp Med* 2009;206(5):981.
58. Compagno M, Lim WK, Grunn A, et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. *Nature* 2009;459(7247):717.
59. Kato M, Sanada M, Kato I, et al. Frequent inactivation of A20 in B-cell lymphomas. *Nature* 2009;459(7247):712.
60. Novak U, Rinaldi A, Kwee I, et al. The NF-kappaB negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas. *Blood* 2009;113(20):4918.
61. Harbour JW, Onken MD, Roberson ED, et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. *Science* 2010;330(6009):1410.
62. Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. *Science* 2008;321(5897):1801.
63. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. *Science* 2008;321(5897):1807.
64. Jones S, Wang TL, Shih Ie M, et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. *Science* 2010; 330(6001):228.
65. Parsons DW, Li M, Zhang X, et al. The genetic landscape of the childhood cancer medulloblastoma. *Science* 2010; (in press).
66. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. *N Engl J Med* 2009;360(8):765.
67. Bleeker FE, Lamba S, Leenstra S, et al. IDH1 mutations at residue pR132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. *Hum Mutat* 2009;30(1):7.
68. Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. *Acta Neuropathol* 2009;118(4):469.
69. Hayden JT, Fruhwald MC, Hasselblatt M, et al. Frequent IDH1 mutations in supratentorial primitive neuroectodermal tumors (sPNET) of adults but not children. *Cell Cycle* 2009;8(11):1806.
70. Ichimura K, Pearson DM, Kocalkowski S, et al. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. *Neuro Oncol* 2009;11(4):341.
71. Kang MR, Kim MS, Oh JE, et al. Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers. *Int J Cancer* 2009;125(2):353.
72. Watanabe T, Nobusawa S, Kleihues P, et al. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. *Am J Pathol* 2009;174(4):1149.
73. Mardis ER, Ding L, Dooling DJ, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. *N Engl J Med* 2009;361(11):1058.
74. Green A, Beer P. Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms. *N Engl J Med* 2010;362(4):369.
75. Gross S, Cairns RA, Minden MD, et al. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. *J Exp Med* 2010;207(2):339.
76. Lopez GY, Reitman ZJ, Solomon D, et al. IDH1(R132) mutation identified in one human melanoma metastasis, but not correlated with metastases to the brain. *Biochem Biophys Res Commun* 2010;398(3):585.
77. Mardis ER, Wilson RK. Cancer genome sequencing: a review. *Hum Mol Genet* 2009;18(R2):R163.
78. Meyerson M, Gabriel S, Getz G. Advances in understanding cancer genomes through second-generation sequencing. *Nat Rev Genet* 2010;11(10):685.
79. Metzker ML. Sequencing technologies—the next generation. *Nat Rev Genet* 2010;11(1):31.
80. Bell DW. Our changing view of the genomic landscape of cancer. *J Pathol* 2010;220(2):231.
81. Campbell PJ, Pleasance ED, Stephens PJ, et al. Subclonal phylogenetic structures in cancer revealed by ultra-deep sequencing. *Proc Natl Acad Sci U S A* 2008;105(35):13081.
82. Kidd JM, Cooper GM, Donahue WF, et al. Mapping and sequencing of structural variation from eight human genomes. *Nature* 2008;453(7191):56.
83. Drmanac R, Sparks AB, Callow MJ, et al. Human genome sequencing using unchained base reads on self-assembling DNA nanoarrays. *Science* 2010;327(5961):78.
84. Clarke J, Wu HC, Jayasinghe L, et al. Continuous base identification for single-molecule nanopore DNA sequencing. *Nat Nanotechnol* 2009;4(4):265.
85. Schadt EE, Turner S, Kasarskis A. A window into third-generation sequencing. *Hum Mol Genet* 2010;19(R2):R227.
86. Dressman D, Yan H, Traverso G, et al. Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations. *Proc Natl Acad Sci U S A* 2003;100(15):8817.
87. Fedurco M, Romieu A, Williams S, et al. BTA, a novel reagent for DNA attachment on glass and efficient generation of solid-phase amplified DNA colonies. *Nucleic Acids Res* 2006;34(3):e22.
88. Harris TD, Buzby PR, Babcock H, et al. Single-molecule DNA sequencing of a viral genome. *Science* 2008; 320(5872):106.
89. Morozova O, Hirst M, Marra MA. Applications of new sequencing technologies for transcriptome analysis. *Annu Rev Genomics Hum Genet* 2009;10:135.
90. Pop M, Salzberg SL. Bioinformatics challenges of new sequencing technology. *Trends Genet* 2008;24(3):142.
91. Ley TJ, Mardis ER, Ding L, et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. *Nature* 2008;456(7218):66.
92. Pleasance ED, Cheetham RK, Stephens PJ, et al. A comprehensive catalogue of somatic mutations from a human cancer genome. *Nature* 2010; 463(7278):191.
93. Pleasance ED, Stephens PJ, O'Meara S, et al. A small-cell lung cancer genome with complex signatures of tobacco exposure. *Nature* 2010;463(7278):184.

94. Ding L, Ellis MJ, Li S, et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. *Nature* 2010;464(7291):999.
95. Ley TJ, Ding L, Walter MJ, et al. DNMT3A mutations in acute myeloid leukemia. *N Engl J Med* 2010;363(25):2424.
96. Marcucci G, Maharry K, Wu YZ, et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. *J Clin Oncol* 2010;28(14):2348.
97. Paschka P, Schlenk RF, Gaidzik VI, et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. *J Clin Oncol* 2010;28(22):3636.
98. Ward PS, Patel J, Wise DR, et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. *Cancer Cell* 2010;17(3):225.
99. Lee W, Jiang Z, Liu J, et al. The mutation spectrum revealed by paired genome sequences from a lung cancer patient. *Nature* 2010;465(7297):473.
100. Yachida S, Jones S, Bozic I, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. *Nature* 2010;467(7319):1114.
101. Shah SP, Morin RD, Khattri J, et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. *Nature* 2009;461(7265):809.
102. Campbell PJ, Yachida S, Mudie LJ, et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. *Nature* 2010;467(7319): 1109.
103. Jones SJ, Laskin J, Li YY, et al. Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors. *Genome Biol* 2010;11(8):R82.
104. Turner EH, Lee C, Ng SB, et al. Massively parallel exon capture and library-free resequencing across 16 genomes. *Nat Methods* 2009;6(5):315.
105. Gnirke A, Melnikov A, Maguire J, et al. Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing. *Nat Biotechnol* 2009;27(2):182.
106. Levin JZ, Berger MF, Adiconis X, et al. Targeted next-generation sequencing of a cancer transcriptome enhances detection of sequence variants and novel fusion transcripts. *Genome Biol* 2009;10(10):R115.
107. Landreville S, Agapova OA, Harbour JW. Emerging insights into the molecular pathogenesis of uveal melanoma. *Future Oncol* 2008;4(5):629.
108. Worley LA, Onken MD, Person E, et al. Transcriptomic versus chromosomal prognostic markers and clinical outcome in uveal melanoma. *Clin Cancer Res* 2007;13(5):1466.
109. Wang Z, Gerstein M, Snyder M. RNA-Seq: a revolutionary tool for transcriptomics. *Nat Rev Genet* 2009;10(1):57.
110. Wiegand KC, Shah SP, Al-Agha OM, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. *N Engl J Med* 2010;363(16):1532.
111. Farazi TA, Spitzer JJ, Morozov P, et al. miRNAs in human cancer. *J Pathol* 2011;223(2):102.
112. Huarte M, Rinn JL. Large non-coding RNAs: missing links in cancer? *Hum Mol Genet* 2010;19(R2):R152.
113. Maher CA, Kumar-Sinha C, Cao X, et al. Transcriptome sequencing to detect gene fusions in cancer. *Nature* 2009;458(7234):97.
114. Berger MF, Levin JZ, Vijayendran K, et al. Integrative analysis of the melanoma transcriptome. *Genome Res* 2010;20(4):413.
115. Park PJ. ChIP-seq: advantages and challenges of a maturing technology. *Nat Rev Genet* 2009;10(10):669.
116. Laird PW. Principles and challenges of genome-wide DNA methylation analysis. *Nat Rev Genet* 2010;11(3):191.
117. Mullaney JM, Mills RE, Pittard WS, et al. Small insertions and deletions (INDELs) in human genomes. *Hum Mol Genet* 2010;19(R2):R131.
118. Tomlins SA, Rhodes DS, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. *Science* 2005;310(5748): 644.
119. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. *Nature* 2007; 448(7153):561.
120. Palanisamy N, Ateeq B, Kalyana-Sundaram S, et al. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. *Nat Med* 2010;16(7):793.
121. Leary RJ, Kinde I, Diehl F, et al. Development of personalized tumor biomarkers using massively parallel sequencing. *Sci Transl Med* 2010;2(20): 20ra14.
122. Stephens PJ, McBride DJ, Lin ML, et al. Complex landscapes of somatic rearrangement in human breast cancer genomes. *Nature* 2009;462(7276): 1005.
123. Feng H, Shuda M, Chang Y, et al. Clonal integration of a polyomavirus in human Merkel cell carcinoma. *Science* 2008;319(5866):1096.
124. Davies H, Hunter C, Smith R, et al. Somatic mutations of the protein kinase gene family in human lung cancer. *Cancer Res* 2005;65(17):7591.
125. Bozic I, Antal T, Ohtsuki H, et al. Accumulation of driver and passenger mutations during tumor progression. *Proc Natl Acad Sci U S A* 2010;107(43):18545.
126. Parmigiani G, Boca S, Lin J, et al. Design and analysis issues in genome-wide somatic mutation studies of cancer. *Genomics* 2009;93(1):17.
127. Kaminker JS, Zhang Y, Waugh A, et al. Distinguishing cancer-associated missense mutations from common polymorphisms. *Cancer Res* 2007;67(2): 465.
128. Futreal PA. Backseat drivers take the wheel. *Cancer Cell* 2007;12(6):493.
129. Greenman C, Wooster R, Futreal PA, et al. Statistical analysis of pathogenicity of somatic mutations in cancer. *Genetics* 2006;173(4):2187.
130. Baudot A, Real FX, Izarzugaza JM, et al. From cancer genomes to cancer models: bridging the gaps. *EMBO Rep* 2009;10(4):359.
131. Carter H, Chen S, Isik L, et al. Cancer-specific high-throughput annotation of somatic mutations: computational prediction of driver missense mutations. *Cancer Res* 2009;69(16):6660.
132. Ng PC, Henikoff S. SIFT: predicting amino acid changes that affect protein function. *Nucleic Acids Res* 2003; 31(13):3812.
133. Kohli M, Rago C, Lengauer C, et al. Facile methods for generating human somatic cell gene knockouts using recombinant adeno-associated viruses. *Nucleic Acids Res* 2004;32(1):e3.
134. The Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. *Nature* 2008; 455(7216):1061.
135. Hudson TJ, Anderson W, Artez A, et al. International network of cancer genome projects. *Nature* 2010;464(7291): 993.
136. Bignell GR, Greenman CD, Davies H, et al. Signatures of mutation and selection in the cancer genome. *Nature* 2010;463(7283):893.
137. Dalglish GL, Furge K, Greenman C, et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. *Nature* 2010;463(7279):360.
138. Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. *Cancer Cell* 2010; 17(1):98.
139. Fox EJ, Salk JJ, Loeb LA. Cancer genome sequencing—an interim analysis. *Cancer Res* 2009;69(12):4948.
140. Diamandis EP, Hudson T, Kallioniemi O, et al. Cancer genomes. *Clin Chem* 2010;56(11):1660.
141. Sieber OM, Tomlinson SR, Tomlinson IP. Tissue, cell and stage specificity of (epi)mutations in cancers. *Nat Rev Cancer* 2005;5(8):649.

142. Benvenuti S, Frattini M, Arena S, et al. PIK3CA cancer mutations display gender and tissue specificity patterns. *Hum Mutat* 2008;29(2):284.
143. Karakas B, Bachman KE, Park BH. Mutation of the PIK3CA oncogene in human cancers. *Br J Cancer* 2006;94(4):455.
144. Bleeker FE, Bardelli A. Genomic landscapes of cancers: prospects for targeted therapies. *Pharmacogenomics* 2007;8(12):1629.
145. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. *Science* 2004;304(5676):1497.
146. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. *N Engl J Med* 2008;358(11):1160.
147. Janku F, Stewart DJ, Kurzrock R. Targeted therapy in non-small-cell lung cancer—is it becoming a reality? *Nat Rev Clin Oncol* 2010;7(7):401.
148. Pao W, Chmielecki J. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. *Nat Rev Cancer* 2010;10(11):760.
149. Gerber DE, Minna JD. ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time. *Cancer Cell* 2010;18(6):548.
150. Andreyev HJ, Norman AR, Cunningham D, et al. Kirsten ras mutations in patients with colorectal cancer: the multicenter “RASCAL” study. *J Natl Cancer Inst* 1998;90(9):675.
151. Roth AD, Tejpar S, Delorenzi M, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. *J Clin Oncol* 2010;28(3):466.
152. Bardelli A, Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. *J Clin Oncol* 2010;28(7):1254.
153. Siena S, Sartore-Bianchi A, Di Nicolantonio F, et al. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. *J Natl Cancer Inst* 2009;101(19):1308.
154. Tejpar S, Bertagnolli M, Bosman F, et al. Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery. *Oncologist* 2010;15(4):390.
155. Hunter C, Smith R, Cahill DP, et al. A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. *Cancer Res* 2006;66(8):3987.
156. Cahill DP, Levine KK, Betensky RA, et al. Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. *Clin Cancer Res* 2007;13(7):2038.
157. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. *Science* 2007;316(5827):1039.
158. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. *Science* 2001;293(5531):876.
159. Heinrich MC, Corless CL, Blanke CD, et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. *J Clin Oncol* 2006;24(29):4764.
160. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. *N Engl J Med* 2005;353(2):123.
161. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. *N Engl J Med* 2005;352(8):786.
162. Kwak EL, Sordella R, Bell DW, et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. *Proc Natl Acad Sci U S A* 2005;102(21):7665.
163. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. *PLoS Med* 2005;2(3):e73.
164. Shih JY, Gow CH, Yang PC. EGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer. *N Engl J Med* 2005;353(2):207.
165. Bell DW, Gore I, Okimoto RA, et al. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. *Nat Genet* 2005;37(12):1315.
166. Inukai M, Toyooka S, Ito S, et al. Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. *Cancer Res* 2006;66(16):7854.
167. Daub H, Specht K, Ullrich A. Strategies to overcome resistance to targeted protein kinase inhibitors. *Nat Rev Drug Discov* 2004;3(12):1001.
168. Choi YL, Soda M, Yamashita Y, et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. *N Engl J Med* 2010;363(18):1734.
169. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. *N Engl J Med* 2010;363(9):809.
170. Nazarian R, Shi H, Wang Q, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. *Nature* 2010;468(7326):973.
171. Diehl F, Schmidt K, Choti MA, et al. Circulating mutant DNA to assess tumor dynamics. *Nat Med* 2008;14(9):985.
172. Pompetti F, Spadano A, Sau A, et al. Long-term remission in BCR/ABL-positive AML-M6 patient treated with Imatinib Mesylate. *Leuk Res* 2007;31(4):563.
173. Druker BJ, Guilhot F, O’Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. *N Engl J Med* 2006;355(23):2408.

Chapter 2 – References

1. Hanahan D, Weinberg RA. The hallmarks of cancer. *Cell* 2000;100:57.
2. Hansemann D. Ueber asymmetrische Zelltheilung in Epithelkrebsen und deren biologische Bedeutung. *Virchows Arch Path Anat* 1890;119:299.
3. Boveri T. Baltimore, MD: William & Wilkins; 1929.
4. Weinberg R. *The Biology of Cancer*. New York: Garland Science; 2006.
5. Loeb LA, Bielas JH, Beckman RA. Cancers exhibit a mutator phenotype: clinical implications. *Cancer Res* 2008;68:3551–3557; discussion 3557.
6. Nowak M. *Evolutionary Dynamics: Exploring the Equations of Life*. Cambridge, MA: Belknap Press; 1996.
7. Michor F, Iwasa Y, Vogelstein B, et al. Can chromosomal instability initiate tumorigenesis? *Semin Cancer Biol* 2005;15:43–49.
8. Attolini CS, Michor F. Evolutionary theory of cancer. *Ann N Y Acad Sci* 2009;1168:23–51.
9. Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. *Nature* 2001;411:366–374.
10. Kastan MB, Bartek J. Cell-cycle checkpoints and cancer. *Nature* 2004;432:316–323.
11. Morgan D. *The Cell Cycle: Principles of Control*. Sunderland, MA: Sinauer; 2007.
12. Weinberg RA. The retinoblastoma protein and cell cycle control. *Cell* 1995;81:323–330.
13. Frolov MV, Dyson NJ. Molecular mechanisms of E2F-dependent activation and pRB-mediated repression. *J Cell Sci* 2004;117:2173–2181.
14. Chen HZ, Tsai SY, Leone G. Emerging roles of E2Fs in cancer: an exit from cell cycle control. *Nat Rev Cancer* 2009;9:785–797.
15. Hwang HC, Clurman BE. Cyclin E in normal and neoplastic cell cycles. *Oncogene* 2005;24:2776–2786.
16. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. *Nat Rev Cancer* 2009;9:153–166.
17. Avni D, Yang H, Martelli F, et al. Active localization of the retinoblastoma protein in chromatin and its response to S phase DNA damage. *Mol Cell* 2003;12:735–746.
18. Kastan MB. Wild-type p53: tumors can't stand it. *Cell* 2007;128:837–840.
19. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. *Nature* 2000;408:307–310.
20. Junttila MR, Evan GI. p53—a Jack of all trades but master of none. *Nat Rev Cancer* 2009;9:821–829.
21. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. *Nature* 1998;396:643.
22. Zhou BB, Elledge SJ. The DNA damage response: putting checkpoints in perspective. *Nature* 2000;408:433–439.
23. Jackson SP, Bartek J. The DNA-damage response in human biology and disease. *Nature* 2009;461:1071–1078.
24. Rouse J, Jackson SP. Interfaces between the detection, signaling, and repair of DNA damage. *Science* 2002;297:547–551.
25. Lavin MF. Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and cancer. *Nat Rev Mol Cell Biol* 2008;9:759–769.
26. Reinhardt HC, Aslanian AS, Lees JA, Yaffe MB. p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage. *Cancer Cell* 2007;11:175–189.
27. Thornton TM, Rincon M. Non-classical p38 map kinase functions: cell cycle checkpoints and survival. *Int J Biol Sci* 2009;5:44–51.
28. Falck J, Mailand N, Syljuasen RG, et al. The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis. *Nature* 2001;410:842–847.
29. Musacchio A, Salmon ED. The spindle-assembly checkpoint in space and time. *Nat Rev Mol Cell Biol* 2007;8:379–393.
30. Lowe SW, Cepero E, Evan G. Intrinsic tumour suppression. *Nature* 2004;432:307–315.
31. Campisi J. Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. *Cell* 2005;120:513–522.
32. Collado M, Serrano M. Senescence in tumours: evidence from mice and humans. *Nat Rev Cancer* 2010;10:51–57.
33. Sharpless NE, DePinho RA. Cancer: crime and punishment. *Nature* 2005;436:636–637.
34. Serrano M, Lin AW, McCurrach ME, et al. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. *Cell* 1997;88:593–602.
35. Narita M, Krizhanovsky V, Nunez S, et al. A novel role for high-mobility group proteins in cellular senescence and heterochromatin formation. *Cell* 2006;126:503–514.
36. Bartkova J, Rezaei N, Liontos M, et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. *Nature* 2006;444: 633–637.
37. Di Micco R, Fumagalli M, Cicalese A, et al. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. *Nature* 2006;444:638–642.
38. Johnson L, Mercer K, Greenbaum D, et al. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. *Nature* 2001;410:1111–1116.
39. DeNicola GM, Tuveson DA. RAS in cellular transformation and senescence. *Eur J Cancer* 2009;45(suppl 1): 211–216.
40. Tuveson DA, Shaw AT, Willis NA, et al. Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. *Cancer Cell* 2004;5:375–387.
41. Guerra C, Mijimolle N, Dhawahir A, et al. Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. *Cancer Cell* 2003;4:111–120.
42. Sarkisian CJ, Keister BA, Stairs DB, et al. Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis. *Nat Cell Biol* 2007;9: 493–505.
43. Peters AH, O'Carroll D, Scherthan H, et al. Loss of the Suv39h histone methyltransferases impairs mammalian heterochromatin and genome stability. *Cell* 2001;107:323.
44. Beckman RA, Loeb LA. Efficiency of carcinogenesis with and without a mutator mutation. *Proc Natl Acad Sci U S A* 2006;103:14140–14145.
45. Tam IY, Chung LP, Suen WS, et al. Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. *Clin Cancer Res* 2006;12:1647–1653.
46. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. *Nature* 2009;458:719–724.
47. Mardis ER, Wilson RK. Cancer genome sequencing: a review. *Hum Mol Genet* 2009;18:R163–R168.
48. Sjoblom T, Jones S, Wood LD, et al. The consensus coding sequences of human breast and colorectal cancers. *Science* 2006;314:268–274.
49. Greenman C, Stephens P, Smith R, et al. Patterns of somatic mutation in human cancer genomes. *Nature* 2007;446:153–158.
50. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. *Nature* 2008;455:1061–1068.
51. Ding L, Getz G, Wheeler DA, et al. Somatic mutations affect key pathways in lung adenocarcinoma. *Nature* 2008;455:1069–1075.
52. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. *Science* 2008;321:1807–1812.
53. Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. *Nature* 2009;462:739–744.

54. Mardis ER, Ding L, Dooling DJ, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. *N Engl J Med* 2009;361:1058–1066.
55. Ward PS, Patel J, Wise DR, et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. *Cancer Cell* 2010;17:225–234.
56. Ley TJ, Mardis ER, Ding L, et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. *Nature* 2008;456:66–72.
57. Pleasance ED, Stephens PJ, O'Meara S, et al. A small-cell lung cancer genome with complex signatures of tobacco exposure. *Nature* 2010;463:184–190.
58. Stephens PJ, McBride DJ, Lin ML, et al. Complex landscapes of somatic rearrangement in human breast cancer genomes. *Nature* 2009;462:1005–1010.
59. Pleasance ED, Cheetham RK, Stephens PJ, et al. A comprehensive catalogue of somatic mutations from a human cancer genome. *Nature* 2010;463:191–196.
60. Wang Z, Gerstein M, Snyder M. RNA-Seq: a revolutionary tool for transcriptomics. *Nat Rev Genet* 2009;10:57–63.
61. Levin JZ, Berger MF, Adiconis X, et al. Targeted next-generation sequencing of a cancer transcriptome enhances detection of sequence variants and novel fusion transcripts. *Genome Biol* 2009;10:R115.
62. Shah SP, Kobel M, Senz J, et al. Mutation of FOXL2 in granulosa-cell tumors of the ovary. *N Engl J Med* 2009;360:2719–2729.
63. Maher CA, Kumar-Sinha C, Cao X, et al. Transcriptome sequencing to detect gene fusions in cancer. *Nature* 2009;458:97–101.
64. Harvey RC, Mullighan CG, Chen IM, et al. Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. *Blood* 2010;115(26):5312.
65. Yoda A, Yoda Y, Chiaretti S, et al. Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. *Proc Natl Acad Sci U S A* 2010;107:252–257.
66. Garzon R, Fabbri M, Cimmino A, et al. MicroRNA expression and function in cancer. *Trends Mol Med* 2006;12:580–5870.
67. Li Z, Lu J, Sun M, et al. Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. *Proc Natl Acad Sci U S A* 2008;105:15535–15540.
68. Garzon R, Calin GA, Croce CM. MicroRNAs in Cancer. *Annu Rev Med* 2009;60:167–179.
69. Lin C, Yang L, Tanasa B, et al. Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer. *Cell* 2009;139:1069–1083.
70. Mani RS, Tomlins SA, Callahan K, et al. Induced chromosomal proximity and gene fusions in prostate cancer. *Science* 2009;326:1230.
71. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. *Science* 2005;310:644–648.
72. Beroukhi R, Mermel CH, Porter D, et al. The landscape of somatic copy-number alteration across human cancers. *Nature* 2010;463:899–905.
73. Mitelman F, Johansson B, Mertens F. *Mitelman Database of Chromosome Aberrations in Cancer*. <http://cgap.nci.gov/chromosomes/Mitelman>; 2003.
74. Vogelstein B, Fearon ER, Kern SE, et al. Allelotype of colorectal carcinomas. *Science* 1989;244:207–211.
75. Tuna M, Knuutila S, Mills GB. Uniparental disomy in cancer. *Trends Mol Med* 2009;15:120–128.
76. Tiu RV, Gondek LP, O'Keefe CL, et al. New lesions detected by single nucleotide polymorphism array-based chromosomal analysis have important clinical impact in acute myeloid leukemia. *J Clin Oncol* 2009;27:5219–5226.
77. O'Keefe C, McDevitt MA, Maciejewski JP. Copy neutral loss of heterozygosity: a novel chromosomal lesion in myeloid malignancies. *Blood* 2010.
78. Baker DJ, Jin F, Jeganathan KB, van Deursen JM. Whole chromosome instability caused by Bub1 insufficiency drives tumorigenesis through tumor suppressor gene loss of heterozygosity. *Cancer Cell* 2009;16:475–486.
79. Ellis L, Atadja PW, Johnstone RW. Epigenetics in cancer: targeting chromatin modifications. *Mol Cancer Ther* 2009;8:1409–1420.
80. McKenna ES, Roberts CW. Epigenetics and cancer without genomic instability. *Cell Cycle* 2009;8:23–26.
81. McKenna ES, Sansam CG, Cho YJ, et al. Loss of the epigenetic tumor suppressor SNF5 leads to cancer without genomic instability. *Mol Cell Biol* 2008;28:6223–6233.
82. Sharma SV, Lee DY, Li B, et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. *Cell* 2010;141:69–80.
83. Kolodner R. Biochemistry and genetics of eukaryotic mismatch repair. *Genes Dev* 1996;10:1433–1442.
84. Lindahl T, Wood RD. Quality control by DNA repair. *Science* 1999;286:1897–1905.
85. Goecke T, Schulmann K, Engel C, et al. Genotype-phenotype comparison of German MLH1 and MSH2 mutation carriers clinically affected with Lynch syndrome: a report by the German HNPCC Consortium. *J Clin Oncol* 2006;24:4285.
86. Rajagopalan H, Nowak MA, Vogelstein B, Lengauer C. The significance of unstable chromosomes in colorectal cancer. *Nat Rev Cancer* 2003;3:695–701.
87. Hoeijmakers JH. DNA damage, aging, and cancer. *N Engl J Med* 2009;361:1475–1485.
88. Andressou JO, Hoeijmakers JH, Mitchell JR. Nucleotide excision repair disorders and the balance between cancer and aging. *Cell Cycle* 2006;5:2886–2888.
89. Cleaver JE, Lam ET, Revet I. Disorders of nucleotide excision repair: the genetic and molecular basis of heterogeneity. *Nat Rev Genet* 2009;10:756–768.
90. Lehmann AR. The xeroderma pigmentosum group D (XPD) gene: one gene, two functions, three diseases. *Genes Dev* 2001;15:15–23.
91. Lu Y, Lian H, Sharma P, et al. Disruption of the Cockayne syndrome B gene impairs spontaneous tumorigenesis in cancer-predisposed Ink4a/ARF knockout mice. *Mol Cell Biol* 2001;21:1810–1818.
92. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. *N Engl J Med* 2006;355:983–991.
93. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. *Nature* 2005;434:917–921.
94. Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. *Nature* 2005;434:913–917.
95. Hartlerode AJ, Scully R. Mechanisms of double-strand break repair in somatic mammalian cells. *Biochem J* 2009;423:157–168.
96. O'Driscoll M, Ruiz-Perez VL, Woods CG, et al. A splicing mutation affecting expression of ataxia-telangiectasia and Rad3-related protein (ATR) results in Seckel syndrome. *Nat Genet* 2003;33:497–501.
97. Bartek J, Lukas J, Chk1 and Chk2 kinases in checkpoint control and cancer. *Cancer Cell* 2003;3:421–429.
98. Petrini JH. The Mre11 complex and ATM: collaborating to navigate S phase. *Curr Opin Cell Biol* 2000;12:293–296.
99. Kennedy RD, D'Andrea AD. The Fanconi Anemia/BRCA pathway: new faces in the crowd. *Genes Dev* 2005;19:2925–2940.
100. Moldovan GL, D'Andrea AD. How the Fanconi anemia pathway guards the genome. *Annu Rev Genet* 2009;43:223–249.
101. Andressen PR, D'Andrea AD, Taniguchi T. ATR couples FANCD2 monoubiquitination to the DNA-damage response. *Genes Dev* 2004;18:1958–1963.
102. Nakanishi K, Yang YG, Pierce AJ, et al. Human Fanconi anemia monoubiquitination pathway promotes homologous DNA repair. *Proc Natl Acad Sci U S A* 2005;102:1110–1115.

103. Smogorzewska A, Matsuoka S, Vinciguerra P, et al. Identification of the FANCI protein, a monoubiquitinated FANCD2 paralog required for DNA repair. *Cell* 2007;129:289–301.
104. Howlett NG, Taniguchi T, Olson S, et al. Biallelic inactivation of BRCA2 in Fanconi anemia. *Science* 2002;297:606–609.
105. Knipscheer P, Raschle M, Smogorzewska A, et al. The Fanconi anemia pathway promotes replication-dependent DNA interstrand cross-link repair. *Science* 2009;326:1698–1701.
106. Sharma S, Doherty KM, Brosh RM Jr. Mechanisms of RecQ helicases in pathways of DNA metabolism and maintenance of genomic stability. *Biochem J* 2006;398:319.
107. Haber JE. DNA recombination: the replication connection. *Trends Biochem Sci* 1999;24:271–275.
108. McEachern MJ, Haber JE. Break-induced replication and recombinational telomere elongation in yeast. *Annu Rev Biochem* 2006;75:111–135.
109. McMurray MA, Gottschling DE. An age-induced switch to a hyper-recombinational state. *Science* 2003;301:1908–1911.
110. Chu WK, Hickson ID. RecQ helicases: multifunctional genome caretakers. *Nat Rev Cancer* 2009;9:644–654.
111. Bohr VA. Rising from the RecQ-age: the role of human RecQ helicases in genome maintenance. *Trends Biochem Sci* 2008;33:609–620.
112. Gudmundsdottir K, Ashworth A. The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. *Oncogene* 2006;25:5864–5874.
113. Wooster R, Weber BL. Breast and ovarian cancer. *N Engl J Med* 2003;348:2339–2347.
114. Huen MS, Sy SM, Chen J. BRCA1 and its toolbox for the maintenance of genome integrity. *Nat Rev Mol Cell Biol* 11:138–148.
115. Erkko H, Xia B, Nikkila J, et al. A recurrent mutation in PALB2 in Finnish cancer families. *Nature* 2007;446:316–319.
116. Reid S, Schindler D, Hanenberg H, et al. Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. *Nat Genet* 2007;39:162–164.
117. Xia B, Dorsman JC, Ameziane N, et al. Fanconi anemia is associated with a defect in the BRCA2 partner PALB2. *Nat Genet* 2007;39:159–161.
118. Richardson AL, Wang ZC, De Nicolo A, et al. X chromosomal abnormalities in basal-like human breast cancer. *Cancer Cell* 2006;9:121–132.
119. Bassing CH, Alt FW. The cellular response to general and programmed DNA double strand breaks. *DNA Repair (Amst)* 2004;3:781–796.
120. Franco S, Alt FW, Manis JP. Pathways that suppress programmed DNA breaks from progressing to chromosomal breaks and translocations. *DNA Repair (Amst)* 2006;5:1030–1041.
121. Lieber MR, Ma Y, Pannicke U, Schwarz K. Mechanism and regulation of human non-homologous DNA end-joining. *Nat Rev Mol Cell Biol* 2003;4:712–720.
122. Weterings E, Chen DJ. The endless tale of non-homologous end-joining. *Cell Res* 2008;18:114–124.
123. Maser RS, DePinho RA. Take care of your chromosomes lest cancer take care of you. *Cancer Cell* 2003;3:4–6.
124. Riballo E, Critchlow SE, Teo SH, et al. Identification of a defect in DNA ligase IV in a radiosensitive leukaemia patient. *Curr Biol* 1999;9:699–702.
125. Blackburn EH, Greider CW, Szostak JW. Telomeres and telomerase: the path from maize, Tetrahymena and yeast to human cancer and aging. *Nat Med* 2006;12:1133–1138.
126. DePinho RA. The age of cancer. *Nature* 2000;408:248–254.
127. Artandi SE, DePinho RA. Telomeres and telomerase in cancer. *Carcinogenesis* 2010;31:9–18.
128. Artandi SE, Chang S, Lee SL, et al. Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice. *Nature* 2000;406:641–645.
129. O'Hagan RC, Chang S, Maser RS, et al. Telomere dysfunction provokes regional amplification and deletion in cancer genomes. *Cancer Cell* 2002;2:149.
130. Maser RS, Choudhury B, Campbell PJ, et al. Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. *Nature* 2007;447:966–971.
131. Blanco R, Munoz P, Flores JM, et al. Telomerase abrogation dramatically accelerates TRF2-induced epithelial carcinogenesis. *Genes Dev* 2007;21:206–220.
132. de Lange T. Shelterin: the protein complex that shapes and safeguards human telomeres. *Genes Dev* 2005;19:2100–2110.
133. Munoz P, Blanco R, Flores JM, Blasco MA. XPF nuclease-dependent telomere loss and increased DNA damage in mice overexpressing TRF2 result in premature aging and cancer. *Nat Genet* 2005;37:1063–1071.
134. Masutomi K, Possemato R, Wong JM, et al. The telomerase reverse transcriptase regulates chromatin state and DNA damage responses. *Proc Natl Acad Sci U S A* 2005;102:8222–8227.
135. Masutomi K, Yu EY, Khurts S, et al. Telomerase maintains telomere structure in normal human cells. *Cell* 2003;114:241–253.
136. Blasco MA. The epigenetic regulation of mammalian telomeres. *Nat Rev Genet* 2007;8:299–309.
137. Benetti R, Garcia-Cao M, Blasco MA. Telomere length regulates the epigenetic status of mammalian telomeres and subtelomeres. *Nat Genet* 2007;39:243–250.
138. Schoeftner S, Blasco MA. A 'higher order' of telomere regulation: telomere heterochromatin and telomeric RNAs. *EMBO J* 2009;28:2323–2336.
139. Lengauer C, Kinzler KW, Vogelstein B. Genetic instability in colorectal cancers. *Nature* 1997;386:623–627.
140. Cahill DP, Lengauer C, Yu J, et al. Mutations of mitotic checkpoint genes in human cancers. *Nature* 1998;392:300–303.
141. Nasmyth K, Haering CH. The structure and function of SMC and kleisin complexes. *Annu Rev Biochem* 2005;74:595–648.
142. Diaz-Martinez LA, Clarke DJ. Chromosome cohesion and the spindle checkpoint. *Cell Cycle* 2009;8:2733–2740.
143. Oliveira RA, Hamilton RS, Pauli A, et al. Cohesin cleavage and Cdk inhibition trigger formation of daughter nuclei. *Nat Cell Biol* 2010;12:185–192.
144. Barber TD, McManus K, Yuen KW, et al. Chromatid cohesion defects may underlie chromosome instability in human colorectal cancers. *Proc Natl Acad Sci U S A* 2008;105:3443–3448.
145. Meyer R, Fofanov V, Panigrahi A, et al. Overexpression and mislocalization of the chromosomal segregation protein separase in multiple human cancers. *Clin Cancer Res* 2009;15:2703–2710.
146. Pati D. Oncogenic activity of separase. *Cell Cycle* 2008;7:3481–3482.
147. Zhang N, Ge G, Meyer R, et al. Overexpression of Separase induces aneuploidy and mammary tumorigenesis. *Proc Natl Acad Sci U S A* 2008;105:13033–13038.
148. Kops GJ, Weaver BA, Cleveland DW. On the road to cancer: aneuploidy and the mitotic checkpoint. *Nat Rev Cancer* 2005;5:773–785.
149. Li M, Zhang P. Spindle assembly checkpoint, aneuploidy and tumorigenesis. *Cell Cycle* 2009;8:3440.
150. Schwartzman JM, Sotillo R, Benezra R. Mitotic chromosomal instability and cancer: mouse modelling of the human disease. *Nat Rev Cancer* 2010;10:102.
151. Gascoigne KE, Taylor SS. Cancer cells display profound intra- and interline variation following prolonged exposure to antimetabolic drugs. *Cancer Cell* 2008;14:111–122.

152. Thompson SL, Compton DA. Examining the link between chromosomal instability and aneuploidy in human cells. *J Cell Biol* 2008;180:665–672.
153. Tighe A, Johnson VL, Albertella M, Taylor SS. Aneuploid colon cancer cells have a robust spindle checkpoint. *EMBO Rep* 2001;2:609–614.
154. Pinsky BA, Biggins S. The spindle checkpoint: tension versus attachment. *Trends Cell Biol* 2005;15:486–493.
155. Dewar H, Tanaka K, Nasmyth K, Tanaka TU. Tension between two kinetochores suffices for their bi-orientation on the mitotic spindle. *Nature* 2004;428:93–97.
156. Liu D, Lampson MA. Regulation of kinetochore-microtubule attachments by Aurora B kinase. *Biochem Soc Trans* 2009;37:976–980.
157. Liu D, Vader G, Vromans MJ, et al. Sensing chromosome bi-orientation by spatial separation of aurora B kinase from kinetochore substrates. *Science* 2009;323:1350–1353.
158. Bakhoun SF, Genovese G, Compton DA. Deviant kinetochore microtubule dynamics underlie chromosomal instability. *Curr Biol* 2009;19:1937–1942.
159. Bakhoun SF, Thompson SL, Manning AL, Compton DA. Genome stability is ensured by temporal control of kinetochore-microtubule dynamics. *Nat Cell Biol* 2009;11:27–35.
160. Nigg EA. Centrosome aberrations: cause or consequence of cancer progression? *Nat Rev Cancer* 2002;2:815–825.
161. Ganem NJ, Godinho SA, Pellman D. A mechanism linking extra centrosomes to chromosomal instability. *Nature* 2009;460:278–282.
162. Silkworth WT, Nardi IK, Scholl LM, Cimini D. Multipolar spindle pole coalescence is a major source of kinetochore mis-attachment and chromosome mis-segregation in cancer cells. *PLoS One* 2009;4:e6564.
163. Brinkley BR. Managing the centrosome numbers game: from chaos to stability in cancer cell division. *Trends Cell Biol* 2001;11:18–21.
164. Ring D, Hubble R, Kirschner M. Mitosis in a cell with multiple centrosomes. *J Cell Biol* 1982;94:549–556.
165. Cimini D, Howell B, Maddox P, et al. Merotelic kinetochore orientation is a major mechanism of aneuploidy in mitotic mammalian tissue cells. *J Cell Biol* 2001;153:517–527.
166. Cimini D, Moree B, Canman JC, Salmon ED. Merotelic kinetochore orientation occurs frequently during early mitosis in mammalian tissue cells and error correction is achieved by two different mechanisms. *J Cell Sci* 2003;116:4213–4225.
167. Heselmeyer K, Macville M, Schrock E, et al. Advanced-stage cervical carcinomas are defined by a recurrent pattern of chromosomal aberrations revealing high genetic instability and a consistent gain of chromosome arm 3q. *Genes Chromosomes Cancer* 1997;19:233–240.
168. Weaver BA, Cleveland DW. Does aneuploidy cause cancer? *Curr Opin Cell Biol* 2006;18:658–667.
169. Nicholson JM, Duesberg P. On the karyotypic origin and evolution of cancer cells. *Cancer Genet Cytogenet* 2009;194:96–110.
170. Baker DJ, Chen J, van Deursen JM. The mitotic checkpoint in cancer and aging: what have mice taught us? *Curr Opin Cell Biol* 2005;17:583.
171. Rao CV, Yamada HY, Yao Y, Dai W. Enhanced genomic instabilities caused by deregulated microtubule dynamics and chromosome segregation: a perspective from genetic studies in mice. *Carcinogenesis* 2009;30:1469–1474.
172. Ricke RM, van Ree JH, van Deursen JM. Whole chromosome instability and cancer: a complex relationship. *Trends Genet* 2008;24:457–466.
173. Hernando E, Nahle Z, Juan G, et al. Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control. *Nature* 2004;430:797–802.
174. Sotillo R, Hernando E, Diaz-Rodriguez E, et al. Mad2 overexpression promotes aneuploidy and tumorigenesis in mice. *Cancer Cell* 2007;11:9–23.
175. Weaver BA, Silk AD, Montagna C, et al. Aneuploidy acts both oncogenically and as a tumor suppressor. *Cancer Cell* 2007;11:25–36.
176. Torres EM, Sokolsky T, Tucker CM, et al. Effects of aneuploidy on cellular physiology and cell division in haploid yeast. *Science* 2007;317:916–924.
177. Williams BR, Prabhu VR, Hunter KE, et al. Aneuploidy affects proliferation and spontaneous immortalization in mammalian cells. *Science* 2008;322:703–709.
178. Storchova Z, Pellman D. From polyploidy to aneuploidy, genome instability and cancer. *Nat Rev Mol Cell Biol* 2004;5:45–54.
179. Fujiwara T, Bandi M, Nitta M, et al. Cytokinesis failure generating tetraploids promotes tumorigenesis in p53-null cells. *Nature* 2005;437:1043–1047.
180. Andreassen PR, Lohez OD, Margolis RL. G2 and spindle assembly checkpoint adaptation, and tetraploidy arrest: implications for intrinsic and chemically induced genomic instability. *Mutat Res* 2003;532:245–253.
181. Davoli T, Denchi EL, de Lange T. Persistent telomere damage induces bypass of mitosis and tetraploidy. *Cell* 2010;141:81–93.
182. Galipeau PC, Cowan DS, Sanchez CA, et al. 17p (p53) allelic losses, 4N (G2/tetraploid) populations, and progression to aneuploidy in Barrett's esophagus. *Proc Natl Acad Sci U S A* 1996;93:7081–7084.
183. Dikovskaya D, Schiffmann D, Newton IP, et al. Loss of APC induces polyploidy as a result of a combination of defects in mitosis and apoptosis. *J Cell Biol* 2007;176:183–195.
184. Wasch R, Robbins JA, Cross FR. The emerging role of APC/CCdh1 in controlling differentiation, genomic stability and tumor suppression. *Oncogene* 2010;29:1–10.
185. Haigis KM, Caya JG, Reichelderfer M, Dove WF. Intestinal adenomas can develop with a stable karyotype and stable microsatellites. *Proc Natl Acad Sci U S A* 2002;99:8927–8931.
186. Selmecki A, Forche A, Berman J. Aneuploidy and isochromosome formation in drug-resistant *Candida albicans*. *Science* 2006;313:367–370.
187. Rancati G, Pavelka N, Fleharty B, et al. Aneuploidy underlies rapid adaptive evolution of yeast cells deprived of a conserved cytokinesis motor. *Cell* 2008;135:879–893.
188. Taniguchi T, Tischkowitz M, Ameziane N, et al. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. *Nat Med* 2003;9:568–574.
189. Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: oncogene and non-oncogene addiction. *Cell* 2009;136:823–837.
190. Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. *Nat Rev Cancer* 2006;6:789–802.
191. Lee EA, Keutmann MK, Dowling ML, et al. Inactivation of the mitotic checkpoint as a determinant of the efficacy of microtubule-targeted drugs in killing human cancer cells. *Mol Cancer Ther* 2004;3:661.
192. Sudo T, Nitta M, Saya H, Ueno NT. Dependence of paclitaxel sensitivity on a functional spindle assembly checkpoint. *Cancer Res* 2004;64:2502–2508.
193. Kaelin WG Jr. The concept of synthetic lethality in the context of anticancer therapy. *Nat Rev Cancer* 2005;5:689–698.
194. Hartwell LH, Szankasi P, Roberts CJ, et al. Integrating genetic approaches into the discovery of anticancer drugs. *Science* 1997;278:1064–1068.
195. Ashworth A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. *J Clin Oncol* 2008;26:3785–3790.
196. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. *N Engl J Med* 2009;361:123–134.
197. Mendes-Pereira AM, Martin SA, Brough R, et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. *EMBO Mol Med* 2009;1:315–322.

198. Bommi-Reddy A, Almeciga I, Sawyer J, et al. Kinase requirements in human cells: III. Altered kinase requirements in VHL-/- cancer cells detected in a pilot synthetic lethal screen. *Proc Natl Acad Sci U S A* 2008;105:16484–16489.
199. Martin SA, McCarthy A, Barber LJ, et al. Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2. *EMBO Mol Med* 2009;1:323–337.
200. Barbie DA, Tamayo P, Boehm JS, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. *Nature* 2009;462:108–112.
201. Scholl C, Frohling S, Dunn IF, et al. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. *Cell* 2009;137:821–834.
202. Storchova Z, Breneman A, Cande J, et al. Genome-wide genetic analysis of polyploidy in yeast. *Nature* 2006;443:541–547.
203. Kwon M, Godinho SA, Chandhok NS, et al. Mechanisms to suppress multipolar divisions in cancer cells with extra centrosomes. *Genes Dev* 2008;22:2189–203.

Chapter 3 – References

1. Jones PA, Liang G. Rethinking how DNA methylation patterns are maintained. *Nat Rev Genet* 2009;10:805.
2. Bernstein BE, Mikkelsen TS, Xie X, et al. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. *Cell* 2006;125:315.
3. Campos EI, Reinberg D. Histones: annotating chromatin. *Annu Rev Genet* 2009;43:559.
4. Lin JC, Jeong S, Liang G, et al. Role of nucleosomal occupancy in the epigenetic silencing of the MLH1 CpG island. *Cancer Cell* 2007;12:432.
5. Riggs AD, Jones PA. 5-methylcytosine, gene regulation, and cancer. *Adv Cancer Res* 1983;40:1.
6. Jones PA, Laird PW. Cancer epigenetics comes of age. *Nat Genet* 1999;21:163.
7. Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. *Proc Natl Acad Sci U S A* 1971;68:820.
8. Grady WM, Willis J, Guilford PJ, et al. Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer. *Nat Genet* 2000;26:16.
9. Toyota M, Ahuja N, Ohe-Toyota M, et al. CpG island methylator phenotype in colorectal cancer. *Proc Natl Acad Sci U S A* 1999;96:8681.
10. Issa JP. Epigenetic variation and human disease. *J Nutr* 2002;132:2388S.
11. Christensen BC, Houseman EA, Marsit CJ, et al. Aging and environmental exposures alter tissue-specific DNA methylation dependent upon CpG island context. *PLoS Genet* 2009;5:e1000602.
12. Waterland RA, Michels KB. Epigenetic epidemiology of the developmental origins hypothesis. *Annu Rev Nutr* 2007;27:363.
13. Marsit CJ, Houseman EA, Schned AR, et al. Promoter hypermethylation is associated with current smoking, age, gender and survival in bladder cancer. *Carcinogenesis* 2007;28:1745.
14. Michels KB. The promises and challenges of epigenetic epidemiology. *Exp Gerontol* 2010;45:297.
15. Niwa T, Tsukamoto T, Toyoda T, et al. Inflammatory processes triggered by *Helicobacter pylori* infection cause aberrant DNA methylation in gastric epithelial cells. *Cancer Res* 2010;70:1430.
16. Gal-Yam EN, Egger G, Iniguez L, et al. Frequent switching of polycomb repressive marks and DNA hypermethylation in the PC3 prostate cancer cell line. *Proc Natl Acad Sci U S A* 2008;105:12979.
17. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. *Nat Rev Genet* 2002;3:415.
18. Myohanen SK, Baylin SB, Herman JG. Hypermethylation can selectively silence individual p16ink4A alleles in neoplasia. *Cancer Res* 1998;58:591.
19. Varambally S, Cao Q, Mani RS, et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. *Science* 2008;322:1695.
20. Varambally S, Dhanasekaran SM, Zhou M, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. *Nature* 2002;419:624.
21. Friedman JM, Liang G, Liu CC, et al. The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2. *Cancer Res* 2009;69:2623.
22. Wolff EM, Byun HM, Han HF, et al. Hypomethylation of a LINE-1 promoter activates an alternate transcript of the MET oncogene in bladders with cancer. *PLoS Genet* 2010;6(4):e1000917.
23. Laird PW. The power and the promise of DNA methylation markers. *Nat Rev Cancer* 2003;3:253.
24. Nagrath S, Sequist LV, Maheswaran S, et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. *Nature* 2007;450:1235.
25. Sharma G, Mirza S, Prasad CP, et al. Promoter hypermethylation of p16INK4A, p14ARF, CyclinD2 and Slit2 in serum and tumor DNA from breast cancer patients. *Life Sci* 2007;80:1873.
26. Cairns P, Esteller M, Herman JG, et al. Molecular detection of prostate cancer in urine by GSTP1 hypermethylation. *Clin Cancer Res* 2001;7:2727.
27. Hoque MO, Begum S, Topaloglu O, et al. Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection. *J Natl Cancer Inst* 2006;98:996.
28. Novak P, Jensen TJ, Garbe JC, et al. Stepwise DNA methylation changes are linked to escape from defined proliferation barriers and mammary epithelial cell immortalization. *Cancer Res* 2009;69:5251.
29. Palmisano WA, Divine KK, Saccomanno G, et al. Predicting lung cancer by detecting aberrant promoter methylation in sputum. *Cancer Res* 2000;60:5954.
30. Brooks J, Cairns P, Zeleniuch-Jacquotte A. Promoter methylation and the detection of breast cancer. *Cancer Causes Control* 2009;20:1539.
31. Cairns P. Gene methylation and early detection of genitourinary cancer: the road ahead. *Nat Rev Cancer* 2007;7:531.
32. Vesely J, Cihak A. 5-Azacytidine: mechanism of action and biological effects in mammalian cells. *Pharmac Ther* 1978;2:813.
33. Jones PA, Taylor SM. Cellular differentiation, cytidine analogs and DNA methylation. *Cell* 1980;20:85.
34. Ghoshal K, Datta J, Majumder S, et al. 5-Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal. *Mol Cell Biol* 2005;25:4727.
35. Bender CM, Gonzalgo ML, Gonzales FA, et al. Roles of cell division and gene transcription in the methylation of CpG islands. *Mol Cell Biol* 1999;19:6690.
36. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. *Lancet Oncol* 2009;10:223.
37. Yang AS, Doshi KD, Choi SW, et al. DNA methylation changes after 5-aza-2'-deoxycytidine therapy in patients with leukemia. *Cancer Res* 2006;66:5495.
38. Lübbert M. Epigenetic therapy for myelodysplastic syndromes has entered center stage. *Leuk Res* 2009;33(Suppl 2):S27.
39. Marks PA, Xu WS. Histone deacetylase inhibitors: potential in cancer therapy. *J Cell Biochem* 2009;107:600.
40. Cheng JC, Yoo CB, Weisenberger DJ, et al. Preferential response of cancer cells to zebularine. *Cancer Cell* 2004;6:151.

Chapter 4 – References

1. Mori H, Colman SM, Xiao Z, et al. Chromosome translocations and covert leukemic clones are generated during normal fetal development. *Proc Natl Acad Sci U S A*. 2002;4:4.
2. Liu Y, Hernandez AM, Shibata D, Cortopassi GA. BCL2 translocation frequency rises with age in humans. *Proc Natl Acad Sci U S A* 1994;91:8910.
3. Sahin E, Depinho RA. Linking functional decline of telomeres, mitochondria and stem cells during ageing. *Nature*. 2010;464:520.
4. Calado RT, Young NS. Telomere diseases. *N Engl J Med*. 2009;361:2353.
5. de Lange T. Protection of mammalian telomeres. *Oncogene*. 2002;21:532.
6. O'Sullivan RJ, Karlseder J. Telomeres: protecting chromosomes against genome instability. *Nature Rev*. 2010;11:171.
7. de Lange T. How telomeres solve the end-protection problem. *Science* 2009;326:948.
8. de Lange T. Shelterin: the protein complex that shapes and safeguards human telomeres. *Genes Dev*. 2005;19:2100.
9. Szilard RK, Durocher D. Telomere protection: an act of God. *Curr Biol*. 2006;16:R544.
10. Zhu XD, Kuster B, Mann M, Petrini JH, de Lange T. Cell-cycle-regulated association of RAD50/MRE11/NBS1 with TRF2 and human telomeres. *Nat Genet*. 2000;25:347.
11. Goytisolo FA, Blasco MA. Many ways to telomere dysfunction: in vivo studies using mouse models. *Oncogene*. 2002;21:584.
12. Takai H, Smogorzewska A, de Lange T. DNA damage foci at dysfunctional telomeres. *Curr Biol*. 2003;13:1549.
13. Deng Y, Chan SS, Chang S. Telomere dysfunction and tumour suppression: the senescence connection. *Nat Rev Cancer*. 2008;8:450.
14. Cong YS, Wright WE, Shay JW. Human telomerase and its regulation. *Microbiol Mol Biol Rev*. 2002;66:407.
15. Rufer N, Brummendorf TH, Kolvraa S, et al. Telomere fluorescence measurements in granulocytes and T lymphocyte subsets point to a high turnover of hematopoietic stem cells and memory T cells in early childhood. *J Exp Med*. 1999;190:157.
16. Valdes AM, Andrew T, Gardner JP, et al. Obesity, cigarette smoking, and telomere length in women. *Lancet*. 2005;366:662.
17. Vaziri H, Schachter F, Uchida I, et al. Loss of telomeric DNA during aging of normal and trisomy 21 human lymphocytes. *Am J Hum Genet* 1993;52:661.
18. Baerlocher GM, Sloand EM, Young NS, Lansdorp PM. Telomere length in paroxysmal nocturnal hemoglobinuria correlates with clone size. *Exp Hematol*. 2007;35:1777.
19. Artandi SE, DePinho RA. Telomeres and telomerase in cancer. *Carcinogenesis*. 2010;31:9.
20. Masutomi K, Yu EY, Khurts S, et al. Telomerase maintains telomere structure in normal human cells. *Cell*. 2003;114:241.
21. Blackburn EH. Telomere states and cell fates. *Nature*. 2000;408:53.
22. Maida Y, Yasukawa M, Furuuchi M, et al. An RNA-dependent RNA polymerase formed by TERT and the RMRP RNA. *Nature*. 2009;461:230.
23. Choi J, Southworth LK, Sarin KY, et al. TERT promotes epithelial proliferation through transcriptional control of a Myc- and Wnt-related developmental program. *PLoS Genet*. 2008;4:e10.
24. Park JI, Venteicher AS, Hong JY, et al. Telomerase modulates Wnt signalling by association with target gene chromatin. *Nature*. 2009;460:66.
25. Sharpless NE, DePinho RA. Telomeres, stem cells, senescence, and cancer. *J Clin Invest*. 2004;113:160.
26. Hayflick L, Moorhead P. The serial cultivation of human diploid cell strains. *Exp Cell Res*. 1961;25:585.
27. Alcorta DA, Xiong Y, Phelps D, Hannon G, Beach D, Barrett JC. Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts. *Proc Natl Acad Sci U S A* 1996;93:13742.
28. Kamijo T, Zindy F, Roussel MF, et al. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. *Cell*. 1997;91:649.
29. Sage J, Miller AL, Perez-Mancera PA, Wysocki JM, Jacks T. Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entry. *Nature*. 2003;424:223.
30. Stein GH, Drullinger LF, Soular A, Dulic V. Differential roles for cyclin-dependent kinase inhibitors p21 and p16 in the mechanisms of senescence and differentiation in human fibroblasts. *Mol Cell Biol*. 1999;19:2109.
31. Classon M, Harlow E. The retinoblastoma tumour suppressor in development and cancer. *Nat Rev Cancer*. 2002;2:910.
32. de Stanchina E, McCurrach ME, Zindy F, et al. E1A signaling to p53 involves the p19(ARF) tumor suppressor. *Genes Dev*. 1998;12:2434.
33. Pomerantz J, Schreiber-Agus N, Liegeois NJ, et al. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. *Cell*. 1998;92:713.
34. Kamijo T, Weber JD, Zambetti G, Zindy F, Roussel MF, Sherr CJ. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. *Proc Natl Acad Sci U S A*. 1998;95:8292.
35. Stott FJ, Bates S, James MC, et al. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. *EMBO J*. 1998;17:5001.
36. Zhang Y, Xiong Y, Yarbrough WG. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. *Cell*. 1998;92:725.
37. Kim WY, Sharpless NE. The regulation of INK4/ARF in cancer and aging. *Cell*. 2006;127:265.
38. McConnell BB, Starborg M, Brookes S, Peters G. Inhibitors of cyclin-dependent kinases induce features of replicative senescence in early passage human diploid fibroblasts. *Curr Biol*. 1998;8:351.
39. Brenner AJ, Stampfer MR, Aldaz CM. Increased p16 expression with first senescence arrest in human mammary epithelial cells and extended growth capacity with p16 inactivation. *Oncogene*. 1998;17:199.
40. Foster SA, Wong DJ, Barrett MT, Galloway DA. Inactivation of p16 in human mammary epithelial cells by CpG island methylation. *Mol Cell Biol*. 1998;18:1793.
41. Huschtscha LI, Noble JR, Neumann AA, et al. Loss of p16INK4 expression by methylation is associated with lifespan extension of human mammary epithelial cells. *Cancer Res*. 1998;58:3508.
42. Duan J, Zhang Z, Tong T. Senescence delay of human diploid fibroblast induced by anti-sense p16INK4a expression. *J Biol Chem*. 2001;276:48325.
43. Jacobs JJ, de Lange T. Significant role for p16INK4a in p53-independent telomere-directed senescence. *Curr Biol*. 2004;14:2302.
44. Chicas A, Wang X, Zhang C, et al. Dissecting the unique role of the retinoblastoma tumor suppressor during cellular senescence. *Cancer Cell*. 2010;17:376.
45. Donehower LA, Harvey M, Slagle BL, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. *Nature*. 1992;356:215.
46. Jacks T, Remington L, Williams BO, et al. Tumor spectrum analysis in p53-mutant mice. *Curr Biol*. 1994;4:1.

47. Sharpless NE, Bardeesy N, Lee KH, et al. Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis. *Nature*. 2001;413:86.
48. Braig M, Lee S, Loddenkemper C, et al. Oncogene-induced senescence as an initial barrier in lymphoma development. *Nature*. 2005;436:660.
49. Collado M, Gil J, Efeyan A, et al. Tumour biology: senescence in premalignant tumours. *Nature*. 2005;436:642.
50. Chen Z, Trotman LC, Shaffer D, et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. *Nature*. 2005;436:725.
51. Ventura A, Kirsch DG, McLaughlin ME, et al. Restoration of p53 function leads to tumour regression in vivo. *Nature*. 2007;445:661.
52. Xue W, Zender L, Miething C, et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. *Nature*. 2007;445:656.
53. Michaloglou C, Vredeveldt LC, Soengas MS, et al. BRAF600-associated senescence-like cell cycle arrest of human naevi. *Nature*. 2005;436:720.
54. Gray-Schopfer VC, Cheong SC, Chong H, et al. Cellular senescence in naevi and immortalisation in melanoma: a role for p16? *Br J Cancer*. 2006;95:496.
55. Chin L, Artandi SE, Shen Q, et al. p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. *Cell*. 1999;97:527.
56. Martins CP, Brown-Swigart L, Evan GI. Modeling the therapeutic efficacy of p53 restoration in tumors. *Cell*. 2006;127:1323.
57. Schmitt CA, Fridman JS, Yang M, Baranov E, Hoffman RM, Lowe SW. Dissecting p53 tumor suppressor functions in vivo. *Cancer Cell*. 2002;1:289.
58. Campisi J. Suppressing cancer: the importance of being senescent. *Science*. 2005;309:886.
59. Baker DJ, Perez-Terzic C, Jin F, et al. Opposing roles for p16Ink4a and p19Arf in senescence and ageing caused by BubR1 insufficiency. *Nat Cell Biol*. 2008;10:825.
60. Dumble M, Moore L, Chambers SM, et al. The impact of altered p53 dosage on hematopoietic stem cell dynamics during aging. *Blood*. 2007;109:1736.
61. Krishnamurthy J, Ramsey MR, Ligon KL, et al. p16INK4a induces an age-dependent decline in islet regenerative potential. *Nature*. 2006;443:453.
62. Molofsky AV, Slutsky SG, Joseph NM, et al. Increasing p16INK4a expression decreases forebrain progenitors and neurogenesis during ageing. *Nature*. 2006;443:448.
63. Tyner SD, Venkatchalam S, Choi J, et al. p53 mutant mice that display early ageing-associated phenotypes. *Nature*. 2002;415:45.
64. Sharpless NE, DePinho RA. How stem cells age and why this makes us grow old. *Nature Rev*. 2007;8:703.
65. Wang Y, Schulte BA, LaRue AC, Ogawa M, Zhou D. Total body irradiation selectively induces murine hematopoietic stem cell senescence. *Blood*. 2006;107:358.
66. Meng A, Wang Y, Van Zant G, Zhou D. Ionizing radiation and busulfan induce premature senescence in murine bone marrow hematopoietic cells. *Cancer Res*. 2003;63:5414.
67. Forbes S, Clements J, Dawson E, et al. Cosmic 2005. *Br J Cancer*. 2006;94:318.
68. Beroukhi R, Mermel CH, Porter D, et al. The landscape of somatic copy-number alteration across human cancers. *Nature*. 2010;463:899.
69. Krimpenfort P, Ijpenberg A, Song JY, et al. p15Ink4b is a critical tumour suppressor in the absence of p16Ink4a. *Nature*. 2007;448:943.
70. Stewart SA, Weinberg RA. Telomerase and human tumorigenesis. *Semin Cancer Biol*. 2000;10:399.
71. Greenberg RA, Rudolph KL. Telomere structural dynamics in genome integrity control and carcinogenesis. *Adv Exp Med Biol*. 2005;570:311.
72. Greenberg RA. Telomeres, crisis and cancer. *Curr Mol Med*. 2005;5:213.
73. Blasco MA. Telomerase beyond telomeres. *Nat Rev Cancer*. 2002;2:627.
74. Lin SY, Elledge SJ. Multiple tumor suppressor pathways negatively regulate telomerase. *Cell*. 2003;113:881.
75. O'Hagan RC, Chang S, Maser RS, et al. Telomere dysfunction provokes regional amplification and deletion in cancer genomes. *Cancer Cell*. 2002;2:149.
76. Henson JD, Neumann AA, Yeager TR, Reddel RR. Alternative lengthening of telomeres in mammalian cells. *Oncogene*. 2002;21:598.
77. Rizki A, Lundblad V. Defects in mismatch repair promote telomerase-independent proliferation. *Nature*. 2001;411:713.
78. Chang S, Khoo CM, Naylor ML, Maser RS, DePinho RA. Telomere-based crisis: functional differences between telomerase activation and ALT in tumor progression. *Genes Dev*. 2003;17:88.
79. Hakin-Smith V, Jellinek DA, Levy D, et al. Alternative lengthening of telomeres and survival in patients with glioblastoma multiforme. *Lancet*. 2003;361:836.
80. Ulaner GA, Huang HY, Otero J, et al. Absence of a telomere maintenance mechanism as a favorable prognostic factor in patients with osteosarcoma. *Cancer Res*. 2003;63:1759.
81. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. *Eur J Cancer*. 1997;33:787.
82. Feldser DM, Hackett JA, Greider CW. Telomere dysfunction and the initiation of genome instability. *Nat Rev Cancer*. 2003;3:623.
83. Hills M, Lansdorp PM. Short telomeres resulting from heritable mutations in the telomerase reverse transcriptase gene predispose for a variety of malignancies. *Ann N Y Acad Sci*. 2009;1176:178.
84. Allsopp RC, Morin GB, DePinho R, Harley CB, Weissman IL. Telomerase is required to slow telomere shortening and extend replicative lifespan of HSCs during serial transplantation. *Blood*. 2003;102:517.
85. Rossi DJ, Bryder D, Seitza J, Nussenzweig A, Hoeijmakers J, Weissman IL. Deficiencies in DNA damage repair limit the function of haematopoietic stem cells with age. *Nature*. 2007;447:725.
86. Calado RT, Regal JA, Hills M, et al. Constitutional hypomorphic telomerase mutations in patients with acute myeloid leukemia. *Proc Natl Acad Sci U S A*. 2009;106:1187.
87. Calado RT, Regal JA, Kleiner DE, et al. A spectrum of severe familial liver disorders associate with telomerase mutations. *PLoS One*. 2009;4:e7926.
88. Marrone A, Sokhal P, Walne A, et al. Functional characterization of novel telomerase RNA (TERC) mutations in patients with diverse clinical and pathological presentations. *Haematologica*. 2007;92:1013.
89. Rafnar T, Sulem P, Stacey SN, et al. Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. *Nat Genet*. 2009;41:221.
90. Artandi SE, Chang S, Lee SL, et al. Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice. *Nature*. 2000;406:641.
91. Campisi J. Cellular senescence as a tumor-suppressor mechanism. *Trends Cell Biol*. 2001;11:527.
92. Al-Mulla F, Keith WN, Pickford IR, Going JJ, Birnie GD. Comparative genomic hybridization analysis of primary colorectal carcinomas and their synchronous metastases. *Genes Chromosomes Cancer*. 1999;24:306.
93. Buerger H, Otterbach F, Simon R, et al. Comparative genomic hybridization of ductal carcinoma in situ of the breast-evidence of multiple genetic pathways. *J Pathol*. 1999;187:396.
94. Yen CC, Chen YJ, Chen JT, et al. Comparative genomic hybridization of esophageal squamous cell carcinoma: correlations between chromosomal aberrations and disease progression/prognosis. *Cancer*. 2001;92:2769.
95. Tang R, Cheng A-J, Wang J-Y, Wang T-CV. Close correlation between telomerase expression and adenomatous polyp progression in multistep colorectal carcinogenesis. *Cancer Res*. 1998;58:4052.
96. Gisselsson D, Jonson T, Petersen A, et al. Telomere dysfunction triggers extensive DNA fragmentation and evolution of complex chromosome abnormalities in human malignant tumors. *Proc Natl Acad Sci U S A*. 2001;98:12683.

97. O'Sullivan JN, Bronner MP, Brentnall TA, et al. Chromosomal instability in ulcerative colitis is related to telomere shortening. *Nat Genet.* 2002;32:280.
98. Farazi PA, Glickman J, Horner J, DePinho RA. Cooperative interactions of p53 mutation, telomere dysfunction, and chronic liver damage in hepatocellular carcinoma progression. *Cancer Res.* 2006;66:4766.
99. Farazi PA, Glickman J, Jiang S, Yu A, Rudolph KL, DePinho RA. Differential impact of telomere dysfunction on initiation and progression of hepatocellular carcinoma. *Cancer Res.* 2003;63:5021.
100. Rudolph KL, Chang S, Millard M, Schreiber-Agus N, DePinho RA. Inhibition of experimental liver cirrhosis in mice by telomerase gene delivery. *Science.* 2000;287:1253.
101. Saretzki G. Telomerase inhibition as cancer therapy. *Cancer Lett.* 2003;194:209.
102. Shay JW, Wright WE. Telomerase therapeutics for cancer: challenges and new directions. *Nat Rev Drug Discov.* 2006;5:577.
103. Brunsvig PF, Aamdal S, Gjertsen MK, et al. Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer. *Cancer Immunol Immunother.* 2006;55:1553.
104. Bernhardt SL, Gjertsen MK, Trachsel S, et al. Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating phase I/II study. *Br J Cancer.* 2006;95:1474.
105. Su Z, Dannull J, Yang BK, et al. Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer. *J Immunol.* 2005;174:3798.

Chapter 5 – References

1. Kao J, Rosenstein BS, Peters S, Milano MT, Kron SJ. Cellular response to DNA damage. *Ann N Y Acad Sci* 2005;1066:243.
2. Ferrell JE Jr. Self-perpetuating states in signal transduction: positive feedback, double-negative feedback and bistability. *Curr Opin Cell Biol* 2002;14:140.
3. Schlessinger J. Cell signaling by receptor tyrosine kinases. *Cell* 2000; 103:211.
4. Rothenberg SM, Engelman JA, Le S, et al. Modeling oncogene addiction using RNA interference. *Proc Natl Acad Sci U S A* 2008;105:12480.
5. Fretto LJ, Snape AJ, Tomlinson JE, et al. Mechanism of platelet-derived growth factor (PDGF) AA, AB, and BB binding to alpha and beta PDGF receptor. *J Biol Chem* 1993;268:3625.
6. de Vos AM, Ultsch M, Kossiakoff AA. Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. *Science* 1992;255:306.
7. Spivak-Kroizman T, Lemmon A, Dikic A, et al. Heparin-induced oligomerization of FGF molecules is responsible for FGF receptor dimerization, activation, and cell proliferation. *Cell* 1994;79:1015.
8. Schlessinger J. Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. *Cell* 2002;110:669.
9. Pasquale EB. Eph receptor signalling casts a wide net on cell behaviour. *Nat Rev Mol Cell Biol* 2005;6:462.
10. Harris RC, Chung E, Coffey RJ. EGF receptor ligands. *Exp Cell Res* 2003;284:2.
11. Zhang X, Pickin KA, Bose R, et al. Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface. *Nature* 2007; 450:741.
12. Zhang X, Gureasko J, Shen K, Cole PA, Kuriyan J. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. *Cell* 2006; 125:1137.
13. Kerr IM, Costa-Pereira AP, Lillemeier BF, Strobl B. Of JAKs, STATs, blind watchmakers, jeeps and trains. *FEBS Lett* 2003;546:1.
14. Mustelin T, Abraham RT, Rudd CE, Alonso A, Merlo JJ. Protein tyrosine phosphorylation in T cell signaling. *Front Biosci* 2002;7:d918.
15. Gauld SB, Dal Porto JM, Cambier JC. B cell antigen receptor signaling: roles in cell development and disease. *Science* 2002;296:1641.
16. Shi Y, Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. *Cell* 2003;113:685.
17. Tonks NK. Protein tyrosine phosphatases: from genes, to function, to disease. *Nat Rev Mol Cell Biol* 2006;7:833.
18. Hermiston ML, Xu Z, Weiss A. CD45: a critical regulator of signaling thresholds in immune cells. *Annu Rev Immunol* 2003;21:107.
19. Pierce KL, Premont RT, Lefkowitz RJ. Seven-transmembrane receptors. *Nat Rev Mol Cell Biol* 2002; 3:639.
20. Foord SM. Receptor classification: post genome. *Curr Opin Pharmacol* 2002;2:561.
21. Wettschurek N, Offermanns S. Mammalian G proteins and their cell type specific functions. *Physiol Rev* 2005;85:1159.
22. Hamm HE. The many faces of G protein signaling. *J Biol Chem* 1998;273:669.
23. Bray SJ. Notch signalling: a simple pathway becomes complex. *Nat Rev Mol Cell Biol* 2006;7:678.
24. Murad F. Shattuck lecture. Nitric oxide and cyclic GMP in cell signaling and drug development. *N Engl J Med* 2006;355:2003.
25. Aggarwal BB. Signaling pathways of the TNF superfamily: a double-edged sword. *Nat Rev Immunol* 2003;3:745.
26. van Amerongen R, Nusse R. Towards an integrated view of Wnt signaling in development. *Development* 2009;136:3205.
27. Arnaout MA, Mahalingam B, Xiong JP. Integrin structure, allostery, and bidirectional signaling. *Annu Rev Cell Dev Biol* 2005;21:381.
28. Humphries MJ, McEwan PA, Barton SJ, et al. Integrin structure: heady advances in ligand binding, but activation still makes the knees wobble. *Trends Biochem Sci* 2003;28:313.
29. Bjorge JD, Jakyimiw A, Fujita DJ. Selected glimpses into the activation and function of Src kinase. *Oncogene* 2000;19:5620.
30. Hubbard SR. Protein tyrosine kinases: autoregulation and small-molecule inhibition. *Curr Opin Struct Biol* 2002;12:735.
31. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. *Science* 2002;298:1912.
32. Barford D, Das AK, Egloff MP. The structure and mechanism of protein phosphatases: insights into catalysis and regulation. *Annu Rev Biophys Biomol Struct* 1998; 27:133.
33. Barford D, Neel BG. Revealing mechanisms for SH2 domain mediated regulation of the protein tyrosine phosphatase SHP-2. *Structure* 1998;6:249.
34. Simonds WF. G protein regulation of adenylate cyclase. *Trends Pharmacol Sci* 1999;20:66.
35. Chong H, Vikis HG, Guan KL. Mechanisms of regulating the Raf kinase family. *Cell Signal* 2003;15:463.
36. Antoni FA. Molecular diversity of cyclic AMP signalling. *Front Neuroendocrinol* 2000;21:103.
37. Rhee SG. Regulation of phosphoinositide-specific phospholipase C. *Annu Rev Biochem* 2001;70:281.
38. Freedman BD. Mechanisms of calcium signaling and function in lymphocytes. *Crit Rev Immunol* 2006;26:97.
39. Soberman RJ, Christmas P. The organization and consequences of eicosanoid signaling. *J Clin Invest* 2003; 111:1107.
40. Bunney TD, Katan M. Phosphoinositide signalling in cancer: beyond PI3K and PTEN. *Nat Rev Cancer* 2010; 10:342.
41. Grant S. Cotargeting survival signaling pathways in cancer. *J Clin Invest* 2008;118:3003.
42. Lei EP, Silver PA. Protein and RNA export from the nucleus. *Dev Cell* 2002;2:261.
43. Hogan PG, Chen L, Nardone J, Rao A. Transcriptional regulation by calcium, calcineurin, and NFAT. *Genes Dev* 2003;17:2205.
44. Virshup DM. Protein phosphatase 2A: a panoply of enzymes. *Curr Opin Cell Biol* 2000;12:180.
45. Shaw AS. Lipid rafts: now you see them, now you don't. *Nat Immunol* 2006;7:1139.
46. Schlessinger J, Lemmon MA. SH2 and PTB domains in tyrosine kinase signaling. *Sci STKE* 2003;2003(191): RE12.
47. Yaffe MB, Elia AE. Phosphoserine/threonine-binding domains. *Curr Opin Cell Biol* 2001;13:131.
48. Nourry C, Grant SG, Borg JP. PDZ domain proteins: plug and play! *Sci STKE* 2003;2003(179):RE7.
49. Colon-Gonzalez F, Kazanietz MG. C1 domains exposed: from diacylglycerol binding to protein-protein interactions. *Biochim Biophys Acta* 2006;1761:827.
50. Hurley JH. Membrane binding domains. *Biochim Biophys Acta* 2006;1761:805.
51. Maehama T, Taylor GS, Dixon JE. PTEN and myotubularin: novel phosphoinositide phosphatases. *Annu Rev Biochem* 2001;70:247.
52. Rohrschneider LR, Fuller JF, Wolf I, Liu Y, Lucas DM. Structure, function, and biology of SHIP proteins. *Genes Dev* 2000;14:505.
53. Mora A, Komander D, van Aalten DM, Alessi DR. PDK1, the master regulator of AGC kinase signal transduction. *Semin Cell Dev Biol* 2004;15:161.

54. Levy DE, Darnell JE Jr. Stats: transcriptional control and biological impact. *Nat Rev Mol Cell Biol* 2002;3:651.
55. Dever TE. Gene-specific regulation by general translation factors. *Cell* 2002;108:545.
56. Kerscher O, Felberbaum R, Hochstrasser M. Modification of proteins by ubiquitin and ubiquitin-like proteins. *Annu Rev Cell Dev Biol* 2006;22:159.
57. Di Fiore PP, De Camilli P. Endocytosis and signaling. an inseparable partnership. *Cell* 2001;106:1.
58. Hatzivassiliou G, Song K, Yen I, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. *Nature* 2010;464:431.
59. Poulidakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF. *Nature* 2010;464:427.
60. Heidorn SJ, Milagre C, Whittaker S, et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. *Cell* 2010;140:209.

Chapter 6 – References

- Howard A, Pelc SR. Nuclear incorporation of p32 as demonstrated by autoradiographs. *Exp Cell Res* 1951;2:178.
- Johnson RT, Rao PN. Mammalian cell fusion: induction of premature chromosome condensation in interphase nuclei. *Nature* 1970;226:717.
- Rao PN, Johnson RT. Mammalian cell fusion: studies on the regulation of DNA synthesis and mitosis. *Nature* 1970;225:159.
- Masui Y, Markert CL. Cytoplasmic control of nuclear behavior during meiotic maturation of frog oocytes. *J Exp Zool* 1971;177:129.
- Hartwell LH, Culotti J, Pringle JR, et al. Genetic control of the cell division cycle in yeast. *Science* 1974;183:46.
- Harper JW, Adams PD. Cyclin-dependent kinases. *Chem Rev* 2001; 101:2511.
- Jeffrey PD, Russo AA, Polyak K, et al. Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex. *Nature* 1995; 376:313.
- Stevens C, La Thangue NB. E2F and cell cycle control: a double-edged sword. *Arch Biochem Biophys* 2003;412:157.
- Stiegler P, Giordano A. The family of retinoblastoma proteins. *Crit Rev Eukaryot Gene Expr* 2001;11:59.
- Ohtsubo M, Roberts JM. Cyclin-dependent regulation of G1 in mammalian fibroblasts. *Science* 1993;259:1908.
- Resnitzky D, Gossen M, Bujard H, et al. Acceleration of the G1/S phase transition by expression of cyclins D1 and E with an inducible system. *Mol Cell Biol* 1994;14:1669.
- Geng Y, Yu Q, Sicinska E, et al. Cyclin E ablation in the mouse. *Cell* 2003; 114:431.
- Berthet C, Aleem E, Coppola V, et al. CDK2 knockout mice are viable. *Curr Biol* 2003;13:1775.
- Ortega S, Prieto I, Odajima J, et al. Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice. *Nat Genet* 2003; 35:25.
- Aleem E, Kiyokawa H, Kaldis P. Cdc2-cyclin E complexes regulate the G1/S phase transition. *Nat Cell Biol* 2005;7:831.
- Polanowska J, Fabbriozzi E, Le Cam L, et al. The periodic down regulation of cyclin E gene expression from exit of mitosis to end of G(1) is controlled by a deacetylase- and E2F-associated bipartite repressor element. *Oncogene* 2001;20:4115.
- Fung TK, Poon RY. A roller coaster ride with the mitotic cyclins. *Semin Cell Dev Biol* 2005;16:335.
- Russo AA, Jeffrey PD, Pavletich NP. Structural basis of cyclin-dependent kinase activation by phosphorylation. *Nat Struct Biol* 1996;3:696.
- Russo AA, Tong L, Lee JO, et al. Structural basis for inhibition of the cyclin-dependent kinase CDK6 by the tumour suppressor p16INK4a. *Nature* 1998;395:237.
- Cheng M, Olivier P, Diehl JA, et al. The p21(Cip1) and p27(Kip1) CDK inhibitors are essential activators of cyclin D-dependent kinases in murine fibroblasts. *EMBO J* 1999;18:1571.
- Russo AA, Jeffrey PD, Patten AK, et al. Crystal structure of the p27Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex. *Nature* 1996;382:325.
- Yang J, Bardes ES, Moore JD, et al. Control of cyclin B1 localization through regulated binding of the nuclear export factor CRM1. *Genes Dev* 1998;12:2131.
- Nasmyth K. Disseminating the genome: joining, resolving, and separating sister chromatids during mitosis and meiosis. *Annu Rev Genet* 2001;35:673.
- Reed SI. Ratchets and clocks: the cell cycle, ubiquitylation and protein turnover. *Nat Rev Mol Cell Biol* 2003;4:855.
- Carrano AC, Eytan E, Hershko A, et al. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. *Nat Cell Biol* 1999; 1:193.
- Tedesco D, Lukas J, Reed SI. The pRb-related protein p130 is regulated by phosphorylation-dependent proteolysis via the protein-ubiquitin ligase SCF(Skp2). *Genes Dev* 2002;16:2946.
- Strohmaier H, Spruck CH, Kaiser P, et al. Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line. *Nature* 2001; 413:316.
- Koepp DM, Schaefer LK, Ye X, et al. Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7 ubiquitin ligase. *Science* 2001;294:173.
- Moberg KH, Bell DW, Wahrer DC, et al. Archipelago regulates cyclin E levels in Drosophila and is mutated in human cancer cell lines. *Nature* 2001;413:311.
- Davis RJ. Transcriptional regulation by MAP kinases. *Mol Reprod Dev* 1995;42:459.
- Chang F, Lee JT, Navolanic PM, et al. Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. *Leukemia* 2003;17:590.
- Shi Y, Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. *Cell* 2003;113:685.
- Reynisdottir I, Polyak K, Iavarone A, et al. Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta. *Genes Dev* 1995;9:1831.
- Elledge SJ. Cell cycle checkpoints: preventing an identity crisis. *Science* 1996;274:1664.
- Yang J, Yu Y, Hamrick HE. ATM, ATR, and DNA-PK: initiators of the cellular genotoxic stress responses. *Carcinogenesis* 2003;24:1571.
- Vousden KH. Activation of the p53 tumor suppressor protein. *Biochim Biophys Acta* 2002;1602:47.
- Taylor WR, Stark GR. Regulation of the G2/M transition by p53. *Oncogene* 2001;20:1803.
- Bartek J, Lukas J, Chk1 and Chk2 kinases in checkpoint control and cancer. *Cancer Cell* 2003;3:421.
- Sorensen CS, Syljuasen RG, Falck J, et al. Chk1 regulates the S phase checkpoint by coupling the physiological turnover and ionizing radiation-induced accelerated proteolysis of Cdc25A. *Cancer Cell* 2003;3:247.
- Allshire RC. Centromeres, checkpoints and chromatid cohesion. *Curr Opin Genet Dev* 1997;7:264.
- Blagosklonny MV, Pardee AB. The restriction point of the cell cycle. *Cell Cycle* 2002;1:103.
- Ekholm SV, Zickert P, Reed SI, et al. Accumulation of cyclin E is not a prerequisite for passage through the restriction point. *Mol Cell Biol* 2001;21:3256.
- Martinsson HS, Starborg M, Erlandsson F, et al. Single cell analysis of G1 check points—the relationship between the restriction point and phosphorylation of pRb. *Exp Cell Res* 2005;305:383.
- Smith JR, Pereira-Smith OM. Replicative senescence: implications for in vivo aging and tumor suppression. *Science* 1996;273:63.
- Harley CB, Sherwood SW. Telomerase, checkpoints and cancer. *Cancer Surv* 1997;29:263.
- Woo RA, Poon RY. Cyclin-dependent kinases and S phase control in mammalian cells. *Cell Cycle* 2003;2:316.
- Knudson AG Jr. Hereditary cancer. *JAMA* 1979;241:279.
- Sherr CJ, DePinho RA. Cellular senescence: mitotic clock or culture shock? *Cell* 2000;102:407.
- Schmitt CA. Cellular senescence and cancer treatment. *Biochim Biophys Acta* 2007;1775:5.
- Yarden Y. Biology of HER2 and its importance in breast cancer. *Oncology* 2001;61(Suppl 2):1.
- Ortega S, Malumbres M, Barbacid M. Cyclin D-dependent kinases, INK4 inhibitors and cancer. *Biochim Biophys Acta* 2002;1602:73.
- Lee J, Kim SS. The function of p27^{KIP1} during tumor development. *Ex. Mol Med* 2009; 41:765.
- Varley J. TP53, hChk2, and the Li-Fraumeni syndrome. *Methods Mol Biol* 2003;222:117.
- Tsukada T, Tomooka Y, Takai S, et al. Enhanced proliferative potential in culture of cells from p53-deficient mice. *Oncogene* 1993;8:3313.

55. D'Amours D, Jackson SP. The Mre11 complex: at the crossroads of DNA repair and checkpoint signaling. *Nat Rev Mol Cell Biol* 2002;3:317.
56. Kyo S, Takakura M, Taira T, et al. Sp1 cooperates with *c-Myc* to activate transcription of the human telomerase reverse transcriptase gene (*hTERT*). *Nucleic Acids Res* 2000;28:669.
57. Lin SY, Elledge SJ. Multiple tumor suppressor pathways negatively regulate telomerase. *Cell* 2003;113:881.
58. Zhang Y, Xiong Y. Control of p53 ubiquitination and nuclear export by MDM2 and ARF. *Cell Growth Differ* 2001;12:175.
59. Chicas A, Wang X, Zhang C, et al. Dissecting the unique role of the retinoblastoma tumor suppressor during cellular senescence. *Cancer Cell* 2010; 17:376.
60. Loeb KR, Loeb LA. Significance of multiple mutations in cancer. *Carcinogenesis* 2000;21:379.
61. Vessey CJ, Norbury CJ, Hickson ID. Genetic disorders associated with cancer predisposition and genomic instability. *Prog Nucleic Acid Res Mol Biol* 1999;63:189.
62. Jallepalli PV, Lengauer C. Chromosome segregation and cancer: cutting through the mystery. *Nat Rev Cancer* 2001;1:109.
63. Donnellan R, Chetty R. Cyclin E in human cancers. *FASEB J* 1999;13: 773.
64. Spruck CH, Won KA, Reed SI. Deregulated cyclin E induces chromosome instability. *Nature* 1999;401:297.
65. Smith AP, Henze M, Lee JA, et al. Deregulated cyclin E promotes p53 loss of heterozygosity and tumorigenesis in the mouse mammary gland. *Oncogene* 2006;25:7245.
66. Spruck CH, Strohmaier H, Sangfelt O, et al. hCDC4 gene mutations in endometrial cancer. *Cancer Res* 2002;62:4535.
67. Rajagopalan H, Jallepalli PV, Rago C, et al. Inactivation of hCDC4 can cause chromosomal instability. *Nature* 2004;428:77.
68. Migliore C, Giordano S. MiRNAs as new master players. *Cell Cycle* 2009; 8:2185.
69. Yu Z, Baserga R, Chen L, et al. microRNA, cell cycle and human breast cancer. *Am J Pathol* 2010;176:1058.
70. McCormick F. Future prospects for oncolytic therapy. *Oncogene* 2005;24:7817.
71. Levi F, Alper O, Dulong S, et al. Circadian timing in cancer treatments. *Annu Rev Pharmacol. Toxicol* 2010; 50:377.

Chapter 7 – References

1. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. *Br J Cancer* 1972;26:239.
2. Wyllie AH, Kerr JF, Currie AR. Cell death: the significance of apoptosis. *Int Rev Cytol* 1980;68:251.
3. Rao L, Debbas M, Sabbatini P, Hockenbery D, Korsmeyer S, White E. The adenovirus E1A proteins induce apoptosis, which is inhibited by the E1B 19-kDa and Bcl-2 proteins. *Proc Natl Acad Sci U S A* 1992;89:7742.
4. Fanidi A, Harrington EA, Evan GI. Cooperative interaction between c-myc and bcl-2 proto-oncogenes. *Nature* 1992;359:554.
5. Evan GI, Wyllie AH, Gilbert CS, et al. Induction of apoptosis in fibroblasts by c-myc protein. *Cell* 1992;69:119.
6. Morgenbesser SD, Williams BO, Jacks T, DePinho RA. p53-dependent apoptosis produced by Rb-deficiency in the developing mouse lens. *Nature* 1994;371:72.
7. Certo M, Del Gaizo Moore V, Nishino M, et al. Mitochondria primed by death signals determine cellular addition to antiapoptotic BCL-2 family members. *Cancer Cell* 2006;9:351.
8. Ellis HM, Horvitz HR. Genetic control of programmed cell death in the nematode *C. elegans*. *Cell* 1986;44:817.
9. Hengartner MO, Ellis RE, Horvitz HR. *Caenorhabditis elegans* gene *ced-9* protects cells from programmed cell death. *Nature* 1992;356:494.
10. Conradt B, Horvitz HR. The *C. elegans* protein EGL-1 is required for programmed cell death and interacts with the Bcl-2-like protein CED-9. *Cell* 1998;93:519.
11. Hengartner MO, Horvitz HR. Activation of *C. elegans* cell death protein CED-9 by an amino-acid substitution in a domain conserved in Bcl-2. *Nature* 1994;369:318.
12. Yuan J, Shaham S, Ledoux S, Ellis HM, Horvitz HR. The *C. elegans* cell death gene *ced-3* encodes a protein similar to mammalian interleukin-1 beta-converting enzyme. *Cell* 1993;75:641.
13. Zou H, Henzel WJ, Liu X, Lutschg A, Wang X. Apaf-1, a human protein homologous to *C. elegans* CED-4, participates in cytochrome c-dependent activation of caspase-3. *Cell* 1997;90:405.
14. Kornbluth S, White K. Apoptosis in *Drosophila*: neither fish nor fowl (nor man, nor worm). *J Cell Sci* 2005;118:1779.
15. Bakhshi A, Jensen JP, Goldman P, et al. Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18. *Cell* 1985;41:899.
16. Cleary ML, Smith SD, Sklar J. Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation. *Cell* 1986;47:19.
17. Tsujimoto Y, Gorham J, Cossman J, Jaffe E, Croce CM. The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining. *Science* 1985;229:1390.
18. Vaux DL, Cory S, Adams JM. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. *Nature* 1988;335:440.
19. McDonnell TJ, Korsmeyer SJ. Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14;18). *Nature* 1991;349:254.
20. Strasser A, Harris AW, Bath ML, Cory S. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. *Nature* 1990;348:331.
21. Hockenbery D, Nunez G, Millman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. *Nature* 1990;348:334.
22. Debbas M, White E. Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B. *Genes Dev* 1993;7:546.
23. Lowe SW, Ruley HE. Stabilization of the p53 tumor suppressor is induced by adenovirus 5 E1A and accompanies apoptosis. *Genes Dev* 1993;7: 535.
24. Adams JM. Ways of dying: multiple pathways to apoptosis. *Genes Dev* 2003;17:2481.
25. Cuconati A, White E. Viral homologs of BCL-2: role of apoptosis in the regulation of virus infection. *Genes Dev* 2002;16:2465.
26. Danial NN, Korsmeyer SJ. Cell death: critical control points. *Cell* 2004;116:205.
27. Lettre G, Hengartner MO. Developmental apoptosis in *C. elegans*: a complex CEDnario. *Nat Rev Mol Cell Biol* 2006;7:97.
28. Chipuk JE, Moldoveanu T, Llambi F, Parsons MJ, Green DR. The BCL-2 family reunion. *Mol Cell* 2010;37:299.
29. Willis SN, Chen L, Dewson G, et al. Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. *Genes Dev* 2005;19:1294.
30. Willis SN, Fletcher JI, Kaufmann T, et al. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. *Science* 2007;315:856.
31. Wei MC, Zong WX, Cheng EH, et al. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. *Science* 2001;292:727.
32. Zong WX, Lindsten T, Ross AJ, MacGregor GR, Thompson CB. BH3-only proteins that bind pro-survival Bcl-2 family members fail to induce apoptosis in the absence of Bax and Bak. *Genes Dev* 2001;15:1481.
33. Fesik SW. Promoting apoptosis as a strategy for cancer drug discovery. *Nat Rev Cancer* 2005;5:876.
34. Muchmore SW, Sattler M, Liang H, et al. X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death. *Nature* 1996;381:335.
35. Gelinas C, White E. BH3-only proteins in control: specificity regulates MCL-1 and BAK-mediated apoptosis. *Genes Dev* 2005;19:1263.
36. Lovell JF, Billen LP, Bindner S, et al. Membrane binding by tBid initiates an ordered series of events culminating in membrane permeabilization by Bax. *Cell* 2008;135:1074.
37. Oltsersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. *Nature* 2005;435:677.
38. Sattler M, Liang H, Nettessheim D, et al. Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis. *Science* 1997;275:983.
39. Walensky LD, Kung AL, Escher I, et al. Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. *Science* 2004;305:1466.
40. Du C, Fang M, Li Y, Li L, Wang X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. *Cell* 2000;102:33.
41. Green DR, Kroemer G. The pathophysiology of mitochondrial cell death. *Science* 2004;305:626.
42. Kluck RM, Bossy-Wetzell E, Green DR, Newmeyer DD. The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. *Science* 1997;275:1132.
43. Verhagen AM, Ekert PG, Pakusch M, et al. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. *Cell* 2000;102:43.
44. Yang J, Liu X, Bhalla K, et al. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. *Science* 1997;275:1129.
45. Acehan D, Jiang X, Morgan DG, Heuser JE, Wang X, Akey CW. Three-dimensional structure of the apoptosome: implications for assembly, procaspase-9 binding, and activation. *Mol Cell* 2002;9:423.
46. Cryns V, Yuan J. Proteases to die for. *Genes Dev* 1998;12:1551.

47. Kelley RF, Totpal K, Lindstrom SH, et al. Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. *J Biol Chem* 2005;280:2205.
48. Soria JC, Smit E, Khayat D, et al. Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer. *J Clin Oncol* 2010;28:1527.
49. Trarbach T, Moehler M, Heinemann V, et al. Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer. *Br J Cancer* 2010;102:506.
50. Leong S, Cohen RB, Gustafson DL, et al. Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study. *J Clin Oncol* 2009;27:4413.
51. Ashkenazi A, Holland P, Eckhardt SG. Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). *J Clin Oncol* 2008;26:3621.
52. Kelley SK, Ashkenazi A. Targeting death receptors in cancer with Apo2L/TRAIL. *Curr Opin Pharmacol* 2004;4:333.
53. Lu J, Bai L, Sun H, et al. SM-164: a novel, bivalent Smac mimetic that induces apoptosis and tumor regression by concurrent removal of the blockade of cIAP-1/2 and XIAP. *Cancer Res* 2008;68:9384.
54. Chen DJ, Huerta S. Smac mimetics as new cancer therapeutics. *Anticancer Drugs* 2009;20:646.
55. Chauhan D, Neri P, Velankar M, et al. Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM). *Blood* 2007;109:1220.
56. Fulda S, Wick W, Weller M, Debatin KM. Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. *Nat Med* 2002;8:808.
57. Toledo F, Wahl GM. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. *Nat Rev Cancer* 2006;6:909.
58. Vousden KH, Prives C. P53 and prognosis: new insights and further complexity. *Cell* 2005;120:7.
59. Xue W, Zender L, Miething C, et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. *Nature* 2007;445:656.
60. Ventura A, Kirsch DG, McLaughlin ME, et al. Restoration of p53 function leads to tumour regression in vivo. *Nature* 2007;445:661.
61. Wang W, El-Deiry WS. Restoration of p53 to limit tumor growth. *Curr Opin Oncol* 2008;20:90.
62. Tan TT, Degenhardt K, Nelson DA, et al. Key roles of BIM-driven apoptosis in epithelial tumors and rational chemotherapy. *Cancer Cell* 2005;7:227.
63. Kuroda J, Puthalakath H, Cragg MS, et al. Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. *Proc Natl Acad Sci U S A* 2006;103:14907.
64. Downward J. PI 3-kinase, Akt and cell survival. *Semin Cell Devel Biol* 2004;15:177.
65. Rahmani M, Anderson A, Habibi JR, et al. The BH3-only protein Bim plays a critical role in leukemia cell death triggered by concomitant inhibition of the PI3K/Akt and MEK/ERK1/2 pathways. *Blood* 2009;114:4507.
66. Karin M. Nuclear factor-kappaB in cancer development and progression. *Nature* 2006;441:431.
67. Baud V, Karin M. Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. *Nat Rev Drug Discov* 2009;8:33.
68. Konopleva M, Contractor R, Tsao T, et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. *Cancer Cell* 2006;10:375.
69. Chauhan D, Velankar M, Brahmandam M, et al. A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. *Oncogene* 2007;26:2374.
70. Del Gaizo Moore V, Brown JR, Certo M, Love TM, Novina CD, Letai A. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. *J Clin Invest* 2007;117:112.
71. Tahir SK, Yang X, Anderson MG, et al. Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. *Cancer Res* 2007;67:1176.
72. Tse C, Shoemaker AR, Adickes J, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. *Cancer Res* 2008;68:3421.
73. Yecies D, Carlson NE, Deng J, Letai A. Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. *Blood* 2010;115:3304.
74. Bray K, Chen HY, Karp CM, et al. Bcl-2 modulation to activate apoptosis in prostate cancer. *Mol Cancer Res* 2009;7:1487.
75. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. *Science* 2009;324:1029.
76. Warburg O. On respiratory impairment in cancer cells. *Science* 1956;124:269.
77. Jin S, DiPaola RS, Mathew R, White E. Metabolic catastrophe as a means to cancer cell death. *J Cell Sci* 2007;120:379.
78. Levine B, Kroemer G. Autophagy in the pathogenesis of disease. *Cell* 2008;132:27.
79. Mizushima N, Levine B, Cuervo AM, Klionsky DJ. Autophagy fights disease through cellular self-digestion. *Nature* 2008;451:1069.
80. Degenhardt K, Mathew R, Beaudoin B, et al. Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. *Cancer Cell* 2006;10:51.
81. Lum JJ, Bauer DE, Kong M, et al. Growth factor regulation of autophagy and cell survival in the absence of apoptosis. *Cell* 2005;120:237.
82. Mathew R, Karantza-Wadsworth V, White E. Role of autophagy in cancer. *Nat Rev Cancer* 2007;7:961.
83. Chen N, Karantza-Wadsworth V. Role and regulation of autophagy in cancer. *Biochim Biophys Acta* 2009;1793:1516.
84. Boya P, Gonzalez-Polo RA, Casares N, et al. Inhibition of macroautophagy triggers apoptosis. *Mol Cell Biol* 2005;25:1025.
85. Karantza-Wadsworth V, Patel S, Kravchuk O, et al. Autophagy mitigates metabolic stress and genome damage in mammary tumorigenesis. *Genes Dev* 2007;21:1621.
86. Mathew R, Kongara S, Beaudoin B, et al. Autophagy suppresses tumor progression by limiting chromosomal instability. *Genes Dev* 2007;21:1367.
87. Kuma A, Hatano M, Matsui M, et al. The role of autophagy during the early neonatal starvation period. *Nature* 2004;432:1032.
88. Yan L, Sadoshima J, Vatner DE, Vatner SF. Autophagy in ischemic preconditioning and hibernating myocardium. *Autophagy* 2009;5:709.
89. Komatsu M, Waguri S, Ueno T, et al. Impairment of starvation-induced and constitutive autophagy in Atg7-deficient mice. *J Cell Biol* 2005;169:425.
90. Komatsu M, Waguri S, Chiba T, et al. Loss of autophagy in the central nervous system causes neurodegeneration in mice. *Nature* 2006;441: 880.
91. Hara T, Nakamura K, Matsui M, et al. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. *Nature* 2006;441:885.
92. Mathew R, Karp CM, Beaudoin B, et al. Autophagy suppresses tumorigenesis through elimination of p62. *Cell* 2009;137:1062.

93. Komatsu M, Waguri S, Koike M, et al. Homeostatic levels of p62 control cytoplasmic inclusion body formation in autophagy-deficient mice. *Cell* 2007;131:1149.
94. Singh SB, Davis AS, Taylor GA, Deretic V. Human IRGM induces autophagy to eliminate intracellular mycobacteria. *Science* 2006;313:1438.
95. Gutierrez MG, Master SS, Singh SB, Taylor GA, Colombo MI, Deretic V. Autophagy is a defense mechanism inhibiting BCG and *Mycobacterium tuberculosis* survival in infected macrophages. *Cell* 2004;119:753.
96. Ogawa M, Yoshimori T, Suzuki T, Sagara H, Mizushima N, Sasakawa C. Escape of intracellular Shigella from autophagy. *Science* 2005;307:727.
97. Deretic V. Autophagy in infection. *Curr Opin Cell Biol* 2010;22:252.
98. Pua HH, Dzhagalov I, Chuck M, Mizushima N, He YW. A critical role for the autophagy gene Atg5 in T cell survival and proliferation. *J Exp Med* 2007;204:25.
99. Cooney R, Baker J, Brain O, et al. NOD2 stimulation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation. *Nat Med* 2010;16:90.
100. Cecconi F, Levine B. The role of autophagy in mammalian development: cell makeover rather than cell death. *Dev Cell* 2008;15:344.
101. Winslow AR, Rubinsztein DC. Autophagy in neurodegeneration and development. *Biochim Biophys Acta* 2008;1782:723.
102. Lee JH, Budanov AV, Park EJ, et al. Sestrin as a feedback inhibitor of TOR that prevents age-related pathologies. *Science* 2010;327:1223.
103. Cuervo AM. Autophagy and aging: keeping that old broom working. *Trends Genet* 2008;24:604.
104. Levine B, Yuan J. Autophagy in cell death: an innocent convict? *J Clin Invest* 2005;115:2679.
105. Kourtis N, Tavernarakis N. Autophagy and cell death in model organisms. *Cell Death Differ* 2009;16:21.
106. Kroemer G, Levine B. Autophagic cell death: the story of a misnomer. *Nat Rev Mol Cell Biol* 2008;9:1004.
107. Neufeld TP, Baehrecke EH. Eating on the fly: function and regulation of autophagy during cell growth, survival and death in *Drosophila*. *Autophagy* 2008;4:557.
108. Baehrecke EH. Autophagy: dual roles in life and death? *Nat Rev Mol Cell Biol* 2005;6:505.
109. Aita VM, Liang XH, Murty VV, et al. Cloning and genomic organization of beclin 1, a candidate tumor suppressor gene on chromosome 17q21. *Genomics* 1999;59:59.
110. Liang XH, Jackson S, Seaman M, et al. Induction of autophagy and inhibition of tumorigenesis by beclin 1. *Nature* 1999;402:672.
111. Kametaka S, Okano T, Ohsumi M, Ohsumi Y. Apg14p and Apg6/Vps30p form a protein complex essential for autophagy in the yeast, *Saccharomyces cerevisiae*. *J Biol Chem* 1998;273:22284.
112. Yue Z, Jin S, Yang C, Levine AJ, Heintz N. Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor. *Proc Natl Acad Sci U S A* 2003;100:15077.
113. Qu X, Yu J, Bhagat G, et al. Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. *J Clin Invest* 2003;112:1809.
114. White E, DiPaola RS. The double-edged sword of autophagy modulation in cancer. *Clin Cancer Res* 2009;15:5308.
115. White E, Karp C, Strohecker AM, Guo Y, Mathew R. Role of autophagy in suppression of inflammation and cancer. *Curr Opin Cell Biol* 2010;22:212.
116. Amaravadi RK, Thompson CB. The roles of therapy-induced autophagy and necrosis in cancer treatment. *Clin Cancer Res* 2007;13:7271.
117. Kondo Y, Kanzawa T, Sawaya R, Kondo S. The role of autophagy in cancer development and response to therapy. *Nat Rev Cancer* 2005;5:726.
118. Ding WX, Ni HM, Gao W, et al. Oncogenic transformation confers a selective susceptibility to the combined suppression of the proteasome and autophagy. *Mol Cancer Ther* 2009;8:2036.
119. Carew JS, Medina EC, Esquivel JA, 2nd, et al. Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation [published online ahead of print July 6, 2009]. *J Cell Mol Med* doi:10.1111/j.1582-4934.2009.00832.x.
120. Hoang B, Benavides A, Shi Y, Frost P, Lichtenstein A. Effect of autophagy on multiple myeloma cell viability. *Mol Cancer Ther* 2009;8:1974.
121. Bellodi C, Lidonnici MR, Hamilton A, et al. Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. *J Clin Invest* 2009;119:1109.
122. Degtyarev M, De Maziere A, Orr C, et al. Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents. *J Cell Biol* 2008;183:101.
123. Maclean KH, Dorsey FC, Cleveland JL, Kastan MB. Targeting lysosomal degradation induces p53-dependent cell death and prevents cancer in mouse models of lymphomagenesis. *J Clin Invest* 2008;118:79.
124. Carew JS, Nawrocki ST, Kahue CN, et al. Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance. *Blood* 2007;110:313.
125. Amaravadi RK, Yu D, Lum JJ, et al. Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. *J Clin Invest* 2007;117:326.
126. Apel A, Herr I, Schwarz H, Rodemann HP, Mayer A. Blocked autophagy sensitizes resistant carcinoma cells to radiation therapy. *Cancer Res* 2008;68:1485.
127. Kanduc D, Mittelman A, Serpico R, et al. Cell death: apoptosis versus necrosis (review). *Int J Oncol* 2002;21:165.
128. Zong WX, Thompson CB. Necrotic death as a cell fate. *Genes Dev* 2006;20:1.
129. Christofferson DE, Yuan J. Necroptosis as an alternative form of programmed cell death. *Curr Opin Cell Biol* 2010;22:263.
130. Degterev A, Huang Z, Boyce M, et al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. *Nat Chem Biol* 2005;1:112.
131. Hitomi J, Christofferson DE, Ng A, et al. Identification of a molecular signaling network that regulates a cellular necrotic cell death pathway. *Cell* 2008;135:1311.
132. Galluzzi L, Kroemer G. Necroptosis: a specialized pathway of programmed necrosis. *Cell* 2008;135:1161.
133. Degterev A, Hitomi J, Germscheid M, et al. Identification of RIP1 kinase as a specific cellular target of necrostatins. *Nat Chem Biol* 2008;4:313.
134. Declercq W, Vanden Berghe T, Vandenabeele P. RIP kinases at the crossroads of cell death and survival. *Cell* 2009;138:229.
135. Cho YS, Challa S, Moquin D, et al. Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation. *Cell* 2009;137:1112.
136. He S, Wang L, Miao L, et al. Receptor interacting protein kinase-3 determines cellular necrotic response to TNF- α . *Cell* 2009;137:1100.
137. Zong WX, Ditsworth D, Bauer DE, Wang ZQ, Thompson CB. Alkylating DNA damage stimulates a regulated form of necrotic cell death. *Genes Dev* 2004;18:1272.
138. Suzuki M, Youle RJ, Tjandra N. Structure of Bax: coregulation of dimer formation and intracellular localization. *Cell* 2000;103:645.

Chapter 8 – References

1. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. *Science* 2009;324:1029.
2. Warburg O. On the origin of cancer cells. *Science* 1956;123:309.
3. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? *Nat Rev Cancer* 2004;4:891.
4. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, et al. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. *Cell Metab* 2008;7:11.
5. Hsu PP, Sabatini DM. Cancer cell metabolism: Warburg and beyond. *Cell* 2008;134:703.
6. Warburg O. Über den Stoffwechsel der Carcinomzelle. *Klin Wochenschr* 1925;4:534.
7. Warburg O, Posener K, Negelein E. Ueber den Stoffwechsel der Tumoren. *Biochemische Zeitschrift* 1924;152:319.
8. Pessin JE, Bell GL. Mammalian facilitative glucose transporter family: structure and molecular regulation. *Annu Rev Physiol* 1992;54:911.
9. Yamamoto T, Seino Y, Fukumoto H, et al. Over-expression of facilitative glucose transporter genes in human cancer. *Biochem Biophys Res Commun* 1990;170:223.
10. Macheda ML, Rogers S, Best JD. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. *J Cell Physiol* 2005;202:654.
11. Lehninger AL, Nelson DL, Cox MM. *Principles of biochemistry*. New York: Worth Publishers, 1993.
12. Mathupala SP, Ko YH, Pedersen PL. The pivotal roles of mitochondria in cancer: Warburg and beyond and encouraging prospects for effective therapies. *Biochim Biophys Acta* 2010;1797:1225.
13. Robey RB, Hay N. Mitochondrial hexokinases, novel mediators of the antiapoptotic effects of growth factors and Akt. *Oncogene* 2006;25:4683.
14. Yalcin A, Telang S, Clem B, et al. Regulation of glucose metabolism by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases in cancer. *Exp Mol Pathol* 2009;86:174.
15. Christofk HR, Vander Heiden MG, Wu N, et al. Pyruvate kinase M2 is a phosphotyrosine-binding protein. *Nature* 2008;452:181.
16. Mazurek S, Boschek CB, Hugo F, et al. Pyruvate kinase type M2 and its role in tumor growth and spreading. *Semin Cancer Biol* 2005;15:300.
17. Weinhouse S. The Warburg hypothesis fifty years later. *Z Krebsforsch Klin Onkol Cancer Res Clin Oncol* 1976;87:115.
18. Fantin VR, St-Pierre J, Leder P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. *Cancer Cell* 2006;9:425.
19. Folkman J. Angiogenesis. *Annu Rev Med* 2006;57:1.
20. Bertout JA, Patel SA, Simon MC. The impact of O₂ availability on human cancer. *Nat Rev Cancer* 2008;8:967.
21. Semenza GL. Regulation of cancer cell metabolism by hypoxia-inducible factor 1. *Semin Cancer Biol* 2009;19:12.
22. Diaz-Ruiz R, Uribe-Carvajal S, Devin A, et al. Tumor cell energy metabolism and its common features with yeast metabolism. *Biochim Biophys Acta* 2009;1796:252.
23. Scholnick P, Lang D, Racker E. Regulatory mechanisms in carbohydrate metabolism. IX. Stimulation of aerobic glycolysis by energy-linked ion transport and inhibition by dextran sulfate. *J Biol Chem* 1973;248:5175.
24. Racker E. Why do tumor cells have a high aerobic glycolysis? *J Cell Physiol* 1976;89:697.
25. Sonveau P, Vegran F, Schroeder T, et al. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. *J Clin Invest* 2008;118:3930.
26. Semenza GL. Tumor metabolism: cancer cells give and take lactate. *J Clin Invest* 2008;118:3835.
27. Guppy M, Leedman P, Zu X, et al. Contribution by different fuels and metabolic pathways to the total ATP turnover of proliferating MCF-7 breast cancer cells. *Biochem J* 2002;364:309.
28. Schmidt H, Siems W, Muller M, et al. ATP-producing and consuming processes of Ehrlich mouse ascites tumor cells in proliferating and resting phases. *Exp Cell Res* 1991;194:122.
29. DeBerardinis RJ, Mancuso A, Daikhin E, et al. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. *Proc Natl Acad Sci U S A* 2007;104:19345.
30. Wise DR, DeBerardinis RJ, Mancuso A, et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. *Proc Natl Acad Sci U S A* 2008;105:18782.
31. Song WS, Nielson BR, Banks KP, et al. Normal organ standard uptake values in carbon-11 acetate PET imaging. *Nucl Med Commun* 2009;30:462.
32. Hatzivassiliou G, Zhao F, Bauer DE, et al. ATP citrate lyase inhibition can suppress tumor cell growth. *Cancer Cell* 2005;8:311.
33. Tamura K, Makino A, Hullin-Matsuda F, et al. Novel lipogenic enzyme ELOVL7 is involved in prostate cancer growth through saturated long-chain fatty acid metabolism. *Cancer Res* 2009;69:8133.
34. Nomura DK, Long JZ, Niessen S, et al. Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. *Cell* 2010;140:49.
35. Lockart RZ Jr, Eagle H. Requirements for growth of single human cells. *Science* 1959;129:252.
36. Trowbridge IS, Lopez F. Monoclonal antibody to transferrin receptor blocks transferrin binding and inhibits human tumor cell growth in vitro. *Proc Natl Acad Sci U S A* 1982;79:1175.
37. Tisdale MJ. Mechanisms of cancer cachexia. *Physiol Rev* 2009;89:381.
38. Plegemann PG, Richey DP. Transport of nucleosides, nucleic acid bases, choline and glucose by animal cells in culture. *Biochim Biophys Acta* 1974;344:263.
39. Bachelard HS, Clark AG, Thompson MF. Cerebral-cortex hexokinase. Elucidation of reaction mechanisms by substrate and dead-end inhibitor kinetic analysis. *Biochem J* 1971;123:707.
40. Hawkins RA, Phelps ME. PET in clinical oncology. *Cancer Metastasis Rev* 1988;7:119.
41. Ben-Haim S, Ell P. 18F-FDG PET and PET/CT in the evaluation of cancer treatment response. *J Nucl Med* 2009;50:88.
42. Geus-Oei LF, Oyen WJ. Predictive and prognostic value of FDG-PET. *Cancer Imaging* 2008;8:70.
43. Oyama N, Akino H, Kanamaru H, et al. 11C-acetate PET imaging of prostate cancer. *J Nucl Med* 2002;43:181.
44. Kato T, Tsukamoto E, Kuge Y, et al. Accumulation of [11C]acetate in normal prostate and benign prostatic hyperplasia: comparison with prostate cancer. *Eur J Nucl Med Mol Imaging* 2002;29:1492.
45. Hanahan D, Weinberg RA. The hallmarks of cancer. *Cell* 2000;100:57.
46. Kaelin WG Jr. The von Hippel-Lindau tumour suppressor protein: O₂ sensing and cancer. *Nat Rev Cancer* 2008;8:865.
47. Kaelin WG Jr, Ratcliffe PJ. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. *Mol Cell* 2008;30:393.
48. Rankin EB, Giaccia AJ. The role of hypoxia-inducible factors in tumorigenesis. *Cell Death Differ* 2008;15:678.
49. Majumder PK, Febbo PG, Bikoff R, et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. *Nat Med* 2004;10:594.
50. Dang CV, Kim JW, Gao P, et al. The interplay between MYC and HIF in cancer. *Nat Rev Cancer* 2008;8:51.

51. Papandreou I, Cairns RA, Fontana L, et al. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. *Cell Metab* 2006;3:187.
52. Kim JW, Tchernyshyov I, Semenza GL, et al. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. *Cell Metab* 2006;3:177.
53. Tong X, Zhao F, Mancuso A, et al. The glucose-responsive transcription factor ChREBP contributes to glucose-dependent anabolic synthesis and cell proliferation. *Proc Natl Acad Sci U S A* 2009;106:21660.
54. Kaadige MR, Looper RE, Kamalanaadhan S, et al. Glutamine-dependent anapleurosis dictates glucose uptake and cell growth by regulating MondoA transcriptional activity. *Proc Natl Acad Sci U S A* 2009;106:14878.
55. Brown MS, Goldstein JL. A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood. *Proc Natl Acad Sci U S A* 1999;96:11041.
56. Porstmann T, Santos CR, Griffiths B, et al. SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth. *Cell Metab* 2008;8:224.
57. Flier JS, Mueckler MM, Usher P, et al. Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. *Science* 1987;235:1492.
58. Birnbaum MJ, Haspel HC, Rosen OM. Transformation of rat fibroblasts by FSV rapidly increases glucose transporter gene transcription. *Science* 1987;235:1495.
59. Cantley LC. The phosphoinositide 3-kinase pathway. *Science* 2002;296:1655.
60. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. *Nat Rev Genet* 2006;7:606.
61. Gewinner C, Wang ZC, Richardson A, et al. Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. *Cancer Cell* 2009;16:115.
62. Li YM, Zhou BP, Deng J, et al. A hypoxia-independent hypoxia-inducible factor-1 activation pathway induced by phosphatidylinositol-3 kinase/Akt in HER2 overexpressing cells. *Cancer Res* 2005;65:3257.
63. Zhong H, Chiles K, Feldser D, et al. Modulation of hypoxia-inducible factor 1 alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. *Cancer Res* 2000;60:1541.
64. Thomas GV, Tran C, Mellinghoff IK, et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. *Nat Med* 2006;12:122.
65. Hudson CC, Liu M, Chiang GG, et al. Regulation of hypoxia-inducible factor 1 alpha expression and function by the mammalian target of rapamycin. *Mol Cell Biol* 2002;22:7004.
66. Engelman JA, Chen L, Tan X, et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. *Nat Med* 2008;14:1351.
67. Yun J, Rago C, Cheong I, et al. Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. *Science* 2009;325(5947):1555.
68. Shim H, Dolde C, Lewis BC, et al. c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. *Proc Natl Acad Sci U S A* 1997;94:6658.
69. Gao P, Tchernyshyov I, Chang TC, et al. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. *Nature* 2009;458(7239):762.
70. Yuneva M, Zamboni N, Oefner P, et al. Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells. *J Cell Biol* 2007;178:93.
71. Cheung EC, Voudsen KH. The role of p53 in glucose metabolism. *Curr Opin Cell Biol* 2010;22:186.
72. Bensaad K, Tsuruta A, Selak MA, et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. *Cell* 2006;126:107.
73. Kondoh H, Lleonart ME, Gil J, et al. Glycolytic enzymes can modulate cellular life span. *Cancer Res* 2005;65:177.
74. Polyak K, Xia Y, Zweier JL, et al. A model for p53-induced apoptosis. *Nature* 1997;389:300.
75. Matoba S, Kang JG, Patino WD, et al. p53 regulates mitochondrial respiration. *Science* 2006;312:1650.
76. Woods A, Johnstone SR, Dickerson K, et al. LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. *Curr Biol* 2003;13:2004.
77. Hawley SA, Boudeau J, Reid JL, et al. Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. *J Biol* 2003;2:28.
78. Shaw RJ, Kosmatka M, Bardeesy N, et al. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. *Proc Natl Acad Sci U S A* 2004;101:3329.
79. Hardie DG. AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. *Nat Rev Mol Cell Biol* 2007;8:774.
80. Gwinn DM, Shackelford DB, Egan DF, et al. AMPK phosphorylation of raptor mediates a metabolic checkpoint. *Mol Cell* 2008;30:214.
81. Shackelford DB, Shaw RJ. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. *Nat Rev Cancer* 2009;9:563.
82. Tee AR, Blenis J. mTOR, translational control and human disease. *Semin Cell Dev Biol* 2005;16:29.
83. Dann SG, Thomas G. The amino acid sensitive TOR pathway from yeast to mammals. *FEBS Lett* 2006;580:2821.
84. Huang J, Manning BD. The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. *Biochem J* 2008;412:179.
85. Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. *Nature* 2006;441:424.
86. Kundu M, Thompson CB. Autophagy: basic principles and relevance to disease. *Annu Rev Pathol* 2008;3:427.
87. Jin S, White E. Tumor suppression by autophagy through the management of metabolic stress. *Autophagy* 2008;4:563.
88. Wang RC, Levine B. Autophagy in cellular growth control. *FEBS Lett* 2010;584:1417.
89. Christofk HR, Vander Heiden MG, Harris MH, et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. *Nature* 2008;452:230.
90. Baysal BE, Ferrell RE, Willett-Brozick JE, et al. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. *Science* 2000;287:848.
91. Astuti D, Douglas F, Lennard TW, et al. Germline SDHD mutation in familial pheochromocytoma. *Lancet* 2001;357:1181.
92. Astuti D, Latif F, Dallol A, et al. Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. *Am J Hum Genet* 2001;69:49.
93. Vanharanta S, Buchta M, McWhinney SR, et al. Early-onset renal cell carcinoma as a novel extraparaganglial component of SDHB-associated heritable paraganglioma. *Am J Hum Genet* 2004;74:153.
94. Hao HX, Khalimonchuk O, Schraders M, et al. SDH5, a gene required for flavination of succinate dehydrogenase, is mutated in paraganglioma. *Science* 2009;325(5944):1139.
95. King A, Selak MA, Gottlieb E. Succinate dehydrogenase and fumarate hydratase: linking mitochondrial dysfunction and cancer. *Oncogene* 2006;25:4675.
96. Pollard PJ, Wortham NC, Tomlinson IP. The TCA cycle and tumorigenesis: the examples of fumarate hydratase and succinate dehydrogenase. *Ann Med* 2003;35:632.
97. Lehtonen R, Kiuru M, Vanharanta S, et al. Biallelic inactivation of fumarate hydratase (FH) occurs in nonsyndromic uterine leiomyomas but is rare in other tumors. *Am J Pathol* 2004;164:17.

98. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. *Science* 2008;321:1807.
99. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. *N Engl J Med* 2009;360:765.
100. Mardis ER, Ding L, Dooling DJ, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. *N Engl J Med* 2009;361:1058.
101. Thompson CB. Metabolic enzymes as oncogenes or tumor suppressors. *N Engl J Med* 2009;360:813.
102. Bals J, Meyer J, Mueller W, et al. Analysis of the IDH1 codon 132 mutation in brain tumors. *Acta Neuropathol* 2008;116:597.
103. Marcucci G, Maharry K, Wu YZ, et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. *J Clin Oncol* 2010;28:2348.
104. Kosmider O, Gelsi-Boyer V, Slama L, et al. Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. *Leukemia* 2010;24:1094.
105. Ward PS, Patel J, Wise DR, et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. *Cancer Cell* 2010;17:225.
106. Watanabe T, Nobusawa S, Kleihues P, et al. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. *Am J Pathol* 2009;174:1149.
107. Gross S, Cairns RA, Minden MD, et al. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. *J Exp Med* 2010;207:339.
108. Ho PA, Alonzo TA, Kopecky KJ, et al. Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study. *Leukemia* 2010;24:909.
109. Murugan AK, Bojdani E, Xing M. Identification and functional characterization of isocitrate dehydrogenase 1 (IDH1) mutations in thyroid cancer. *Biochem Biophys Res Commun* 2010;393:555.
110. Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. *Nature* 2009;462:739.
111. Struys EA, Salomons GS, Achouri Y, et al. Mutations in the D-2-hydroxyglutarate dehydrogenase gene cause D-2-hydroxyglutaric aciduria. *Am J Hum Genet* 2005;76:358.
112. Aghili M, Zahedi F, Rafiee E. Hydroxyglutaric aciduria and malignant brain tumor: a case report and literature review. *J Neurooncol* 2009;91:233.
113. Zhao S, Lin Y, Xu W, et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1 alpha. *Science* 2009;324:261.
114. Guda K, Moinova H, He J, et al. Inactivating germ-line and somatic mutations in polypeptide N-acetylgalactosaminyltransferase 12 in human colon cancers. *Proc Natl Acad Sci U S A* 2009;106:12921.
115. Slawson C, Copeland RJ, Hart GW. O-GlcNAc signaling: a metabolic link between diabetes and cancer? *Trends Biochem Sci* 2010;35:547–555.
116. Farber S, Diamond LK. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid. *N Engl J Med* 1948;238:787.
117. Wong KK, Engelman JA, Cantley LC. Targeting the PI3K signaling pathway in cancer. *Curr Opin Genet Dev* 2010;20:87.
118. Evans JM, Donnelly LA, Emslie-Smith AM, et al. Metformin and reduced risk of cancer in diabetic patients. *BMJ* 2005;330:1304.
119. Bowker SL, Majumdar SR, Veugelers P, et al. Increased cancer-mortality for patients with type 2 diabetes who use sulfonylureas or insulin. *Diabetes Care* 2006;29:254.
120. Jiralerspong S, Palla SL, Giordano SH, et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. *J Clin Oncol* 2009;27:3297.
121. Shaw RJ, Lamia KA, Vasquez D, et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. *Science* 2005;310:1642.
122. El-Mir MY, Nogueira V, Fontaine E, et al. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. *J Biol Chem* 2000;275:223.
123. Buzzai M, Jones RG, Amaravadi RK, et al. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. *Cancer Res* 2007;67:6745.
124. Caraci F, Chisari M, Frasca G, et al. Effects of phenformin on the proliferation of human tumor cell lines. *Life Sci* 2003;74:643.
125. Huang X, Wullschlegel S, Shpiro N, et al. Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice. *Biochem J* 2008;412:211.
126. Renehan AG, Zwahlen M, Minder C, et al. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. *Lancet* 2004;363:1346.
127. Pollak M. Insulin and insulin-like growth factor signaling in neoplasia. *Nat Rev Cancer* 2008;8:915.
128. Kalaany NY, Sabatini DM. Tumours with PI3K activation are resistant to dietary restriction. *Nature* 2009;458:725.
129. De Leo V, La Marca A, Orvieto R, et al. Effect of metformin on insulin-like growth factor (IGF) I and IGF-binding protein I in polycystic ovary syndrome. *J Clin Endocrinol Metab* 2000;85:1598.
130. Tennant DA, Duran RV, Gottlieb E. Targeting metabolic transformation for cancer therapy. *Nat Rev Cancer* 2010;10:267.
131. MacKenzie ED, Selak MA, Tennant DA, et al. Cell-permeating alpha-ketoglutarate derivatives alleviate pseudohypoxia in succinate dehydrogenase-deficient cells. *Mol Cell Biol* 2007;27:3282.
132. Laszlo J, Humphreys SR, Goldin A. Effects of glucose analogues (2-deoxy-D-glucose, 2-deoxy-D-galactose) on experimental tumors. *J Natl Cancer Inst* 1960;24:267.
133. Jain VK, Kalia VK, Sharma R, et al. Effects of 2-deoxy-D-glucose on glycolysis, proliferation kinetics and radiation response of human cancer cells. *Int J Radiat Oncol Biol Phys* 1985;11:943.
134. Aft RL, Zhang FW, Gius D. Evaluation of 2-deoxy-D-glucose as a chemotherapeutic agent: mechanism of cell death. *Br J Cancer* 2002;87:805.
135. Kaplan O, Navon G, Lyon RC, et al. Effects of 2-deoxyglucose on drug-sensitive and drug-resistant human breast cancer cells: toxicity and magnetic resonance spectroscopy studies of metabolism. *Cancer Res* 1990;50:544.
136. Landau BR, Laszlo J, Stengle J, et al. Certain metabolic and pharmacologic effects in cancer patients given infusions of 2-deoxy-D-glucose. *J Natl Cancer Inst* 1958;21:485.
137. Mohanti BK, Rath GK, Anantha N, et al. Improving cancer radiotherapy with 2-deoxy-D-glucose: phase I/II clinical trials on human cerebral gliomas. *Int J Radiat Oncol Biol Phys* 1996;35:103.
138. Singh D, Banerji AK, Dwarakanath BS, et al. Optimizing cancer radiotherapy with 2-deoxy-D-glucose dose escalation studies in patients with glioblastoma multiforme. *Strahlenther Onkol* 2005;181:507.
139. Dwarakanath B, Jain V. Targeting glucose metabolism with 2-deoxy-D-glucose for improving cancer therapy. *Future Oncol* 2009;5:581.
140. Chen Z, Lu W, Garcia-Prieto C, et al. The Warburg effect and its cancer therapeutic implications. *J Bioenerg Biomembr* 2007;39:267.
141. Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer's Achilles' heel. *Cancer Cell* 2008;13:472.

142. Ko YH, Pedersen PL, Geschwind JF. Glucose catabolism in the rabbit VX2 tumor model for liver cancer: characterization and targeting hexokinase. *Cancer Lett* 2001;173:83.
143. Spoden GA, Mazurek S, Morandell D, et al. Isozyme-specific inhibitors of the glycolytic key regulator pyruvate kinase subtype M2 moderately decelerate tumor cell proliferation. *Int J Cancer* 2008;123:312.
144. Vander Heiden MG, Christofk HR, Schuman E, et al. Identification of small molecule inhibitors of pyruvate kinase M2. *Biochem Pharmacol* 2010;79:1118.
145. Boxer MB, Jiang JK, Vander Heiden MG, et al. Evaluation of substituted N,N'-diarylsulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase. *J Med Chem* 2010;53:1048.
146. Le A, Cooper CR, Gouw AM, et al. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. *Proc Natl Acad Sci U S A* 2010;107:2037.
147. Barshop BA, Naviaux RK, McGowan KA, et al. Chronic treatment of mitochondrial disease patients with dichloroacetate. *Mol Genet Metab* 2004;83:138.
148. Michelakis ED, Sutendra G, Dromparis P, et al. Metabolic modulation of glioblastoma with dichloroacetate. *Sci Transl Med* 2010;2:31.
149. Bonnet S, Archer SL, Allalunis-Turner J, et al. A mitochondria-K⁺ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. *Cancer Cell* 2007;11:37.
150. Bleeker FE, Lamba S, Leenstra S, et al. IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. *Hum Mutat* 2009;30:7.
151. Gravendeel LA, Kloosterhof NK, Bralten LB, et al. Segregation of non-p.R132H mutations in IDH1 in distinct molecular subtypes of glioma. *Hum Mutat* 2010; 31:E1186.
152. Capper D, Weissert S, Bals J, et al. Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. *Brain Pathol* 2010; 20:245.
153. Kang MR, Kim MS, Oh JE, et al. Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers. *Int J Cancer* 2009;125:353.
154. Watanabe T, Vital A, Nobusawa S, et al. Selective acquisition of IDH1 R132C mutations in astrocytomas associated with Li-Fraumeni syndrome. *Acta Neuropathol* 2009;117:653.
155. Hartmann C, Meyer J, Bals J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. *Acta Neuropathol* 2009;118:469.
156. Andrusis M, Capper D, Luft T, et al. Detection of isocitrate dehydrogenase 1 mutation R132H in myelodysplastic syndrome by mutation-specific antibody and direct sequencing. *Leuk Res* 2010;34(8):1091.
157. Gaal J, Burnichon N, Korpershoek E, et al. Isocitrate dehydrogenase mutations are rare in pheochromocytomas and paragangliomas. *J Clin Endocrinol Metab* 2010;95:1274.
158. Ichimura K, Pearson DM, Kocialkowski S, et al. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. *Neuro Oncol* 2009;11:341.
159. Nobusawa S, Watanabe T, Kleihues P, et al. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. *Clin Cancer Res* 2009;15:6002.
160. Park SW, Chung NG, Han JY, et al. Absence of IDH2 codon 172 mutation in common human cancers. *Int J Cancer* 2009;125:2485.
161. Hayden JT, Fruhwald MC, Hasselblatt M, et al. Frequent IDH1 mutations in supratentorial primitive neuroectodermal tumors (sPNET) of adults but not children. *Cell Cycle* 2009;8:1806.
162. Abdel-Wahab O, Manshoury T, Patel J, et al. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. *Cancer Res* 2010;70:447.
163. Chou WC, Hou HA, Chen CY, et al. Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation. *Blood* 2010;115:2749.
164. Wagner K, Damm F, Gohring G, et al. Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor. *J Clin Oncol* 2010;28:2356.

Chapter 9 – References

1. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. *N Engl J Med* 2004; 350:2335.
2. Folkman J. Tumor angiogenesis: therapeutic implications. *N Engl J Med* 1971;285:1182.
3. Folkman J. Angiogenesis: an organizing principle for drug discovery?. *Nat Rev Drug Discov* 2007;6:273.
4. Kerbel RS. Tumor angiogenesis. *New Engl J Med* 2008; 358:2039.
5. Kerbel RS. Antiangiogenic therapy: a universal chemosensitization strategy for cancer? *Science* 2006;312:1171.
6. Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. *Nat Clin Pract Oncol* 2006;3:24.
7. Ribatti D, Vacca A, Dammacco F, English D. Angiogenesis and anti-angiogenesis in hematological malignancies. *J Hematother Stem Cell Res* 2003;12:11.
8. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. *Science* 1997;275:964.
9. Bertolini F, Shaked Y, Mancuso P, Kerbel RS. The multifaceted circulating endothelial cell in cancer: from promiscuity to surrogate marker and target identification. *Nat Rev Cancer* 2006;6:835.
10. Fantin A, Vieira JM, Gestri G, et al. Tissue macrophages act as cellular chaperones for vascular anastomosis downstream of VEGF-mediated endothelial tip cell induction. *Blood* 2010;116(5):829.
11. Holash J, Maisonpierre PC, Compton D, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. *Science* 1999;284:1994.
12. Chang YS, di Tomaso E, McDonald DM, Jones R, Jain RK, Munn LL. Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. *Proc Natl Acad Sci U S A* 2000;97:14608.
13. Maniatis AJ, Folberg R, Hess A, et al. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. *Am J Pathol* 1999;155:739.
14. St. Croix B, Rago C, Velculescu V, et al. Genes expressed in human tumor endothelium. *Science* 2000;289:1197.
15. Seaman S, Stevens J, Yang MY, Logsdon D, Graff-Cherry C, St Croix B. Genes that distinguish physiological and pathological angiogenesis. *Cancer Cell* 2007;11:539.
16. Hida K, Klagsbrun M. A new perspective on tumor endothelial cells: unexpected chromosome and centrosome abnormalities. *Cancer Res* 2005;65:2507.
17. Al-Nedawi K, Meehan B, Kerbel RS, Allison AC, Rak J. Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR. *Proc Natl Acad Sci U S A* 2009;106:3794.
18. Gerhardt H, Betsholtz C. Endothelial-pericyte interactions in angiogenesis. *Cell Tissue Res* 2003;314:15.
19. Reinmuth N, Liu W, Jung YD, et al. Induction of VEGF in perivascular cells defines a potential paracrine mechanism for endothelial cell survival. *FASEB J* 2001;15:1239.
20. Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. *J Clin Invest* 1999;103:159.
21. Shaheen RM, Tseng WW, Davis DW, et al. Tyrosine kinase inhibition of multiple angiogenic growth factor receptors improves survival in mice bearing colon cancer liver metastases by inhibition of endothelial cell survival mechanisms. *Cancer Res* 2001;61:1464.
22. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. *J Clin Invest* 2003;111:1287.
23. Xian X, Hakansson J, Stahlberg A, et al. Pericytes limit tumor cell metastasis. *J Clin Invest* 2006;116:642.
24. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. *Science* 2005; 307:58.
25. Kerbel RS, Folkman J. Clinical translation of angiogenesis inhibitors. *Nat Rev Cancer* 2002;2:727.
26. Ferrara N. Timeline: VEGF and the quest for tumour angiogenesis factors. *Nat Rev Cancer* 2002;2:795.
27. Sawamiphak S, Seidel S, Essmann CL, et al. Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis. *Nature* 2010;465:487.
28. Senger DR, Galli S, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. *Science* 1983;219:983.
29. Leung DW, Cachianes G, Kuang W-J, Goeddel DV, Ferrara N. Vascular Endothelial Growth Factor is a secreted angiogenic molecule. *Science* 1989;246:1306.
30. Dvorak AM, Kohn S, Morgan ES, Fox P, Nagy JA, Dvorak HF. The vesiculo-vacuolar organelle (VVO): a distinct endothelial cell structure that provides a transcellular pathway for macromolecular extravasation. *J Leukoc Biol* 1996;59:100.
31. Bielenberg DR, Pettaway CA, Takashima S, Klagsbrun M. Neuropilins in neoplasms: expression, regulation, and function. *Exp Cell Res* 2006;312:584.
32. Ellis LM. The role of neuropilins in cancer. *Mol Cancer Ther* 2006;5:1099.
33. Pan Q, Chantry Y, Liang WC, et al. Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. *Cancer Cell* 2007;11:53.
34. Shibuya M, Claesson-Welsh L. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. *Exp Cell Res* 2006;312:549.
35. Eriksson A, Cao R, Pawliuk R, et al. Placenta growth factor-1 antagonizes VEGF-induced angiogenesis and tumor growth by the formation of functionally inactive PlGF-1/VEGF heterodimers. *Cancer Cell* 2002;1:99.
36. Ferrara N, Carver-Moore K, Chen H, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. *Nature* 1996;380:439.
37. Carmeliet P, Ferreira V, Breier G, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. *Nature* 1996;380:435.
38. Alon T, Hemo I, Itin A, Pe'er J, Stone J, Keshet E. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. *Nat Med* 1995;1(10):1024.
39. Reinmuth N, Stoeltzing O, Liu W, et al. Endothelial survival factors as targets for antineoplastic therapy. *Cancer J* 2001;7(Suppl 3):S109.
40. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Review: vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. *Am J Pathol* 1995;146:1029.
41. Semenza GL. Targeting HIF-1 for cancer therapy. *Nat Rev Cancer* 2003;3:721.
42. Ahmad SA, Liu W, Jung YD, et al. The effects of angiopoietin-1 and -2 on tumor growth and angiogenesis in human colon cancer. *Cancer Res* 2001;61:1255.
43. Fiedler U, Augustin HG. Angiopoietins: a link between angiogenesis and inflammation. *Trends Immunol* 2006; 27:552.
44. Stoeltzing O, Ahmad SA, Liu W, et al. Angiopoietin-1 inhibits vascular permeability, angiogenesis, and growth of hepatic colon cancer tumors. *Cancer Res* 2003; 63:3370.
45. Herbst RS, Hong D, Chap L, et al. Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. *J Clin Oncol* 2009;27:3557.
46. Hanahan D. Signaling vascular morphogenesis and maintenance. *Science* 1997;277:48.

47. Oliner J, Min H, Leal J, et al. Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. *Cancer Cell* 2004;6:507.
48. Brown JL, Cao ZA, Pinzon-Ortiz M, et al. A human monoclonal anti-ANG2 antibody leads to broad antitumor activity in combination with VEGF inhibitors and chemotherapy agents in preclinical models. *Mol Cancer Ther* 2010;9:145.
49. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. *Nat Rev Cancer* 2008;8:592.
50. Casanovas O, Hicklin D, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late stage pancreatic islet tumors. *Cancer Cell* 2005;8:299.
51. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. *Science* 1994;265:1582.
52. Bouck N, Stellmach V, Hsu SC. How tumors become angiogenic. *Adv Cancer Res* 1996;69:135.
53. O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. *Cell* 1994;79:315.
54. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. *Cell* 1997;88:277.
55. Maeshima Y, Colorado PC, Torre A, et al. Distinct antitumor properties of a type IV collagen domain derived from basement membrane. *J Biol Chem* 2000;275:21340.
56. Kamphaus GD, Colorado PC, Panka DJ, et al. Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth. *J Biol Chem* 2000;275:1209.
57. Aardal S, Helle KB. The vasoinhibitory activity of bovine chromogranin A fragment (vasostatin) and its independence of extracellular calcium in isolated segments of human blood vessels. *Regul Pept* 1992;41:9.
58. Kerbel RS. Vasohibin: the feedback on a new inhibitor of angiogenesis. *J Clin Invest* 2004;114:884–6.
59. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. *Cell* 1996;86:353.
60. Noguera-Troise I, Daly C, Papadopoulos NJ, et al. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. *Nature* 2006;444:1032.
61. Hellstrom M, Phng LK, Hofmann JJ, et al. Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. *Nature* 2007;445:776.
62. Lobov IB, Renard RA, Papadopoulos N, et al. Delta-like ligand 4 (Dll4) is induced by VEGF as a negative regulator of angiogenic sprouting. *Proc Natl Acad Sci U S A* 2007;104:3219.
63. Gale NW, Dominguez MG, Noguera I, et al. Haploinsufficiency of delta-like 4 ligand results in embryonic lethality due to major defects in arterial and vascular development. *Proc Natl Acad Sci U S A* 2004;101:15949.
64. Ridgway J, Zhang G, Wu Y, et al. Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. *Nature* 2006;444:1083.
65. Yan M, Callahan CA, Beyer JC, et al. Chronic DLL4 blockade induces vascular neoplasms. *Nature* 2010;463:E6.
66. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth *in vivo*. *Nature* 1993;362:841.
67. Spratlan JL, Cohen RB, Eadens M, et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. *J Clin Oncol* 2010;28:780.
68. Prewett M, Huber J, Li Y, et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. *Cancer Res* 1999;59:5209.
69. Lockhart AC, Rothenberg ML, Dupont J, et al. Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. *J Clin Oncol* 2010;28:207.
70. Rini BI, Atkins MB. Resistance to targeted therapy in renal-cell carcinoma. *Lancet Oncol* 2009;10:992.
71. Eskens FA, Verweij J. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review. *Eur J Cancer* 2006;42:3127.
72. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. *J Clin Oncol* 2010;28:1061.
73. Laird AD, Vajkoczy P, Shawver LK, et al. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. *Cancer Res* 2000;60:4152.
74. Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. *J Clin Invest* 2000;105:1045.
75. Herbst RS, Hess KR, Tran HT, et al. Phase I study of recombinant human endostatin in patients with advanced solid tumors. *J Clin Oncol* 2002;20:3792.
76. Kerbel RS, Vitoria-Petit A, Klement G, Rak J. 'Accidental' anti-angiogenic drugs. anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples. *Eur J Cancer* 2000;36:1248.
77. Miller KD, Sweeney CJ, Sledge GW, Jr. Redefining the target: chemotherapeutics as antiangiogenics. *J Clin Oncol* 2001;19:1195.
78. Browder T, Butterfield CE, Kraling BM, Marshall B, O'Reilly MS, Folkman J. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. *Cancer Res* 2000;60:1878.
79. Bertolini F, Paul S, Mancuso P, et al. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. *Cancer Res* 2003;63:4342.
80. Shaked Y, Ciarrocchi A, Franco M, et al. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. *Science* 2006;313:1785.
81. Klement G, Baruchel S, Rak J, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. *J Clin Invest* 2000;105:R15.
82. Pietras K, Hanahan D. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is anti-angiogenic, producing objective responses and survival benefit in a mouse model of cancer. *J Clin Oncol* 2005;23:939.
83. Garcia AA, Hirte H, Fleming G, et al. Phase II clinical trial of bevacizumab and low dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago and Princess Margaret Hospital Phase II Consortia. *J Clin Oncol* 2007;26:76.
84. Dellapasqua S, Bertolini F, Bagnardi V, et al. Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer: clinical and biological activity. *J Clin Oncol* 2008;26:4899.
85. Bellmunt J, Trigo JM, Calvo E, et al. Activity of a multi-targeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06). *Lancet Oncol* 2010;11:350.
86. Kato H, Ichinose Y, Ohta M, et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. *N Engl J Med* 2004;350:1713.
87. Watanabe T, Sano M, Takashima S, et al. Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial. *J Clin Oncol* 2009;27:1368.

88. Teicher BA, Sotomayor EA, Huang ZD. Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. *Cancer Res* 1992;52:6702.
89. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. *N Engl J Med* 2006;355:2542.
90. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. *N Engl J Med* 2007;357:2666.
91. Winkler F, Kozin SV, Tong RT, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. *Cancer Cell* 2004;6:553.
92. Jung YD, Mansfield PF, Akagi M, et al. Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model. *Eur J Cancer* 2002;38:1133.
93. Kottke T, Hall G, Pulido J, et al. Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice. *J Clin Invest* 2010;120:1551.
94. Hudis CA. Clinical implications of antiangiogenic therapies. *Oncology* 2005;19:26–31.
95. Shaked Y, Henke E, Roodhart J, et al. Rapid chemotherapy-induced surge in endothelial progenitor cells: implications for antiangiogenic drugs as chemosensitizing agents. *Cancer Cell* 2008;14:263.
96. Furstenberger G, von Moos R, Lucas R, et al. Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy or primary breast cancer. *Br J Cancer* 2006;94:524.
97. Calabrese C, Poppleton H, Kocak M, et al. A perivascular niche for brain tumor stem cells. *Cancer Cell* 2007;11:69.
98. Folkins C, Man S, Shaked Y, Xu P, Hicklin DJ, Kerbel RS. Anti-cancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. *Cancer Res* 2007;67:3560.
99. Bao S, Wu Q, Sathornsumetee S, et al. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. *Cancer Res* 2006;66:7843–8.
100. Bjerkvig R, Johansson M, Miletic H, Niclou SP. Cancer stem cells and angiogenesis. *Semin Cancer Biol* 2009;19:279.
101. Sweeney CJ, Miller KD, Sissons SE, et al. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. *Cancer Res* 2001;61:3369.
102. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. *N Engl J Med* 2003;349:427.
103. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. *J Clin Oncol* 2005;23:1011.
104. Wey JS, Fan F, Gray MJ, et al. Vascular endothelial growth factor receptor-1 promotes migration and invasion in pancreatic carcinoma cell lines. *Cancer* 2005;104:427.
105. Kerbel RS. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. *BioEssays* 1991;13:31–6.
106. Hida K, Hida Y, Amin DN, et al. Tumor-associated endothelial cells with cytogenetic abnormalities. *Cancer Res* 2004;64:8249–55.
107. Streubel B, Chott A, Huber D, et al. Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas. *N Engl J Med* 2004;351:250.
108. Ellis LM, Hicklin DJ. Pathways mediating resistance to vascular endothelial growth factor-targeted therapy. *Clin Cancer Res* 2008;14:6371.
109. Relf M, LeJeune S, Scott PA, et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. *Cancer Res* 1997;57:963.
110. Ferrara N. Pathways mediating VEGF-independent tumor angiogenesis. *Cytokine Growth Factor Rev* 2010;21:21.
111. Huang D, Ding Y, Zhou M, et al. Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. *Cancer Res* 2010;70:1063.
112. Ebos JML, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. *Cancer Cell* 2009;15:232.
113. Yu JL, Rak JW, Coomber BL, Hicklin DJ, Kerbel RS. Effect of p53 status on tumor response to antiangiogenic therapy. *Science* 2002;295:1526.
114. Glade Bender J, Cooney EM, Kandel JJ, Yamashiro DJ. Vascular remodeling and clinical resistance to antiangiogenic cancer therapy. *Drug Resist Updat* 2004;7:289.
115. Saharinen P, Bry M, Alitalo K. How do angiopoietins Tie in with vascular endothelial growth factors? *Curr Opin Hematol* 2010;17:198.
116. Murukesh N, Dive C, Jayson GC. Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. *Br J Cancer* 2010;102:8.
117. Nikolinakos PG, Altorki N, Yankelevitz D, et al. Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib. *Cancer Res* 2010;70:2171.
118. Hanrahan EO, Lin HY, Kim ES, et al. Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer. *J Clin Oncol* 2010;28:193.
119. Verheul HM, Pinedo HM. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. *Nat Rev Cancer* 2007;7:475.
120. Chen HX, Cleck JN. Adverse effects of anticancer agents that target the VEGF pathway. *Nat Rev Clin Oncol* 2009;6:465.
121. Dahlberg SE, Sandler AB, Brahmer JR, Schiller JH, Johnson DH. Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. *J Clin Oncol* 2010;28:949.
122. Jubb AM, Hurwitz HI, Bai W, et al. Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. *J Clin Oncol* 2006;24:217.
123. Longo R, Gasparini G. Challenges for patient selection with VEGF inhibitors. *Cancer Chemother Pharmacol* 2007;60(2):151.
124. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. *Nat Rev Cancer* 2008;8:579.
125. Vergh J, Greif R, Voytko N, et al. Sunitinib (SU) in combination with docetaxel (D) versus D alone for the first-line treatment of advanced breast cancer (ABC). *J Clin Oncol* 2010; abstract no. LBA 1010.
126. Crown J, Dieras V, Starosiawska E, et al. Phase III trial of sunitinib (SU) in combination with capecitabine (C) versus C in previously treated advanced breast cancer (ABC). *J Clin Oncol* 2010; abstract no. LBA 1011.
127. Hurwitz H, Saini S. Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events. *Semin Oncol* 2006;33:S26.
128. Burger RA, Brady MF, Bookman MA, et al. Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): a Gynecologic Oncology Group study. *J Clin Oncol* 2010;28:Abstract no. LBA1.

129. Wolmark N, Yothers G, O'Connell MJ, et al. A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: results of NSABP Protocol C-08. *J Clin Oncol* 2009; 27:abstract no. LBA4.
130. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. *J Clin Oncol* 2008;26:2013.
131. Kang Y, Ohtsu A, Van Cutsem E, et al. AVAGAST: a randomized double-blind, placebo-controlled, phase III study of first-line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer (AGC). *J Clin Oncol* 2010;28:abstract no. LBA4007.
132. Paez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. *Cancer Cell* 2009;15:220.
133. Narayana A, Kelly P, Golfinos J, et al. Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. *J Neurosurg* 2009;110:173.
134. Norden AD, Young GS, Setayesh K, et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. *Neurology* 2008;70:779.
135. Steeg PS. Angiogenesis inhibitors: motivators of metastasis? *Nat Med* 2003;9:822.
136. Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio PM. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. *Cancer Cell* 2003;3:347.
137. Heusschen R, van GM, Griffioen AW, Thijssen VL. MicroRNAs in the tumor endothelium: novel controls on the angioregulatory switchboard. *Biochim Biophys Acta* 2010;1805:87.
138. Wurdinger T, Tannous BA, Saydam O, et al. miR-296 regulates growth factor receptor overexpression in angiogenic endothelial cells. *Cancer Cell* 2008;14:382.
139. Bonauer A, Boon RA, Dimmeler S. Vascular microRNAs. *Curr Drug Targets* 2010;11:943.
140. Doebele C, Bonauer A, Fischer A, et al. Members of the microRNA-17-92 cluster exhibit a cell intrinsic anti-angiogenic function in endothelial cells. *Blood* 2010; 115(23):4944.
141. Nicoli S, Standley C, Walker P, Hurlstone A, Fogarty KE, Lawson ND. MicroRNA-mediated integration of haemodynamics and Vegf signalling during angiogenesis. *Nature* 2010;464:1196.
142. Reynolds LE, Watson AR, Baker M, et al. Tumour angiogenesis is reduced in the Tc1 mouse model of Down's syndrome. *Nature* 2010;465:813.
143. Ohm JE, Carbone DP. VEGF as a mediator of tumor-associated immunodeficiency. *Immunol Res* 2001;23:263.

Chapter 10 – References

1. Tomlinson I, Sasieni P, Bodmer W. How many mutations in a cancer? *Am J Pathol* 2002;160:755.
2. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. *Nature* 1998;396:643.
3. Michor F, Iwasa Y, Nowak MA. Dynamics of cancer progression. *Nat Rev Cancer* 2004;4:197.
4. Heimann R, Hellman S. Clinical progression of breast cancer malignant behavior: what to expect and when to expect it. *J Clin Oncol* 2000;18:591.
5. Suit HD, Mankin HJ, Wood WC, et al. Treatment of the patient with stage M0 soft tissue sarcoma. *J Clin Oncol* 1988;6:854.
6. Ellis ER, Mendenhall WM, Rao PV, Parsons JT, Spangler AE, Million RR. Does node location affect the incidence of distant metastases in head and neck squamous cell carcinoma? *Int J Radiat Oncol Biol Phys* 1989;17:293.
7. Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. *Nat Rev Cancer* 2003;3:453.
8. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. *Nat Rev Cancer* 2002;2:563.
9. Hellman S. Karnofsky memorial lecture: natural history of small breast cancers. *J Clin Oncol* 1994;12:2229.
10. Hellman S. Stopping metastases at their source. *N Engl J Med* 1997;337:996.
11. Waghorne C, Thomas M, Lagarde A, Kerbel RS, Breitman ML. Genetic evidence for progressive selection and overgrowth of primary tumors by metastatic cell subpopulations. *Cancer Res* 1988;48:6109.
12. Harris JF, Chambers AF, Hill RP, Ling V. Metastatic variants are generated spontaneously at a high rate in mouse KHT tumor. *Proc Natl Acad Sci U S A* 1982;79:5547.
13. Bernards R, Weinberg RA. A progression puzzle. *Nature* 2002;418:823.
14. Nguyen DX, Bos PD, Massague J. Metastasis: from dissemination to organ-specific colonization. *Nat Rev Cancer* 2009;9:274.
15. Hanahan D, Weinberg RA. The hallmarks of cancer. *Cell* 2000;100:57.
16. Gupta GP, Nguyen DX, Chiang AC, et al. Mediators of vascular remodeling co-opted for sequential steps in lung metastasis. *Nature* 2007;446:765.
17. Minn AJ, Gupta GP, Siegel PM, et al. Genes that mediate breast cancer metastasis to lung. *Nature* 2005;436:518.
18. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. *Nat Rev Cancer* 2003;3:401.
19. Gordan JD, Simon MC. Hypoxia-inducible factors: central regulators of the tumor phenotype. *Curr Opin Genet Dev* 2007;17:71.
20. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? *Nat Rev Cancer* 2004;4:891.
21. Eming SA, Krieg T, Davidson JM. Inflammation in wound repair: molecular and cellular mechanisms. *J Invest Dermatol* 2007;127:514.
22. Singer AJ, Clark RA. Cutaneous wound healing. *N Engl J Med* 1999;341:738.
23. Wu Y, Zhao RC, Tredget EE. Concise review: bone marrow-derived stem/progenitor cells in cutaneous repair and regeneration. *Stem Cells* 2010;28:905.
24. Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. *Nat Rev Immunol* 2006;6:836.
25. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. *Cell* 2010;141:39.
26. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. *Nat Rev Cancer* 2009;9:239.
27. Yang L, Huang J, Ren X, et al. Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. *Cancer Cell* 2008;13:23.
28. Cotter TG. Apoptosis and cancer: the genesis of a research field. *Nat Rev Cancer* 2009;9:501.
29. Levine AJ, Oren M. The first 30 years of p53: growing ever more complex. *Nat Rev Cancer* 2009;9:749.
30. Aoudjit F, Vuori K. Matrix attachment regulates Fas-induced apoptosis in endothelial cells: a role for c-flip and implications for anoikis. *J Cell Biol* 2001;152:633.
31. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. *Nat Rev Cancer* 2008;8:755.
32. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ. Efficient tumour formation by single human melanoma cells. *Nature* 2008;456:593.
33. Thiery JP, Aclouque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. *Cell* 2009;139:871.
34. Yang MH, Wu MZ, Chiou SH, et al. Direct regulation of TWIST by HIF-1alpha promotes metastasis. *Nat Cell Biol* 2008;10:295.
35. Wu Y, Deng J, Rychahou PG, Qiu S, Evers BM, Zhou BP. Stabilization of snail by NF-kappaB is required for inflammation-induced cell migration and invasion. *Cancer Cell* 2009;15:416.
36. Kudo-Saito C, Shirako H, Takeuchi T, Kawakami Y. Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells. *Cancer Cell* 2009;15:195.
37. Barrallo-Gimeno A, Nieto MA. The Snail genes as inducers of cell movement and survival: implications in development and cancer. *Development* 2005;132:3151-61.
38. Puisieux A, Valsesia-Wittmann S, Ansieau S. A twist for survival and cancer progression. *Br J Cancer* 2006;94:13.
39. Ansieau S, Bastid J, Doreau A, et al. Induction of EMT by twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence. *Cancer Cell* 2008;14:79.
40. Mani SA, Guo W, Liao MJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. *Cell* 2008;133:704.
41. Wicki A, Lehembre F, Wick N, Hantusch B, Kerjaschki D, Christofori G. Tumor invasion in the absence of epithelial-mesenchymal transition: podoplanin-mediated remodeling of the actin cytoskeleton. *Cancer Cell* 2006;9:261.
42. Yang J, Mani SA, Donaher JL, et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. *Cell* 2004;117:927.
43. Tsuji T, Ibaragi S, Hu GF. Epithelial-mesenchymal transition and cell cooperativity in metastasis. *Cancer Res* 2009;69:7135.
44. Hermann PC, Huber SL, Herrler T, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. *Cell Stem Cell* 2007;1:313.
45. Pantel K, Brakenhoff RH, Brandt B. Detection, clinical relevance and specific biological properties of disseminating tumour cells. *Nat Rev Cancer* 2008;8:329.
46. Husemann Y, Geigl JB, Schubert F, et al. Systemic spread is an early step in breast cancer. *Cancer Cell* 2008;13:58.
47. Podyspanina K, Du YC, Jechlinger M, Beverly LJ, Hambarzumyan D, Varmus H. Seeding and propagation of untransformed mouse mammary cells in the lung. *Science* 2008;321:1841.
48. Psaila B, Lyden D. The metastatic niche: adapting the foreign soil. *Nat Rev Cancer* 2009;9:285.
49. Kaplan RN, Riba RD, Zacharoulis S, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. *Nature* 2005;438:820.
50. Hiratsuka S, Watanabe A, Aburatani H, Maru Y. Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermine lung metastasis. *Nat Cell Biol* 2006;8:1369.

51. Hiratsuka S, Watanabe A, Sakurai Y, et al. The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phase. *Nat Cell Biol* 2008;10:1349.
52. Erler JT, Bennewith KL, Cox TR, et al. Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. *Cancer Cell* 2009;15:35.
53. Chang YS, di Tomaso E, McDonald DM, Jones R, Jain RK, Munn LL. Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. *Proc Natl Acad Sci U S A* 2000;97:14608.
54. Tarin D, Price JE, Kettlewell MG, Souter RG, Vass AC, Crossley B. Mechanisms of human tumor metastasis studied in patients with peritoneovenous shunts. *Cancer Res* 1984;44:3584.
55. Wang HH, McIntosh AR, Hasinoff BB, et al. B16 melanoma cell arrest in the mouse liver induces nitric oxide release and sinusoidal cytotoxicity: a natural hepatic defense against metastasis. *Cancer Res* 2000;60:5862.
56. Bandyopadhyay S, Zhan R, Chaudhuri A, et al. Interaction of KAI1 on tumor cells with DARC on vascular endothelium leads to metastasis suppression. *Nat Med* 2006;12:933.
57. Mehlen P, Puisieux A. Metastasis: a question of life or death. *Nat Rev Cancer* 2006;6:449.
58. Meng S, Tripathy D, Frenkel EP, et al. Circulating tumor cells in patients with breast cancer dormancy. *Clin Cancer Res* 2004;10:8152.
59. Martin SS, Ridgeway AG, Pinkas J, et al. A cytoskeleton-based functional genetic screen identifies Bcl-xL as an enhancer of metastasis, but not primary tumor growth. *Oncogene* 2004;23:4641.
60. Stupack DG, Teitz T, Potter MD, et al. Potentiation of neuroblastoma metastasis by loss of caspase-8. *Nature* 2006;439:95.
61. Guo W, Giancotti FG. Integrin signalling during tumour progression. *Nat Rev Mol Cell Biol* 2004;5:816.
62. Sun YX, Fang M, Wang J, Cooper CR, Pienta KJ, Taichman RS. Expression and activation of alpha v beta 3 integrins by SDF-1/CXCL12 increases the aggressiveness of prostate cancer cells. *Prostate* 2007;67:61.
63. Felding-Habermann B, O'Toole TE, Smith JW, et al. Integrin activation controls metastasis in human breast cancer. *Proc Natl Acad Sci U S A* 2001;98:1853.
64. Al-Mehdi AB, Tozawa K, Fisher AB, Shientag L, Lee A, Muschel RJ. Intravascular origin of metastasis from the proliferation of endothelium-attached tumor cells: a new model for metastasis. *Nat Med* 2000;6:100.
65. Kim YJ, Borsig L, Varki NM, Varki A. P-selectin deficiency attenuates tumor growth and metastasis. *Proc Natl Acad Sci U S A* 1998;95:9325.
66. Khanna C, Wan X, Bose S, et al. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. *Nat Med* 2004;10:182.
67. Criscuoli ML, Nguyen M, Eliceiri BP. Tumor metastasis but not tumor growth is dependent on Src-mediated vascular permeability. *Blood* 2005;105:1508.
68. Muller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. *Nature* 2001;410:50.
69. Padua D, Zhang XH, Wang Q, et al. TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. *Cell* 2008;133:66.
70. Karnoub AE, Dash AB, Vo AP, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. *Nature* 2007;449:557.
71. Norton L, Massague J. Is cancer a disease of self-seeding? *Nat Med* 2006;12:875.
72. Kim MY, Oskarsson T, Acharyya S, et al. Tumor self-seeding by circulating cancer cells. *Cell* 2009;139:1315.
73. Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. *Nat Rev Cancer* 2007;7:834.
74. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. *Nat Med* 1995;1:149.
75. McAllister SS, Gifford AM, Greiner AL, et al. Systemic endocrine instigation of indolent tumor growth requires osteopontin. *Cell* 2008;133:994.
76. Dangi-Garimella S, Yun J, Eves EM, et al. Raf kinase inhibitory protein suppresses a metastasis signalling cascade involving LIN28 and let-7. *EMBO J* 2009;28:347.
77. Klein CA, Blankenstein TJ, Schmidt-Kittler O, et al. Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer. *Lancet* 2002;360:683.
78. Schmidt-Kittler O, Ragg T, Daskalakis A, et al. From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. *Proc Natl Acad Sci U S A* 2003;100:7737.
79. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. *Nat Rev Cancer* 2002;2:584.
80. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. *Nature* 2003;423:337.
81. Zhang XH, Wang Q, Gerald W, et al. Latent bone metastasis in breast cancer tied to Src-dependent survival signals. *Cancer Cell* 2009;16:67.
82. Jones DH, Nakashima T, Sanchez OH, et al. Regulation of cancer cell migration and bone metastasis by RANKL. *Nature* 2006;440:692.
83. Kang Y, Siegel PM, Shu W, et al. A multigenic program mediating breast cancer metastasis to bone. *Cancer Cell* 2003;3:537.
84. Lu X, Wang Q, Hu G, et al. ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis. *Genes Dev* 2009;23:1882.
85. Kang Y, He W, Tulley S, et al. Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. *Proc Natl Acad Sci U S A* 2005;102:13909.
86. Logothetis CJ, Lin SH. Osteoblasts in prostate cancer metastasis to bone. *Nat Rev Cancer* 2005;5:21.
87. Minn AJ, Kang Y, Serganova I, et al. Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. *J Clin Invest* 2005;115:44.
88. Minn AJ, Gupta GP, Padua D, et al. Lung metastasis genes couple breast tumor size and metastatic spread. *Proc Natl Acad Sci U S A* 2007;104:6740.
89. Gupta GP, Perk J, Acharyya S, et al. ID genes mediate tumor reinitiation during breast cancer lung metastasis. *Proc Natl Acad Sci U S A* 2007;104:19506.
90. Zvibel I, Brill S, Halpern Z, Papa M. Hepatocyte extracellular matrix modulates expression of growth factors and growth factor receptors in human colon cancer cells. *Exp Cell Res* 1998;245:123.
91. Nakagawa H, Liyanarachchi S, Davuluri RV, et al. Role of cancer-associated stromal fibroblasts in metastatic colon cancer to the liver and their expression profiles. *Oncogene* 2004;23:7366.
92. Budhu A, Forgues M, Ye QH, et al. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. *Cancer Cell* 2006;10:99.
93. Saha S, Bardelli A, Buckhaults P, et al. A phosphatase associated with metastasis of colorectal cancer. *Science* 2001;294:1343.
94. Bardelli A, Saha S, Sager JA, et al. PRL-3 expression in metastatic cancers. *Clin Cancer Res* 2003;9:5607.
95. Sierra A, Price JE, Garcia-Ramirez M, Mendez O, Lopez L, Fabra A. Astrocyte-derived cytokines contribute to the metastatic brain specificity of breast cancer cells. *Lab Invest* 1997;77:357.
96. Xie TX, Huang FJ, Aldape KD, et al. Activation of stat3 in human melanoma promotes brain metastasis. *Cancer Res* 2006;66:3188.
97. Wei D, Le X, Zheng L, et al. Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. *Oncogene* 2003;22:319.
98. Bos PD, Zhang XH, Nadal C, et al. Genes that mediate breast cancer metastasis to the brain. *Nature* 2009;459:1005.

99. Alitalo K, Tammela T, Petrova TV. Lymphangiogenesis in development and human disease. *Nature* 2005;438:946.
100. Cao Y. Opinion: emerging mechanisms of tumour lymphangiogenesis and lymphatic metastasis. *Nat Rev Cancer* 2005;5:735.
101. Wong SY, Haack H, Crowley D, Barry M, Bronson RT, Hynes RO. Tumor-secreted vascular endothelial growth factor-C is necessary for prostate cancer lymphangiogenesis, but lymphangiogenesis is unnecessary for lymph node metastasis. *Cancer Res* 2005;65:9789.
102. Skobe M, Hawighorst T, Jackson DG, et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. *Nat Med* 2001;7:192.
103. Stacker SA, Caesar C, Baldwin ME, et al. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. *Nat Med* 2001;7:186.
104. LeBedis C, Chen K, Fallavollita L, Boutros T, Brodt P. Peripheral lymph node stromal cells can promote growth and tumorigenicity of breast carcinoma cells through the release of IGF-I and EGF. *Int J Cancer* 2002;100:2.
105. Kawada K, Hosogi H, Sonoshita M, et al. Chemokine receptor CXCR3 promotes colon cancer metastasis to lymph nodes. *Oncogene* 2007;26:4679.
106. He Y, Kozaki K, Karpanen T, et al. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. *J Natl Cancer Inst* 2002;94:819.
107. Krishnan J, Kirkin V, Steffen A, et al. Differential in vivo and in vitro expression of vascular endothelial growth factor (VEGF)-C and VEGF-D in tumors and its relationship to lymphatic metastasis in immunocompetent rats. *Cancer Res* 2003;63:713.
108. Gupta PB, Kuperwasser C, Brunet JP, et al. The melanocyte differentiation program predisposes to metastasis after neoplastic transformation. *Nat Genet* 2005;37:1047.
109. Nguyen DX, Chiang AC, Zhang XH, et al. WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. *Cell* 2009;138:51.
110. Gupta RA, Shah N, Wang KC, et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. *Nature* 2010;464:1071.
111. Han HJ, Russo J, Kohwi Y, Kohwi-Shigematsu T. SATB1 reprogrammes gene expression to promote breast tumour growth and metastasis. *Nature* 2008;452:187.
112. Nicoloso MS, Spizzo R, Shimizu M, Rossi S, Calin GA. MicroRNAs—the micro steering wheel of tumour metastases. *Nat Rev Cancer* 2009;9:293.
113. Cui Q, Yu Z, Purisima EO, Wang E. Principles of microRNA regulation of a human cellular signaling network. *Mol Syst Biol* 2006;2:46.
114. Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. *Nature* 2007;449:682.
115. Ma L, Young J, Prabhala H, et al. miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. *Nat Cell Biol* 2010;12:247.
116. Gregory PA, Bert AG, Paterson EL, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. *Nat Cell Biol* 2008;10:593.
117. Korpala M, Lee ES, Hu G, Kang Y. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. *J Biol Chem* 2008;283:14910.
118. Park SM, Gaur AB, Lengyel E, Peter ME. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. *Genes Dev* 2008;22:894.
119. Tavazoie SF, Alarcón C, Oskarsson T, et al. Endogenous human microRNAs that suppress breast cancer metastasis. *Nature* 2008;451:147.
120. Valastyan S, Reinhardt F, Benaich N, et al. A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. *Cell* 2009;137:1032.
121. Yu F, Yao H, Zhu P, et al. let-7 regulates self renewal and tumorigenicity of breast cancer cells. *Cell* 2007;131:1109.

Chapter 11 – References

1. Bruce WR, van der Gaag H. A quantitative assay for the number of murine lymphoma cells capable of proliferation in vivo. *Nature* 1963;199:79.
2. Southam CM, Brunschwig A, Dizon Q. Autologous and homologous transplantation of human cancer. In: Brennan MJ, Simpson WL, eds. *Biological interactions in normal and neoplastic growth. A contribution to the host-tumor problem*. Boston: Little, Brown, 1962:723.
3. Wang JC, Dick JE. Cancer stem cells: lessons from leukemia. *Trends Cell Biol* 2005;15:494.
4. Shackleton M, Quintana E, Fearon ER, et al. Heterogeneity in cancer: cancer stem cells versus clonal evolution. *Cell* 2009;138:822.
5. Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukemia after transplantation into SCID mice. *Nature* 1994;367:645.
6. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. *Nat Med* 1997;3:730.
7. Jordan CT, Upchurch D, Szilvassy SJ, et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. *Leukemia* 2000;14:1777.
8. Jin L, Lee EM, Ramshaw HS, et al. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. *Cell Stem Cell* 2009;5:31.
9. Guzman ML, Neering SJ, Upchurch D, et al. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. *Blood* 2001;98:2301.
10. Guzman ML, Rossi RM, Karnischky L, et al. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. *Blood* 2005;105:4163.
11. Xu Q, Thompson JE, Carroll M. mTOR regulates cell survival after etoposide treatment in primary AML cells. *Blood* 2005;106:4261.
12. Yilmaz OH, Valdez R, Theisen BK, et al. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. *Nature* 2006;441:475.
13. Zhang J, Grindley JC, Yin T, et al. PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. *Nature* 2006;441:518.
14. Jin L, Hope KJ, Zhai Q, et al. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. *Nat Med* 2006;12:1167.
15. Al Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells. *Proc Natl Acad Sci U S A* 2003;100:3983.
16. Gnestier C, Hur MH, Charafe-Jauffret E, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. *Cell Stem Cell* 2007;1:555.
17. Yu F, Yao H, Zhu P, et al. let-7 regulates self renewal and tumorigenicity of breast cancer cells. *Cell* 2007;131:1109.
18. Hemmati HD, Nakano I, Lazareff JA, et al. Cancerous stem cells can arise from pediatric brain tumors. *Proc Natl Acad Sci U S A* 2003;100:15178.
19. Galli R, Binda E, Orfanelli U, et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. *Cancer Res* 2004;64:7011.
20. Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human brain tumors. *Cancer Res* 2003;63:5821.
21. Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. *Nature* 2004;432:396.
22. Beier D, Hau P, Proescholdt M, et al. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. *Cancer Res* 2007;67:4010.
23. Wang J, Sakariassen PO, Tsinkalovsky O, et al. CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. *Int J Cancer* 2008;122:761.
24. Ogden AT, Waziri AE, Lochhead RA, et al. Identification of A2B5+CD133- tumor-initiating cells in adult human gliomas. *Neurosurgery* 2008;62:505.
25. Chen R, Nishimura MC, Bumbaca SM, et al. A hierarchy of self-renewing tumor-initiating cell types in glioblastoma. *Cancer Cell* 2010;17:362.
26. Dorrell C, Gan OI, Pereira DS, et al. Expansion of human cord blood CD34(+)CD38(-) cells in ex vivo culture during retroviral transduction without a corresponding increase in SCID repopulating cell (SRC) frequency: dissociation of SRC phenotype and function. *Blood* 2000;95:102.
27. Jaksch M, Munera J, Bajpai R, et al. Cell cycle-dependent variation of a CD133 epitope in human embryonic stem cell, colon cancer, and melanoma cell lines. *Cancer Res* 2008;68:7882.
28. O'Brien CA, Pollett A, Gallinger S, et al. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. *Nature* 2007;445:106.
29. Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al. Identification and expansion of human colon-cancer-initiating cells. *Nature* 2007;445:111.
30. Hope KJ, Jin L, Dick JE. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. *Nat Immunol* 2004;5:738.
31. Dalerba P, Dylla SJ, Park IK, et al. Phenotypic characterization of human colorectal cancer stem cells. *Proc Natl Acad Sci U S A* 2007;104:10158.
32. Prince ME, Sivanandan R, Kaczorowski A, et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. *Proc Natl Acad Sci U S A* 2007;104:973.
33. Park IK, Qian D, Kiel M, et al. Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. *Nature* 2003;423:302.
34. Lessard J, Sauvageau G. Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. *Nature* 2003;423:255.
35. Molofsky AV, Pardal R, Iwashita T, et al. Bmi-1 dependence distinguishes neural stem cell self-renewal from progenitor proliferation. *Nature* 2003;425:962.
36. Li C, Heidt DG, Dalerba P, et al. Identification of pancreatic cancer stem cells. *Cancer Res* 2007;67:1030.
37. Hermann PC, Huber SL, Herrler T, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. *Cell Stem Cell* 2007;1:313.
38. Kelly PN, Dakic A, Adams JM, et al. Tumor growth need not be driven by rare cancer stem cells. *Science* 2007;317:337.
39. Schatton T, Murphy GF, Frank NY, et al. Identification of cells initiating human melanomas. *Nature* 2008;451:345.
40. Quintana E, Shackleton M, Sabel MS, et al. Efficient tumour formation by single human melanoma cells. *Nature* 2008;456:593.
41. Feuring-Busch M, Gerhard B, Cashman J, et al. Improved engraftment of human acute myeloid leukemia progenitor cells in beta 2-microglobulin-deficient NOD/SCID mice and in NOD/SCID mice transgenic for human growth factors. *Leukemia* 2003;17:760.
42. Kennedy JA, Barabe F, Poepl AG, et al. Comment on "Tumor growth need not be driven by rare cancer stem cells." *Science* 2007;318:1722.
- 42a. Ishizawa K, Rasheed ZA, Karisch R, et al. Tumor-initiating cells are rare in many human tumors. *Cell Stem Cell* 2010;7:279.
43. Huntly BJ, Shigematsu H, Deguchi K, et al. MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. *Cancer Cell* 2004;6:587.

44. Barabe F, Kennedy JA, Hope KJ, et al. Modeling the initiation and progression of human acute leukemia in mice. *Science* 2007;316:600.
45. Krivtsov AV, Twomey D, Feng Z, et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. *Nature* 2006; 442:818.
46. Hirschmann-Jax C, Foster AE, Wulf GG, et al. A distinct “side population” of cells with high drug efflux capacity in human tumor cells. *Proc Natl Acad Sci U S A* 2004;101:14228.
47. Pearce DJ, Taussig D, Simpson C, et al. Characterization of cells with a high aldehyde dehydrogenase activity from cord blood and acute myeloid leukemia samples. *Stem Cells* 2005;23:752.
48. Marusyk A, Polyak K. Tumor heterogeneity: causes and consequences. *Biochim Biophys Acta* 2010;1805:105.
49. Maley CC, Galipeau PC, Finley JC, et al. Genetic clonal diversity predicts progression to esophageal adenocarcinoma. *Nat Genet* 2006;38:468.
50. Nowell PC. The clonal evolution of tumor cell populations. *Science* 1976;194:23.
51. Shipitsin M, Campbell LL, Argani P, et al. Molecular definition of breast tumor heterogeneity. *Cancer Cell* 2007;11:259.
52. Park SY, Gonen M, Kim HJ, et al. Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype. *J Clin Invest* 2010; 120:636.
53. Geyer FC, Weigelt B, Natrajan R, et al. Molecular analysis reveals a genetic basis for the phenotypic diversity of metaplastic breast carcinomas. *J Pathol* 2010;220:562.
54. Notta F, Mullighan CG, Wang JCY, et al. Evolution of human BCR-ALB1 lymphoblastic leukaemia-initiating cells. *Nature In Press*.
- 54a. Anderson K, Lutz C, van Delft FW, et al. Genetic variegation of clonal architecture and propagating cells in leukaemia. *Nature* 2010 doi:10.1038/nature09650.
55. Mullighan CG, Phillips LA, Su X, et al. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. *Science* 2008;322:1377.
56. Wang JC. Good cells gone bad: the cellular origins of cancer. *Trends Mol Med* 2010;16:145.
57. Jordan CT. Cancer stem cells: controversial or just misunderstood? *Cell Stem Cell* 2009;4:203.
58. Huntly BJ, Gilliland DG. Leukaemia stem cells and the evolution of cancer-stem-cell research. *Nat Rev Cancer* 2005;5:311.
59. McCulloch EA. Stem cells in normal and leukemic hemopoiesis (Henry Stratton Lecture, 1982). *Blood* 1983; 62:1.
60. So CW, Karsunky H, Passegue E, et al. MLL-GAS7 transforms multipotent hematopoietic progenitors and induces mixed lineage leukemias in mice. *Cancer Cell* 2003; 3:161.
61. Cozzio A, Passegue E, Ayton PM, et al. Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors. *Genes Dev* 2003; 17:3029.
62. Chen W, Kumar AR, Hudson WA, et al. Malignant transformation initiated by Mll-AF9: gene dosage and critical target cells. *Cancer Cell* 2008;13:432.
63. Somerville TC, Cleary ML. Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia. *Cancer Cell* 2006;10:257.
64. Mullighan CG, Goorha S, Radtke I, et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. *Nature* 2007;446:758.
65. Armstrong SA, Staunton JE, Silverman LB, et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. *Nat Genet* 2002; 30:41.
66. Perez-Caro M, Cobaleda C, Gonzalez-Herrero I, et al. Cancer induction by restriction of oncogene expression to the stem cell compartment. *EMBO J* 2009;28:8.
67. Passegue E, Wagner EF, Weissman IL. JunB deficiency leads to a myeloproliferative disorder arising from hematopoietic stem cells. *Cell* 2004;119:431.
68. Rosenbauer F, Wagner K, Kutok JL, et al. Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU.1. *Nat Genet* 2004;36:624.
69. Shimizu R, Kuroha T, Ohneda O, et al. Leukemogenesis caused by incapacitated GATA-1 function. *Mol Cell Biol* 2004;24:10814.
70. Jamieson CH, Ailles LE, Dylla SJ, et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. *N Engl J Med* 2004;351:657.
71. Hahn WC, Weinberg RA. Rules for making human tumor cells. *N Engl J Med* 2002;347:1593.
72. Shackleton M, Vaillant F, Simpson KJ, et al. Generation of a functional mammary gland from a single stem cell. *Nature* 2006;439:84.
73. Stingl J, Eirew P, Ricketson I, et al. Purification and unique properties of mammary epithelial stem cells. *Nature* 2006;439:993.
74. Eirew P, Stingl J, Raouf A, et al. A method for quantifying normal human mammary epithelial stem cells with in vivo regenerative ability. *Nat Med* 2008;14:1384.
75. Lawson DA, Xin L, Lucaks RU, et al. Isolation and functional characterization of murine prostate stem cells. *Proc Natl Acad Sci U S A* 2007;104:181.
76. Leong KG, Wang BE, Johnson L, et al. Generation of a prostate from a single adult stem cell. *Nature* 2008; 456:804.
77. Wang X, Julio MK, Economides KD, et al. A luminal epithelial stem cell that is a cell of origin for prostate cancer. *Nature* 2009;461:495.
78. Lim E, Vaillant F, Wu D, et al. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. *Nat Med* 2009;15:907.
79. Dai C, Celestino JC, Okada Y, et al. PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. *Genes Dev* 2001;15:1913.
80. Holland EC, Celestino J, Dai C, et al. Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. *Nat Genet* 2000;25:55.
81. Chojnacki AK, Mak GK, Weiss S. Identity crisis for adult periventricular neural stem cells: subventricular zone astrocytes, ependymal cells or both? *Nat Rev Neurosci* 2009;10:153.
82. Bruggeman SW, Hulsman D, Tanger E, et al. Bmi1 controls tumor development in an Ink4a/Arf-independent manner in a mouse model for glioma. *Cancer Cell* 2007; 12:328.
83. Ferretti E, De Smaele E, Di Marcotullio L, et al. Hedgehog checkpoints in medulloblastoma: the chromosome 17p deletion paradigm. *Trends Mol Med* 2005;11:537.
84. Schuller U, Heine VM, Mao J, et al. Acquisition of granule neuron precursor identity is a critical determinant of progenitor cell competence to form Shh-induced medulloblastoma. *Cancer Cell* 2008;14:123.
85. Yang ZJ, Ellis T, Markant SL, et al. Medulloblastoma can be initiated by deletion of Patched in lineage-restricted progenitors or stem cells. *Cancer Cell* 2008;14:135.
86. Zhu Y, Guignard F, Zhao D, et al. Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma. *Cancer Cell* 2005;8:119.
87. Alcantara LS, Chen J, Kwon CH, et al. Malignant astrocytomas originate from neural stem/progenitor cells in a somatic tumor suppressor mouse model. *Cancer Cell* 2009;15:45.
88. Sangiorgi E, Capecchi MR. Bmi1 is expressed in vivo in intestinal stem cells. *Nat Genet* 2008;40:915.
89. Barker N, van Es JH, Kuipers J, et al. Identification of stem cells in small intestine and colon by marker gene Lgr5. *Nature* 2007;449:1003.

90. Zhu L, Gibson P, Currle DS, et al. Prominin 1 marks intestinal stem cells that are susceptible to neoplastic transformation. *Nature* 2009;457:603.
91. Bienz M, Clevers H. Linking colorectal cancer to Wnt signaling. *Cell* 2000;103:311.
92. Barker N, Ridgway RA, van Es JH, et al. Crypt stem cells as the cells-of-origin of intestinal cancer. *Nature* 2009;457:608.
93. Albuquerque C, Breukel C, van der LR, et al. The “just-right” signaling model: APC somatic mutations are selected based on a specific level of activation of the beta-catenin signaling cascade. *Hum Mol Genet* 2002;11:1549.
94. Yang J, Weinberg RA. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. *Dev Cell* 2008;14:818.
95. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. *Nat Rev Cancer* 2009;9:265.
96. Mani SA, Guo W, Liao MJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. *Cell* 2008;133:704.
97. Franci C, Takkunen M, Dave N, et al. Expression of Snail protein in tumor-stroma interface. *Oncogene* 2006;25:5134.
98. Sheehan KM, Gulmann C, Eichler GS, et al. Signal pathway profiling of epithelial and stromal compartments of colonic carcinoma reveals epithelial-mesenchymal transition. *Oncogene* 2008;27:323.
99. Dumont N, Wilson MB, Crawford YG, et al. Sustained induction of epithelial to mesenchymal transition activates DNA methylation of genes silenced in basal-like breast cancers. *Proc Natl Acad Sci U S A* 2008;105:14867.
100. Gupta PB, Onder TT, Jiang G, et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. *Cell* 2009;138:645.
101. Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. *Nature* 2006;444:756.
102. Calabrese C, Poppleton H, Kocak M, et al. A perivascular niche for brain tumor stem cells. *Cancer Cell* 2007;11:69.
103. Diehn M, Cho RW, Lobo NA, et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. *Nature* 2009;458:780.
104. Li X, Lewis MT, Huang J, et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. *J Natl Cancer Inst* 2008;100:672.
105. Todaro M, Alea MP, Di Stefano AB, et al. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. *Cell Stem Cell* 2007;1:389.
106. Dylla SJ, Beviglia L, Park IK, et al. Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy. *PLoS One* 2008;3:e2428.
107. Bao S, Wu Q, Sathornsumetee S, et al. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. *Cancer Res* 2006;66:7843.
108. Ginestier C, Liu S, Diebel ME, et al. CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. *J Clin Invest* 2010;120:485.
109. Charafe-Jauffret E, Ginestier C, Iovino F, et al. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. *Cancer Res* 2009;69:1302.
110. Inoue K, Slaton JW, Eve BY, et al. Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. *Clin Cancer Res* 2000;6:2104.
111. Piccirillo SG, Reynolds BA, Zanetti N, et al. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. *Nature* 2006;444:761.
112. Lee J, Son MJ, Woolard K, et al. Epigenetic-mediated dysfunction of the bone morphogenetic protein pathway inhibits differentiation of glioblastoma-initiating cells. *Cancer Cell* 2008;13:69.
113. Wurdak H, Zhu S, Romero A, et al. An RNAi screen identifies TRRAP as a regulator of brain tumor-initiating cell differentiation. *Cell Stem Cell* 2010;6:37.
114. Matsui W, Huff CA, Wang Q, et al. Characterization of clonogenic multiple myeloma cells. *Blood* 2004;103:2332.
115. Eramo A, Lotti F, Sette G, et al. Identification and expansion of the tumorigenic lung cancer stem cell population. *Cell Death Differ* 2008;15:504.
116. Yang ZF, Ngai P, Ho DW, et al. Identification of local and circulating cancer stem cells in human liver cancer. *Hepatology* 2008;47:919.
117. Wu C, Wei Q, Utomo V, et al. Side population cells isolated from mesenchymal neoplasms have tumor initiating potential. *Cancer Res* 2007;67:8216.

Chapter 12 – References

- Lichtenstein P, Holm NV, Verkasalo PK, et al. Environmental and heritable factors in the causation of cancer—analyses of cohorts of twins from Sweden, Denmark, and Finland. *N Engl J Med* 2000;343:78.
- Ashley DJ. Oesophageal cancer in Wales. *J Med Genet* 1969;6:70.
- St. John DJ, McDermott FT, Hopper JL, et al. Cancer risk in relatives of patients with common colorectal cancer. *Ann Intern Med* 1993;118:785.
- Nishisho I, Nakamura Y, Miyoshi Y, et al. Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. *Science* 1991;253:665.
- Kinzler KW, Nilbert MC, Su LK, et al. Identification of FAP locus genes from chromosome 5q21. *Science* 1991;253(5020):661.
- Nakamura Y, Nishisho I, Kinzler KW, et al. Mutations of the adenomatous polyposis coli gene in familial polyposis coli patients and sporadic colorectal tumors. *Princess Takamatsu Symp* 1991;22:285.
- Lynch HT, Krush AJ. Heredity and adenocarcinoma of the colon. *Gastroenterology* 1967;53:517.
- Parsons R, Li GM, Longley MJ, et al. Hypermutability and mismatch repair deficiency in RER+ tumor cells. *Cell* 1993;75:1227.
- Aaltonen LA, Peltomäki P, Leach FS, et al. Clues to the pathogenesis of familial colorectal cancer. *Science* 1993;260:812.
- Powell SM, Zilz N, Beazer-Barclay Y, et al. APC mutations occur early during colorectal tumorigenesis. *Nature* 1992;359:235.
- Leach FS, Nicolaides NC, Papadopoulos N, et al. Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. *Cell* 1993;75:1215.
- Fishel R, Lescoe MK, Rao MR, et al. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. *Cell* 1993;75:1027.
- Papadopoulos N, Nicolaides NC, Wei YF, et al. Mutation of a MutL homolog in hereditary colon cancer. *Science* 1994;263:1625.
- Bronner CE, Baker SM, Morrison PT, et al. Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. *Nature* 1994;368:258.
- Nicolaides NC, Papadopoulos N, Liu B, et al. Mutations of two PMS homologues in hereditary nonpolyposis colon cancer. *Nature* 1994;371:75.
- Miyaki M, Konishi M, Tanaka K, et al. Germline mutation of MSH6 as the cause of hereditary nonpolyposis colorectal cancer. *Nat Genet* 1997;17:271.
- Lipkin SM, Wang Y, Jacoby R, et al. MLH3: a DNA mismatch repair gene associated with mammalian microsatellite instability. *Nat Genet* 2000;24:27.
- Loukola A, Vilkki S, Singh J, Launonen V, Aaltonen LA. Germline and somatic mutation analysis of MLH3 in MSI-positive colorectal cancer. *Am J Pathol* 2000;157:347.
- Aaltonen LA, Salovaara R, Kristo P, et al. Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. *N Engl J Med* 1998;338:1481.
- Loukola A, Salovaara R, Kristo P, et al. Microsatellite instability in adenomas as a marker for hereditary nonpolyposis colorectal cancer. *Am J Pathol* 1998;155:1849.
- Salovaara R, Loukola A, Kristo P, et al. Population-based molecular detection of hereditary nonpolyposis colorectal cancer. *J Clin Oncol* 2000;18:2193.
- de la Chapelle A. Genetic predisposition to colorectal cancer. *Nat Rev Cancer* 2004;4:769.
- Zanke BW, Greenwood CM, Rangrej J, et al. Genome-wide association scan identifies a colorectal cancer susceptibility locus on chromosome 8q24. *Nat Genet* 2007;39:989.
- Al Olama AA, Kote-Jarai Z, Giles GG, et al. Multiple loci on 8q24 associated with prostate cancer susceptibility. *Nat Genet* 2009;41:1058.
- Gudmundsson J, Sulem P, Gudbjartsson DF, et al. Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility. *Nat Genet* 2009;41:1122.
- Tenesa A, Farrington SM, Prendergast JG, et al. Genome-wide association scan identifies a colorectal cancer susceptibility locus on 11q23 and replicates risk loci at 8q24 and 18q21. *Nat Genet* 2008;40:631.
- Pomerantz MM, Ahmadiyeh N, Jia L, et al. The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer. *Nat Genet* 2009;41:882.
- Ahmadiyeh N, Pomerantz MM, Grisanzio C, et al. 8q24 prostate, breast, and colon cancer risk loci show tissue-specific long-range interaction with MYC. *2010 Proc Natl Acad Sci U S A* 2010;107:9742.
- Hall JM, Lee MK, Newman B, et al. Linkage of early-onset familial breast cancer to chromosome 17q21. *Science* 1990;250:1684.
- Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. *Science* 1994;266:66.
- Futreal PA, Liu Q, Shattuck-Eidens D, et al. BRCA1 mutations in primary breast and ovarian carcinomas. *Science* 1994;266:120.
- Faca VM, Song KS, Wang H, et al. A mouse to human search for plasma proteome changes associated with pancreatic tumor development. *PLoS Med* 2008;5:e123.
- Pitteri SJ, JeBailey L, Faça VM, et al. Integrated proteomic analysis of human cancer cells and plasma from tumor bearing mice for ovarian cancer biomarker discovery. *PLoS One* 2009;4:e7916.
- Hung KE, Faça V, Song K, et al. Comprehensive proteome analysis of an Apc mouse model uncovers proteins associated with intestinal tumorigenesis. *Cancer Prev Res* 2009;2:224.
- Nagrath S, Sequist LV, Maheswaran S, et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. *Nature* 2007;450(7173):1235.
- Nowell PC, Hungerford DA. Chromosome studies on normal and leukemic human leukocytes. *J Natl Cancer Inst* 1960;25:85.
- Mitelman F, Johansson B, Mertens F. The impact of translocations and gene fusions on cancer causation. *Nat Rev Cancer* 2007;7(4):233.
- Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. *Nature* 2007;448:561.
- Tomlins SA, Laxman B, Dhanasekaran SM, et al. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. *Nature* 2007;448:595.
- Dave SS, Fu K, Wright GW, et al. Lymphoma/Leukemia Molecular Profiling Project. Molecular diagnosis of Burkitt's lymphoma. *N Engl J Med* 2006;354:2431.
- Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. *N Engl J Med* 2004;351(27):2817.
- Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. *Nature* 2008;455:1061.
- Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. *Science* 2008;321:1807.
- Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. *Science* 2008;321:1801.
- Pleasance ED, Cheetham RK, Stephens PJ, et al. A comprehensive catalogue of somatic mutations from a human cancer genome. *Nature* 2010;463:191.

46. Mardis ER, Ding L, Dooling DJ, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. *N Engl J Med* 2009;361:1058.
47. Nowell P, Hungerford D. A minute chromosome in human chronic granulocytic leukemia. *Science* 1960;132:1497.
48. Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukemia. *N Engl J Med* 1973;243:290.
49. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. *N Engl J Med* 2001;344:1031.
50. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. *N Engl J Med* 2001;344:1038.
51. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. *N Engl J Med* 2001;344:783.
52. Arteaga CL. ErbB-targeted therapeutic approaches in human cancer. *Exp Cell Res* 2003;284:122.
53. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. *Science* 2004;304:1497.
54. Lynch TJ, Bell DW, Sordella R, et al. activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. *N Engl J Med* 2004;350:2129.
55. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. *Proc Natl Acad Sci U S A* 2004; 101:13306.
56. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. *N Engl J Med* 2009;361:947.
57. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. *N Engl J Med* 2005;352:786.
58. van Zandwijk N, Mathy A, Boerrigter L, et al. EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer. *Ann Oncol* 2007;18:99.
59. Massarelli E, Varella-Garcia M, Tang X, et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. *Clin Cancer Res* 2007;13:2890.
60. Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. *PLoS Med* 2005;2(1):e17.
61. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. *N Engl J Med* 2008;359:1757.
62. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. *J Clin Oncol* 2008;26:1626.
63. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. *N Engl J Med* 2010;363:809.
64. Poulidakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF. *Nature* 2010;464:427.
65. Heidorn SJ, Milagre C, Whittaker S, et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. *Cell* 2010;140:209.
66. Bang Y, Kwak EL, Shaw AT, et al. Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC). *J Clin Oncol* 2010;28:7.

Chapter 13 – References

1. Sawyers CL. Shifting paradigms: the seeds of oncogene addiction. *Nat Med* 2009;15(10):1158.
2. Weinstein IB. Cancer. Addiction to oncogenes—the Achilles heel of cancer. *Science* 2002;297(5578):63.
3. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. *N Engl J Med* 2001;344(14):1031.
4. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. *Science* 1998; 279(5350):577.
5. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. *Science* 2003;299(5607):708.
6. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. *N Engl J Med* 2002;347(7):472.
7. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. *N Engl J Med* 2006;355 (26):2733.
8. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. *JAMA* 2003;290(16):2149.
9. Miller VA, Kris MG, Shah N, et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. *J Clin Oncol* 2004;22(6):1103.
10. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. *Science* 2004; 304(5676):1497.
11. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. *N Engl J Med* 2004;350(21):2129.
12. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. *Proc Natl Acad Sci U S A* 2004;101(36):13306.
13. Cohen MH, Williams GA, Sridhara R, Chen G, Pazdur R. FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. *Oncologist* 2003;8(4):303.
14. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. *N Engl J Med* 2005;353(2):123.
15. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). *Lancet* 2005;366(9496):1527.
16. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial—INTACT 2. *J Clin Oncol* 2004;22(5):785.
17. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial—INTACT 1. *J Clin Oncol* 2004;22(5):777.
18. Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. *J Clin Oncol* 2005;23(25):5892.
19. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer—molecular and clinical predictors of outcome. *N Engl J Med* 2005;353(2):133.
20. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. *N Engl J Med* 2009;361(10):947.
21. Schaller JL, Burkland GA. Case report: rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate. *MedGenMed* 2001;3(5):9.
22. Ault P, Cortes J, Koller C, Kaled ES, Kantarjian H. Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate. *Leuk Res* 2002;26(9):881.
23. Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. *N Engl J Med* 2003;348(13):1201.
24. Golub TR, Barker GF, Lovett M, Gilliland DG. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. *Cell* 1994;77(2):307.
25. Apperley JF, Gardembas M, Melo JV, et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. *N Engl J Med* 2002;347(7):481.
26. Rutkowski P, Van Glabbeke M, Rankin CJ, et al. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. *J Clin Oncol* 2010;28(10):1772.
27. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. *Nature* 2002;417(6892):949.
28. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. *Lancet* 2005;365(9464):1054.
29. James C, Ugo V, Le Couédic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. *Nature* 2005;434(7037):1144.
30. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. *Cancer Cell* 2005;7(4):387.
31. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. *Science* 2004;304(5670):554.
32. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. *Nature* 2008;455(7216):1061.
33. International Cancer Genome Consortium. International network of cancer genome projects. *Nature* 2010; 464(7291):993.
34. Verstovsek S, et al. Long-term follow-up and optimized dosing regimen of INCB018424 in patients with myelofibrosis: durable clinical, functional, and symptomatic responses with improved hematologic safety. American Society of Hematology, 2009 Annual Meeting Abstracts.
35. Mesa RA, Tefferi A. Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis. *Expert Opin Emerg Drugs* 2009;14(3):471.
36. Eisen T, Ahmad T, Flaherty KT, et al. Sorafenib in advanced melanoma: a phase II randomised discontinuation trial analysis. *Br J Cancer* 2006;95(5):581.
37. Solit DB, Garraway LA, Pratilas CA, et al. BRAF mutation predicts sensitivity to MEK inhibition. *Nature* 2006;439(7074):358.
38. McDermott U, Sharma SV, Dowell L, et al. Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. *Proc Natl Acad Sci U S A* 2007;104(50):19936.
39. Pratilas CA, Taylor BS, Ye Q, et al. (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. *Proc Natl Acad Sci U S A* 2009;106(11):4519.
40. LoRusso PM, Krishnamurthi SS, Rinehart JJ, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers. *Clin Cancer Res* 2010;16(6):1924.

41. Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. *J Clin Oncol* 2008;26(13):2139.
42. Dummer R, Robert C, Chapman PB, et al. AZD6244 (ARRY-142886) vs temozolomide (TMZ) in patients (pts) with advanced melanoma: an open-label, randomized, multicenter, phase II study. *J Clin Oncol* 2008;26(Suppl): (abst 9033).
43. Joseph EW, Pratilas CA, Poulidakos PI, et al. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. *Proc Natl Acad Sci U S A* 2010;107(33):14903.
44. Flaherty K, Puzanov I, Sosman J, et al. Phase I study of PLX4032: Proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. *J Clin Oncol* 2009;27(15s, Suppl): (abst 9000).
45. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. *N Engl J Med* 2010;363(9):809.
46. Bollag G, Hirth P, Tsai J, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. *Nature* 2010;467:596.
47. Kefford R, et al. Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. *J Clin Oncol* 2010;28(15s Suppl): (abst 8503).
48. Infante JR, et al. Safety and efficacy results from the first-in-human study of the oral MEK 1/2 inhibitor GSK1120212. *J Clin Oncol* 2010;28(15s Suppl): (abst 2503).
49. Kwak EL, et al. Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066. *J Clin Oncol* 2009;27(15s Suppl): (abst 3509).
50. Morris SW, et al. Fusion of a kinase gene, ALK, to a nuclear protein gene, NPM, in non-Hodgkin's lymphoma. *Science* 1994;263(5151):1281.
51. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. *Nature* 2007; 448(7153):561.
52. Bang Y, Kwak EL, Shaw AT, et al. Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC). *J Clin Oncol* 2010;28(18s Suppl): (abst 3).
53. Chen Y, Takita J, Choi YL, et al. Oncogenic mutations of ALK kinase in neuroblastoma. *Nature* 2008;455(7215): 971.
54. Sirvent N, Hawkins AL, Moeglin D, et al. ALK probe rearrangement in a t(2;11;2)(p23;p15;q31) translocation found in a prenatal myofibroblastic fibrous lesion: toward a molecular definition of an inflammatory myofibroblastic tumor family? *Genes Chromosomes Cancer* 2001; 31(1):85.
55. Fagin JA, Mitsiades N. Molecular pathology of thyroid cancer: diagnostic and clinical implications. *Best Pract Res Clin Endocrinol Metab* 2008;22(6):955.
56. Wells SA Jr, Gosnell JE, Gagel RF, et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. *J Clin Oncol* 2010;28(5):767.
57. Lam ET, Ringel MD, Kloos RT, et al. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. *J Clin Oncol* 2010;28(14):2323.
58. Kloos RT, Ringel MD, Knopp MV, et al. Phase II trial of sorafenib in metastatic thyroid cancer. *J Clin Oncol* 2009;27(10):1675.
59. Schlumberger MJ, Elisei R, Bastholt L, et al. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. *J Clin Oncol* 2009;27(23):3794.
60. Kurzrock R, et al. Long-term results in a cohort of medullary thyroid cancer (MTC) patients (pts) in a phase I study of XL184 (BMS 907351), an oral inhibitor of MET, VEGFR2, and RET. *J Clin Oncol* 2010;28(15s Suppl): (abst 5502).
61. Sawyers CL. Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia. *Cancer Cell* 2002;1(5):413.
62. Kelly LM, Liu Q, Kutok JL, et al. FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model. *Blood* 2002;99(1):310.
63. Stone RM, DeAngelo DJ, Klimek V, et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. *Blood* 2005;105(1):54.
64. Knapper S, Burnett AK, Littlewood T, et al. A phase 2 trial of the FLT3 inhibitor lestaurinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. *Blood* 2006;108(10):3262.
65. Fiedler W, Serve H, Döhner H, et al. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. *Blood* 2005;105(3):986.
66. Stone RM, et al. A Phase 1b study of midostaurin (PKC412) in combination with daunorubicin and cytarabine induction and high-dose cytarabine consolidation in patients under age 61 with newly diagnosed de novo acute myeloid leukemia: overall survival of patients whose blasts have FLT3 mutations is similar to those with wild-type FLT3. American Society of Hematology. 2009 Annual Meeting.
67. Zarrinkar PP, Gunawardane RN, Cramer MD, et al. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). *Blood* 2009;114(14):2984.
68. Cortes J, et al. AC220, a potent, selective, second generation FLT3 receptor tyrosine kinase (RTK) inhibitor, in a first-in-human (FIH) phase 1 AML study. American Society of Hematology. 2009 Annual Meeting.
69. Kaelin WG Jr. The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer. *Nat Rev Cancer* 2008;8(11):865.
70. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. *N Engl J Med* 2003;349(5):427.
71. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. *N Engl J Med* 2007;356(2):125.
72. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. *N Engl J Med* 2007;356(2):115.
73. Rini BI, Wilding G, Hudes G, et al. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. *J Clin Oncol* 2009;27(27):4462.
74. Sonpavde G, Hutson TE, Sternberg CN. Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma. *Expert Opin Investig Drugs* 2008;17(2):253.
75. Bhargava P, et al. Activity of tivozanib (AV-951) in patients with renal cell carcinoma (RCC): Subgroup analysis from a phase II randomized discontinuation trial (RDT). *J Clin Oncol* 2010;28(15 Suppl): (abst 4599).
76. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. *N Engl J Med* 2007;356(22):2271.
77. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. *Lancet* 2008;372(9637):449.
78. McKeage K, Murdoch D, Goa KL. The sirolimus-eluting stent: a review of its use in the treatment of coronary artery disease. *Am J Cardiovasc Drugs* 2003;3(3):211.

79. Atkins MB, Hidalgo M, Stadler WM, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. *J Clin Oncol* 2004;22(5):909.
80. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. *Cancer Cell* 2007;12(1):9.
81. Thomas GV, Tran C, Mellinshoff IK, et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. *Nat Med* 2006;12(1):122.
82. Hess G, Herbrecht R, Romaguera J, et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. *J Clin Oncol* 2009; 27(23):3822.
83. Johnston PB, et al. Phase II trial of the oral mTOR inhibitor everolimus (RAD001) for patients with relapsed or refractory lymphoma. ASCO Annual Meeting Proceedings Part 1. *J Clin Oncol* 2007;25 (18s Suppl): (abst 8055).
84. Slomovitz BM, et al. A phase II study of oral mammalian target of rapamycin (mTOR) inhibitor, RAD001 (everolimus), in patients with recurrent endometrial carcinoma (EC). *J Clin Oncol* 2008;26(Suppl): (abst 5502).
85. Oza AM, et al. A phase II study of temsirolimus (CCI-779) in patients with metastatic and/or locally advanced recurrent endometrial cancer previously treated with chemotherapy: NCIC CTG IND 160b. *J Clin Oncol* 2008;26(Suppl): (abst 5516).
86. Neshat MS, Mellinshoff IK, Tran C, et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. *Proc Natl Acad Sci U S A* 2001;98(18):10314.
87. Majumder PK, Febbo PG, Bikoff R, et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. *Nat Med* 2004;10(6):594.
88. Podsypanina K, Lee RT, Politis C, et al. An inhibitor of mTOR reduces neoplasia and normalizes p70S6 kinase activity in Pten^{-/-} mice. *Proc Natl Acad Sci U S A* 2001; 98(18):10320.
89. O'Reilly KE, Rojo F, She QB, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. *Cancer Res* 2006;66 (3):1500.
90. Kalinsky K, Jacks LM, Heguy A, et al. PIK3CA mutation associates with improved outcome in breast cancer. *Clin Cancer Res* 2009;15(16):5049.
91. Hayes MP, Wang H, Espinal-Witter R, et al. PIK3CA and PTEN mutations in uterine endometrioid carcinoma and complex atypical hyperplasia. *Clin Cancer Res* 2006;12(20 Pt 1):5932.
92. Brachmann SM, Hofmann I, Schnell C, et al. Specific apoptosis induction by the dual PI3K/mTOR inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells. *Proc Natl Acad Sci U S A* 2009; 106(52):22299.
93. She QB, Halilovic E, Ye Q, et al. 4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors. *Cancer Cell* 2010;18(1):39.
94. Engelman JA, Chen L, Tan X, et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. *Nat Med* 2008; 14(12):1351.
95. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. *Science* 2001;293(5531): 876.
96. Shah NP, Nicoll JM, Nagar B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. *Cancer Cell* 2002;2(2):117.
97. Shah NP, Tran C, Lee FY, et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. *Science* 2004;305(5682):399.
98. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. *N Engl J Med* 2006; 354(24):2531.
99. Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. *N Engl J Med* 2010;362(24):2260.
100. Sawyers CL. Even better kinase inhibitors for chronic myeloid leukemia. *N Engl J Med* 2010;362(24):2314.
101. Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. *N Engl J Med* 2010;362(24): 2251.
102. O'Hare T, Shakespeare WC, Zhu X, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potentially inhibits the T315I mutant and overcomes mutation-based resistance. *Cancer Cell* 2009;16(5):401.
103. Cortes J, et al. A phase 1 trial of oral AP24534 in patients with refractory chronic myeloid leukemia and other hematologic malignancies: first results of safety and clinical activity against T315I and resistant mutations. American Society of Hematology. 2009 Annual Meeting.
104. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. *PLoS Med* 2005;2(3):e73.
105. Antonescu CR, Besmer P, Guo T, et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. *Clin Cancer Res* 2005; 11(11):4182.
106. Shah NP, et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. *J Clin Oncol* 2008;26(19):3204.
107. Shah NP, Kasap C, Weier C, et al. Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. *Cancer Cell* 2008;14(6):485.
108. Von Hoff DD, LoRusso PM, Rudin CM, et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. *N Engl J Med* 2009;361(12):1164.
109. Rudin CM, Hann CL, Laterra J, et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. *N Engl J Med* 2009;361(12):1173.
110. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. *Science* 2008;321(5897):1807.
111. Mardis ER, Ding L, Dooling DJ, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. *N Engl J Med* 2009;361(11):1058.
112. Ward PS, Patel J, Wise DR, et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. *Cancer Cell* 2010;17(3):225.
113. Dalglish GL, Furge K, Greenman C, et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. *Nature* 2010;463(7279):360.
114. Pratilas CA, Solit DB. Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response. *Clin Cancer Res* 2010;16(13):3329.
115. Chalhoub N, Baker SJ. PTEN and the PI3-kinase pathway in cancer. *Annu Rev Pathol* 2009;4:127.

Chapter 14 – References

1. Foulkes WD, Brunet JS, Sieh W, Black MJ, Shenouda G, Narod SA. Familial risks of squamous cell carcinoma of the head and neck: retrospective case-control study. *BMJ* 1996;313:716.
2. Copper MP, Jovanovic A, Nauta JJ, et al. Role of genetic factors in the etiology of squamous cell carcinoma of the head and neck. *Arch Otolaryngol Head Neck Surg* 1995;121:157.
3. Foulkes WD, Brunet JS, Kowalski LP, Narod SA, Franco EL. Family history of cancer is a risk factor for squamous cell carcinoma of the head and neck in Brazil: a case-control study. *Int J Cancer* 1995;63:769.
4. Bongers V, Braakhuis BJ, Tobi H, Lubsen H, Snow GB. The relation between cancer incidence among relatives and the occurrence of multiple primary carcinomas following head and neck cancer. *Cancer Epidemiol Biomarkers Prev* 1996;5:595.
5. Kutler DI, Auerbach AD, Satagopan J, et al. High incidence of head and neck squamous cell carcinoma in patients with Fanconi anemia. *Arch Otolaryngol Head Neck Surg* 2003;129:106.
6. van Zeeburg HJ, Sniijders PJ, Wu T, et al. Clinical and molecular characteristics of squamous cell carcinomas from Fanconi anemia patients. *J Natl Cancer Inst* 2008;100:1649.
7. Baez A. Genetic and environmental factors in head and neck cancer genesis. *J Environ Sci Health C Environ Carcinog Ecotoxicol Rev* 2008;26:174.
8. Canova C, Hashibe M, Simonato L, et al. Genetic associations of 115 polymorphisms with cancers of the upper aerodigestive tract across 10 European countries: the ARCAGE project. *Cancer Res* 2009;69:2956.
9. Hashibe M, McKay JD, Curado MP, et al. Multiple ADH genes are associated with upper aerodigestive cancers. *Nat Genet* 2008;40:707.
10. Haddad RI, Shin DM. Recent advances in head and neck cancer. *N Engl J Med* 2008;359:1143.
11. Forastiere A, Koch W, Trotti A, Sidransky D. Head and neck cancer. *N Engl J Med* 2001;345:1890.
12. Califano J, van der Riet P, Westra W, et al. Genetic progression model for head and neck cancer: implications for field cancerization. *Cancer Res* 1996;56:2488.
13. Field JK. The role of oncogenes and tumour-suppressor genes in the aetiology of oral, head and neck squamous cell carcinoma. *J R Soc Med* 1995;88:35P.
14. Jin YT, Myers J, Tsai ST, et al. Microsatellite instability in preinvasive and invasive head and neck squamous carcinoma. *Am J Pathol* 1996;148:2067.
15. el-Naggar AK, Hurr K, Luna MA, Goepfert H, Hong WK, Batsakis JG. Intratumoral genetic heterogeneity in primary head and neck squamous carcinoma using microsatellite markers. *Diagn Mol Pathol* 1997;6:305.
16. Mao L, Lee JS, Fan YH, et al. Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment. *Nat Med* 1996;2:682.
17. Li G, Sturgis EM, Wang LE, et al. Association of a p73 exon 2 G4C14-to-A4T14 polymorphism with risk of squamous cell carcinoma of the head and neck. *Carcinogenesis* 2004;25:1911.
18. van der Riet P, Nawroz H, Hruban RH, et al. Frequent loss of chromosome 9p21-22 early in head and neck cancer progression. *Cancer Res* 1994;54:1156.
19. Cairns P, Polascik TJ, Eby Y, et al. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. *Nat Genet* 1995;11:210.
20. Munro J, Stott FJ, Vousden KH, Peters G, Parkinson EK. Role of the alternative INK4A proteins in human keratinocyte senescence: evidence for the specific inactivation of p16INK4A upon immortalization. *Cancer Res* 1999;59:2516.
21. Papadimitrakopoulou V, Izzo J, Lippman SM, et al. Frequent inactivation of p16INK4a in oral premalignant lesions. *Oncogene* 1997;14:1799.
22. Merlo A, Herman JG, Mao L, et al. 5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. *Nat Med* 1995;1:686.
23. Reed AL, Califano J, Cairns P, et al. High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. *Cancer Res* 1996;56:3630.
24. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. *Science* 1991;253:49.
25. Boyle JO, Hakim J, Koch W, et al. The incidence of p53 mutations increases with progression of head and neck cancer. *Cancer Res* 1993;53:4477.
26. Somers KD, Merrick MA, Lopez ME, Incognito LS, Schechter GL, Casey G. Frequent p53 mutations in head and neck cancer. *Cancer Res* 1992;52:5997.
27. Balz V, Scheckenbach K, Gotte K, Bockmuhl U, Petersen I, Bier H. Is the p53 inactivation frequency in squamous cell carcinomas of the head and neck underestimated? Analysis of p53 exons 2-11 and human papillomavirus 16/18 E6 transcripts in 123 unselected tumor specimens. *Cancer Res* 2003;63:1188.
28. Poeta ML, Manola J, Goldwasser MA, et al. TP53 mutations and survival in squamous-cell carcinoma of the head and neck. *N Engl J Med* 2007;357:2552.
29. Brennan JA, Boyle JO, Koch WM, et al. Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. *N Engl J Med* 1995;332:712.
30. Berenson JR, Yang J, Mickel RA. Frequent amplification of the bcl-1 locus in head and neck squamous cell carcinomas. *Oncogene* 1989;4:1111.
31. Callender T, el-Naggar AK, Lee MS, Frankenthaler R, Luna MA, Batsakis JG. PRAD-1 (CCND1)/cyclin D1 oncogene amplification in primary head and neck squamous cell carcinoma. *Cancer* 1994;74:152.
32. Okami K, Reed AL, Cairns P, et al. Cyclin D1 amplification is independent of p16 inactivation in head and neck squamous cell carcinoma. *Oncogene* 1999;18:3541.
33. Cully M, You H, Levine AJ, Mak TW. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. *Nat Rev Cancer* 2006;6:184.
34. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. *Nat Rev Drug Discov* 2005;4:988.
35. Janssen HL, Haustermans KM, Balm AJ, Begg AC. Hypoxia in head and neck cancer: how much, how important? *Head Neck* 2005;27:622.
36. Hoogsteen IJ, Marres HA, Bussink J, van der Kogel AJ, Kaanders JH. Tumor microenvironment in head and neck squamous cell carcinomas: predictive value and clinical relevance of hypoxic markers. A review. *Head Neck* 2007;29:591.
37. Keith B, Simon MC. Hypoxia-inducible factors, stem cells, and cancer. *Cell* 2007;129:465.
38. Axelson H, Fredlund E, Ovenberger M, Landberg G, Pahlman S. Hypoxia-induced dedifferentiation of tumor cells—a mechanism behind heterogeneity and aggressiveness of solid tumors. *Semin Cell Dev Biol* 2005;16:554.
39. Covelto KL, Kehler J, Yu H, et al. HIF-2alpha regulates Oct-4: effects of hypoxia on stem cell function, embryonic development, and tumor growth. *Genes Dev* 2006;20:557.
40. Cavallaro U, Christofori G. Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. *Nat Rev Cancer* 2004;4:118.

41. Mandal M, Myers JN, Lippman SM, et al. Epithelial to mesenchymal transition in head and neck squamous carcinoma: association of Src activation with E-cadherin down-regulation, vimentin expression, and aggressive tumor features. *Cancer* 2008;112:2088.
42. Ziober BL, Silverman SS Jr, Kramer RH. Adhesive mechanisms regulating invasion and metastasis in oral cancer. *Crit Rev Oral Biol Med* 2001;12:499.
43. Pyke C, Salo S, Ralfkiaer E, Romer J, Dano K, Tryggvason K. Laminin-5 is a marker of invading cancer cells in some human carcinomas and is coexpressed with the receptor for urokinase plasminogen activator in budding cancer cells in colon adenocarcinomas. *Cancer Res* 1995; 55:4132.
44. Ono Y, Nakanishi Y, Ino Y, et al. Clinicopathologic significance of laminin-5 gamma2 chain expression in squamous cell carcinoma of the tongue: immunohistochemical analysis of 67 lesions. *Cancer* 1999;85:2315.
45. Manohar A, Shome SG, Lamar J, et al. Alpha 3 beta 1 integrin promotes keratinocyte cell survival through activation of a MEK/ERK signaling pathway. *J Cell Sci* 2004;117:4043.
46. Gonzales M, Haan K, Baker SE, et al. A cell signal pathway involving laminin-5, alpha3beta1 integrin, and mitogen-activated protein kinase can regulate epithelial cell proliferation. *Mol Biol Cell* 1999;10:259.
47. Kosmehl H, Berndt A, Strassburger S, et al. Distribution of laminin and fibronectin isoforms in oral mucosa and oral squamous cell carcinoma. *Br J Cancer* 1999; 81:1071.
48. Ginos MA, Page GP, Michalowicz BS, et al. Identification of a gene expression signature associated with recurrent disease in squamous cell carcinoma of the head and neck. *Cancer Res* 2004;64:55.
49. Sok JC, Kuriakose MA, Mahajan VB, Pearlman AN, DeLacure M, Chen FA. Tissue-specific gene expression of head and neck squamous cell carcinoma in vivo by complementary DNA microarray analysis. *Arch Otolaryngol Head Neck Surg* 2003;129:760.
50. Belbin TJ, Singh B, Smith RV, et al. Molecular profiling of tumor progression in head and neck cancer. *Arch Otolaryngol Head Neck Surg* 2005;131:10.
51. Lauffenburger DA, Horwitz AF. Cell migration: a physically integrated molecular process. *Cell* 1996;84:359.
52. Kantak SS, Kramer RH. E-cadherin regulates anchorage-independent growth and survival in oral squamous cell carcinoma cells. *J Biol Chem* 1998;273:16953.
53. Shen X, Kramer RH. Adhesion-mediated squamous cell carcinoma survival through ligand-independent activation of epidermal growth factor receptor. *Am J Pathol* 2004;165:1315.
54. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. *Nat Rev Cancer* 2005;5:341.
55. Kalyankrishna S, Grandis JR. Epidermal growth factor receptor biology in head and neck cancer. *J Clin Oncol* 2006;24:2666.
56. Rogers SJ, Harrington KJ, Rhys-Evans P, O-Charoenrat P, Eccles SA. Biological significance of c-erbB family oncogenes in head and neck cancer. *Cancer Metastasis Rev* 2005;24:47.
57. Maxwell SA, Sacks PG, Gutterman JU, Gallick GE. Epidermal growth factor receptor protein-tyrosine kinase activity in human cell lines established from squamous carcinomas of the head and neck. *Cancer Res* 1989; 49:1130.
58. Kearsley JH, Furlong KL, Cooke RA, Waters MJ. An immunohistochemical assessment of cellular proliferation markers in head and neck squamous cell cancers. *Br J Cancer* 1990;61:821.
59. Ishitoya J, Toriyama M, Oguchi N, et al. Gene amplification and overexpression of EGF receptor in squamous cell carcinomas of the head and neck. *Br J Cancer* 1989; 59:559.
60. Grandis JR, Tweardy DJ. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. *Cancer Res* 1993;53:3579.
61. Shin DM, Ro JY, Hong WK, Hittelman WN. Dysregulation of epidermal growth factor receptor expression in premalignant lesions during head and neck tumorigenesis. *Cancer Res* 1994;54:3153.
62. Rubin Grandis J, Melhem MF, Gooding WE, et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. *J Natl Cancer Inst* 1998;90:824.
63. Bentzen SM, Atasoy BM, Daley FM, et al. Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial. *J Clin Oncol* 2005;23:5560.
64. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. *N Engl J Med* 2006;354:567.
65. Karamouzis MV, Grandis JR, Argiris A. Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas. *JAMA* 2007;298:70.
66. Simon J, Stewart W, E. E. C., Lisa Licitra, et al. A Phase III randomized parallel-group study of gefitinib (IRESSA) versus methotrexate (IMEX) in patients with recurrent squamous cell carcinoma of the head and neck. *Proceedings of the American Association for Cancer Research Annual Meeting*, A3522, 2007.
67. Bossi P, Locati LD, Licitra L. Biological agents in head and neck cancer. *Expert Rev Anticancer Ther* 2007; 7:1643.
68. Calvo E, Baselga J. Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors. *J Clin Oncol* 2006;24:2158.
69. Shigematsu H, Gazdar AF. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. *Int J Cancer* 2006;118:257.
70. Willmore-Payne C, Holden JA, Layfield LJ. Detection of EGFR- and HER2-activating mutations in squamous cell carcinoma involving the head and neck. *Mod Pathol* 2006;19:634.
71. Loeffler-Ragg J, Witsch-Baumgartner M, Tzankov A, et al. Low incidence of mutations in EGFR kinase domain in Caucasian patients with head and neck squamous cell carcinoma. *Eur J Cancer* 2006;42:109.
72. Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. *J Clin Oncol* 2005;23:5900.
73. Han SW, Kim TY, Hwang PG, et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. *J Clin Oncol* 2005;23:2493.
74. Mitsudomi T, Kosaka T, Endoh H, et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. *J Clin Oncol* 2005;23:2513.
75. Taron M, Ichinose Y, Rosell R, et al. Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. *Clin Cancer Res* 2005;11:5878.
76. Inoue A, Suzuki T, Fukuhara T, et al. Prospective phase II study of gefitinib for chemotherapy-naïve patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. *J Clin Oncol* 2006;24:3340.
77. Asahina H, Yamazaki K, Kinoshita I, et al. A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. *Br J Cancer* 2006;95:998.

78. Andl T, Kahn T, Pfuhl A, et al. Etiological involvement of oncogenic human papillomavirus in tonsillar squamous cell carcinomas lacking retinoblastoma cell cycle control. *Cancer Res* 1998;58:5.
79. Gillison ML, Koch WM, Capone RB, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. *J Natl Cancer Inst* 2000;92:709.
80. Hafkamp HC, Speel EJ, Haesevoets A, et al. A subset of head and neck squamous cell carcinomas exhibits integration of HPV 16/18 DNA and overexpression of p16INK4A and p53 in the absence of mutations in p53 exons 5-8. *Int J Cancer* 2003;107:394.
81. Mork J, Lie AK, Glatre E, et al. Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. *N Engl J Med* 2001;344:1125.
82. Schwartz SM, Daling JR, Doody DR, et al. Oral cancer risk in relation to sexual history and evidence of human papillomavirus infection. *J Natl Cancer Inst* 1998;90:1626.
83. van Houten VM, Snijders PJ, van den Brekel MW, et al. Biological evidence that human papillomaviruses are etiologically involved in a subgroup of head and neck squamous cell carcinomas. *Int J Cancer* 2001;93:232.
84. Wiest T, Schwarz E, Enders C, Flechtenmacher C, Bosch FX. Involvement of intact HPV16 E6/E7 gene expression in head and neck cancers with unaltered p53 status and perturbed pRb cell cycle control. *Oncogene* 2002;21:1510.
85. Paz IB, Cook N, Odom-Maryon T, Xie Y, Wilczynski SP. Human papillomavirus (HPV) in head and neck cancer. An association of HPV 16 with squamous cell carcinoma of Waldeyer's tonsillar ring. *Cancer* 1997;79:595.
86. Fouret P, Monceaux G, Temam S, Lacourreye L, St Guily JL. Human papillomavirus in head and neck squamous cell carcinomas in nonsmokers. *Arch Otolaryngol Head Neck Surg* 1997;123:513.
87. Ritchie JM, Smith EM, Summersgill KF, et al. Human papillomavirus infection as a prognostic factor in carcinomas of the oral cavity and oropharynx. *Int J Cancer* 2003;104:336.
88. Haraf DJ, Nodzinski E, Brachman D, et al. Human papilloma virus and p53 in head and neck cancer: clinical correlates and survival. *Clin Cancer Res* 1996;2:755.
89. Ringstrom E, Peters E, Hasegawa M, Posner M, Liu M, Kelsey KT. Human papillomavirus type 16 and squamous cell carcinoma of the head and neck. *Clin Cancer Res* 2002;8:3187.
90. Brandsma JL, Abramson AL. Association of papillomavirus with cancers of the head and neck. *Arch Otolaryngol Head Neck Surg* 1989;115:621.
91. zur Hausen H. Papillomavirus infections—a major cause of human cancers. *Biochim Biophys Acta* 1996;1288:F55.
92. Werness BA, Levine AJ, Howley PM. Association of human papillomavirus types 16 and 18 E6 proteins with p53. *Science* 1990;248:76.
93. Wilczynski SP, Lin BT, Xie Y, Paz IB. Detection of human papillomavirus DNA and oncoprotein overexpression are associated with distinct morphological patterns of tonsillar squamous cell carcinoma. *Am J Pathol* 1998;152:145.
94. Munger K, Phelps WC, Bubbs V, Howley PM, Schlegel R. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. *J Virol* 1989;63:4417.
95. Munoz N. Human papillomavirus and cancer: the epidemiological evidence. *J Clin Virol* 2000;19:1.
96. Oda D, Bigler L, Lee P, Blanton R. HPV immortalization of human oral epithelial cells: a model for carcinogenesis. *Exp Cell Res* 1996;226:164.
97. Park NH, Min BM, Li SL, Huang MZ, Cherick HM, Doniger J. Immortalization of normal human oral keratinocytes with type 16 human papillomavirus. *Carcinogenesis* 1991;12:1627.
98. Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. *Cancer Epidemiol Biomarkers Prev* 2005;14:467.
99. Fakhry C, Gillison ML. Clinical implications of human papillomavirus in head and neck cancers. *J Clin Oncol* 2006;24:2606.
100. Herrero R, Castellsague X, Pawlita M, et al. Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. *J Natl Cancer Inst* 2003;95:1772.
101. Begum S, Gillison ML, Ansari-Lari MA, Shah K, Westra WH. Detection of human papillomavirus in cervical lymph nodes: a highly effective strategy for localizing site of tumor origin. *Clin Cancer Res* 2003;9:6469.
102. Koch WM, Bhatti N, Williams MF, Eisele DW. Oncologic rationale for bilateral tonsillectomy in head and neck squamous cell carcinoma of unknown primary source. *Otolaryngol Head Neck Surg* 2001;124:331.
103. Lapeyre M, Malissard L, Peiffert D, et al. Cervical lymph node metastasis from an unknown primary: is a tonsillectomy necessary? *Int J Radiat Oncol Biol Phys* 1997;39:291.
104. McQuone SJ, Eisele DW, Lee DJ, Westra WH, Koch WM. Occult tonsillar carcinoma in the unknown primary. *Laryngoscope* 1998;108:1605.
105. Mendenhall WM, Mancuso AA, Parsons JT, Stringer SP, Cassisi NJ. Diagnostic evaluation of squamous cell carcinoma metastatic to cervical lymph nodes from an unknown head and neck primary site. *Head Neck* 1998;20:739.
106. Cruz IB, Snijders PJ, Steenberg RD, et al. Age-dependence of human papillomavirus DNA presence in oral squamous cell carcinomas. *Eur J Cancer B Oral Oncol* 1996;32B:55.
107. Mellin H, Friesland S, Lewensohn R, Dalianis T, Munck-Wikland E. Human papillomavirus (HPV) DNA in tonsillar cancer: clinical correlates, risk of relapse, and survival. *Int J Cancer* 2000;89:300.
108. Sisk EA, Soltys SG, Zhu S, Fisher SG, Carey TE, Bradford CR. Human papillomavirus and p53 mutational status as prognostic factors in head and neck carcinoma. *Head Neck* 2002;24:841.
109. Strome SE, Savva A, Brissett AE, et al. Squamous cell carcinoma of the tonsils: a molecular analysis of HPV associations. *Clin Cancer Res* 2002;8:1093.
110. D'Souza G, Kreimer AR, Viscidi R, et al. Case-control study of human papillomavirus and oropharyngeal cancer. *N Engl J Med* 2007;356:1944.
111. Lindel K, Beer KT, Laissue J, Greiner RH, Aebersold DM. Human papillomavirus positive squamous cell carcinoma of the oropharynx: a radiosensitive subgroup of head and neck carcinoma. *Cancer* 2001;92:805.
112. Li W, Thompson CH, O'Brien CJ, et al. Human papillomavirus positivity predicts favourable outcome for squamous carcinoma of the tonsil. *Int J Cancer* 2003;106:553.
113. Schwartz SR, Yueh B, McDougall JK, Daling JR, Schwartz SM. Human papillomavirus infection and survival in oral squamous cell cancer: a population-based study. *Otolaryngol Head Neck Surg* 2001;125:1.
114. Weinberger PM, Yu Z, Haffty BG, et al. Molecular classification identifies a subset of human papillomavirus-associated oropharyngeal cancers with favorable prognosis. *J Clin Oncol* 2006;24:736.
115. Hsu KF, Hung CF, Cheng WF, et al. Enhancement of suicidal DNA vaccine potency by linking Mycobacterium tuberculosis heat shock protein 70 to an antigen. *Gene Ther* 2001;8:376.
116. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. *Lancet* 2004;364:1757.

117. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. *N Engl J Med* 2002;347:1645.
118. Capone RB, Pai SI, Koch WM, et al. Detection and quantitation of human papillomavirus (HPV) DNA in the sera of patients with HPV-associated head and neck squamous cell carcinoma. *Clin Cancer Res* 2000;6:4171.
119. Razin A, Riggs AD. DNA methylation and gene function. *Science* 1980;210:604.
120. Feinberg AP, Vogelstein B. Hypomethylation of ras oncogenes in primary human cancers. *Biochem Biophys Res Commun* 1983;111:47.
121. Feinberg AP, Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. *Nature* 1983;301:89.
122. Sakai T, Toguchida J, Ohtani N, Yandell DW, Rapaport JM, Dryja TP. Allele-specific hypermethylation of the retinoblastoma tumor-suppressor gene. *Am J Hum Genet* 1991;48:880.
123. Frommer M, McDonald LE, Millar DS, et al. A Genomic Sequencing Protocol that Yields a Positive Display of 5-Methylcytosine Residues in Individual DNA Strands. *Proc Natl Acad Sci U S A* 1992;89:1827.
124. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. *Proc Natl Acad Sci U S A* 1996;93:9821.
125. Lo YMD, Wong IHN, Zhang J, Tein MSC, Ng MHL, Hjelm NM. Quantitative Analysis of Aberrant p16 Methylation Using Real-Time Quantitative Methylation-specific Polymerase Chain Reaction. *Cancer Res* 1999; 59:3899.
126. Yamashita K, Upadhyay S, Osada M, et al. Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. *Cancer Cell* 2002;2:485.
127. El-Naggar AK, Lai S, Clayman G, et al. Methylation, a major mechanism of p16/CDKN2 gene inactivation in head and neck squamous carcinoma. *Am J Pathol* 1997; 151:1767.
128. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. *N Engl J Med* 2003;349:2042.
129. Ai L, Vo QN, Zuo C, et al. Ataxia-telangiectasia-mutated (ATM) gene in head and neck squamous cell carcinoma: promoter hypermethylation with clinical correlation in 100 cases. *Cancer Epidemiol Biomarkers Prev* 2004; 13:150.
130. Chang HW, Ling GS, Wei WI, Yuen AP. Smoking and drinking can induce p15 methylation in the upper aerodigestive tract of healthy individuals and patients with head and neck squamous cell carcinoma. *Cancer* 2004; 101:125.
131. Hasegawa M, Nelson HH, Peters E, Ringstrom E, Posner M, Kelsey KT. Patterns of gene promoter methylation in squamous cell cancer of the head and neck. *Oncogene* 2002;21:4231.
132. Ogi K, Toyota M, Ohe-Toyota M, et al. Aberrant methylation of multiple genes and clinicopathological features in oral squamous cell carcinoma. *Clin Cancer Res* 2002;8:3164.
133. Maruya S, Issa JP, Weber RS, et al. Differential methylation status of tumor-associated genes in head and neck squamous carcinoma: incidence and potential implications. *Clin Cancer Res* 2004;10:3825.
134. Youssef EM, Lotan D, Issa JP, et al. Hypermethylation of the retinoic acid receptor-beta(2) gene in head and neck carcinogenesis. *Clin Cancer Res* 2004;10:1733.
135. Shaw RJ, Liloglou T, Rogers SN, et al. Promoter methylation of P16, RARBeta, E-cadherin, cyclin A1 and cytoglobin in oral cancer: quantitative evaluation using pyrosequencing. *Br J Cancer* 2006;94:561.
136. Dong SM, Sun DI, Benoit NE, Kuzmin I, Lerman MI, Sidransky D. Epigenetic inactivation of RASSF1A in head and neck cancer. *Clin Cancer Res* 2003;9:3635.
137. Nayak CS, Carvalho AL, Jeronimo C, et al. Positive correlation of tissue inhibitor of metalloproteinase-3 and death-associated protein kinase hypermethylation in head and neck squamous cell carcinoma. *Laryngoscope* 2007;117:1376.
138. Estecio MR, Youssef EM, Rahal P, et al. LHX6 is a sensitive methylation marker in head and neck carcinomas. *Oncogene* 2006;25:5018.
139. Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. *Cancer Res* 1999;59:793.
140. Ha PK, Califano JA. Promoter methylation and inactivation of tumour-suppressor genes in oral squamous-cell carcinoma. *Lancet Oncol* 2006;7:77.
141. Saito Y, Liang G, Egger G, et al. Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. *Cancer Cell* 2006;9:435.
142. Lujambio A, Ropero S, Ballestar E, et al. Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. *Cancer Res* 2007;67:1424.
143. Rosin MP, Cheng X, Poh C, et al. Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia. *Clin Cancer Res* 2000;6:357.

Chapter 15 – References

1. Hecht SS. Tobacco smoke carcinogens and lung cancer. *J Natl Cancer Inst* 1999;91:1194.
2. Denissenko MF, Pao A, Tang M, Pfeifer GP. Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53. *Science* 1996;274:430.
3. Wiencke JK, Thurston SW, Kelsey KT, et al. Early age at smoking initiation and tobacco carcinogen DNA damage in the lung. *J Natl Cancer Inst* 1999;91:614.
4. Phillips DH, Hewer A, Martin CN, Garner RC, King MM. Correlation of DNA adduct levels in human lung with cigarette smoking. *Nature* 1988;336:790.
5. Landi MT, Chatterjee N, Yu K, et al. A genome-wide association study of lung cancer identifies a region of chromosome 5p15 associated with risk for adenocarcinoma. *Am J Hum Genet* 2009;85:679.
6. Truong T, Hung RJ, Amos CI, et al. Replication of lung cancer susceptibility loci at chromosomes 15q25, 5p15, and 6p21: a pooled analysis from the International Lung Cancer Consortium. *J Natl Cancer Inst* 2010;102:959.
7. Sherva R, Wilhelmson K, Pomerleau CS, et al. Association of a single nucleotide polymorphism in neuronal acetylcholine receptor subunit alpha 5 (CHRNA5) with smoking status and with “pleasurable buzz” during early experimentation with smoking. *Addiction* 2008;103:1544.
8. Lonardo F, Rusch V, Langenfeld J, Dmitrovsky E, Klimstra DS. Overexpression of cyclins D1 and E is frequent in bronchial preneoplasia and precedes squamous cell carcinoma development. *Cancer Res* 1999;59:2470.
9. Wistuba II, Behrens C, Virmani AK, et al. High resolution chromosome 3p allelotyping of human lung cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints. *Cancer Res* 2000;60:1949.
10. Westra WH. Early glandular neoplasia of the lung. *Respir Res* 2000;1:163.
11. Braakhuis BJ, Tabor MP, Kummer JA, Leemans CR, Brakenhoff RH. A genetic explanation of Slaughter’s concept of field cancerization: evidence and clinical implications. *Cancer Res* 2003;63:1727.
12. Park IW, Wistuba II, Maitra A, et al. Multiple clonal abnormalities in the bronchial epithelium of patients with lung cancer. *J Natl Cancer Inst* 1999;91:1863.
13. Balsara BR, Testa JR. Chromosomal imbalances in human lung cancer. *Oncogene* 2002;21:6877.
14. Braithwaite KL, Rabbitts PH. Multi-step evolution of lung cancer. *Semin Cancer Biol* 1999;9:255.
15. Virmani AK, Gazdar AF. Tumor suppressor genes in lung cancer. *Methods Mol Biol* 2003;222:97.
16. Miura I, Graziano SL, Cheng JQ, Doyle LA, Testa JR. Chromosome alterations in human small cell lung cancer: frequent involvement of 5q. *Cancer Res* 1992;52:1322.
17. Testa JR, Siegfried JM. Chromosome abnormalities in human non-small cell lung cancer. *Cancer Res* 1992;52:2702s.
18. Haruki N, Kawaguchi KS, Eichenberger S, et al. Cloned fusion product from a rare t(15;19)(q13.2;p13.1) inhibit S phase in vitro. *J Med Genet* 2005;42:558.
19. Achar RDOD, Nikiforova MN, Dacic S, Nicholson AG, Yousem SA. Mammalian mastermind like 2 11q21 gene rearrangement in bronchopulmonary mucoepidermoid carcinoma. *Hum Pathol* 2009;40:854.
20. Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. *Cell* 2007;131:1190.
21. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small cell lung cancer. *Nature* 2007;448:561.
22. Sekido Y, Fong KM, Minna JD. Molecular genetics of lung cancer. *Annu Rev Med* 2003;54:73.
23. Klein G, Klein E. Surveillance against tumors—is it mainly immunological? *Immunol Lett* 2005;100:29.
24. Sakumi K, Tominaga Y, Furuchi M, et al. Ogg1 knock-out-associated lung tumorigenesis and its suppression by Mth1 gene disruption. *Cancer Res* 2003;63:902.
25. Zienoldiny S, Campa D, Lind H, et al. Polymorphisms of DNA repair genes and risk of non-small cell lung cancer. *Carcinogenesis* 2006;27:560.
26. Olausson KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small cell lung cancer and cisplatin-based adjuvant chemotherapy. *N Engl J Med* 2006;355:983.
27. Janne PA, Engelman JA, Johnson BE. Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. *J Clin Oncol* 2005;23:3227.
28. Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small cell lung cancer. *J Natl Cancer Inst* 2005;97:643.
29. Mitsudomi T, Kosaka T, Endoh H, et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small cell lung cancer with postoperative recurrence. *J Clin Oncol* 2005;23:2513.
30. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. *J Natl Cancer Inst* 2005;97:339.
31. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer—molecular and clinical predictors of outcome. *N Engl J Med* 2005;353:133.
32. Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. *N Engl J Med* 2009;361:958.
33. Miller VA, Kris MG, Shah N, et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small cell lung cancer. *J Clin Oncol* 2004;22:1103.
34. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). *Lancet* 2005;366:1527.
35. Mok TS, Wu Y-L, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. *N Engl J Med* 2009;361:947.
36. Tamura K, Okamoto I, Kashii T, et al. Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403). *Br J Cancer* 2008;98:907.
37. O’Byrne KJ, Bondarenko I, Barrios C, et al. Molecular and clinical predictors of outcome for cetuximab in non-small cell lung cancer (NSCLC): data from the FLEX study. *J Clin Oncol* 2009;27: (abst 8007).
38. Hirsch FR, Varella-Garcia M, McCoy J, et al. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. *J Clin Oncol* 2005;23:6838.
39. Nakamura H, Kawasaki N, Taguchi M, Kabasawa K. Association of HER-2 overexpression with prognosis in non-small cell lung carcinoma: a meta-analysis. *Cancer* 2005;103:1865.
40. Swanton C, Futreal A, Eisen T. Her2-targeted therapies in non-small cell lung cancer. *Clin Cancer Res* 2006;12:4377s.
41. Yun CH, Mengwasser KE, Toms AV, et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. *Proc Natl Acad Sci U S A* 2008;105:2070.

42. Micke P, Basrai M, Faldum A, et al. Characterization of c-kit expression in small cell lung cancer: prognostic and therapeutic implications. *Clin Cancer Res* 2003;9:188.
43. Sekido Y, Obata Y, Ueda R, et al. Preferential expression of c-kit protooncogene transcripts in small cell lung cancer. *Cancer Res* 1991;51:2416.
44. Potti A, Moazzam N, Ramar K, et al. CD117 (c-KIT) overexpression in patients with extensive-stage small-cell lung carcinoma. *Ann Oncol* 2003;14:894.
45. Naem M, Dahiya M, Clark JL, Creech SD, Alkan S. Analysis of c-kit protein expression in small-cell lung carcinoma and its implication for prognosis. *Hum Pathol* 2002;33:1182.
46. Wang WL, Healy ME, Sattler M, et al. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571. *Oncogene* 2000;19:3521.
47. Dy GK, Miller AA, Mandrekra SJ, et al. A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study. *Ann Oncol* 2005;16:1811.
48. Johnson BE, Fischer T, Fischer B, et al. Phase II study of imatinib in patients with small cell lung cancer. *Clin Cancer Res* 2003;9:5880.
49. Krug LM, Crapanzano JP, Azzoli CG, et al. Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial. *Cancer* 2005;103:2128.
50. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. *Science* 2007;316:1039.
51. Schiller JH, Akerley WL, Brugger W, et al. Results from ARQ 197-209: a global randomized placebo-controlled phase II clinical trial of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated EGFR inhibitor-naïve patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). *J Clin Oncol* 2010;28: (abst LBA7502).
52. Chaudhry A, Carrasquillo JA, Avis IL, et al. Phase I and imaging trial of a monoclonal antibody directed against gastrin-releasing peptide in patients with lung cancer. *Clin Cancer Res* 1999;5:3385.
53. Watkins DN, Berman DM, Burkholder SG, et al. Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer. *Nature* 2003;422:313.
54. Haruki N, Kawaguchi KS, Eichenberger S, et al. Dominant-negative Notch 3 receptor inhibits mitogen-activated protein kinase pathway and the growth of human lung cancers. *Cancer Res* 2005;65:3555.
55. Rodenhuis S, Slebos RJ, Boor AJ, et al. Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung. *Cancer Res* 1988;48:5738.
56. Johnson L, Mercer K, Greenbaum D, et al. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. *Nature* 2001;410:1111.
57. Zhang Z, Wang Y, Vikis HG, et al. Wild type Kras2 can inhibit lung carcinogenesis in mice. *Nat Genet* 2001; 29:25.
58. Ahrendt SA, Decker PA, Alawi EA, et al. Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. *Cancer* 2001;92:1525.
59. Mascaux C, Iannino N, Martin B, et al. The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. *Br J Cancer* 2005;92:131.
60. Schiller JH, Adak S, Feins RH, et al. Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small cell lung cancer on E4592: a laboratory ancillary study on an Eastern Cooperative Oncology Group prospective randomized trial of postoperative adjuvant therapy. *J Clin Oncol* 2001;19:448.
61. Adjei AA, Mauer A, Bruzek L, et al. Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small cell lung cancer. *J Clin Oncol* 2003; 21:1760.
62. Ravi RK, Weber E, McMahon M, et al. Activated Raf-1 causes growth arrest in human small cell lung cancer cells. *J Clin Invest* 1998;101:153.
63. Johnson BE, Russell E, Simmons AM, et al. MYC family DNA amplification in 126 tumor cell lines from patients with small cell lung cancer. *J Cell Biochem Suppl* 1996; 24:210.
64. Choi YL, Takeuchi K, Soda M, et al. Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. *Cancer Res* 2008;68:4971.
65. Koivunen JP, Mermel C, Zejnullahu K, et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. *Clin Cancer Res* 2008;14:4275.
66. Takeuchi K, Choi YL, Togashi Y, et al. KIF5B-ALK, a novel fusion onco-kinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. *Clin Cancer Res* 2009;15:3143.
67. Wong DW, Leung EL, So KK, et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. *Cancer* 2009;115:1723.
68. Inamura K, Takeuchi K, Togashi Y, et al. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. *Mod Pathol* 2009;22:508.
69. Inamura K, Takeuchi K, Togashi Y, et al. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. *J Thorac Oncol* 2008;3:13.
70. Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small cell lung cancer who harbor EML4-ALK. *J Clin Oncol* 2009; 27:4247.
71. Bang Y, Kwak EL, Shaw AT, et al. Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC). *J Clin Oncol* 2010;28: (abst 3).
72. Tammemagi MC, McLaughlin JR, Bull SB. Meta-analyses of p53 tumor suppressor gene alterations and clinicopathological features in resected lung cancers. *Cancer Epidemiol Biomarkers Prev* 1999;8:625.
73. Steels E, Paesmans M, Berghmans T, et al. Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. *Eur Respir J* 2001;18:705.
74. Hwang S-J, Cheng LS-C, Lozano G, et al. Lung cancer risk in germline p53 mutation carriers: association between an inherited cancer predisposition, cigarette smoking, and cancer risk. *Hum Genet* 2003;113:238.
75. Joerger AC, Fersht AR. Structural biology of the tumor suppressor p53. *Annu Rev Biochem* 2008;77:557.
76. Lang GA, Iwakuma T, Suh Y-A, et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. *Cell* 2004;119:861.
77. Cheng Q, Chen J. Mechanism of p53 stabilization by ATM after DNA damage. *Cell Cycle* 2010;9:472.
78. Song H, Hollstein M, Xu Y. p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM. *Nat Cell Biol* 2007;9:573.
79. Weir BA, Woo MS, Getz G, et al. Characterizing the cancer genome in lung adenocarcinoma: SUPPLEMENT. *Nature* 2007;450:893.
80. Klein C, Vassilev LT. Targeting the p53-MDM2 interaction to treat cancer. *Br J Cancer* 2004;91:1415.
81. Eymin B, Gazzeri S, Brambilla C, Brambilla E. Mdm2 overexpression and p14(ARF) inactivation are two mutually exclusive events in primary human lung tumors. *Oncogene* 2002;21:2750.
82. Menendez D, Inga A, Resnick MA. The expanding universe of p53 targets. *Nat Rev Cancer* 2009;9:474.
83. Tarasov V, Jung P, Verdoodt B, et al. Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. *Cell Cycle* 2007;6:1586.

84. Raver-Shapira N, Marciano E, Meiri E, et al. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. *Molecular Cell* 2007;26:731.
85. Wang W, El-Deiry WS. Restoration of p53 to limit tumor growth. *Curr Opin Oncol* 2008;20:90.
86. Hege KM, Carbone DP. Lung cancer vaccines and gene therapy. *Lung Cancer* 2003;41(Suppl 1):S103.
87. Wang Z, Sun Y. Targeting p53 for novel anticancer therapy. *Transl Oncol* 2010;3:1.
88. Carbone DP, Ciernik IF, Kelley MJ, et al. Immunization with mutant p53- and K-ras-derived peptides in cancer patients: immune response and clinical outcome. *J Clin Oncol* 2005;23:5099.
89. Antonia SJ, Mirza N, Fricke I, et al. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. *Clin Cancer Res* 2006;12:878.
90. Chiappori AA, Soliman H, Janssen WE, Antonia SJ, Gabrilovich DI. INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect. *Expert Opin Biol Ther* 2010;10:983.
91. Belinsky SA, Nikula KJ, Palmisano WA, et al. Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. *Proc Natl Acad Sci U S A* 1998;95:11891.
92. Zhang Y, Xiong Y, Yarbrough WG. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. *Cell* 1998;92:725.
93. Meuwissen R, Linn SC, Linnola RI, et al. Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model. *Cancer Cell* 2003;4:181.
94. Beroukhi R, Mermel CH, Porter D, et al. The landscape of somatic copy-number alteration across human cancers. *Nature* 2010;463:899.
95. Hearle N, Schumacher V, Menko FH, et al. Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. *Clin Cancer Res* 2006;12:3209.
96. Jansen M, Ten Klooster JP, Offerhaus GJ, Clevers H. LKB1 and AMPK family signaling: the intimate link between cell polarity and energy metabolism. *Physiol Rev* 2009;89:777.
97. Carretero J, Medina PP, Pio R, Montuenga LM, Sanchez-Cespedes M. Novel and natural knockout lung cancer cell lines for the LKB1/STK11 tumor suppressor gene. *Oncogene* 2004;23:4037.
98. Ji H, Ramsey MR, Hayes DN, et al. LKB1 modulates lung cancer differentiation and metastasis. *Nature* 2007;448:807.
99. Matsumoto S, Iwakawa R, Takahashi K, et al. Prevalence and specificity of LKB1 genetic alterations in lung cancers. *Oncogene* 2007;26:5911.
100. Amin RMS, Hiroshima K, Iyoda A, et al. LKB1 protein expression in neuroendocrine tumors of the lung. *Pathol Int* 2008;58:84.
101. Gwinn D, Shackelford D, Egan D, et al. AMPK phosphorylation of raptor mediates a metabolic checkpoint. *Molecular Cell* 2008;30:214.
102. Mahoney CL, Choudhury B, Davies H, et al. LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition. *Br J Cancer* 2009;100:370.
103. Robinson J, Lai C, Martin A, et al. Oral rapamycin reduces tumour burden and vascularization in Lkb1(+/-) mice. *J Pathol* 2009;219:35.
104. Liu B, Fan Z, Edgerton SM, et al. Metformin induces unique biological and molecular responses in triple negative breast cancer cells. *Cell Cycle* 2009;8:2031.
105. Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin: Response to Farooki and Schneider. *Diabetes Care* 2006;29:1990.
106. Evans JMM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. *BMJ* 2005;330:1304.
107. Libby G, Donnelly L, Donnan P, et al. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. *Diabetes Care* 2009;32:1620.
108. Jiralerspong S, Palla SL, Giordano SH, et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. *J Clin Oncol* 2009;27:3297.
109. Baas AF, Kuipers J, van der Wel NN, et al. Complete polarization of single intestinal epithelial cells upon activation of LKB1 by STRAD. *Cell* 2004;116:457.
110. Shackelford DB, Shaw RJ. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. *Nat Rev Cancer* 2009;9:563.
111. Baykara O, Demirkaya A, Kaynak K, et al. WWOX gene may contribute to progression of human small cell lung cancer (NSCLC). *Tumour Biol* 2010;31:315.
112. Ding L, Getz G, Wheeler DA, et al. Somatic mutations affect key pathways in lung adenocarcinoma. *Nature* 2008;455:1069.
113. Hesson LB, Cooper WN, Latif F. Evaluation of the 3p21.3 tumour-suppressor gene cluster. *Oncogene* 2007;26:7283.
114. Lerman MI, Minna JD. The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: identification and evaluation of the resident candidate tumor suppressor genes. The International Lung Cancer Chromosome 3p21.3 Tumor Suppressor Gene Consortium. *Cancer Res* 2000;60:6116.
115. Lundberg AS, Randell SH, Stewart SA, et al. Immortalization and transformation of primary human airway epithelial cells by gene transfer. *Oncogene* 2002;21:4577.
116. Zhu CQ, Cutz JC, Liu N, et al. Amplification of telomerase (hTERT) gene is a poor prognostic marker in non-small cell lung cancer. *Br J Cancer* 2006;94:1452.
117. Miura N, Nakamura H, Sato R, et al. Clinical usefulness of serum telomerase reverse transcriptase (hTERT) mRNA and epidermal growth factor receptor (EGFR) mRNA as a novel tumor marker for lung cancer. *Cancer Sci* 2006;97:1366.
118. Marchetti A, Pellegrini C, Buttitta F, et al. Prediction of survival in stage I lung carcinoma patients by telomerase function evaluation. *Lab Invest* 2002;82:729.
119. Shibuya K, Fujisawa T, Hoshino H, et al. Increased telomerase activity and elevated hTERT mRNA expression during multistage carcinogenesis of squamous cell carcinoma of the lung. *Cancer* 2001;92:849.
120. Brunsvig PE, Aamdal S, Gjertsen MK, et al. Telomerase peptide vaccination: a phase III study in patients with non-small cell lung cancer. *Cancer Immunol Immunother* 2006;55:1553.
121. Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. *Oncogene* 2007;26:1324.
122. Pezzella F, Turley H, Kuzu I, et al. Bcl-2 protein in non-small cell lung carcinoma. *N Engl J Med* 1993;329:690.
123. Ikegaki N, Katsumata M, Minna J, Tsujimoto Y. Expression of Bcl-2 in small cell lung carcinoma cells. *Cancer Res* 1994;54:6.
124. Martin B, Paesmans M, Berghmans T, et al. Role of Bcl-2 as a prognostic factor for survival in lung cancer: a systematic review of the literature with meta-analysis. *Br J Cancer* 2003;89:55.
125. Campos L, Rouault JP, Sabido O, et al. High expression of Bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. *Blood* 1993;81:3091.
126. Mortenson MM, Schlieman MG, Virudachalam S, et al. Reduction in BCL-2 levels by 26S proteasome inhibition with bortezomib is associated with induction of apoptosis in small cell lung cancer. *Lung Cancer* 2005;49:163.
127. Rudin CM, Kozloff M, Hoffman PC, et al. Phase I study of G3139, a Bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small cell lung cancer. *J Clin Oncol* 2004;22:1110-7.

128. Rudin CM, Salgia R, Wang X, et al. Randomized phase II study of carboplatin and etoposide with or without the Bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103. *J Clin Oncol* 2008;26:870.
129. Shivapurkar N, Reddy J, Matta H, et al. Loss of expression of death-inducing signaling complex (DISC) components in lung cancer cell lines and the influence of MYC amplification. *Oncogene* 2002;21:8510.
130. Park JY, Park JM, Jang JS, et al. Caspase 9 promoter polymorphisms and risk of primary lung cancer. *Hum Mol Genet* 2006;15:1963.
131. Lu B, Mu Y, Cao C, et al. Survivin as a therapeutic target for radiation sensitization in lung cancer. *Cancer Res* 2004;64:2840.
132. Isobe T, Herbst RS, Onn A. Current management of advanced non-small cell lung cancer: targeted therapy. *Semin Oncol* 2005;32:315.
133. Acuff HB, Sinnamon M, Fingleton B, et al. Analysis of host- and tumor-derived proteinases using a custom dual species microarray reveals a protective role for stromal matrix metalloproteinase-12 in non-small cell lung cancer. *Cancer Res* 2006;66:7968.
134. Ikushima H, Miyazono K. TGFbeta signalling: a complex web in cancer progression. *Nat Rev Cancer* 2010;10:415.
135. Gregory PA, Bert AG, Paterson EL, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. *Nat Cell Biol* 2008;10:593.
136. Gibbons DL, Lin W, Creighton CJ, et al. Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression. *Genes Dev* 2009;23:2140.
137. Sandler AB. Targeting angiogenesis in lung cancer. *Semin Oncol* 2005;32:S16.
138. Mineo TC, Ambrogi V, Baldi A, et al. Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumour vessel invasion after radical surgery for IB-IIA non-small cell lung cancer. *J Clin Pathol* 2004;57:591.
139. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small cell lung cancer: AVAIL. *J Clin Oncol* 2009;27:1227.
140. Reck M, von Pawel J, Zatloukal P, et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). *Ann Oncol* 2010;21:1804.
141. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer. *N Engl J Med* 2006;355:2542.
142. Jordan CT, Guzman ML, Noble M. Cancer stem cells. *N Engl J Med* 2006;355:1253.
143. Germano D, Blyszczuk P, Valaperti A, et al. Prominin-1/CD133+ lung epithelial progenitors protect from bleomycin-induced pulmonary fibrosis. *Am J Respir Crit Care Med* 2009;179:939.
144. Kim CFB, Jackson EL, Woolfenden AE, et al. Identification of bronchioalveolar stem cells in normal lung and lung cancer. *Cell* 2005;121:823.
145. Bertolini G, Roz L, Perego P, et al. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. *Proc Natl Acad Sci U S A* 2009;106:16281.
146. Chen Y-C, Hsu H-S, Chen Y-W, et al. Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells. *PLoS One* 2008;3:e2637.
147. Eramo A, Lotti F, Sette G, et al. Identification and expansion of the tumorigenic lung cancer stem cell population. *Cell Death Differ* 2008;15:504.
148. Jiang T, Collins BJ, Jin N, et al. Achaete-scute complex homologue 1 regulates tumor-initiating capacity in human small cell lung cancer. *Cancer Res* 2009;69:845.
149. Jiang F, Qiu Q, Khanna A, et al. Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. *Mol Cancer Res* 2009;7:330.
150. Pine SR, Ryan BM, Varticovski L, Robles AI, Harris CC. Microenvironmental modulation of asymmetric cell division in human lung cancer cells. *Proc Natl Acad Sci U S A* 2010;107:2195.
151. Jaksch M, Múnera J, Bajpai R, Terskikh A, Oshima RG. Cell cycle-dependent variation of a CD133 epitope in human embryonic stem cell, colon cancer, and melanoma cell lines. *Cancer Res* 2008;68:7882.
152. Shmelkov SV, Butler JM, Hooper AT, et al. CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. *J Clin Invest* 2008;118:2111.
153. Kelly PN, Dakic A, Adams JM, Nutt SL, Strasser A. Tumor growth need not be driven by rare cancer stem cells. *Science* 2007;317:337.
154. Shedden K, Taylor JM, Enkemann SA, et al. Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. *Nat Med* 2008;14:822.
155. Chitale D, Gong Y, Taylor BS, et al. An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors. *Oncogene* 2009;28:2773.
156. Raponi M, Zhang Y, Yu J, et al. Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. *Cancer Res* 2006;66:7466.
157. Potti A, Dressman HK, Bild A, et al. Genomic signatures to guide the use of chemotherapeutics. *Nat Med* 2006;12:1294.
158. Sos ML, Fischer S, Ullrich R, et al. Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. *Proc Natl Acad Sci U S A* 2009;106:18351.
159. Sos ML, Michel K, Zander T, et al. Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. *J Clin Invest* 2009;119:1727.
160. Bild AH, Yao G, Chang JT, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. *Nature* 2006;439:353.
161. Lamb J, Crawford ED, Peck D, et al. The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease. *Science* 2006;313:1929.
162. Luo J, Emanuele MJ, Li D, et al. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. *Cell* 2009;137:835.
163. Whitehurst AW, Bodemann BO, Cardenas J, et al. Synthetic lethal screen identification of chemosensitizer loci in cancer cells. *Nature* 2007;446:815.
164. Gustafson AM, Soldi R, Anderlind C, et al. Airway PI3K pathway activation is an early and reversible event in lung cancer development. *Sci Transl Med* 2010;2:26ra25.

Chapter 16 – References

1. Hanahan D, Weinberg RA. The hallmarks of cancer. *Cell* 2000;100:57.
2. Risk JM, Field EA, Field JK, et al. Tylosis oesophageal cancer mapped. *Nat Genet* 1994;8(4):319.
3. Schlessinger J. Cell signaling by receptor tyrosine kinases. *Cell* 2000;103(2):211.
4. al-Kasspooles M, Moore JH, Orringer MB, Beer DG. Amplification and over-expression of the EGFR and erbB-2 genes in human esophageal adenocarcinomas. *Int J Cancer* 1993;54:213.
5. Torzewski M, Sarbia M, Verreet P, et al. The prognostic significance of epidermal growth factor receptor expression in squamous cell carcinomas of the oesophagus. *Anticancer Res* 1997;17(5B):3915.
6. Inada S, Koto T, Futami K, Arima S, Iwashita A. Evaluation of malignancy and the prognosis of esophageal cancer based on an immunohistochemical study (p53, E-cadherin, epidermal growth factor receptor). *Surg Today* 1999;29:493.
7. Rusch V, Mendelsohn J, Dmitrovsky E. The epidermal growth factor receptor and its ligands as therapeutic targets in human tumors. *Cytokine Growth Factor Rev* 1996;7(2):133.
8. Jankowski J, McMenemin R, Hopwood D, et al. Abnormal expression of growth regulatory factors in Barrett's oesophagus. *Clin Sci (Lond)* 1991;81:663.
9. Yoshida K, Kuniyasu H, Yasui W, et al. Expression of growth factors and their receptors in human esophageal carcinomas: regulation of expression by epidermal growth factor and transforming growth factor alpha. *J Cancer Res Clin Oncol* 1993;119:401.
10. Jankowski J, Hopwood D, Wormsley KG. Flow-cytometric analysis of growth-regulatory peptides and their receptors in Barrett's oesophagus and oesophageal adenocarcinoma. *Scand J Gastroenterol* 1992;27:147.
11. Brito MJ, Filipe MI, Linehan J, et al. Association of transforming growth factor alpha (TGFA) and its precursors with malignant change in Barrett's epithelium: biological and clinical variables. *Int J Cancer* 1995;60:27.
12. Yacoub L, Goldman H, Odze RD. Transforming growth factor-alpha, epidermal growth factor receptor, and MiB-1 expression in Barrett's-associated neoplasia: correlation with prognosis. *Mod Pathol* 1997;10:105.
13. Itakura Y, Sasano H, Shiga C, et al. Epidermal growth factor receptor overexpression in esophageal carcinoma: an immunohistochemical study correlated with clinicopathologic findings and DNA amplification. *Cancer* 1994;74:795.
14. Hickey K, Grehan D, Reid IM, et al. Expression of epidermal growth factor receptor and proliferating cell nuclear antigen predicts response of esophageal squamous cell carcinoma to chemoradiotherapy. *Cancer* 1994;74:1693.
15. Kitagawa Y, Ueda M, Ando N, et al. Further evidence for prognostic significance of epidermal growth factor receptor gene amplification in patients with esophageal squamous cell carcinoma. *Clin Cancer Res* 1996;2:909.
16. Deshpande A, Sicinski P, Hinds PW. Cyclins and CDKs in development and cancer: a perspective. *Oncogene* 2005;24(17):2909.
17. Arber N, Lightdale C, Rotterdam H, et al. Increased expression of the cyclin D1 gene in Barrett's esophagus. *Cancer Epidemiol Biomarkers Prev* 1996;5:457.
18. Roncalli M, Bosari S, Marchetti A, et al. Cell cycle-related gene abnormalities and product expression in esophageal carcinoma. *Lab Invest* 1998;78:1049.
19. Shamma A, Doki Y, Shiozaki H, et al. Cyclin D1 overexpression in esophageal dysplasia: a possible biomarker for carcinogenesis of esophageal squamous cell carcinoma. *Int J Oncol* 2000;16:261.
20. Sarbia M, Bektas N, Muller W, et al. Expression of cyclin E in dysplasia, carcinoma, and nonmalignant lesions of Barrett esophagus. *Cancer* 1999;86:2597.
21. Barbash O, Zamfirova P, Lin DI, et al. Mutations in Fbx4 inhibit dimerization of the SCF(Fbx4) ligase and contribute to cyclin D1 overexpression in human cancer. *Cancer Cell* 2008;14(1):68.
22. Barrett MT, Sanchez CA, Galipeau PC, et al. Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barrett's esophagus. *Oncogene* 1996;13:1867.
23. Wong DJ, Barrett MT, Stoger R, et al. p16INK4a promoter is hypermethylated at a high frequency in esophageal adenocarcinomas. *Cancer Res* 1997;57:2619.
24. Klump B, Hsieh CJ, Holzmann K, et al. Hypermethylation of the CDKN2/p16 promoter during neoplastic progression in Barrett's esophagus. *Gastroenterology* 1998;115:1381.
25. Xing EP, Nie Y, Wang LD, et al. Aberrant methylation of p16INK4a and deletion of p15INK4b are frequent events in human esophageal cancer in Linxian, China. *Carcinogenesis* 1999;20:77.
26. Maesawa C, Tamura G, Nishizuka S, et al. Inactivation of the CDKN2 gene by homozygous deletion and de novo methylation is associated with advanced stage esophageal squamous cell carcinoma. *Cancer Res* 1996;56:3875.
27. Boynton RF, Huang Y, Blount PL, et al. Frequent loss of heterozygosity at the retinoblastoma locus in human esophageal cancers. *Cancer Res* 1991;51:5766.
28. Coppola D, Schreiber RH, Mora L, et al. Significance of Fas and retinoblastoma protein expression during the progression of Barrett's metaplasia to adenocarcinoma. *Ann Surg Oncol* 1999;6:298.
29. Ikeguchi M, Oka S, Gomyo Y, et al. Clinical significance of retinoblastoma protein (pRB) expression in esophageal squamous cell carcinoma. *J Surg Oncol* 2000;73:104.
30. Joerger AC, Ang HC, Veprintsev DB, Blair CM, Fersht AR. Structures of p53 cancer mutants and mechanism of rescue by second-site suppressor mutations. *J Biol Chem* 2005;280:16030.
31. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. *Nat Med* 2004;10:789.
32. Sengupta S, Harris CC. p53: traffic cop at the crossroads of DNA repair and recombination. *Nat Rev Mol Cell Biol* 2005;6:44.
33. Hamelin R, Flejou JF, Muzeau F, et al. TP53 gene mutations and p53 protein immunoreactivity in malignant and premalignant Barrett's esophagus. *Gastroenterology* 1994;107:1012.
34. Ramel S, Reid BJ, Sanchez CA, et al. Evaluation of p53 protein expression in Barrett's esophagus by two-parameter flow cytometry. *Gastroenterology* 1992;102:1220.
35. Younes M, Lebovitz RM, Lechago LV, et al. p53 protein accumulation in Barrett's metaplasia, dysplasia, and carcinoma: a follow-up study. *Gastroenterology* 1993;105:1637.
36. Casson AG, Mukhopadhyay T, Cleary KR, et al. p53 gene mutations in Barrett's epithelium and esophageal cancer. *Cancer Res* 1991;51:4495.
37. Gaur D, Arora S, Mathur M, et al. High prevalence of p53 gene alterations and protein overexpression in human esophageal cancer: correlation with dietary risk factors in India. *Clin Cancer Res* 1997;3:2129.
38. Kato H, Yoshikawa M, Miyazaki T, et al. Expression of p53 protein related to smoking and alcoholic beverage drinking habits in patients with esophageal cancers. *Cancer Lett* 2001;167:65.
39. Lam KY, Tsao SW, Zhang D, et al. Prevalence and predictive value of p53 mutation in patients with esophageal squamous cell carcinomas: a prospective clinicopathological study and survival analysis of 70 patients. *Int J Cancer* 1997;74:212.
40. Taniere P, Martel-Planche G, Saurin JC, et al. TP53 mutations, amplification of P63 and expression of cell cycle proteins in squamous cell carcinoma of the oesophagus from a low incidence area in Western Europe. *Br J Cancer* 2001;85:721.

41. Ribeiro U Jr, Finkelstein SD, Safatle-Ribeiro AV, et al. p53 sequence analysis predicts treatment response and outcome of patients with esophageal carcinoma. *Cancer* 1998;83:7.
42. Koyanagi K, Ozawa S, Ando N, et al. Clinical significance of telomerase activity in the non-cancerous epithelial region of esophageal squamous cell carcinoma. *Br J Surg* 1999;86:674.
43. Morales CP, Lee EL, Shay JW. In situ hybridization for the detection of telomerase RNA in the progression from Barrett's esophagus to esophageal adenocarcinoma. *Cancer* 1998;83:652.
44. Opitz OG, Suliman Y, Hahn WC, et al. Cyclin D1 overexpression and p53 inactivation immortalize primary oral keratinocytes by a telomerase-independent mechanism. *J Clin Invest* 2001;108(5):725.
45. Christofori G, Semb H. The role of the cell-adhesion molecule E-cadherin as a tumour-suppressor gene. *Trends Biochem Sci* 1999;24:73.
46. Swami S, Kumble S, Triadafilopoulos G. E-cadherin expression in gastroesophageal reflux disease, Barrett's esophagus, and esophageal adenocarcinoma: an immunohistochemical and immunoblot study. *Am J Gastroenterol* 1995;90:1808.
47. Takeno S, Noguchi T, Fumoto S, et al. E-cadherin expression in patients with esophageal squamous cell carcinoma: promoter hypermethylation, Snail overexpression, and clinicopathologic implications. *Am J Clin Pathol* 2004;122(1):78.
48. Okawa T, Michaylira CZ, Kalabis J, et al. The functional interplay between EGFR overexpression, hTERT activation, and p53 mutation in esophageal epithelial cells with activation of stromal fibroblasts induces tumor development, invasion, and differentiation. *Genes Dev* 2007;21(21):2788.
49. Xu X, LoCicero J 3rd, Macri E, Loda M, Ellis FH Jr. Barrett's esophagus and associated adenocarcinoma in a mouse surgical model. *J Surg Res* 2000;88(2):120.
50. Opitz OG, Harada H, Suliman Y, et al. A mouse model of human oral-esophageal cancer. *J Clin Invest* 2002;110:761.
51. Siglin JC, Khare L, Stoner GD. Evaluation of dose and treatment duration on the esophageal tumorigenicity of N-nitrosomethylbenzylamine in rats. *Carcinogenesis* 1995;16(2):259.
52. Wang QS, Sabourin CL, Bijur GN, Robertson FM, Stoner GD. Alterations in transforming growth factor-alpha and epidermal growth factor receptor expression during rat esophageal tumorigenesis. *Mol Carcinog* 1996;15(2):144.
53. Bass AJ, Watanabe H, Mermel CH, et al. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. *Nat Genet* 2009;41(11):1238.
54. Zanghieri G, Di Gregorio C, Sacchetti C, et al. Familial occurrence of gastric cancer in the 2-year experience of a population-based registry. *Cancer* 1990;66:2047.
55. Mecklin JP, Nordling S, Saario I. Carcinoma of the stomach and its heredity in young patients. *Scand J Gastroenterol* 1988;23:307.
56. Gorer P. Genetic interpretation of studies on cancer in twins. *Ann Eugen* 1938;8:219.
57. Lee FI. Carcinoma of the gastric antrum in identical twins. *Postgrad Med J* 1971;47:622.
58. Guilford P, Hopkins J, Harraway J, et al. E-cadherin germline mutations in familial gastric cancer. *Nature* 1998;392:402.
59. Gayther SA, Goringe KL, Ramus SJ, et al. Identification of germ-line E-cadherin mutations in gastric cancer families of European origin. *Cancer Res* 1998;58:4086.
60. Yoon KA, Ku JL, Yang HK, et al. Germline mutations of E-cadherin gene in Korean familial gastric cancer patients. *J Hum Genet* 1999;44:177.
61. Shimamura K, Kohno T, Takahashi M, et al. Familial gastric cancer: clinicopathological characteristics, RER phenotype and germline p53 and E-cadherin mutations. *Carcinogenesis* 1999;20:1127.
62. Pharoah PD, Caldas C. Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. *Gastroenterology* 2001;121:1348.
63. Lewis FR, Mellinger JD, Hayashi A, et al. Prophylactic total gastrectomy for familial gastric cancer. *Surgery* 2001;130(4):612.
64. Chung DC, Rustgi AK. The hereditary nonpolyposis colorectal cancer syndrome: genetics and clinical implications. *Ann Intern Med* 2003;138(7):560.
65. El Omar EM, Rabkin CS, Gammon MD, et al. Increased risk of noncardiac gastric cancer associated with proinflammatory cytokine gene polymorphisms. *Gastroenterology* 2003;124:1193.
66. Billington BP. Gastric cancer relationships between blood groups, site, and epidemiology. *Lancet* 1956;2:859.
67. Buckwalter JA, Wholwend CB, Colter DC. The association of the ABO blood groups to gastric carcinoma. *Surg Gynecol Obstet* 1957;104:176.
68. Boren T, Falk P, Roth KA, et al. Attachment of Helicobacter pylori to human gastric epithelium mediated by blood group antigens. *Science* 1993;262:1892.
69. Silva F, Carvalho F, Peixoto A, et al. MUC1 polymorphism confers increased risk for intestinal metaplasia in a Colombian population with chronic gastritis. *Eur J Hum Genet* 2003;11(5):380.
70. Lee HS, Chang MS, Yang HK, Lee BL, Kim WH. Epstein-Barr virus-positive gastric carcinoma has a distinct protein expression profile in comparison with Epstein-Barr virus-negative carcinoma. *Clin Cancer Res* 2004;10(5):1698.
71. Kim SJ, Bang YJ, Park JG, et al. Genetic changes in the transforming growth factor beta (TGF-beta) type II receptor gene in human gastric cancer cells: correlation with sensitivity to growth inhibition by TGF-beta. *Proc Natl Acad Sci U S A* 1994;91:8772.
72. Yamamoto H, Sawai H, Peruchio M. Frameshift somatic mutations in gastrointestinal cancer of the microsatellite mutator phenotype. *Cancer Res* 1997;57:4420.
73. Yin J, Kong D, Wang S, et al. Mutation of hMSH3 and hMSH6 mismatch repair genes in genetically unstable human colorectal and gastric carcinomas. *Hum Mutat* 1997;10:474.
74. Souza RF, Appel R, Yin J, et al. Microsatellite instability in the insulin-like growth factor II receptor gene in gastrointestinal tumors. *Nat Genet* 1996;14:255.
75. Souza RF, Yin J, Smolinski KN, et al. Frequent mutation of the E2F-4 cell cycle gene in primary human gastrointestinal tumors. *Cancer Res* 1997;57:2350.
76. Seruca R, Santos NR, David L, et al. Sporadic gastric carcinomas with microsatellite instability display a particular clinicopathologic profile. *Int J Cancer* 1995;64:32.
77. dos Santos NR, Seruca R, Constancia M, et al. Microsatellite instability at multiple loci in gastric carcinoma: clinicopathologic implications and prognosis. *Gastroenterology* 1996;110:38.
78. Hollstein M, Shomer B, Greenblatt M, et al. Somatic point mutations in the p53 gene of human tumors and cell lines: updated compilation. *Nucleic Acids Res* 1996;24:141.
79. Suzuki H, Itoh F, Toyota M, et al. Distinct methylation pattern and microsatellite instability in sporadic gastric cancer. *Int J Cancer* 1999;83:309.
80. Toyota M, Ahuja N, Suzuki H, et al. Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. *Cancer Res* 1999;59:5438.
81. Ascano JJ, Moskaluk CA, Harper JC, et al. Inactivation of the E-cadherin gene in sporadic diffuse-type gastric cancer. *Mod Pathol* 2001;14:942.
82. Grady WM, Willis J, Guilford PJ, et al. Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer. *Nat Genet* 2000;26:16.
83. Taketo MM. Wnt signaling and gastrointestinal tumorigenesis in mouse models. *Oncogene* 2006;25(57):7522.

84. Fox JG, Dangler CA, Whary MT, et al. Mice carrying a truncated *Apc* gene have diminished gastric epithelial proliferation, gastric inflammation, and humoral immunity in response to *Helicobacter felis* infection. *Cancer Res* 1997;57(18):3972.
85. Teng Y, Sun AN, Pan XC, et al. Synergistic function of Smad4 and PTEN in suppressing forestomach squamous cell carcinoma in the mouse. *Cancer Res* 2006;66(14):6972.
86. Watson SA, Grabowska AM, El-Zaatari M, Takhar A. Gastrin—active participant or bystander in gastric carcinogenesis? *Nat Rev Cancer* 2006;6(12):936.
87. Wang TC, Dangler CA, Chen D, et al. Synergistic interaction between hypergastrinemia and *Helicobacter* infection in a mouse model of gastric cancer. *Gastroenterology* 2000;118(1):36.
88. Rogers AB, Taylor NS, Whary MT, et al. *Helicobacter pylori* but not high salt induces gastric intraepithelial neoplasia in B6129 mice. *Cancer Res* 2005;65(23):10709.
89. Cai X, Carlson J, Stoicov C, et al. *Helicobacter felis* eradication restores normal architecture and inhibits gastric cancer progression in C57BL/6 mice. *Gastroenterology* 2005;128(7):1937.
90. Houghton J, Stoicov C, Nomura S, et al. Gastric cancer originating from bone marrow-derived cells. *Science* 2004;306(5701):1568.
91. Tu S, Bhagat G, Cui G, et al. Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. *Cancer Cell* 2008;14(5):408.

Chapter 17 – References

1. Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. *Science* 2008;321:1801.
2. Shibata DK, Kern SE. Ancestral trees for modeling stem cell lineages genetically rather than functionally: understanding mutation accumulation and distinguishing the restrictive cancer stem cell propagation theory and the unrestricted cell propagation theory of human tumorigenesis. *Breast Dis* 2008;29:15.
3. Blackford A, Parmigiani G, Kensler TW, et al. Genetic mutations associated with cigarette smoking in pancreatic cancer. *Cancer Res* 2009;69:3681.
4. Goggins M, Schutte M, Lu J, et al. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. *Cancer Res* 1996;56:5360.
5. Ozelik H, Schmock B, Di Nicola N, et al. Germline BRCA2 6174delT mutations in Ashkenazi Jewish pancreatic cancer patients. *Nat Genet* 1997;16:17.
6. Murphy KM, Brune KA, Griffin C, et al. Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. *Cancer Res* 2002;62:3789.
7. Hahn SA, Greenhalf B, Ellis I, et al. BRCA2 germline mutations in familial pancreatic carcinoma. *J Natl Cancer Inst* 2003;95:214.
8. Goggins M, Offerhaus GJA, Hilgers W, et al. Adenocarcinomas of the pancreas with DNA replication errors (RER+) are associated with wild-type K-ras and characteristic histopathology: poor differentiation, a syncytial growth pattern, and pushing borders suggest RER+. *Am J Pathol* 1998;152:1501.
9. Wilentz RE, Goggins M, Redston M, et al. Genetic, immunohistochemical, and clinical features of medullary carcinomas of the pancreas: a newly described and characterized entity. *Am J Pathol* 2000;156:1641.
10. Hruban RH, Wilentz R, Kern SE. Genetic progression in the pancreatic ducts. *Am J Pathol* 2000;156:1821.
11. van Heek NT, Meeker AK, Kern SE, et al. Telomere shortening is nearly universal in pancreatic intraepithelial neoplasia. *Am J Pathol* 2002;161:1541.
12. Gisselsson D, Jonson T, Petersen A, et al. Telomere dysfunction triggers extensive DNA fragmentation and evolution of complex chromosome abnormalities in human malignant tumors. *Proc Natl Acad Sci U S A* 2001;98:12683.
13. Hiyama E, Kodama T, Shinbara K, et al. Telomerase activity is detected in pancreatic cancer but not in benign tumors. *Cancer Res* 1997;57:326.
14. Iwao T, Hiyama E, Yokoyama T, et al. Telomerase activity for the preoperative diagnosis of pancreatic cancer. *J Natl Cancer Inst* 1997;89:1621.
15. Montgomery E, Wilentz RE, Argani P, et al. Analysis of anaphase figures in routine histologic sections distinguishes chromosomally unstable from chromosomally stable malignancies. *Cancer Biol Ther* 2003;2:248.
16. Cox AD, Der CJ. Ras family signaling: therapeutic targeting. *Cancer Biol Ther* 2002;1:599.
17. Almoguera C, Shibata D, Forrester K, et al. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. *Cell* 1988;53:549.
18. Caldas C, Hahn SA, Hruban RH, et al. Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. *Cancer Res* 1994;54:3568.
19. Klimstra DS, Longnecker DS. K-ras mutations in pancreatic ductal proliferative lesions. *Am J Pathol* 1994;145:1547.
20. Lerner EC, Qian Y, Blaskovich MA, et al. Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes. *J Biol Chem* 1995;270:26802.
21. Cox AD, Der CJ. Farnesyltransferase inhibitors: promises and realities. *Curr Opin Pharmacol* 2002;2:388.
22. Riggins GJ, Thiagalingam S, Rozenblum E, et al. Mad-related genes in the human. *Nat Genet* 1996;13:347.
23. Zawel L, Dai JL, Buckhaults P, et al. Human Smad3 and Smad4 are sequence-specific transcription activators. *Molec Cell* 1998;1:611.
24. Hahn SA, Schutte M, Hoque ATMS, et al. DPC4, a candidate tumor-suppressor gene at 18q21.1. *Science* 1996;271:350.
25. Goggins M, Shekher M, Turnacioglu K, et al. Genetic alterations of the TGF beta receptor genes in pancreatic and biliary adenocarcinomas. *Cancer Res* 1998;58:5329.
26. Baldwin RL, Friess H, Yokoyama M, et al. Attenuated ALK5 receptor expression in human pancreatic cancer: correlation with resistance to growth inhibition. *Int J Cancer* 1996;67:283.
27. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. *Nature* 1993;366:704.
28. Russo AA, Tong L, Lee JO, et al. Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the tumour suppressor p16INK4a. *Nature* 1998;395:237.
29. Coleman KG, Wautlet BS, Morrissey D, et al. Identification of CDK4 sequences involved in cyclin D1 and p16 binding. *J Biol Chem* 1997;272:18869.
30. Caldas C, Hahn SA, da Costa LT, et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. *Nature Genetics* 1994;8:27.
31. Schutte M, Hruban RH, Geradts J, et al. Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. *Cancer Res* 1997;57:3126.
32. Goldstein AM, Fraser MC, Struewing JB, et al. Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. *N Engl J Med* 1995;333: 970.
33. Moskaluk CA, Hruban RH, Lietman AS, et al. Novel germline p16INK4a allele (Asp145Cys) in a family with multiple pancreatic carcinomas. *Human Mutation, Mutation in Brief* 148 1997;12:70.
34. Whelan AJ, Bartsch D, Goodfellow PJ. Brief report: a familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor-suppressor gene. *N Engl J Med* 1995;333:975.
35. Ciotti P, Strigini P, Bianchi-Scarra G. Familial melanoma and pancreatic cancer. *N Engl J Med* 1996;334:469.
36. Bartsch DK, Langer P, Habbe N, et al. Clinical and genetic analysis of 18 pancreatic carcinoma/melanoma-prone families. *Clin Genet* 2010;77(4):333.
37. Huang L, Lang D, Geradts J, et al. Molecular and immunohistochemical analyses of RB1 and cyclin D1 in human ductal pancreatic carcinomas and cell lines. *Mol Carcinog* 1996;15:85.
38. Kern SE, Kinzler KW, Bruskin A, et al. Identification of p53 as a sequence-specific DNA-binding protein. *Science* 1991;252:1708.
39. El-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. *Cell* 1993;75:817.
40. Kern SE, Pietenpol JA, Thiagalingam S, et al. Oncogenic forms of p53 inhibit p53-regulated gene expression. *Science* 1992;256:827.
41. Redston MS, Caldas C, Seymour AB, et al. p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. *Cancer Res* 1994;54:3025.
42. Rozenblum E, Schutte M, Goggins M, et al. Tumor-suppressive pathways in pancreatic carcinoma. *Cancer Res* 1997;57:1731.
43. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. *Nature* 1998;396:643.

44. Johansson B, Bardi G, Heim S, et al. Nonrandom chromosomal rearrangements in pancreatic carcinomas. *Cancer* 1992;69:1.
45. Griffin CA, Hruban RH, Morsberger LA, et al. Consistent chromosome abnormalities in adenocarcinoma of the pancreas. *Cancer Res* 1995;55:2394.
46. Brat DJ, Hahn SA, Griffin CA, et al. The structural basis of molecular genetic deletions: an integration of classical cytogenetic and molecular analyses in pancreatic adenocarcinoma. *Am J Pathol* 1997;150:383.
47. Hahn SA, Seymour AB, Hoque ATMS, et al. Allelotype of pancreatic adenocarcinoma using a xenograft model. *Cancer Res* 1995;55:4670.
48. Ionov Y, Peinado MA, Malkhosyan S, et al. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. *Nature* 1993;363:558.
49. Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. *Science* 1993;260:816.
50. Aaltonen LA, Peltomäki P, Leach FS, et al. Clues to the pathogenesis of familial colorectal cancer. *Science* 1993;260:812.
51. Yamamoto H, Itoh F, Nakamura H, et al. Genetic and clinical features of human pancreatic ductal adenocarcinomas with widespread microsatellite instability. *Cancer Res* 2001;61:3139.
52. Markowitz S, Wang J, Myeroff L, et al. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. *Science* 1995;268:1336.
53. Hempen PM, Zhang L, Bansal RK, et al. Evidence of selection for clones having genetic inactivation of the activin A type II receptor (ACVR2) gene in gastrointestinal cancers. *Cancer Res* 2003;63:994.
54. Rampino N, Yamamoto H, Ionov Y, et al. Somatic frame-shift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. *Science* 1997;275:967.
55. Day JD, DiGiuseppe JA, Yeo CJ, et al. Immunohistochemical evaluation of Her-2/neu oncogene expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasms. *Human Pathol* 1996;27:119.
56. Lei S, Appert HE, Nakata B, et al. Overexpression of HER2/neu oncogene in pancreatic cancer correlates with shortened survival. *Int J Pancreatol* 1995;17:15.
57. Yamanaka Y, Friess H, Kobrin MS, et al. Overexpression of HER2/neu oncogene in human pancreatic carcinoma. *Hum Pathol* 1993;24:1127.
58. Sakorafas GH, Lazaris A, Tsiotou AG, et al. Oncogenes in cancer of the pancreas. *Eur J Surg Oncol* 1995;21:251.
59. Matsubayashi H, Canto M, Sato N, et al. DNA methylation alterations in the pancreatic juice of patients with suspected pancreatic disease. *Cancer Res* 2006;66:1208.
60. Schonleben F, Qiu W, Ciau NT, et al. PIK3CA mutations in intraductal papillary mucinous neoplasm/carcinoma of the pancreas. *Clin Cancer Res* 2006;12:3851.
61. Abraham SC, Klimstra DS, Wilentz RE, et al. Solid-pseudopapillary tumors of the pancreas are genetically distinct from pancreatic ductal adenocarcinomas and almost always harbor beta-catenin mutations. *Am J Pathol* 2002;160:1361.
62. Abraham SC, Wu TT, Klimstra DS, et al. Distinctive molecular genetic alterations in sporadic and familial adenomatous polyposis-associated pancreatoblastomas: frequent alterations in the APC/beta-catenin pathway and chromosome 11p. *Am J Pathol* 2001;159:1619.
63. Chung DC, Brown SB, Graeme-Cook F, et al. Localization of putative tumor suppressor loci by genome-wide allelotyping in human pancreatic endocrine tumors. *Cancer Res* 1998;58:3706.
64. Mizuta R, LaSalle JM, Cheng HL, et al. RAB22 and RAB163/mouse BRCA2: proteins that specifically interact with the RAD51 protein. *Proc Natl Acad Sci U S A* 1997;94:6927.
65. Xia B, Sheng Q, Nakanishi K, et al. Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. *Mol Cell* 2006;22:719.
66. Jones S, Hruban RH, Kamiyama M, et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. *Science* 2009;324:217.
67. Slater EP, Langer P, Niemczyk E, et al. PALB2 mutations in European familial pancreatic cancer families. *Clin Genet* 2010;78(5):490.
68. Van Der Heijden MS, Yeo CJ, Hruban RH, et al. Fanconi anemia gene mutations in young-onset pancreatic cancer. *Cancer Res* 2003;63:2585.
69. Kern SE, Hruban RH, Hidalgo M, et al. An introduction to pancreatic carcinoma genetics, pathology, and therapy. *Cancer Biol Ther* 2002;1:607.
70. Moynahan ME, Cui TY, Jasin M. Homology-directed DNA repair, mitomycin-c resistance, and chromosome stability is restored with correction of a Brca1 mutation. *Cancer Res* 2001;61:4842.
71. Tutt A, Bertwistle D, Valentine J, et al. Mutation in Brca2 stimulates error-prone homology-directed repair of DNA double-strand breaks occurring between repeated sequences. *Embo J* 2001;20:4704.
72. Gallmeier E, Calhoun ES, Rago C, et al. Targeted disruption of FANCC and FANCG in human cancer provides a preclinical model of specific therapeutic options. *Gastroenterology* 2006;130:2145.
73. Todd KE, Gloor B, Lane JS, et al. Resection of locally advanced pancreatic cancer after downstaging with continuous-infusion 5-fluorouracil, mitomycin-C, leucovorin, and dipyrindamol. *J Gastrointest Surg* 1998;2:159.
74. Takada T, Nimura Y, Katoh H, et al. Prospective randomized trial of 5-fluorouracil, doxorubicin, and mitomycin C for non-resectable pancreatic and biliary carcinoma: multicenter randomized trial. *Hepatogastroenterology* 1998;45:2020.
75. Sadoff L, Latino F. Complete clinical remission in a patient with advanced pancreatic cancer using mitomycin C-based chemotherapy: the role of adjunctive heparin. *Am J Clin Oncol* 1999;22:187.
76. Miura T, Endo Y, Matumoto Y, et al. Intra-arterial infusion chemotherapy in combination with microwave hyperthermia for cancer of head of pancreas and liver metastasis—a case of 16 years survival. *Gan To Kagaku Ryoho* 2000;27:1794.
77. Vaughn C, Chapman J, Chinn B, et al. Activity of 5-fluorouracil, mitomycin C, and methyl CCNU in inoperable adenocarcinoma of pancreas. *Am J Clin Oncol* 1989;12:49.
78. James E, Waldron-Lynch MG, Saif MW. Prolonged survival in a patient with BRCA2 associated metastatic pancreatic cancer after exposure to camptothecin: a case report and review of literature. *Anticancer Drugs* 2009;20:634.
79. Chalasani P, Kurtin S, Dragovich T. Response to a third-line mitomycin C (MMC)-based chemotherapy in a patient with metastatic pancreatic adenocarcinoma carrying germline BRCA2 mutation. *JOP* 2008;9:305.
80. Gallmeier E, Kern SE. Targeting Fanconi anemia/BRCA2 pathway defects in cancer: the significance of preclinical pharmacogenomic models. *Clin Cancer Res* 2007;13:4.
81. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. *N Engl J Med* 2009;361:123.
82. Axilbund JE, Argani P, Kamiyama M, et al. Absence of germline BRCA1 mutations in familial pancreatic cancer patients. *Cancer Biol Ther* 2009;8:131.
83. Al-Sukhni W, Rothenmund H, Borgida AE, et al. Germline BRCA1 mutations predispose to pancreatic adenocarcinoma. *Hum Genet* 2008;124:271.
84. Lal G, Liu G, Schmocker B, et al. Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1, and BRCA2 mutations. *Cancer Res* 2000;60:409.
85. Polyak K, Li Y, Zhu H, et al. Somatic mutations of the mitochondrial genome in human colorectal tumours. *Nat Genet* 1998;20:291.

86. Fliss MS, Usadel H, Caballero OL, et al. Facile detection of mitochondrial DNA mutations in tumors and bodily fluids. *Science* 2000;287:2017.
87. Jones JB, Song JJ, Hempen PM, et al. Detection of mitochondrial DNA mutations in pancreatic cancer offers a “mass”-ive advantage over detection of nuclear DNA mutations. *Cancer Res* 2001;61:1299.
88. Su GH, Hilgers W, Shekher M, et al. Alterations in pancreatic, biliary, and breast carcinomas support MKK4 as a genetically targeted tumor-suppressor gene. *Cancer Res* 1998;58:2339.
89. Teng DH-F, Perry WL III, Hogan JK, et al. Human mitogen-activated protein kinase kinase 4 as a candidate tumor suppressor. *Cancer Res* 1997;57:4177.
90. Cunningham SC, Gallmeier E, Hucl T, et al. Theoretical proposal: allele dosage of MAP2K4/MKK4 could rationalize frequent 17p loss in diverse human cancers. *Cell Cycle* 2006;5:1090.
91. Hemminki A, Markie D, Tomlinson I, et al. A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. *Nature* 1998;391:184.
92. Jenne DE, Reimann H, Nezu J, et al. Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. *Nature Genet* 1998;18:38.
93. Giardiello FM, Welsh SB, Hamilton SR, et al. Increased risk of cancer in the Peutz-Jeghers syndrome. *N Engl J Med* 1987;316:1511.
94. Giardiello FM, Brensinger JD, Tersmette AC, et al. Very high risk of cancer in familial Peutz-Jeghers syndrome. *Gastroenterology* 2000;119:1447.
95. Su GH, Hruban RH, Bova GS, et al. Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers. *Am J Pathol* 1999;154:1835.
96. Calhoun ES, Jones JB, Ashfaq R, et al. BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: potential therapeutic targets. *Am J Pathol* 2003;163:1255.
97. Iacobuzio-Donahue CA, Van Der Heijden MS, Baumgartner MR, et al. Large-scale allelotyping of pancreaticobiliary carcinoma provides quantitative estimates of genome-wide allelic loss. *Cancer Res* 2004;64:871.
98. Calhoun ES, Hucl T, Gallmeier E, et al. Identifying allelic loss and homozygous deletions in pancreatic cancer without matched normals using high-density single-nucleotide polymorphism arrays. *Cancer Res* 2006;66:7920.
99. Lengauer C, Kinzler KW, Vogelstein B. Genetic instability in colorectal cancers. *Nature* 1997;386:623.
100. Whitcomb DC, Gorry MC, Preston RA, et al. Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene. *Nature Genet* 1996;14:141.
101. Lowenfels AB, Maisonneuve P, DiMagno EP, et al. Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. *J Natl Cancer Inst* 1997;89:442.

Chapter 18 – References

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. *CA Cancer J Clin* 2005;55:74.
2. El Serag HB. Hepatocellular carcinoma: recent trends in the United States. *Gastroenterology* 2004;127:S27.
3. El-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. *Clin Gastroenterol Hepatol* 2006;4(3):369.
4. Libbrecht L, Desmet V, Roskams T. Preneoplastic lesions in human hepatocarcinogenesis. *Liver Int* 2005;25(1):16.
5. Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. *Nat Genet* 2002; 31:339.
6. Bruix J, Boix L, Sala M, Llovet JM. Focus on hepatocellular carcinoma. *Cancer Cell* 2004;5:215.
7. Quackenbush J. Microarray analysis and tumor classification. *N Engl J Med* 2006;354(23):2463.
8. Hood L, Heath JR, Phelps ME, Lin B. Systems biology and new technologies enable predictive and preventative medicine. *Science* 2004;306:640.
9. Pinkel D, Albertson DG. Array comparative genomic hybridization and its applications in cancer. *Nat Genet* 2005;37(Suppl):S11.
10. Moinzadeh P, Breuhahn K, Stutzer H, Schrmacher P. Chromosome alterations in human hepatocellular carcinomas correlate with aetiology and histological grade—results of an explorative CGH meta-analysis. *Br J Cancer* 2005;14:92:935.
11. Poon TCW, Wong N, Lai PBS, et al. A tumor progression model for hepatocellular carcinoma: bioinformatics analysis of genomic data. *Gastroenterology* 2006;131:1262.
12. Davies JJ, Wilson IM, Lam WL. Array CGH technologies and their applications to cancer genomes. *Chromosome Res* 2005;13:237.
13. Woo HG, Park ES, Lee JS, et al. Identification of potential driver genes in human liver carcinoma by genomewide screening. *Cancer Res* 2009;69(9):4059.
14. Kim CK, Lim JH, Lee WJ. Detection of hepatocellular carcinomas and dysplastic nodules in cirrhotic liver: accuracy of ultrasonography in transplant patients. *J Ultrasound Med* 2001;20:99.
15. Kojiro M, Roskams T. Early hepatocellular carcinoma and dysplastic nodules. *Semin Liver Dis* 2005;25:133.
16. Kaposi-Novak P, Libbrecht L, Woo HG, et al. Central role of c-Myc during malignant conversion in human hepatocarcinogenesis. *Cancer Res* 2009;69(7):2775.
17. Thorgeirsson SS, Lee JS, Grisham JW. Molecular prognostication of liver cancer: end of the beginning. *J Hepatol* 2006;44(4):798.
18. Lee JS, Chu IS, Heo J, et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. *Hepatology* 2004;40:667.
19. Boyault S, Rickman DS, de Reynies A, et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. *Hepatology* 2007;45(1):42.
20. Hoshida Y, Nijman SM, Kobayashi M, et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. *Cancer Res* 2009;69(18):7385.
21. Woo HG, Lee JH, Yoon JH, et al. Identification of a cholangiocarcinoma-like gene expression trait in hepatocellular carcinoma. *Cancer Res* 2010;70(8):3034.
22. Lee JS, Thorgeirsson SS. Comparative and integrative functional genomics of HCC. *Oncogene* 2006; 25(27): 3801.
23. Lee JS, Chu IS, Mikaelyan A, et al. Application of comparative functional genomics to identify best-fit mouse models to study human cancer. *Nat Genet* 2004; 36(12):1306.
24. Ellwood-Yen K, Graeber TG, Wongvipat J, et al. Myc-driven murine prostate cancer shares molecular features with human prostate tumors. *Cancer Cell* 2003;4:223.
25. Sweet-Cordero A, Mukherjee S, Subramanian A, et al. An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. *Nat Genet* 2005; 37:48.
26. Lee JS, Heo J, Libbrecht L, et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. *Nat Med* 2006;12(4):410.
27. Chang HY, Nuyten DS, Sneddon JB, et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. *Proc Natl Acad Sci U S A* 2005;102:3738.
28. International Cancer Genome Consortium. International network of cancer genome projects. *Nature* 2010; 464(7291):993.

Chapter 19 – References

1. Noffsinger AE. Serrated polyps and colorectal cancer: new pathway to malignancy. *Annu Rev Pathol* 2009; 4:343.
2. Leggett B, Whitehall V. Role of the serrated pathway in colorectal cancer pathogenesis. *Gastroenterology* 2010;138:2088.
3. Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. *Gastroenterology* 2008;134:1570.
4. Winawer SJ, Zauber AG, O'Brien MJ, et al. The National Polyp Study. Design, methods, and characteristics of patients with newly diagnosed polyps. The National Polyp Study Workgroup. *Cancer* 1992;70:1236.
5. Jones S, Chen WD, Parmigiani G, et al. Comparative lesion sequencing provides insights into tumor evolution. *Proc Natl Acad Sci U S A* 2008;105:4283.
6. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. *Nat Med* 2004;10:789.
7. Hanahan D, Weinberg RA. The hallmarks of cancer. *Cell* 2000;100:57.
8. Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. *N Engl J Med* 2009;360:1408.
9. Souglakos J, Philips J, Wang R, et al. Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. *Br J Cancer* 2009;101:465.
10. Pino MS, Chung DC. The chromosomal instability pathway in colon cancer. *Gastroenterology* 2010;138:2059.
11. Baker DJ, Jin F, Jeganathan KB, van Deursen JM. Whole chromosome instability caused by Bub1 insufficiency drives tumorigenesis through tumor suppressor gene loss of heterozygosity. *Cancer Cell* 2009;16:475.
12. Ionov Y, Peinado MA, Malkhosyan S, Shibata D, Perucho M. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. *Nature* 1993;363:558.
13. Spring KJ, Zhao ZZ, Karamatic R, et al. High prevalence of sessile serrated adenomas with BRAF mutations: a prospective study of patients undergoing colonoscopy. *Gastroenterology* 2006;131:1400.
14. Goelz SE, Vogelstein B, Hamilton SR, Feinberg AP. Hypomethylation of DNA from benign and malignant human colon neoplasms. *Science* 1985;228:187.
15. Feinberg AP, Gehrke CW, Kuo KC, Ehrlich M. Reduced genomic 5-methylcytosine content in human colonic neoplasia. *Cancer Res* 1988;48:1159.
16. Cui H, Cruz-Correa M, Giardiello FM, et al. Loss of IGF2 imprinting: a potential marker of colorectal cancer risk. *Science* 2003;299:1753.
17. Eden A, Gaudet F, Waghmare A, Jaenisch R. Chromosomal instability and tumors promoted by DNA hypomethylation. *Science* 2003;300:455.
18. Lin H, Yamada Y, Nguyen S, et al. Suppression of intestinal neoplasia by deletion of Dnmt3b. *Mol Cell Biol* 2006;26:2976.
19. Linhart HG, Lin H, Yamada Y, et al. Dnmt3b promotes tumorigenesis in vivo by gene-specific de novo methylation and transcriptional silencing. *Genes Dev* 2007;21:3110.
20. Toyota M, Ahuja N, Ohe-Toyota M, et al. CpG island methylator phenotype in colorectal cancer. *Proc Natl Acad Sci U S A* 1999;96:8681.
21. Suzuki H, Watkins DN, Jair KW, et al. Epigenetic inactivation of SFRP genes allows constitutive Wnt signaling in colorectal cancer. *Nat Genet* 2004;36:417.
22. Jess T, Loftus EV Jr, Velayos FS, et al. Risk of intestinal cancer in inflammatory bowel disease: a population-based study from Olmsted county, Minnesota. *Gastroenterology* 2006;130:1039.
23. Hussain SP, Amstad P, Raja K, et al. Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory disease. *Cancer Res* 2000;60:3333.
24. Hsieh CJ, Klump B, Holzmann K, et al. Hypermethylation of the p16INK4a promoter in colectomy specimens of patients with long-standing and extensive ulcerative colitis. *Cancer Res* 1998;58:3942.
25. Gardner EJ. A genetic and clinical study of intestinal polyposis, a predisposing factor for carcinoma of the colon and rectum. *Am J Hum Genet* 1951;3:167.
26. Hamilton SR, Liu B, Parsons RE, et al. The molecular basis of Turcot's syndrome. *N Engl J Med* 1995;332:839.
27. Parc Y, Piquard A, Dozois RR, Parc R, Tiret E. Long-term outcome of familial adenomatous polyposis patients after restorative colectomy. *Ann Surg* 2004;239:378.
28. Miyoshi Y, Nagase H, Ando H, et al. Somatic mutations of the APC gene in colorectal tumors: mutation cluster region in the APC gene. *Hum Mol Genet* 1992;1:229.
29. Spirio L, Olschwang S, Groden J, et al. Alleles of the APC gene: an attenuated form of familial polyposis. *Cell* 1993;75:951.
30. Laken SJ, Petersen GM, Gruber SB, et al. Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC. *Nat Genet* 1997;17:79.
31. Smalley WE, DuBois RN. Colorectal cancer and non-steroidal anti-inflammatory drugs. *Adv Pharmacol* 1997; 39:1.
32. Powell SM, Zilz N, Beazer-Barclay Y, et al. APC mutations occur early during colorectal tumorigenesis. *Nature* 1992;359:235.
33. Hadjihannas MV, Bruckner M, Jerchow B, et al. Aberrant Wnt/beta-catenin signaling can induce chromosomal instability in colon cancer. *Proc Natl Acad Sci U S A* 2006;103:10747.
34. Morin PJ, Sparks AB, Korinek V, et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. *Science* 1997;275:1787.
35. Sparks AB, Morin PJ, Vogelstein B, Kinzler KW. Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer. *Cancer Res* 1998;58:1130.
36. Sansom OJ, Reed KR, Hayes AJ, et al. Loss of Apc in vivo immediately perturbs Wnt signaling, differentiation, and migration. *Genes Dev* 2004;18:1385.
37. Clevers H. Wnt/beta-catenin signaling in development and disease. *Cell* 2006;127:469.
38. Roose J, Clevers H. TCF transcription factors: molecular switches in carcinogenesis. *Biochim Biophys Acta* 1999;1424:M23.
39. Korinek V, Barker N, Moerer P, et al. Depletion of epithelial stem-cell compartments in the small intestine of mice lacking Tcf-4. *Nat Genet* 1998;19:379.
40. Liu W, Dong X, Mai M, et al. Mutations in AXIN2 cause colorectal cancer with defective mismatch repair by activating beta-catenin/TCF signalling. *Nat Genet* 2000; 26:146.
41. Barker N, Ridgway RA, van Es JH, et al. Crypt stem cells as the cells-of-origin of intestinal cancer. *Nature* 2009;457:608.
42. van de Wetering M, Sancho E, Verweij C, et al. The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. *Cell* 2002;111:241.
43. He TC, Sparks AB, Rago C, et al. Identification of c-MYC as a target of the APC pathway. *Science* 1998;281:1509.
44. Sansom OJ, Meniel VS, Muncan V, et al. Myc deletion rescues Apc deficiency in the small intestine. *Nature* 2007;446:676.
45. Zeilstra J, Joosten SP, Dokter M, et al. Deletion of the WNT target and cancer stem cell marker CD44 in Apc(Min/+) mice attenuates intestinal tumorigenesis. *Cancer Res* 2008;68:3655.

46. Van Der Flier LG, van Gijn ME, Hatzis P, et al. Transcription factor achaete scute-like 2 controls intestinal stem cell fate. *Cell* 2009;136:903.
47. Gruber SB. New developments in Lynch syndrome (hereditary nonpolyposis colorectal cancer) and mismatch repair gene testing. *Gastroenterology* 2006;130:577.
48. Vasen HF, Watson P, Mecklin JP, Lynch HT. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. *Gastroenterology* 1999;116:1453.
49. Watson P, Vasen HF, Mecklin JP, et al. The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. *Int J Cancer* 2008;123:444.
50. Fishel R, Kolodner RD. Identification of mismatch repair genes and their role in the development of cancer. *Curr Opin Genet Dev* 1995;5:382.
51. Vasen HF, Boland CR. Progress in genetic testing, classification, and identification of Lynch syndrome. *JAMA* 2005;293:2028.
52. Liu T, Yan H, Kuismanen S, et al. The role of hPMS1 and hPMS2 in predisposing to colorectal cancer. *Cancer Res* 2001;61:7798.
53. Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. *J Natl Cancer Inst* 2004;96:261.
54. Pinol V, Castells A, Andreu M, et al. Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. *JAMA* 2005;293:1986.
55. Balmana J, Stockwell DH, Steyerberg EW, et al. Prediction of MLH1 and MSH2 mutations in Lynch syndrome. *J Am Med Assoc* 2006;296:1469.
56. Dove-Edwin I, de Jong AE, Adams J, et al. Prospective results of surveillance colonoscopy in dominant familial colorectal cancer with and without Lynch syndrome. *Gastroenterology* 2006;130:1995.
57. Markowitz S, Wang J, Myeroff L, et al. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. *Science* 1995;268:1336.
58. Grady WM, Myeroff LL, Swinler SE, et al. Mutational inactivation of transforming growth factor beta receptor type II in microsatellite stable colon cancers. *Cancer Res* 1999;59:320.
59. Rampino N, Yamamoto H, Ionov Y, et al. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. *Science* 1997;275:967.
60. Duval A, Gayet J, Zhou XP, et al. Frequent frameshift mutations of the TCF-4 gene in colorectal cancers with microsatellite instability. *Cancer Res* 1999;59:4213.
61. Yuan Z, Shin J, Wilson A, et al. An A13 repeat within the 3'-untranslated region of epidermal growth factor receptor (EGFR) is frequently mutated in microsatellite instability colon cancers and is associated with increased EGFR expression. *Cancer Res* 2009;69:7811.
62. Huang J, Papadopoulos N, McKinley AJ, et al. APC mutations in colorectal tumors with mismatch repair deficiency. *Proc Natl Acad Sci U S A* 1996;93:9049.
63. Sieber OM, Lipton L, Crabtree M, et al. Multiple colorectal adenomas, classic adenomatous polyposis, and germline mutations in MYH. *N Engl J Med* 2003;348:791.
64. Balaguer F, Castellvi-Bel S, Castells A, et al. Identification of MYH mutation carriers in colorectal cancer: a multicenter, case-control, population-based study. *Clin Gastroenterol Hepatol* 2007;5:379.
65. Thibodeau SN, French AJ, Cunningham JM, et al. Microsatellite instability in colorectal cancer: different mutator phenotypes and the principal involvement of hMLH1. *Cancer Res* 1998;58:1713.
66. Liu B, Nicolaidis NC, Markowitz S, et al. Mismatch repair gene defects in sporadic colorectal cancers with microsatellite instability. *Nat Genet* 1995;9:48.
67. Cunningham JM, Christensen ER, Tester DJ, et al. Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. *Cancer Res* 1998;58:3455.
68. Kambara T, Simms LA, Whitehall VL, et al. BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum. *Gut* 2004;53:1137.
69. Weisenberger DJ, Siegmund KD, Campan M, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. *Nat Genet* 2006;38:787.
70. Giardiello FM, Hamilton SR, Kern SE, et al. Colorectal neoplasia in juvenile polyposis or juvenile polyps. *Arch Dis Child* 1991;66:971.
71. Jass JR, Williams CB, Bussey HJ, Morson BC. Juvenile polyposis—a precancerous condition. *Histopathology* 1988;13:619.
72. Howe JR, Sayed MG, Ahmed AF, et al. The prevalence of MADH4 and BMPR1A mutations in juvenile polyposis and absence of BMPR2, BMPR1B, and ACVR1 mutations. *J Med Genet* 2004;41:484.
73. Sweet K, Willis J, Zhou XP, et al. Molecular classification of patients with unexplained hamartomatous and hyperplastic polyposis. *J Am Med Assoc* 2005;294:2465.
74. Haramis AP, Begthel H, Van Den Born M, et al. De novo crypt formation and juvenile polyposis on BMP inhibition in mouse intestine. *Science* 2004;303:1684.
75. He XC, Zhang J, Tong WG, et al. BMP signaling inhibits intestinal stem cell self-renewal through suppression of Wnt-beta-catenin signaling. *Nat Genet* 2004;36:1117.
76. Batts LE, Polk DB, Dubois RN, Kulessa H. Bmp signaling is required for intestinal growth and morphogenesis. *Dev Dyn* 2006;235:1563.
77. Kim BG, Li C, Qiao W, et al. Smad4 signalling in T cells is required for suppression of gastrointestinal cancer. *Nature* 2006;441:1015.
78. Giardiello FM, Brensinger JD, Tersmette AC, et al. Very high risk of cancer in familial Peutz-Jeghers syndrome. *Gastroenterology* 2000;119:1447.
79. Hemminki A, Markie D, Tomlinson I, et al. A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. *Nature* 1998;391:184.
80. Hezel AF, Bardeesy N, LKB1; linking cell structure and tumor suppression. *Oncogene* 2008;27:6908.
81. Shaw RJ, Bardeesy N, Manning BD, et al. The LKB1 tumor suppressor negatively regulates mTOR signaling. *Cancer Cell* 2004;6:91.
82. Rustgi AK. The genetics of hereditary colon cancer. *Genes Dev* 2007;21:2525.
83. Liaw D, Marsh DJ, Li J, et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. *Nat Genet* 1997;16:64.
84. Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. *J Biol Chem* 1998;273:13375.
85. Goel A, Arnold CN, Niedzwiecki D, et al. Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers. *Cancer Res* 2004;64:3014.
86. Kim YS, Milner JA. Dietary modulation of colon cancer risk. *J Nutr* 2007;137:2576S.
87. Slatery ML, Fitzpatrick FA. Convergence of hormones, inflammation, and energy-related factors: a novel pathway of cancer etiology. *Cancer Prev Res* 2009;2:922.
88. Cannon-Albright LA, Skolnick MH, Bishop DT, Lee RG, Burt RW. Common inheritance of susceptibility to colonic adenomatous polyps and associated colorectal cancers. *N Engl J Med* 1988;319:533.
89. Johns LE, Houlston RS. A systematic review and meta-analysis of familial colorectal cancer risk. *Am J Gastroenterol* 2001;96:2992.
90. Wiesner GL, Daley D, Lewis S, et al. A subset of familial colorectal neoplasia kindreds linked to chromosome 9q22.2-31.2. *Proc Natl Acad Sci U S A* 2003;100:12961.

91. Gray-McGuire C, Guda K, Adrianto I, et al. Confirmation of linkage to and localization of familial colon cancer risk haplotype on chromosome 9q22. *Cancer Res* 2010; 70:5409.
92. Tomlinson I, Webb E, Carvajal-Carmona L, et al. A genome-wide association scan of tag SNPs identifies a susceptibility variant for colorectal cancer at 8q24.21. *Nat Genet* 2007;39:984.
93. Tenesa A, Farrington SM, Prendergast JG, et al. Genome-wide association scan identifies a colorectal cancer susceptibility locus on 11q23 and replicates risk loci at 8q24 and 18q21. *Nat Genet* 2008;40:631.
94. Broderick P, Carvajal-Carmona L, Pittman AM, et al. A genome-wide association study shows that common alleles of SMAD7 influence colorectal cancer risk. *Nat Genet* 2007;39:1315.
95. Ahmadiyeh N, Pomerantz MM, Grisanzio C, et al. 8q24 prostate, breast, and colon cancer risk loci show tissue-specific long-range interaction with MYC. *Proc Natl Acad Sci U S A* 2010;107:9742.
96. Bos JL, Fearon ER, Hamilton SR, et al. Prevalence of ras gene mutations in human colorectal cancers. *Nature* 1987;327:293.
97. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. *N Engl J Med* 1988;319:525.
98. Pretlow TP. Aberrant crypt foci and K-ras mutations: earliest recognized players or innocent bystanders in colon carcinogenesis? *Gastroenterology* 1995;108:600.
99. Shirasawa S, Furuse M, Yokoyama N, Sasazuki T. Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. *Science* 1993;260:85.
100. Barbie DA, Tamayo P, Boehm JS, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. *Nature* 2009;462:108.
101. Downward J. Targeting RAS signalling pathways in cancer therapy. *Nat Rev Cancer* 2003;3:11.
102. Rajagopalan H, Bardelli A, Lengauer C, et al. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. *Nature* 2002;418:934.
103. Tanaka H, Deng G, Matsuzaki K, et al. BRAF mutation, CpG island methylator phenotype and microsatellite instability occur more frequently and concordantly in mucinous than non-mucinous colorectal cancer. *Int J Cancer* 2006;118:2765.
104. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. *Nature* 2002;417:949.
105. Gupta S, Ramjaun AR, Haiko P, et al. Binding of ras to phosphoinositide 3-kinase p110 α is required for ras-driven tumorigenesis in mice. *Cell* 2007;129:957.
106. Cantley LC. The phosphoinositide 3-kinase pathway. *Science* 2002;296:1655.
107. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. *Science* 2004;304:554.
108. Li W, Zhu T, Guan KL. Transformation potential of Ras isoforms correlates with activation of phosphatidylinositol 3-kinase but not ERK. *J Biol Chem* 2004;279:37398.
109. Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. *Nature* 2006;441:424.
110. Baker SJ, Fearon ER, Nigro JM, et al. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. *Science* 1989;244:217.
111. Vogelstein B, Fearon ER, Kern SE, et al. Allelotype of colorectal carcinomas. *Science* 1989;244:207.
112. Ogino S, Noshu K, Irahara N, et al. Prognostic significance and molecular associations of 18q loss of heterozygosity: a cohort study of microsatellite stable colorectal cancers. *J Clin Oncol* 2009;27:4591.
113. Watanabe T, Wu TT, Catalano PJ, et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. *N Engl J Med* 2001;344:1196.
114. Thiagalingam S, Lengauer C, Leach FS, et al. Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers. *Nat Genet* 1996;13:343.
115. Howe JR, Roth S, Ringold JC, et al. Mutations in the SMAD4/DPC4 gene in juvenile polyposis. *Science* 1998;280:1086.
116. Riggins GJ, Kinzler KW, Vogelstein B, Thiagalingam S. Frequency of Smad gene mutations in human cancers. *Cancer Res* 1997;57:2578.
117. Mehlen P, Fearon ER. Role of the dependence receptor DCC in colorectal cancer pathogenesis. *J Clin Oncol* 2004;22:3420.
118. Bardelli A, Parsons DW, Silliman N, et al. Mutational analysis of the tyrosine kinome in colorectal cancers. *Science* 2003;300:949.
119. Parsons DW, Wang TL, Samuels Y, et al. Colorectal cancer: mutations in a signalling pathway. *Nature* 2005; 436:792.
120. Wang Z, Shen D, Parsons DW, et al. Mutational analysis of the tyrosine phosphatome in colorectal cancers. *Science* 2004;304:1164.
121. Sjoblom T, Jones S, Wood LD, et al. The consensus coding sequences of human breast and colorectal cancers. *Science* 2006;314:268.
122. Martin ES, Tonon G, Sinha R, et al. Common and distinct genomic events in sporadic colorectal cancer and diverse cancer types. *Cancer Res* 2007;67:10736.
123. Leary RJ, Lin JC, Cummins J, et al. Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers. *Proc Natl Acad Sci U S A* 2008;105:16224.
124. Sinicrope FA, Rego RL, Halling KC, et al. Prognostic impact of microsatellite instability and DNA ploidy in human colon carcinoma patients. *Gastroenterology* 2006;131:729.
125. Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. *N Engl J Med* 2003;349:247.
126. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. *J Clin Oncol* 2005;23:609.
127. Sartore-Bianchi A, Di Nicolantonio F, Nichelatti M, et al. Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. *PLoS One* 2009;4:e7287.
128. Ogino S, Meyerhardt JA, Irahara N, et al. KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. *Clin Cancer Res* 2009;15:7322.
129. Moser AR, Pitot HC, Dove WF. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. *Science* 1990;247:322.
130. McCart AE, Vickaryous NK, Silver A. Apc mice: models, modifiers and mutants. *Pathol Res Pract* 2008;204:479.
131. Oshima M, Oshima H, Kitagawa K, et al. Loss of Apc heterozygosity and abnormal tissue building in nascent intestinal polyps in mice carrying a truncated Apc gene. *Proc Natl Acad Sci U S A* 1995;92:4482.
132. Yang K, Edelmann W, Fan K, et al. A mouse model of human familial adenomatous polyposis. *J Exp Zool* 1997;277:245.
133. Amos-Landgraf JM, Kwong LN, Kendzierski CM, et al. A target-selected Apc-mutant rat kindred enhances the modeling of familial human colon cancer. *Proc Natl Acad Sci U S A* 2007;104:4036.
134. Harada N, Tamai Y, Ishikawa T, et al. Intestinal polyposis in mice with a dominant stable mutation of the beta-catenin gene. *EMBO J* 1999; 18:5931.
135. Sansom OJ, Meniel V, Wilkins JA, et al. Loss of Apc allows phenotypic manifestation of the transforming properties of an endogenous K-ras oncogene in vivo. *Proc Natl Acad Sci U S A* 2006;103:14122.
136. Wei K, Kucherlapati R, Edelmann W. Mouse models for human DNA mismatch-repair gene defects. *Trends Mol Med* 2002;8:346.

Chapter 20 – References

1. Rini B I, Campbell S C, Escudier B. Renal cell carcinoma. *Lancet* 2009;373:1119.
2. Heck JE, Charbotel B, Moore LE, et al. Occupation and renal cell cancer in Central and Eastern Europe. *Occup Environ Med* 2010;67:47.
3. Kovacs G, Akhtar M, Beckwith BJ, et al. The Heidelberg classification of renal cell tumours. *J Pathol* 1997; 183:131.
4. Linehan WM, Srinivasan R, Schmidt LS. The genetic basis of kidney cancer: a metabolic disease. *Nat Rev Urol* 2010;7:277.
5. Latif F, Tory K, Gnarr J, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. *Science* 1993;260:1317.
6. Schmidt L, Duh FM, Chen F, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. *Nat Genet* 1997;16:68.
7. Tomlinson IP, Alam NA, Rowan AJ, et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. *Nat Genet* 2002;30:406.
8. Nickerson ML, Warren MB, Toro JR, et al. Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dubé syndrome. *Cancer Cell* 2002;2:157.
9. Vanharanta S, Buchta M, McWhinney SR, et al. Early-onset renal cell carcinoma as a novel extraparaganglial component of SDHB-associated heritable paraganglioma. *Am J Hum Genet* 2004;74:153.
10. Nordstrom-O'Brien M, van der Luijt RB, van Rooijen E, et al. Genetic analysis of von Hippel-Lindau disease. *Hum Mutat* 2010;31(5):521.
11. Zbar B, Brauch H, Talmadge C, Linehan WM. Loss of alleles of loci on the short arm of chromosome 3 in renal cell carcinoma. *Nature* 1987;327:721.
12. Stolle C, Glenn G, Zbar B, et al. Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. *Hum Mutat* 1998;12:417.
13. Cho HJ, Ki CS, Kim JW. Improved detection of germline mutations in Korean VHL patients by multiple ligation-dependent probe amplification analysis. *J Korean Med Sci* 2009;24:77.
14. Kaelin WG Jr. The von Hippel-Lindau tumor suppressor protein: O2 sensing and cancer. *Nat Rev Cancer* 2008; 8:865.
15. Cohen AJ, Li FP, Berg S, et al. Hereditary renal-cell carcinoma associated with a chromosomal translocation. *N Engl J Med* 1979;301:592.
16. Schmidt L, Li F, Brown RS, et al. Mechanism of tumorigenesis of renal carcinomas associated with the constitutional chromosome 3;8 translocation. *Cancer J Sci Am* 1995;1:191.
17. Meléndez B, Rodríguez-Perales S, Martínez-Delgado B, et al. Molecular study of a new family with hereditary renal cell carcinoma and a translocation t(3;8)(p13;q24.1). *Hum Genet* 2003;112:178.
18. Bodmer D, Van Den Hurk W, van Groningen JJ, et al. Understanding familial and non-familial renal cell cancer. *Hum Mol Genet* 2002;11:2489.
19. Gnarr JR, Tory K, Weng Y, et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. *Nat Genet* 1994;7:85.
20. Nickerson ML, Jaeger E, Shi Y, et al. Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. *Clin Cancer Res* 2008;14:4726.
21. Stebbins CE, Kaelin WG Jr, Pavletich NP. Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function. *Science* 1999;284:455.
22. Kondo K, Kico J, Nakamura E, Lechpammer M, Kaelin W. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. *Cancer Cell* 2002;1:237.
23. Maranchie JK, Vasselli JR, Riss J, et al. The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. *Cancer Cell* 2002;1:247.
24. Dharmawardana PG, Giubellino A, Bottaro DP. Hereditary papillary renal carcinoma type I. *Curr Mol Med* 2004;4:855.
25. Schmidt L, Junker K, Weirich G, et al. Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene. *Cancer Res* 1998;58:1719.
26. Schmidt LS, Nickerson ML, Angeloni D, et al. Early onset hereditary papillary renal carcinoma: germline missense mutations in the tyrosine kinase domain of the met proto-oncogene. *J Urol* 2004;172:1256.
27. Zbar B, Glenn G, Lubensky I, et al. Hereditary papillary renal cell carcinoma: clinical studies in 10 families. *J Urol* 1995;153:907.
28. Kovacs G, Fuzesi L, Emanuel A, Kung HF. Cytogenetics of papillary renal cell tumors. *Genes Chromosomes Cancer* 1991;3:249.
29. Schmidt L, Junker K, Nakaigawa N, et al. Novel mutations of the MET proto-oncogene in papillary renal carcinomas. *Oncogene* 1999;18:2343.
30. Gentile A, Trusolino L, Comoglio PM. The Met tyrosine kinase receptor in development and cancer. *Cancer Metastasis Rev* 2008;27:85.
31. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. *Nat Rev Mol Cell Biol* 2003;4:915.
32. Jeffers M, Schmidt L, Nakaigawa N, et al. Activating mutations for the met tyrosine kinase receptor in human cancer. *Proc Natl Acad Sci U S A* 1997;94:11445.
33. Jeffers M, Fiscella M, Webb CP, et al. The mutationally activated Met receptor mediates motility and metastasis. *Proc Natl Acad Sci U S A* 1998;95:14417.
34. Miller M, Ginalski K, Lesyng B, et al. Structural basis of oncogenic activation caused by point mutations in the kinase domain of the MET proto-oncogene: modeling studies. *Proteins* 2001;44:32.
35. Zhuang Z, Park WS, Pack S, et al. Trisomy 7: harboring non-random duplication of the mutant MET allele in hereditary papillary renal carcinomas. *Nat Genet* 1998;20:66.
36. de Jong B, Molenaar IM, Leeuw JA, Idenberg VJ, Oosterhuis JW. Cytogenetics of a renal adenocarcinoma in a 2-year-old child. *Cancer Genet Cytogenet* 1986; 21:165.
37. Sidhar SK, Clark J, Gill S, et al. The t(X;1)(p11.2;q21.2) translocation in papillary renal cell carcinoma fuses a novel gene PRCC to the TFE3 transcription factor gene. *Hum Mol Genet* 1996;5:1333.
38. Weterman MJ, van Groningen JJ, Jansen A, van Kessel AG. Nuclear localization and transactivating capacities of the papillary renal cell carcinoma-associated TFE3 and PRCC (fusion) proteins. *Oncogene* 2000;19:69.
39. Weterman MA, van Groningen JJ, den Hartog A, Geurts van Kessel A. Transformation capacities of the papillary renal cell carcinoma-associated PRCC/TFE3 and TFE3/PRCC fusion genes. *Oncogene*. 2001;20:1414.
40. Armah HB, Parwani AV. Xp11.2 translocation renal cell carcinoma. *Arch Pathol Lab Med* 2010;134:124.
41. Tsuda M, Davis IJ, Argani P, et al. TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition. *Cancer Res* 2007;67:919.
42. Birt AR, Hogg GR, Dubé WJ. Hereditary multiple fibrofolliculomas with trichodiscomas and acrochordons. *Arch Dermatol* 1977;113:1674.
43. Toro JR, Glenn GM, Duray PH, et al. Birt-Hogg-Dubé syndrome: a novel marker of kidney neoplasia. *Arch Dermatol* 1999;135:1195.

44. Zbar B, Alvord WG, Glenn GM, et al. Risk of renal and colonic neoplasms and spontaneous pneumothorax in the Birt-Hogg-Dubé syndrome. *Cancer Epidemiol Biomarkers Prev* 2002;11:393.
45. Menko FH, van Steensel MA, Giraud S, et al. European BHD Consortium. Birt-Hogg-Dubé syndrome: diagnosis and management. *Lancet Oncol* 2009;10:1199.
46. Schmidt LS, Nickerson ML, Warren MB, et al. Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dubé syndrome. *Am J Hum Genet* 2005;76:1023.
47. Toro JR, Wei MH, Glenn GM, et al. BHD mutations, clinical and molecular genetic investigations of Birt-Hogg-Dubé syndrome: a new series of 50 families and a review of published reports. *J Med Genet* 2008;45:321.
48. Toro JR, Pautler SE, Stewart L, et al. Lung cysts, spontaneous pneumothorax and genetic associations in 89 families with Birt-Hogg-Dubé syndrome. *Am J Respir Crit Care Med* 2007;175:1044.
49. Pavlovich CP, Walther MM, Eyler RA, et al. Renal tumors in the Birt-Hogg-Dubé syndrome. *Am J Surg Pathol* 2002;26:1542.
50. Schmidt LS, Warren MB, Nickerson ML, et al. Birt-Hogg-Dubé syndrome, a genodermatosis associated with spontaneous pneumothorax and kidney neoplasia, maps to chromosome 17p11.2. *Am J Hum Genet* 2001;69:876.
51. Khoo SK, Bradley M, Wong FK, et al. Birt-Hogg-Dubé syndrome: mapping of a novel hereditary neoplasia gene to chromosome 17p12-q11.2. *Oncogene* 2001;20:5239.
52. Leter EM, Koopmans AK, Gille JJ, et al. Birt-Hogg-Dubé syndrome: clinical and genetic studies of 20 families. *J Invest Dermatol* 2008;128:45.
53. Kluger N, Giraud S, Coupiet I, et al. Birt-Hogg-Dubé syndrome: clinical and genetic studies of 10 French families. *Br J Dermatol* 2010;162:527.
54. Lim DH, Rehal PK, Nahorski MS, et al. A new locus-specific database (LSDB) for mutations in the folliculin (FLCN) gene. *Hum Mutat* 2010;31:E1043.
55. Vocke CD, Yang Y, Pavlovich CP, et al. High frequency of somatic frameshift BHD gene mutations in Birt-Hogg-Dubé-associated renal tumors. *J Natl Cancer Inst* 2005;97:931.
56. Gad S, Lefevre SH, Khoo SK, et al. mutations in BHD and TP53 genes, but not in HNF1beta gene, in a large series of sporadic chromophobe renal cell carcinoma. *Br J Cancer* 2007;96:336.
57. da Silva NF, Gentle D, Hesson LB, et al. Analysis of the Birt-Hogg-Dubé (BHD) tumour suppressor gene in sporadic renal cell carcinoma and colorectal cancer. *J Med Genet* 2003;40:820.
58. Khoo SK, Kahnoski K, Sugimura J, et al. Inactivation of BHD in sporadic renal tumors. *Cancer Res* 2003;63:4583.
59. Nagy A, Zoubakov D, Stupar Z, Kovacs G. Lack of mutation of the folliculin gene in sporadic chromophobe renal cell carcinoma and renal oncocytoma. *Int J Cancer* 2004;109:472.
60. Baba M, Hong SB, Sharma N, et al. Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling. *Proc Natl Acad Sci U S A* 2006;103:15552.
61. Inoki K, Corradetti MN, Guan KL. Dysregulation of the TSC-mTOR pathway in human disease. *Nat Genet* 2005;37:19.
62. Inoki K, Li Y, Xu T, Guan KL. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. *Genes Dev* 2003;17:1829.
63. Hasumi H, Baba M, Hong SB, et al. Identification and characterization of a novel folliculin-interacting protein FNIP2. *Gene* 2008;415:60.
64. Takagi Y, Kobayashi T, Shiono M, et al. Interaction of folliculin (Birt-Hogg-Dubé gene product) with a novel Fnip1-like (FnipL/Fnip2) protein. *Oncogene* 2008;27:5339.
65. Baba M, Furihata M, Hong SB, et al. Kidney-targeted Birt-Hogg-Dubé gene inactivation in a mouse model: Erk1/2 and Akt-mTOR activation, cell hyperproliferation, and polycystic kidneys. *J Natl Cancer Inst* 2008;100:140.
66. Hasumi Y, Baba M, Ajima R, et al. Homozygous loss of BHD causes early embryonic lethality and kidney tumor development with activation of mTORC1 and mTORC2. *Proc Natl Acad Sci U S A* 2009;106:18722.
67. van Slegtenhorst M, Khabibullin D, Hartman TR, et al. The Birt-Hogg-Dubé and tuberous sclerosis complex homologs have opposing roles in amino acid homeostasis in *Schizosaccharomyces pombe*. *J Biol Chem* 2007;282:24583.
68. Hudon V, Sabourin S, Dydensborg AB, et al. Renal tumor suppressor function of the Birt-Hogg-Dubé syndrome gene product folliculin. *J Med Genet* 2010;47(3):182.
69. Hartman TR, Nicolas E, Klein-Szanto A, et al. The role of the Birt-Hogg-Dubé protein in mTOR activation and renal tumorigenesis. *Oncogene* 2009;28:1594.
70. Kiuru M, Launonen V. Hereditary leiomyomatosis and renal cell cancer (HLRCC). *Curr Mol Med* 2004;4:869.
71. Wei MH, Toure O, Glenn GM, et al. Novel mutations in FH and expansion of the spectrum of phenotypes expressed in families with hereditary leiomyomatosis and renal cell cancer. *J Med Genet* 2006;43:18.
72. Toro JR, Nickerson ML, Wei MH, et al. Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. *Am J Hum Genet* 2003;73:95.
73. Alam NA, Bevan S, Churchman M, et al. Localization of a gene (MCUL1) for multiple cutaneous leiomyomata and uterine fibroids to chromosome 1q42.3-q43. *Am J Hum Genet* 2001;68:1264.
74. Launonen V, Vierimaa O, Kiuru M, et al. Inherited susceptibility to uterine leiomyomas and renal cell cancer. *Proc Natl Acad Sci U S A* 2001;98:3387.
75. Alam NA, Rowan AJ, Wortham NC, et al. Genetic and functional analyses of FH mutations in multiple cutaneous and uterine leiomyomatosis, hereditary leiomyomatosis and renal cancer, and fumarate hydratase deficiency. *Hum Mol Genet* 2003;12:1241.
76. Bayley JP, Launonen VP, Tomlinson IP. The FH mutation database: an online database of fumarate hydratase mutations involved in the MCUL (HLRCC) tumor syndrome and congenital fumarase deficiency. *BMC Med Genet* 2008;9:20.
77. Kiuru M, Lehtonen R, Arola J, et al. Few FH mutations in sporadic counterparts of tumor types observed in hereditary leiomyomatosis and renal cell cancer families. *Cancer Res* 2002;62:4554.
78. Pithukpakorn M, Wei MH, Toure O, et al. Fumarate hydratase enzyme activity in lymphoblastoid cells and fibroblasts of individuals in families with hereditary leiomyomatosis and renal cell cancer. *J Med Genet* 2006;43:755.
79. Pollard PJ, Briere JJ, Alam NA, et al. Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. *Hum Mol Genet* 2005;14:2231.
80. Isaacs JS, Jung YJ, Mole DR, et al. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. *Cancer Cell* 2005;8:143–53.
81. Pollard P, Wortham N, Barclay E, et al. Evidence of increased microvessel density and activation of the hypoxia pathway in tumours from the hereditary leiomyomatosis and renal cell cancer syndrome. *J Pathol* 2005;205:41.
82. Sudarshan S, Sourbier C, Kong HS, et al. Fumarate hydratase deficiency in renal cancer induces glycolytic addiction and hypoxia-inducible transcription factor 1alpha stabilization by glucose-dependent generation of reactive oxygen species. *Mol Cell Biol* 2009;29:4080.

83. Srirangalingam U, Walker L, Khoo B, et al. Clinical manifestations of familial paraganglioma and pheochromocytomas in succinate dehydrogenase B (SDH-B) gene mutation carriers. *Clin Endocrinol (Oxf)* 2008;69:587.
84. Henderson A, Douglas F, Perros P, Morgan C, Maher ER. SDHB-associated renal oncocytoma suggests a broadening of the renal phenotype in hereditary paragangliomatosis. *Fam Cancer* 2009;8:257.
85. Ricketts C, Woodward ER, Killick P, et al. Germline SDHB mutations and familial renal cell carcinoma. *J Natl Cancer Inst* 2008;100:1260.
86. Astuti D, Douglas F, Lennard TW, et al. Germline SDHD mutation in familial pheochromocytoma. *Lancet* 2001;357:1181.
87. Pawlu C, Bausch B, Neumann HPH. Mutations of the SDHB and SDHD genes. *Fam Cancer* 2005;4:49.
88. Astuti D, Latif F, Dallol A, et al. Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. *Am J Hum Genet* 2001;69:49.
89. Ricketts CJ, Forman JR, Rattenberry E, et al. Tumor risks and genotype-phenotype-proteotype analysis in 358 patients with germline mutations in SDHB and SDHD. *Hum Mutat* 2010;31:41.
90. Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. *N Engl J Med* 2006;355:1345.
91. van Slechtenhorst M, de Hoogt R, Hermans C, et al. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. *Science* 1997;277:805.
92. The European Chromosome 16 Tuberous Sclerosis Consortium. Identification and characterization of the tuberous sclerosis gene on chromosome 16. *Cell* 1993;75:1305.
93. Shaw RJ, Bardeesy N, Manning BD, et al. The LKB1 tumor suppressor negatively regulates mTOR signaling. *Cancer Cell* 2004;6:91.
94. Bissler JJ, McCormack FX, Young LR, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. *N Engl J Med* 2008;358:140.

Chapter 21 – References

1. Knowles MA. Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese? *Carcinogenesis* 2006;27(3):361–373.
2. Knowles MA. Bladder cancer subtypes defined by genomic alterations. *Scand J Urol Nephrol Suppl* 2008;116:30.
3. Wu XR. Urothelial tumorigenesis: a tale of divergent pathways. *Nat Rev Cancer* 2005;5:713.
4. Cordon-Cardo C. Molecular alterations associated with bladder cancer initiation and progression. *Scand J Urol Nephrol Suppl* 2008;154–165.
5. Ramchuuren N, Cooper K, Summerhayes IC. Molecular events underlying schistosomiasis-related bladder cancer. *International J Cancer* 1995;62:237–244.
6. Shaw ME, Elder PA, Abbas A, et al. Partial allelotype of schistosomiasis-associated bladder cancer. *Int J Cancer* 1999;80:656–661.
7. Kiemeneij LA, Grotenhuis AJ, Vermeulen SH, et al. Genome-wide association studies in bladder cancer: first results and potential relevance. *Curr Opin Urol* 2009;19:540–546.
8. Horikawa Y, Gu J, Wu X. Genetic susceptibility to bladder cancer with an emphasis on gene-gene and gene-environmental interactions. *Curr Opin Urol* 2008;18:493–498.
9. Wu X, Hildebrandt MAT, Chang DW. Genome-wide association studies of bladder cancer risk: a field synopsis of progress and potential applications. *Cancer Metastasis Rev* 2009;28:269–280.
10. Cairns P. Gene methylation and early detection of genitourinary cancer: the road ahead. *Nat Rev Cancer* 2007;7:531–543.
11. Cebrian V, Alvarez M, Aleman A, et al. Discovery of myopodin methylation in bladder cancer. *J Pathol* 2008;216:111.
12. Yates DR, Rehman I, Abbod MF, et al. Promoter hypermethylation identifies progression risk in bladder cancer. *Clin Cancer Res* 2007;13:2046.
13. Stransky N, Vallot C, Reyat F, et al. Regional copy number-independent deregulation of transcription in cancer. *Nat Genet* 2006;38:1386–1396.
14. Takahashi T, Habuchi T, Kakehi Y, et al. Clonal and chronological genetic analysis of multifocal cancers of the bladder and upper urinary tract. *Cancer Res* 1998;58:5835–5841.
15. Kawanishi H, Takahashi T, Ito M, et al. Genetic analysis of multifocal superficial urothelial cancers by array-based comparative genomic hybridisation. *Br J Cancer* 2007;97:260–266.
16. van Oers JMM, Adam C, Denzinger S, et al. Chromosome 9 deletions are more frequent than FGFR3 mutations in flat urothelial hyperplasias of the bladder. *Int J Cancer* 2006;119:1212–1215.
17. Cairns P, Shaw ME, Knowles MA. Initiation of bladder cancer may involve deletion of a tumour-suppressor gene on chromosome 9. *Oncogene* 1993;8:1083–1085.
18. Linnenbach AJ, Pressler LB, Seng BA, et al. Characterization of chromosome 9 deletions in transitional cell carcinoma by microsatellite assay. *Hum Mol Genet* 1993;2:1407–1411.
19. Tsai YC, Nichols PW, Hiti AL, et al. Allelic losses of chromosomes 9, 11, and 17 in human bladder cancer. *Cancer Research* 1990;50:44–47.
20. Berggren P, Kumar R, Sakano S, et al. Detecting homozygous deletions in the CDKN2A(p16(INK4a))/ARF(p14(ARF)) gene in urinary bladder cancer using real-time quantitative PCR. *Clin Cancer Res* 2003;9:235.
21. Cairns P, Tokino K, Eby Y, et al. Homozygous deletions of 9p21 in primary human bladder tumors detected by comparative multiplex polymerase chain reaction. *Cancer Res* 1994;54:1422.
22. Devlin J, Keen AJ, Knowles MA. Homozygous deletion mapping at 9p21 in bladder carcinoma defines a critical region within 2cM of IFNA. *Oncogene* 1994;9:2757.
23. Orlov I, Lacombe L, Hannon GJ, et al. Deletion of the p16 and p15 genes in human bladder tumors. *J Natl Cancer Inst* 1995;87:524–529.
24. Williamson MP, Elder PA, Shaw ME, et al. p16 (CDKN2) is a major deletion target at 9p21 in bladder cancer. *Human Molecular Genetics* 1995;4:1569–1577.
25. Aboukassim TO, LaRue H, Lemieux P, et al. Alteration of the PATCHED locus in superficial bladder cancer. *Oncogene* 2003;22:2967–2971.
26. McGarvey TW, Maruta Y, Tomaszewski JE, et al. PTCH gene mutations in invasive transitional cell carcinoma of the bladder. *Oncogene* 1998;17:1167–1172.
27. Habuchi T, Luscombe M, Elder PA, et al. Structure and methylation-based silencing of a gene (DBCCR1) within a candidate bladder cancer tumor suppressor region at 9q32-q33. *Genomics* 1998;48:277–288.
28. Nishiyama H, Hornigold N, Davies A, et al. A sequence-ready 840-kb PAC contig spanning the candidate tumor suppressor locus DBC1 on human chromosome 9q32-q33. *Genomics* 1999;59:335–338.
29. Stadler WM, Steinberg G, Yang X, et al. Alterations of the 9p21 and 9q33 chromosomal bands in clinical bladder cancer specimens by fluorescence in situ hybridization. *Clin Cancer Res* 2001;7:1676.
30. Pymar LS, Platt FM, Askham JM, et al. Bladder tumour-derived somatic TSC1 missense mutations cause loss of function via distinct mechanisms. *Hum Mol Genet* 2008;17:2006–2017.
31. Knowles MA, Habuchi T, Kennedy W, et al. Mutation spectrum of the 9q34 tuberous sclerosis gene TSC1 in transitional cell carcinoma of the bladder. *Cancer Res* 2003;63:7652.
32. Hornigold N, Devlin J, Davies AM, et al. Mutation of the 9q34 gene TSC1 in sporadic bladder cancer. *Oncogene* 1999;18:2657–2661.
33. Adachi H, Igawa M, Shiina H, et al. Human bladder tumors with 2-hit mutations of tumor suppressor gene TSC1 and decreased expression of p27. *J Urol* 2003;170:601–604.
34. Chapman EJ, Harnden P, Chambers P, et al. Comprehensive analysis of CDKN2A status in microdissected urothelial cell carcinoma reveals potential haploinsufficiency, a high frequency of homozygous co-deletion and associations with clinical phenotype. *Clin Cancer Res* 2005;11:5740–5747.
35. Carnero A, Hudson JD, Price CM, et al. p16INK4A and p19ARF act in overlapping pathways in cellular immortalization [see comments]. *Nat Cell Biol* 2000;2:148–155.
36. Serrano M. The INK4a/ARF locus in murine tumorigenesis. *Carcinogenesis* 2000;21:865–869.
37. Nishiyama H, Takahashi T, Kakehi Y, et al. Homozygous deletion at the 9q32–33 candidate tumor suppressor locus in primary bladder cancer. *Genes Chromosomes Cancer* 1999;26:171–175.
38. Habuchi T, Takahashi T, Kakinuma H, et al. Hypermethylation at 9q32–33 tumour suppressor region is age-related in normal urothelium and an early and frequent alteration in bladder cancer. *Oncogene* 2001;20:531.
39. Platt FM, Hurst CD, Taylor CF, et al. Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer. *Clin Cancer Res* 2009;15:6008–6017.
40. Cappellen D, De Oliveira C, Ricol D, et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. *Nat Genet* 1999;23:18.
41. Bakkar AA, Wallerand H, Radvanyi F, et al. FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. *Cancer Res* 2003;63:8108–8112.

42. Billerey C, Chopin D, Aubriot-Lorton MH, et al. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. *Am J Pathol* 2001;158:1955–1959.
43. Hernandez S, Lopez-Knowles E, Lloreta J, et al. Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. *J Clin Oncol* 2006;24:3664–3671.
44. Hernandez S, Lopez-Knowles E, Lloreta J, et al. FGFR3 and Tp53 mutations in T1G3 transitional bladder carcinomas: independent distribution and lack of association with prognosis. *Clin Cancer Res* 2005;11:5444.
45. Kimura T, Suzuki H, Ohashi T, et al. The incidence of thanatophoric dysplasia mutations in FGFR3 gene is higher in low-grade or superficial bladder carcinomas. *Cancer* 2001;92:2555–2561.
46. Rieger-Christ KM, Mourtzinou A, Lee PJ, et al. Identification of fibroblast growth factor receptor 3 mutations in urine sediment DNA samples complements cytology in bladder tumor detection. *Cancer* 2003;98:737–744.
47. Sibley K, Cuthbert-Heavens D, Knowles M. Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma. *Oncogene* 2001;20(6):686.
48. van Rhijn BW, Lurkin I, Chopin DK, et al. Combined microsatellite and FGFR3 mutation analysis enables a highly sensitive detection of urothelial cell carcinoma in voided urine. *Clin Cancer Res* 2003;9:257.
49. van Rhijn BW, Lurkin I, Radvanyi F, et al. The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. *Cancer Res* 2001;61:1265.
50. van Rhijn BW, Montironi R, Zwarthoff EC, et al. Frequent FGFR3 mutations in urothelial papilloma. *J Pathol* 2002;198:245–251.
51. van Rhijn BW, van Tilborg AA, Lurkin I, et al. Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders. *Eur J Hum Genet* 2002;10:819–824.
52. van Rhijn BW, Vis AN, van der Kwast TH, et al. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. *J Clin Oncol* 2003;21:1912–1921.
53. Wallerand H, Bakkar AA, de Medina SG, et al. Mutations in TP53, but not FGFR3, in urothelial cell carcinoma of the bladder are influenced by smoking: contribution of exogenous versus endogenous carcinogens. *Carcinogenesis* 2005;26:177.
54. Zieger K, Dyrskjot L, Wiuf C, et al. Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors. *Clin Cancer Res* 2005;11:7709–7719.
55. Ornitz DM, Itoh N. Fibroblast growth factors. *Genome Biol* 2001;2.
56. Kompier LC, van der Aa MNM, Lurkin I, et al. The development of multiple bladder tumour recurrences in relation to the FGFR3 mutation status of the primary tumour. *J Pathol* 2009;218:104.
57. Tomlinson DC, Baldo O, Harnden P, et al. FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. *J Pathol* 2007; 213:91–98.
58. Bernard-Pierrot I, Brams A, Dunois-Larde C, et al. Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b. *Carcinogenesis* 2006;27:740–747.
59. di Martino E, L'Hôte CG, Kennedy W, et al. Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type- and mutation-specific manner. *Oncogene* 2009;28:4306–4316.
60. Jebar AH, Hurst CD, Tomlinson DC, et al. FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. *Oncogene* 2005;24: 5218–5225.
61. van Rhijn BW, van der Kwast TH, Vis AN, et al. FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma. *Cancer Res* 2004;64:1911–1914.
62. Knowles MA. Novel therapeutic targets in bladder cancer: mutation and expression of FGF receptors. *Future Oncol* 2008;4:71–83.
63. Tomlinson DC, Hurst CD, Knowles MA. Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer. *Oncogene* 2007; 26:5889–5899.
64. Miyake M, Ishii M, Koyama N, et al. PD173074, a selective tyrosine kinase inhibitor of FGFR3, inhibits cell proliferation of bladder cancer carrying the FGFR3 gene mutation along with up-regulation of p27/Kip1 and G1/G0 arrest. *J Pharmacol Exp Ther* 2009.
65. Qing J, Du X, Chen Y, et al. Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice. *J Clin Invest* 2009;119:1216–1229.
66. Martinez-Torrecuadrada J, Cifuentes G, Lopez-Serra P, et al. Targeting the extracellular domain of fibroblast growth factor receptor 3 with human single-chain fv antibodies inhibits bladder carcinoma cell line proliferation. *Clin Cancer Res* 2005;11:6280.
67. Gomez-Roman JJ, Saenz P, Molina M, et al. Fibroblast growth factor receptor 3 is overexpressed in urinary tract carcinomas and modulates the neoplastic cell growth. *Clin Cancer Res* 2005;11:459.
68. Martinez-Torrecuadrada JL, Cheung LH, Lopez-Serra P, et al. Antitumor activity of fibroblast growth factor receptor 3-specific immunotoxins in a xenograft mouse model of bladder carcinoma is mediated by apoptosis. *Mol Cancer Ther* 2008;7:862–873.
69. Lopez-Knowles E, Hernandez S, Malats N, et al. PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors. *Cancer Res* 2006;66:7401–7404.
70. Hurst CD, Zuiverloon TC, Hafner C, et al. A SNaPshot assay for the rapid and simple detection of four common hotspot codon mutations in the PIK3CA gene. *BMC Res Notes* 2009;2:66.
71. Zhao L, Vogt PK. Helical domain and kinase domain mutations in p110(alpha) of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. *Proc Natl Acad Sci U S A* 2008;105:2652–2657.
72. Proctor A, Coombs L, Cairns J, et al. Amplification at chromosome 11q13 in transitional cell tumours of the bladder. *Oncogene* 1991.
73. Bringuier PP, Tamimi Y, Schuurin E, et al. Expression of cyclin D1 and EMS1 in bladder tumours: relationship with chromosome 11q13 amplification. *Oncogene* 1996; 12:1747–1753.
74. Takagi Y, Takashi M, Koshikawa T, et al. Immunohistochemical demonstration of cyclin D1 in bladder cancers as an inverse indicator of invasiveness but not an independent prognostic factor. *Int J Urol* 2000; 7:366.
75. Tut VM, Braithwaite KL, Angus B, et al. Cyclin D1 expression in transitional cell carcinoma of the bladder: correlation with p53, waf1, pRb and Ki67. *Br J Cancer* 2001;84:270.
76. Shariat SF, Ashfaq R, Sagalowsky AI, et al. Correlation of cyclin D1 and E1 expression with bladder cancer presence, invasion, progression, and metastasis. *Hum Pathol* 2006;37:1568.
77. Catto JWF, Miah S, Owen HC, et al. Distinct microRNA alterations characterize high- and low-grade bladder cancer. *Cancer Res* 2009;69:8472–8481.
78. Veerla S, Lindgren D, Kvist A, et al. MiRNA expression in urothelial carcinomas: important roles of miR-10a, miR-222, miR-125b, miR-7 and miR-452 for tumor stage and metastasis, and frequent homozygous losses of miR-31. *Int J Cancer* 2009;124:2236–2242.

79. Williamson SR, Montironi R, Lopez-Beltran A, et al. Diagnosis, evaluation and treatment of carcinoma in situ of the urinary bladder: The state of the art. *Crit Rev Oncol Hematol*.
80. Rosin MP, Cairns P, Epstein JI, et al. Partial allelotype of carcinoma *in situ* of the human bladder. *Cancer Res* 1995;55:5213–5216.
81. Spruck CH II, Ohneseit PF, Gonzalez-Zulueta M, et al. Two molecular pathways to transitional cell carcinoma of the bladder. *Cancer Res* 1994;54:784–788.
82. Wagner U, Sauter G, Moch H, et al. Patterns of p53, erbB-2 and EGF-r expression in premalignant lesions of the urinary bladder. *Human Pathol* 1995;26:970–978.
83. Zieger K, Marcussen N, Borre M, et al. Consistent genomic alterations in carcinoma in situ of the urinary bladder confirm the presence of two major pathways in bladder cancer development. *Int J Cancer* 2009; 125: 2095.
84. Hopman AH, Kamps MA, Speel EJ, et al. Identification of chromosome 9 alterations and p53 accumulation in isolated carcinoma in situ of the urinary bladder versus carcinoma in situ associated with carcinoma. *Am J Pathol* 2002;161:1119.
85. Caner V, Turk NS, Duzcan F, et al. No strong association between HER-2/neu protein overexpression and gene amplification in high-grade invasive urothelial carcinomas. *Pathol Oncol Res* 2008;14:261.
86. Chow NH, Chan SH, Tzai TS, et al. Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder. *Clin Cancer Res* 2001;7:1957–1962.
87. Coombs LM, Pigott DA, Sweeney E, et al. Amplification and over-expression of c-erbB-2 in transitional cell carcinoma of the urinary bladder. *Br J Cancer* 1991;63:601–608.
88. Gardiner RA, Samaratunga ML, Walsh MD, et al. An immunohistological demonstration of c-erbB-2 oncoprotein expression in primary urothelial bladder cancer. *Urol Res* 1992;20:117–120.
89. Sauter G, Moch H, Moore D, et al. Heterogeneity of erbB-2 gene amplification in bladder cancer. *Cancer Res* 1993;53:2199–2203.
90. Latif Z, Watters AD, Dunn I, et al. HER2/neu overexpression in the development of muscle-invasive transitional cell carcinoma of the bladder. *Br J Cancer* 2003;89:1305–1309.
91. Gandour-Edwards R, Lara PN Jr, Folkens AK, et al. Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma? *Cancer* 2002;95:1009.
92. Kruger S, Weitsch G, Buttner H, et al. Overexpression of c-erbB-2 oncoprotein in muscle-invasive bladder carcinoma: relationship with gene amplification, clinicopathological parameters and prognostic outcome. *Int J Oncol* 2002;21:981.
93. Lonn U, Lonn S, Friberg S, et al. Prognostic value of amplification of c-erbB-2 in bladder carcinoma. *Clin Cancer Res* 1995;1:1189.
94. Mellon JK, Lunec J, Wright C, et al. C-ERBB-2 in bladder cancer: molecular biology, correlation with epidermal growth factor receptors and prognostic value. *J Urology* 1996;155:321–326.
95. Memon AA, Sorensen BS, Meldgaard P, et al. The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients. *Br J Cancer* 2006;94:1703–1709.
96. Amsellem-Ouazana D, Bieche I, Tozlu S, et al. Gene expression profiling of ERBB receptors and ligands in human transitional cell carcinoma of the bladder. *J Urol* 2006;175:1127–1132.
97. Neal DE, Sharples L, Smith K, et al. The epidermal growth factor receptor and the prognosis of bladder cancer. *Cancer* 1990;65:1619–1625.
98. Mellon K, Wright C, Kelly P, et al. Long-term outcome related to epidermal growth factor receptor status in bladder cancer. *J Urol* 1995;153:919–925.
99. Dovedi SJ, Davies BR. Emerging targeted therapies for bladder cancer: a disease waiting for a drug. *Cancer Metastasis Rev* 2009;28:355–367.
100. Theodorescu D, Cornil I, Sheehan C, et al. Ha-ras induction of the invasive phenotype results in up-regulation of epidermal growth factor receptors and altered responsiveness to epidermal growth factor in human papillary transitional cell carcinoma cells. *Cancer Res* 1991;51:4486.
101. Zhang ZT, Pak J, Huang HY, et al. Role of Ha-ras activation in superficial papillary pathway of urothelial tumor formation. *Oncogene* 2001;20:1973.
102. Tomlinson DC, Lamont FR, Shnyder SD, et al. Fibroblast growth factor receptor 1 promotes proliferation and survival via activation of the mitogen-activated protein kinase pathway in bladder cancer. *Cancer Res* 2009;69:4613–4620.
103. Habuchi T, Kinoshita H, Yamada H, et al. Oncogene amplification in urothelial cancers with p53 gene mutation or MDM2 amplification. *J Natl Cancer Inst* 1994;86:1331–1335.
104. Simon R, Struckmann K, Schraml P, et al. Amplification pattern of 12q13-q15 genes (MDM2, CDK4, GLI) in urinary bladder cancer. *Oncogene* 2002;21:2476–2483.
105. Schmitz-Drager BJ, Schulz WA, Jurgens B, et al. c-myc in bladder cancer. Clinical findings and analysis of mechanism. *Urol Res* 1997;25:S45–S49.
106. Watters AD, Latif Z, Forsyth A, et al. Genetic aberrations of c-myc and CCND1 in the development of invasive bladder cancer. *Br J Cancer* 2002;87:654–658.
107. Williams S, Platt F, Hurst C, et al. High Resolution Analysis of Genomic Alteration on Chromosome Arm 8p in Urothelial Carcinoma. *Genes Chromosomes Cancer* 2010;In Press.
108. Oeggerli M, Tomovska S, Schraml P, et al. E2F3 amplification and overexpression is associated with invasive tumor growth and rapid tumor cell proliferation in urinary bladder cancer. *Oncogene* 2004;23:5616–5623.
109. Hurst CD, Fiegler H, Carr P, et al. High-resolution analysis of genomic copy number alterations in bladder cancer by microarray-based comparative genomic hybridization. *Oncogene* 2004;23:2250–2263.
110. Feber A, Clark J, Goodwin G, et al. Amplification and overexpression of E2F3 in human bladder cancer. *Oncogene* 2004;23:1627.
111. Hurst CD, Tomlinson DC, Williams SV, et al. Inactivation of the Rb pathway and overexpression of both isoforms of E2F3 are obligate events in bladder tumours with 6p22 amplification. *Oncogene* 2008;27:2716–2727.
112. Olsson AY, Feber A, Edwards S, et al. Role of E2F3 expression in modulating cellular proliferation rate in human bladder and prostate cancer cells. *Oncogene* 2007;26:1028–1037.
113. Olivier M, Eeles R, Hollstein M, et al. The IARC TP53 database: new online mutation analysis and recommendations to users. *Hum Mutat* 2002;19:607–614.
114. Schmitz-Drager BJ, Goebell PJ, Ebert T, et al. p53 immunohistochemistry as a prognostic marker in bladder cancer. Playground for urology scientists? *Eur Urol* 2000;38:691–699; discussion 700.
115. Malats N, Bustos A, Nascimento CM, et al. P53 as a prognostic marker for bladder cancer: a meta-analysis and review. *Lancet Oncol* 2005;6:678–686.
116. George B, Datar RH, Wu L, et al. p53 gene and protein status: the role of p53 alterations in predicting outcome in patients with bladder cancer. *J Clin Oncol* 2007;25:5352–5358.
117. Cairns P, Proctor A, Knowles M. Loss of heterozygosity at the RB locus is frequent and correlates with muscle *Oncogene* 1991.
118. Cordon-Cardo C, Wartinger D, Petrylak D, et al. Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer. *J Natl Cancer Inst* 1992;84:1251.

119. Logothetis CJ, Xu H-J, Ro JY, et al. Altered expression of retinoblastoma protein and known prognostic variables in locally advanced bladder cancer. *J Natl Cancer Inst* 1992;84:1256.
120. Xu H, Cairns P, Hu S, et al. Loss of RB protein expression in primary bladder cancer correlates with loss of heterozygosity at the RB locus and tumor progression. *Int J Cancer* 1993;53(5):781.
121. Benedict WF, Lerner SP, Zhou J, et al. Level of retinoblastoma protein expression correlates with p16 (MTS-1/INK4A/CDKN2) status in bladder cancer. *Oncogene* 1999;18:1197–1203.
122. Shariat SF, Tokunaga H, Zhou J, et al. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. *J Clin Oncol* 2004;22:1014–1024.
123. Mitra AP, Birkhahn M, Cote RJ. p53 and retinoblastoma pathways in bladder cancer. *World J Urol* 2007;25:563–571.
124. Chatterjee SJ, Datar R, Youssefzadeh D, et al. Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. *J Clin Oncol* 2004;22:1007–1013.
125. Shariat SF, Chade DC, Karakiewicz PI, et al. Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer. *J Urol* 183:68–75.
126. Shariat SF, Zlotta AR, Ashfaq R, et al. Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness. *Mod Pathol* 2007;20:445.
127. Lu ML, Wikman F, Orntoft TF, et al. Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods. *Clin Cancer Res* 2002;8:171.
128. Hitchings AW, Kumar M, Jordan S, et al. Prediction of progression in pTa and pT1 bladder carcinomas with p53, p16 and pRb. *Br J Cancer* 2004;91:552.
129. Cappellen D, Gil Diez de Medina S, Chopin D, et al. Frequent loss of heterozygosity on chromosome 10q in muscle-invasive. *Oncogene* 1997;14:3059–3066.
130. Kagan J, Liu J, Stein JD, et al. Cluster of allele losses within a 2.5 cM region of chromosome 10 in high-grade invasive bladder cancer. *Oncogene* 1998;16:909–913.
131. Aveyard JS, Skilleter A, Habuchi T, et al. Somatic mutation of PTEN in bladder carcinoma. *Br J Cancer* 1999;80:904–908.
132. Wang DS, Rieger-Christ K, Latini JM, et al. Molecular analysis of PTEN and MXI1 in primary bladder carcinoma. *Int J Cancer* 2000;88:620–625.
133. Liu J, Babaian DC, Liebert M, et al. Inactivation of MMAC1 in bladder transitional-cell carcinoma cell lines and specimens. *Mol Carcinog* 2000;29:143–150.
134. Cairns P, Evron E, Okami K, et al. Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers. *Oncogene* 1998;16:3215–3218.
135. Tsuruta H, Kishimoto H, Sasaki T, et al. Hyperplasia and carcinomas in Pten-deficient mice and reduced PTEN Protein in Human Bladder Cancer Patients. *Cancer Res* 2006;66:8389–8396.
136. Puzio-Kuter AM, Castillo-Martin M, Kinkade CW, et al. Inactivation of p53 and Pten promotes invasive bladder cancer. *Genes Dev* 2009;23:675–689.
137. Di Cristofano A, Pesce B, Cordon-Cardo C, et al. Pten is essential for embryonic development and tumour suppression. *Nat Genet* 1998;19:348.
138. Yoo LI, Liu DW, Le Vu S, et al. Pten deficiency activates distinct downstream signaling pathways in a tissue-specific manner. *Cancer Res* 2006;66:1929.
139. Tanaka M, Grossman HB. In vivo gene therapy of human bladder cancer with PTEN suppresses tumor growth, downregulates phosphorylated Akt, and increases sensitivity to doxorubicin. *Gene Ther* 2003;10:1636–1642.
140. Tanaka M, Koul D, Davies MA, et al. MMAC1/PTEN inhibits cell growth and induces chemosensitivity to doxorubicin in human bladder cancer cells. *Oncogene* 2000;19:5406–5412.
141. Gildea JJ, Herlevsen M, Harding MA, et al. PTEN can inhibit in vitro organotypic and in vivo orthotopic invasion of human bladder cancer cells even in the absence of its lipid phosphatase activity. *Oncogene* 2004;23:6788–6797.
142. Gildea JJ, Seraj MJ, Oxford G, et al. RhoGDI2 is an invasion and metastasis suppressor gene in human cancer. *Cancer Res* 2002;62:6418–6423.
143. Theodorescu D, Sapinoso LM, Conaway MR, et al. Reduced expression of metastasis suppressor RhoGDI2 is associated with decreased survival for patients with bladder cancer. *Clin Cancer Res* 2004;10:3800–3806.
144. Wu Y, Moissoglu K, Wang H, et al. Src phosphorylation of RhoGDI2 regulates its metastasis suppressor function. *Proc Natl Acad Sci U S A* 2009;106:5807–5812.
145. Said N, Theodorescu D. Pathways of metastasis suppression in bladder cancer. *Cancer Metastasis Rev* 2009;28:327–333.
146. Richter J, Wagner U, Schraml P, et al. Chromosomal imbalances are associated with a high risk of progression in early invasive (pT1) urinary bladder cancer. *Cancer Res* 1999;59:5687.
147. Hovey RM, Chu L, Balazs M, et al. Genetic alterations in primary bladder cancers and their metastases. *Cancer Res* 1998;58:3555.
148. Dyrskjot L, Ostefeld MS, Bramsen JB, et al. Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro. *Cancer Res* 2009;69:4851–4860.
149. Neely LA, Rieger-Christ KM, Neto BS, et al. A microRNA expression ratio defining the invasive phenotype in bladder tumors. *Urol Oncol* 2010;28:39–48.
150. Lu Q, Lu C, Zhou G-P, et al. MicroRNA-221 silencing predisposed human bladder cancer cells to undergo apoptosis induced by TRAIL. *Urol Oncol* 2009.
151. Ostefeld MS, Bramsen JB, Lamy P, et al. miR-145 induces caspase-dependent and -independent cell death in urothelial cancer cell lines with targeting of an expression signature present in Ta bladder tumors. *Oncogene* 2010;29:1073–1084.
152. Adam L, Zhong M, Choi W, et al. miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. *Clin Cancer Res* 2009;15:5060–5072.
153. Chiyomaru T, Enokida H, Tatarano S, et al. miR-145 and miR-133a function as tumour suppressors and directly regulate FSCN1 expression in bladder cancer. *Br J Cancer* 2010;102:883–891.
154. Friedman JM, Liang G, Liu C-C, et al. The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2. *Cancer Res* 2009;69:2623.
155. Orntoft TF, Dyrskjot L. Gene signatures for risk-adapted treatment of bladder cancer. *Scand J Urol Nephrol Suppl* 2008;(218):166–174.
156. Dyrskjot L, Thykjaer T, Kruhoffer M, et al. Identifying distinct classes of bladder carcinoma using microarrays. *Nat Genet* 2003;33:90.
157. Sanchez-Carbayo M. Use of high-throughput DNA microarrays to identify biomarkers for bladder cancer. *Clin Chem* 2003;49:23–31.
158. Blaveri E, Simko JP, Korkola JE, et al. Bladder cancer outcome and subtype classification by gene expression. *Clin Cancer Res* 2005;11:4044–4055.
159. Wild PJ, Herr A, Wissmann C, et al. Gene expression profiling of progressive papillary noninvasive carcinomas of the urinary bladder. *Clin Cancer Res* 2005;11:4415–4429.
160. Kim JH, Tuziak T, Hu L, et al. Alterations in transcription clusters underlie development of bladder cancer along papillary and nonpapillary pathways. *Lab Invest* 2005;85:532–549.
161. Modlich O, Prisack HB, Pitschke G, et al. Identifying superficial, muscle-invasive, and metastasizing transitional cell carcinoma of the bladder: use of cDNA array analysis of gene expression profiles. *Clin Cancer Res* 2004;10:3410–3421.

162. Lindgren D, Liedberg F, Andersson A, et al. Molecular characterization of early-stage bladder carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q. *Oncogene* 2006;25:2685–2696.
163. Aaboe M, Marcussen N, Jensen KM, et al. Gene expression profiling of noninvasive primary urothelial tumours using microarrays. *Br J Cancer* 2005;93:1182–1190.
164. Eble JN, Sauter G, Epstein JI, Sesterhenn IA, eds. *World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs*. Lyon, France: IARC Press, 2004.
165. Dyrskjot L, Zieger K, Real FX, et al. Gene expression signatures predict outcome in non-muscle-invasive bladder carcinoma: a multicenter validation study. *Clin Cancer Res* 2007;13:3545.
166. Schultz IJ, Wester K, Straatman H, et al. Gene expression analysis for the prediction of recurrence in patients with primary Ta urothelial cell carcinoma. *Eur Urol* 2007;51:416.
167. Dyrskjot L, Kruhoffer M, Thykjaer T, et al. Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification. *Cancer Res* 2004;64:4040–4048.
168. Sanchez-Carbayo M, Succi ND, Lozano JJ, et al. Gene discovery in bladder cancer progression using cDNA microarrays. *Am J Pathol* 2003;163:505–516.
169. Dyrskjot L, Zieger K, Kruhoffer M, et al. A molecular signature in superficial bladder carcinoma predicts clinical outcome. *Clin Cancer Res* 2005;11:4029–4036.
170. Kim W-J, Kim E-J, Kim S-K, et al. Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer. *Mol Cancer* 2010;9:3.
171. Catto JWF, Abbod MF, Wild PJ, et al. The application of artificial intelligence to microarray data: identification of a novel gene signature to identify bladder cancer progression. *Eur Urol* 2010;57:398–406.
172. Sanchez-Carbayo M, Succi ND, Lozano J, et al. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. *J Clin Oncol* 2006;24:778–789.
173. McConkey DJ, Choi W, Marquis L, et al. Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer. *Cancer Metastasis Rev* 2009;28:335–344.
174. Sayan AE, Griffiths TR, Pal R, et al. SIP1 protein protects cells from DNA damage-induced apoptosis and has independent prognostic value in bladder cancer. *Proc Natl Acad Sci U S A* 2009;106:14884.
175. Baumgart E, Cohen MS, Silva Neto B, et al. Identification and prognostic significance of an epithelial-mesenchymal transition expression profile in human bladder tumors. *Clin Cancer Res* 2007;13:1685.
176. Black PC, Brown GA, Inamoto T, et al. Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells. *Clin Cancer Res* 2008;14:1478–1486.
177. Shrader M, Pino MS, Brown G, et al. Molecular correlates of gefitinib responsiveness in human bladder cancer cells. *Mol Cancer Ther* 2007;6:277–285.
178. Takata R, Katagiri T, Kanehira M, et al. Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. *Clin Cancer Res* 2005;11:2625–2636.
179. Als AB, Dyrskjot L, von der Maase H, et al. Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer. *Clin Cancer Res* 2007;13:4407–4414.
180. Havaleshko DM, Cho H, Conaway M, et al. Prediction of drug combination chemosensitivity in human bladder cancer. *Mol Cancer Ther* 2007;6:578–586.
181. Havaleshko DM, Smith SC, Cho H, et al. Comparison of global versus epidermal growth factor receptor pathway profiling for prediction of lapatinib sensitivity in bladder cancer. *Neoplasia* 2009;11:1185.
182. Lee JK, Havaleshko DM, Cho H, et al. A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. *Proc Natl Acad Sci U S A* 2007;104:13086.
183. Williams PD, Cheon S, Havaleshko DM, et al. Concordant gene expression signatures predict clinical outcomes of cancer patients undergoing systemic therapy. *Cancer Res* 2009;69:8302.
184. Veltman JA, Fridlyand J, Pejavar S, et al. Array-based comparative genomic hybridization for genome-wide screening of DNA copy number in bladder tumors. *Cancer Res* 2003;63:2872–2880.
185. Veerakumarasivam A, Scott HE, Chin SF, et al. High-resolution array-based comparative genomic hybridization of bladder cancers identifies mouse double minute 4 (MDM4) as an amplification target exclusive of MDM2 and TP53. *Clin Cancer Res* 2008;14:2527–2534.
186. Blaveri E, Brewer JL, Roydasgupta R, et al. Bladder cancer stage and outcome by array-based comparative genomic hybridization. *Clin Cancer Res* 2005;11:7012–7022.
187. Nord H, Segersten U, Sandgren J, et al. Focal amplifications are associated with high grade and recurrences in stage Ta bladder carcinoma. *Int J Cancer* 2010;126:1390–1402.
188. Zieger K, Wiuf C, Jensen KM, et al. Chromosomal imbalance in the progression of high-risk non-muscle invasive bladder cancer. *BMC Cancer* 2009;9:149.
189. Chan KS, Espinosa I, Chao M, et al. Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. *Proc Natl Acad Sci U S A* 2009;106:14016.
190. He X, Marchionni L, Hansel DE, et al. Differentiation of a highly tumorigenic basal cell compartment in urothelial carcinoma. *Stem Cells* 2009;27:1487.
191. Brandt WD, Matsui W, Rosenberg JE, et al. Urothelial carcinoma: stem cells on the edge. *Cancer Metastasis Rev* 2009;28:291.
192. Hafner C, Knuichel R, Stoehr R, et al. Clonality of multifocal urothelial carcinomas: 10 years of molecular genetic studies. *Int J Cancer* 2002;101:1–6.
193. Lee S, Jeong J, Majewski T, et al. Forerunner genes contiguous to RB1 contribute to the development of in situ neoplasia. *Proc Natl Acad Sci U S A* 2007;104:13732–13737.
194. Majewski T, Lee S, Jeong J, et al. Understanding the development of human bladder cancer by using a whole-organ genomic mapping strategy. *Lab Invest* 2008;88:694–721.
195. Hoglund M, Sall T, Heim S, et al. Identification of cytogenetic subgroups and karyotypic pathways in transitional cell carcinoma. *Cancer Res* 2001;61:8241–8246.
196. Bulashevskaya S, Szakacs O, Brors B, et al. Pathways of urothelial cancer progression suggested by Bayesian network analysis of allelotyping data. *Int J Cancer* 2004;110:850–856.
197. Hoglund M, Frigyesi A, Sall T, et al. Statistical behavior of complex cancer karyotypes. *Genes Chromosomes Cancer* 2005;42:327–341.
198. Chapman EJ, Hurst CD, Pitt E, et al. Expression of hTERT immortalises normal human urothelial cells without inactivation of the p16/Rb pathway. *Oncogene* 2006;25:5037–5045.
199. Knowles MA, Williamson M. Mutation of H-ras is infrequent in bladder cancer: confirmation by single-strand conformation polymorphism analysis, designed restriction fragment length polymorphisms, and direct sequencing. *Cancer Res* 1993;53:133.
200. Ooi A, Herz F, Li S, et al. Ha-ras codon 12 mutation in papillary tumors of the urinary bladder: a retrospective study. *Int J Oncol* 1994;4:85.
201. Fitzgerald JM, Ramchurren N, Rieger K, et al. Identification of H-ras mutations in urine sediments complements cytology in the detection of bladder tumors. *J Natl Cancer Inst* 1995;87:129.

202. Bringuier PP, Tamimi J, Schuurung E. Amplification of the chromosome 11q13 region in bladder tumours. *Urological Research* 1994;21:451.
203. Lianes P, Orlow I, Zhang Z-F, et al. Altered patterns of MDM2 and TP53 expression in human bladder cancer. *J Natl Cancer Inst* 1994;86:1325–1330.
204. Habuchi T, Yoshida O, Knowles MA. A novel candidate tumour suppressor locus at 9q32–33 in bladder cancer: localisation of the candidate region within a single 840kb YAC. *Hum Mol Genet* 1997;6:913–919.
205. Richter J, Jiang F, Gorog JP, et al. Marked genetic differences between stage pTa and stage pT1 papillary bladder cancer detected by comparative genomic hybridization. *Cancer Res* 1997;57:2860–2864.
206. Zhao J, Richter J, Wagner U, et al. Chromosomal imbalances in noninvasive papillary bladder neoplasms (pTa). *Cancer Res* 1999;59:4658–4661.
207. Sato K, Moriyama M, Mori S, et al. An immunohistologic evaluation of *c-erbB-2* gene product in patients with urinary bladder carcinoma. *Cancer* 1992;70:2493–2498.
208. Zaharieva BM, Simon R, Diener PA, et al. High-throughput tissue microarray analysis of 11q13 gene amplification (CCND1, FGF3, FGF4, EMS1) in urinary bladder cancer. *J Pathol* 2003;201:603.
209. Habuchi T, Takahashi R, Yamada H, et al. Influence of cigarette smoking and schistosomiasis on p53 gene mutation in urothelial cancer. *Cancer Res* 1993;53:3795.
210. Sidransky D, von Eschenbach A, Tsai YC, et al. Identification of p53 gene mutations in bladder cancers and urine samples. *Science* 1991;252:706.
211. Spruck CH, III, Rideout WM, et al. Distinct pattern of p53 mutations in bladder cancer: relationship to tobacco usage. *Cancer Research* 1993;53:1162–1166.
212. Richter J, Beffa L, Wagner U, et al. Patterns of chromosomal imbalances in advanced urinary bladder cancer detected by comparative genomic hybridization. *Am J Pathol* 1998;153:1615–1621.

Chapter 22 – References

1. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. *Science* 2004;304:1497.
2. Sordella R, Bell DW, Haber DA, et al. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. *Science* 2004;305:1163.
3. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. *Proc Natl Acad Sci U S A* 2004;101:13306.
4. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. *Nature* 2007;448:561.
5. Solit DB, Garraway LA, Pratilas CA, et al. BRAF mutation predicts sensitivity to MEK inhibition. *Nature* 2006;439:358.
6. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. *N Engl J Med* 2003;349:366.
7. De Marzo AM, Platz EA, Sutcliffe S, et al. Inflammation in prostate carcinogenesis. *Nat Rev Cancer* 2007;7:256.
8. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. *N Engl J Med* 2009;360:1320.
9. Andriole GL, Crawford ED, Grubb RL 3rd, et al. Mortality results from a randomized prostate-cancer screening trial. *N Engl J Med* 2009;360:1310.
10. Singh AS, Chau CH, Price DK, et al. Mechanisms of disease: polymorphisms of androgen regulatory genes in the development of prostate cancer. *Nat Clin Pract Urol* 2005;2:101.
11. Amundadottir LT, Sulem P, Gudmundsson J, et al. A common variant associated with prostate cancer in European and African populations. *Nat Genet* 2006;38:652.
12. Gudmundsson J, Sulem P, Manolescu A, et al. Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. *Nat Genet* 2007;39:631.
13. Haiman CA, Patterson N, Freedman ML, et al. Multiple regions within 8q24 independently affect risk for prostate cancer. *Nat Genet* 2007;39:638.
14. Yeager M, Orr N, Hayes RB, et al. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. *Nat Genet* 2007;39:645.
15. Al Olama AA, Kote-Jarai Z, Giles GG, et al. Multiple loci on 8q24 associated with prostate cancer susceptibility. *Nat Genet* 2009;41:1058.
16. Ahmadiyeh N, Pomerantz MM, Grisanzio C, et al. 8q24 prostate, breast, and colon cancer risk loci show tissue-specific long-range interaction with MYC. *Proc Natl Acad Sci U S A* 2010;107:9742.
17. Eeles RA, Kote-Jarai Z, Giles GG, et al. Multiple newly identified loci associated with prostate cancer susceptibility. *Nat Genet* 2008;40:316.
18. Thomas G, Jacobs KB, Yeager M, et al. Multiple loci identified in a genome-wide association study of prostate cancer. *Nat Genet* 2008;40:310.
19. Zheng SL, Sun J, Wiklund F, et al. Cumulative association of five genetic variants with prostate cancer. *N Engl J Med* 2008;358:910.
20. Hanahan D, Weinberg RA. The hallmarks of cancer. *Cell* 2000;100:57.
21. Taylor BS, Schultz N, Hieronymus H, et al. Integrative genomic profiling of human prostate cancer. *Cancer Cell* 2010;18:11.
22. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. *Cancer Res* 1941;1:293.
23. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. *Nat Rev Cancer* 2001;1:34.
24. Chen Y, Sawyers CL, Scher HI. Targeting the androgen receptor pathway in prostate cancer. *Curr Opin Pharmacol* 2008;8:440.
25. Berger R, Febbo PG, Majumder PK, et al. Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells. *Cancer Res* 2004;64:8867.
26. Xin L, Teitell MA, Lawson DA, et al. Progression of prostate cancer by synergy of AKT with genotropic and nongenotropic actions of the androgen receptor. *Proc Natl Acad Sci U S A* 2006;103:7789.
27. McCormick DL, Rao KV, Dooley L, et al. Influence of N-methyl-N-nitrosourea, testosterone, and N-(4-hydroxyphenyl)-all-trans-retinamide on prostate cancer induction in Wistar-Unilever rats. *Cancer Res* 1998;58:3282.
28. Stanbrough M, Leav I, Kwan PW, et al. Prostatic intraepithelial neoplasia in mice expressing an androgen receptor transgene in prostate epithelium. *Proc Natl Acad Sci U S A* 2001;98:10823.
29. Taplin ME, Balk SP. Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence. *J Cell Biochem* 2004;91:483.
30. Visakorpi T, Hyytinen E, Koivisto P, et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. *Nat Genet* 1995;9:401.
31. Linja MJ, Savinainen KJ, Saramaki OR, et al. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. *Cancer Res* 2001;61:3550.
32. Holzbeierlein J, Lal P, LaTulippe E, et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. *Am J Pathol* 2004;164:217.
33. Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy. *Nat Med* 2004;10:33.
34. Hu R, Dunn TA, Wei S, et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. *Cancer Res* 2009;69:16.
35. Dehm SM, Schmidt LJ, Heemers HV, et al. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. *Cancer Res* 2008;68:5469.
36. Sun S, Sprenger CC, Vessella RL, et al. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. *J Clin Invest* 2010;120:2715.
37. Mostaghel EA, Page ST, Lin DW, et al. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. *Cancer Res* 2007;67:5033.
38. Montgomery RB, Mostaghel EA, Vessella R, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. *Cancer Res* 2008;68:4447.
39. Stanbrough M, Bubley GJ, Ross K, et al. Increased expression of genes converting androgen to testosterone in androgen-independent prostate cancer. *Cancer Res* 2006;66:2815.
40. Hofland J, van Weerden WM, Dits NF, et al. Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer. *Cancer Res* 2010;70:1256.
41. Mellinghoff IK, Vivanco I, Kwon A, et al. HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. *Cancer Cell* 2004;6:517.
42. Ham WS, Cho NH, Kim WT, et al. Pathological effects of prostate cancer correlate with neuroendocrine differentiation and PTEN expression after bicalutamide monotherapy. *J Urol* 2009;182:1378.

43. Gao H, Ouyang X, Banach-Petrosky WA, et al. Emergence of androgen independence at early stages of prostate cancer progression in Nkx3.1; Pten mice. *Cancer Res* 2006; 66:7929.
44. Jiao J, Wang S, Qiao R, et al. Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development. *Cancer Res* 2007;67:6083.
45. Kelly WK, Scher HI. Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. *J Urol* 1993;149:607.
46. Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. *Science* 2009;324:787.
47. Scher HI, Beer TM, Higano CS, et al. Antitumor activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. *Lancet* 2010;375:1437.
48. Attard G, Reid AH, A'Hern R, et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. *J Clin Oncol* 2009;27:3742.
49. Danila DC, Morris MJ, de Bono JS, et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. *J Clin Oncol* 2010;28:1496.
50. Reid AH, Attard G, Danila DC, et al. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. *J Clin Oncol* 2010;28:1489.
51. Solit DB, Zheng FF, Drobniak M, et al. 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. *Clin Cancer Res* 2002;8:986.
52. Hieronymus H, Lamb J, Ross KN, et al. Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. *Cancer Cell* 2006;10:321.
53. Butler LM, Agus DB, Scher HI, et al. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. *Cancer Res* 2000;60:5165.
54. Welsbie DS, Xu J, Chen Y, et al. Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer. *Cancer Res* 2009;69:958.
55. Heath EI, Hillman DW, Vaishampayan U, et al. A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. *Clin Cancer Res* 2008;14:7940.
56. Tomlins SA, Laxman B, Dhanasekaran SM, et al. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. *Nature* 2007; 448:595.
57. Tomlins SA, Mehra R, Rhodes DR, et al. TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. *Cancer Res* 2006;66:3396.
58. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. *Science* 2005;310:644.
59. Petrovics G, Liu A, Shaheduzzaman S, et al. Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. *Oncogene* 2005;24:3847.
60. Demichelis F, Fall K, Perner S, et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. *Oncogene* 2007;26:4596.
61. Nakagawa T, Kollmeyer TM, Morlan BW, et al. A tissue biomarker panel predicting systemic progression after PSA recurrence post-definitive prostate cancer therapy. *PLoS One* 2008;3:e2318.
62. Gopalan A, Leversha MA, Satagopan JM, et al. TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. *Cancer Res* 2009; 69:1400.
63. Attard G, Clark J, Ambroisine L, et al. Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer. *Br J Cancer* 2008;99:314.
64. Shin S, Kim TD, Jin F, et al. Induction of prostatic intraepithelial neoplasia and modulation of androgen receptor by ETS variant 1/ETS-related protein 81. *Cancer Res* 2009;69:8102.
65. Attard G, Swennenhuis JF, Olmos D, et al. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. *Cancer Res* 2009;69:2912.
66. Liu W, Laitinen S, Khan S, et al. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. *Nat Med* 2009;15:559.
67. Mehra R, Tomlins SA, Yu J, et al. Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. *Cancer Res* 2008; 68:3584.
68. Han B, Mehra R, Lonigro RJ, et al. Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression. *Mod Pathol* 2009;22:1083.
69. Furusato B, Tan SH, Young D, et al. ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification. *Prostate Cancer Prostatic Dis* 2010.
70. Tomlins SA, Laxman B, Varambally S, et al. Role of the TMPRSS2-ERG gene fusion in prostate cancer. *Neoplasia* 2008;10:177.
71. Klezovitch O, Risk M, Coleman I, et al. A causal role for ERG in neoplastic transformation of prostate epithelium. *Proc Natl Acad Sci U S A* 2008;105:2105.
72. Carver BS, Tran J, Gopalan A, et al. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. *Nat Genet* 2009;41:619.
73. King JC, Xu J, Wongvipat J, et al. Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. *Nat Genet* 2009;41:524.
74. Zong Y, Xin L, Goldstein AS, et al. ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells. *Proc Natl Acad Sci U S A* 2009;106:12465.
75. Yu J, Mani RS, Cao Q, et al. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. *Cancer Cell* 2010; 17:443.
76. Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. *Science* 1997;275:1943.
77. Liu W, Chang B, Sauvageot J, et al. Comprehensive assessment of DNA copy number alterations in human prostate cancers using Affymetrix 100K SNP mapping array. *Genes Chromosomes Cancer* 2006;45:1018.
78. Whang YE, Wu X, Suzuki H, et al. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. *Proc Natl Acad Sci U S A* 1998;95:5246.
79. Wang S, Gao J, Lei Q, et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. *Cancer Cell* 2003;4:209.
80. Ma X, Ziel-van der Made AC, Autar B, et al. Targeted biallelic inactivation of Pten in the mouse prostate leads to prostate cancer accompanied by increased epithelial cell proliferation but not by reduced apoptosis. *Cancer Res* 2005;65:5730.
81. Backman SA, Ghazarian D, So K, et al. Early onset of neoplasia in the prostate and skin of mice with tissue-specific deletion of Pten. *Proc Natl Acad Sci U S A* 2004;101: 1725.
82. Kwabi-Addo B, Giri D, Schmidt K, et al. Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression. *Proc Natl Acad Sci U S A* 2001;98: 11563.

83. Chen ML, Xu PZ, Peng XD, et al. The deficiency of Akt1 is sufficient to suppress tumor development in Pten+/- mice. *Genes Dev* 2006;20:1569.
84. Guertin DA, Stevens DM, Saitoh M, et al. mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. *Cancer Cell* 2009;15:148.
85. Vivanco I, Palaskas N, Tran C, et al. Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN. *Cancer Cell* 2007;11:555.
86. Abate-Shen C. Deregulated homeobox gene expression in cancer: cause or consequence? *Nat Rev Cancer* 2002;2:777.
87. Kim MJ, Bhatia-Gaur R, Banach-Petrosky WA, et al. Nkx3.1 mutant mice recapitulate early stages of prostate carcinogenesis. *Cancer Res* 2002;62:2999.
88. Magee JA, Abdulkadir SA, Milbrandt J. Haploinsufficiency at the Nkx3.1 locus. A paradigm for stochastic, dosage-sensitive gene regulation during tumor initiation. *Cancer Cell* 2003;3:273.
89. Ellwood-Yen K, Graeber TG, Wongvipat J, et al. Myc-driven murine prostate cancer shares molecular features with human prostate tumors. *Cancer Cell* 2003;4:223.
90. Lei Q, Jiao J, Xin L, et al. NKX3.1 stabilizes p53, inhibits AKT activation, and blocks prostate cancer initiation caused by PTEN loss. *Cancer Cell* 2006;9:367.
91. Iwata T, Schultz D, Hicks J, et al. MYC overexpression induces prostatic intraepithelial neoplasia and loss of Nkx3.1 in mouse luminal epithelial cells. *PLoS One* 2010;5:e9427.
92. Chi P, Allis CD, Wang GG. Covalent histone modifications—miswritten, misinterpreted and mis-erased in human cancers. *Nat Rev Cancer* 2010;10:457.
93. Lee WH, Morton RA, Epstein JI, et al. Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. *Proc Natl Acad Sci U S A* 1994;91:11733.
94. Seligson DB, Horvath S, Shi T, et al. Global histone modification patterns predict risk of prostate cancer recurrence. *Nature* 2005;435:1262.
95. Varambally S, Dhanasekaran SM, Zhou M, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. *Nature* 2002;419:624.
96. Vire E, Brenner C, Deplus R, et al. The polycomb group protein EZH2 directly controls DNA methylation. *Nature* 2006;439:871.
97. Min J, Zaslavsky A, Fedele G, et al. An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB. *Nat Med* 2010;16:286.
98. Chen Y, Clegg NJ, Scher HI. Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. *Lancet Oncol* 2009;10:981.

Chapter 23 – References

1. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. *Immunity* 2004;21(2):137.
2. Karst AM, Drapkin R. Ovarian cancer pathogenesis: a model in evolution. *J Oncol* 2010; (in press).
3. Levanon K, Crum C, Drapkin R. New insights into the pathogenesis of serous ovarian cancer and its clinical impact. *J Clin Oncol* 2008;26:5284.
4. Auersperg N, Wong AS, Choi KC, et al. Ovarian surface epithelium: biology, endocrinology, and pathology. *Endocr Rev* 2001;22:255.
5. Wright JW, Pejovic T, Fanton J, Stouffer RL. Induction of proliferation in the primate ovarian surface epithelium in vivo. *Hum Reprod* 2008;23:129.
6. Wright JW, Pejovic T, Lawson M, et al. Ovulation in the absence of the ovarian surface epithelium in the primate. *Biol Reprod* 2010;82:599.
7. Schlosshauer PW, Cohen CJ, Penault-Llorca F, et al. Prophylactic oophorectomy: a morphologic and immunohistochemical study. *Cancer* 2003;98(12):2599.
8. Ganesan S, Richardson AL, Wang ZC, et al. Abnormalities of the inactive X chromosome are a common feature of BRCA1 mutant and sporadic basal-like breast cancer. *Cold Spring Harb Symp Quant Biol* 2005;70:93.
9. Garcia-Higuera I, Taniguchi T, Ganesan S, et al. Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. *Mol Cell* 2001;7(2):249.
10. Sakai W, Swisher EM, Karlan BY, et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. *Nature* 2008;451:1116.
11. Boudsocq F, Benaim P, Canitrot Y, et al. Modulation of cellular response to cisplatin by a novel inhibitor of DNA polymerase beta. *Mol Pharmacol* 2005;67(5):1485.
12. Kennedy RD, Chen CC, Stuckert P, et al. Fanconi anemia pathway-deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated. *J Clin Invest* 2007;117:1440.
13. Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. *Nature* 2005;434:913.
14. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. *Nature* 2005;434:917.
15. Song H, Ramus SJ, Tyrer J, et al. A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. *Nat Genet* 2009;41:996.
16. Mayr D, Kanitz V, Anderegg B, et al. Analysis of gene amplification and prognostic markers in ovarian cancer using comparative genomic hybridization for microarrays and immunohistochemical analysis for tissue microarrays. *Am J Clin Pathol* 2006;126:101.
17. Meinhold-Heerlein I, Bauerschlag D, Hilpert F, et al. Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential. *Oncogene* 2005;24:1053.
18. Nakayama K, Nakayama N, Jinawath N, et al. Amplicon profiles in ovarian serous carcinomas. *Int J Cancer* 2007;120:2613.
19. Bonome T, Lee JY, Park DC, et al. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. *Cancer Res*, 2005;65:10602.
20. Gilks CB, Vanderhyden BC, Zhu S, van de Rijn M, Longacre TA. Distinction between serous tumors of low malignant potential and serous carcinomas based on global mRNA expression profiling. *Gynecol Oncol* 2005;96:684.
21. Hough CD, Cho KR, Zonderman AB, Schwartz DR, Morin PJ. Coordinately up-regulated genes in ovarian cancer. *Cancer Res* 2001;61:3869.
22. Hough CD, Sherman-Baust CA, Pizer ES, et al. Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. *Cancer Res* 2000;60:6281.
23. Schwartz DR, Kardias SL, Shedden KA, et al. Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. *Cancer Res* 2002;62:4722.
24. Landen CN Jr, Birrer MJ, Sood AK. Early events in the pathogenesis of epithelial ovarian cancer. *J Clin Oncol* 2008;26:995.
25. Berchuck A, Iversen ES, Lancaster JM, et al. Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarrays. *Am J Obstet Gynecol* 2004;190:910.
26. Hu W, Wu W, Nash MA, et al. Anomalies of the TGF-beta postreceptor signaling pathway in ovarian cancer cell lines. *Anticancer Res* 2000;20(2A):729.
27. Chen T, Triplett J, Dehner B, et al. Transforming growth factor-beta receptor type I gene is frequently mutated in ovarian carcinomas. *Cancer Res* 2001;61(12):4679.
28. van Haaften-Day C, Shen Y, Xu F, et al. OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal. *Cancer* 2001;92(11):2837.
29. Coronado Martin PJ, Fasero Laiz M, Garcia Santos J, Ramirez Mena M, Vidart Aragon JA. Overexpression and prognostic value of p53 and HER2/neu proteins in benign ovarian tissue and in ovarian cancer. *Med Clin (Barc)* 2007;128(1):1.
30. Ren J, Xiao YJ, Singh LS, et al. Lysophosphatidic acid is constitutively produced by human peritoneal mesothelial cells and enhances adhesion, migration, and invasion of ovarian cancer cells. *Cancer Res* 2006;66(6):3006.
31. Sengupta S, Kim KS, Berk MP, et al. Lysophosphatidic acid down-regulates tissue inhibitor of metalloproteinases, which are negatively involved in lysophosphatidic acid-induced cell invasion. *Oncogene* 2007;26:2894.
32. Do TV, Symowicz JC, Berman DM, et al. Lysophosphatidic acid down-regulates stress fibers and up-regulates pro-matrix metalloproteinase-2 activation in ovarian cancer cells. *Mol Cancer Res* 2007;5(2):121.
33. Bursleson KM, Hansen LK, Skubitz AP. Ovarian carcinoma spheroids disaggregate on type I collagen and invade live human mesothelial cell monolayers. *Clin Exp Metastasis* 2004;21(8):685.
34. Schiffenbauer YS, Abramovitch R, Meir G, et al. Loss of ovarian function promotes angiogenesis in human ovarian carcinoma. *Proc Natl Acad Sci U S A* 1997;94(24):13203.
35. Griffon G, Marchal C, Merlin JL, et al. Radiosensitivity of multicellular tumour spheroids obtained from human ovarian cancers. *Eur J Cancer* 1995;31A(1):85.
36. Szafranski P, Goode S. A Fasciclin 2 morphogenetic switch organizes epithelial cell cluster polarity and motility. *Development* 2004;131(9):2023.
37. Kassim SK, El-Salahy EM, Fayed ST, et al. Vascular endothelial growth factor and interleukin-8 are associated with poor prognosis in epithelial ovarian cancer patients. *Clin Biochem* 2004;37(5):363.
38. Jiang H, Feng Y. Hypoxia-inducible factor 1alpha (HIF-1alpha) correlated with tumor growth and apoptosis in ovarian cancer. *Int J Gynecol Cancer* 2006;16(Suppl 1):405.
39. Zhu G, Saed GM, Deppe G, Diamond MP, Munkarah AR. Hypoxia up-regulates the effects of prostaglandin E2 on tumor angiogenesis in ovarian cancer cells. *Gynecol Oncol* 2004;94(2):422.
40. Imai T, Horiuchi A, Wang C, et al. Hypoxia attenuates the expression of E-cadherin via up-regulation of SNAIL in ovarian carcinoma cells. *Am J Pathol* 2003;163(4):1437.

41. Baylin SB, Ohm JE. Epigenetic gene silencing in cancer—a mechanism for early oncogenic pathway addiction? *Nat Rev Cancer* 2006;6(2):107.
42. Wei SH, Chen CM, Strathdee G, et al. Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. *Clin Cancer Res* 2002;8(7):2246.
43. Balch C, Huang TH, Brown R, Nephew KP. The epigenetics of ovarian cancer drug resistance and resensitization. *Am J Obstet Gynecol* 2004;191(5):1552.
44. Smyth MJ, Dunn GP, Schreiber RD. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. *Adv Immunol* 2006;90:1.
45. Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. *N Engl J Med* 2003;348(3):203.
46. Sato E, Olson SH, Ahn J, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. *Proc Natl Acad Sci U S A* 2005;102(51):18538.
47. Goodell V, Salazar LG, Urban N, et al. Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer. *J Clin Oncol* 2006;24(5):762.
48. Odunsi K, Jungbluth AA, Stockert E, et al. NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. *Cancer Res* 2003;63(18):6076.
49. Old LJ. Cancer/testis (CT) antigens—a new link between gametogenesis and cancer. *Cancer Immunity* 2001;1:1.
50. Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P, et al. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. *Proc Natl Acad Sci U S A* 2010;107:7875.
51. Mutter GL, Boynton KA, Faquin WC, Ruiz RE, Jovanovic AS. Allelotype mapping of unstable microsatellites establishes direct lineage continuity between endometrial precancers and cancer. *Cancer Res* 1996;56(19):4483.
52. Mutter GL, Lin MC, Fitzgerald JT, et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. *J Natl Cancer Inst* 2000;92(11):924.
53. Caduff RF, Johnston CM, Frank TS. Mutations of the Ki-ras oncogene in carcinoma of the endometrium. *Am J Pathol* 1995;146(1):182.
54. Mirabelli-Primdahl L, Gryfe R, Kim H, et al. Beta-catenin mutations are specific for colorectal carcinomas with microsatellite instability but occur in endometrial carcinomas irrespective of mutator pathway. *Cancer Res* 1999;59(14):3346.
55. Busmanis I, Ho TH, Tan SB, Khoo KS. p53 and bcl-2 expression in invasive and pre-invasive uterine papillary serous carcinoma and atrophic endometrium. *Ann Acad Med Singapore* 2005;34(7):421.
56. zur Hausen H. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. *J Natl Cancer Inst* 2000;92(9):690.
57. Shope RE. Serial transmission of virus of infectious papillomatosis in domestic rabbits. *Proc Soc Exp Biol Med* 1935;32:830.
58. Wentzensen N, Vinokurova S, von Knebel Doeberitz M. Systematic review of genomic integration sites of human papillomavirus genomes in epithelial dysplasia and invasive cancer of the female lower genital tract. *Cancer Res* 2004;64(11):3878.
59. Duensing S, Munger K. Centrosome abnormalities, genomic instability and carcinogenic progression. *Biochim Biophys Acta* 2001;1471(2):M81.
60. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. *N Engl J Med* 1998;338(7):423.
61. Zhou J, Liu WJ, Peng SW, Sun XY, Frazer I. Papillomavirus capsid protein expression level depends on the match between codon usage and tRNA availability. *J Virol* 1999;73(6):4972.
62. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. *N Engl J Med* 2002;347(21):1645.
63. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. *J Pathol* 1999;189(1):12.
64. Crum CP. The beginning of the end for cervical cancer? *N Engl J Med* 2002;347(21):1703.
65. Fulop V, Mok SC, Genest DR, et al. c-myc, c-erbB-2, c-fms and bcl-2 oncoproteins. Expression in normal placenta, partial and complete mole, and choriocarcinoma. *J Reprod Med* 1998;43(2):101.
66. Matsuda T, Sasaki M, Kato H, et al. Human chromosome 7 carries a putative tumor suppressor gene(s) involved in choriocarcinoma. *Oncogene* 1997;15(23):2773.

Chapter 24 – References

1. Bell DW. Our changing view of the genomic landscape of cancer. *J Pathol* 2010;220(2):231.
2. Wood LD, Parsons DW, Jones S, et al. The genomic landscapes of human breast and colorectal cancers. *Science* 2007;318(5853):1108.
3. Velculescu VE. Defining the blueprint of the cancer genome. *Carcinogenesis* 2008;29(6):1087.
4. Turnbull C, Rahman N. Genetic predisposition to breast cancer: past, present, and future. *Annu Rev Genomics Hum Genet* 2008;9:321.
5. Foulkes WD. Inherited susceptibility to common cancers. *N Engl J Med* 2008;359(20):2143.
6. Hirshfield KM, Rebbeck TR, Levine AJ. Germline mutations and polymorphisms in the origins of cancers in women. *J Oncol* 2010;2010:297671.
7. Narod SA. Modifiers of risk of hereditary breast cancer. *Oncogene* 2006;25(43):5832.
8. Turner NC, Reis-Filho JS. Basal-like breast cancer and the BRCA1 phenotype. *Oncogene* 2006;25(43):5846.
9. Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. *Cell* 2002;108(2):171.
10. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. *N Engl J Med* 2009;361(2):123.
11. Iglehart JD, Silver DP. Synthetic lethality—a new direction in cancer-drug development. *N Engl J Med* 2009;361(2):189.
12. Stratton MR, Rahman N. The emerging landscape of breast cancer susceptibility. *Nat Genet* 2008;40(1):17.
13. Hoffman AE, Zheng T, Yi C, et al. microRNA miR-196a-2 and breast cancer: a genetic and epigenetic association study and functional analysis. *Cancer Res* 2009;69(14):5970.
14. Forbes SA, Bhamra G, Bamford S, et al. The catalogue of somatic mutations in cancer (COSMIC). *Curr Protoc Hum Genet* 2008;chapter 10:unit 10.11.
15. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. *Nature* 2009;458(7239):719.
16. Copeland NG, Jenkins NA. Deciphering the genetic landscape of cancer—from genes to pathways. *Trends Genet* 2009;25(10):455.
17. Kao J, Pollack JR. RNA interference-based functional dissection of the 17q12 amplicon in breast cancer reveals contribution of coamplified genes. *Genes Chromosomes Cancer* 2006;45(8):761.
18. Chin K, DeVries S, Fridlyand J, et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. *Cancer Cell* 2006;10(6):529.
19. Bentires-Alj M, Gil SG, Chan R, et al. A role for the scaffolding adapter GAB2 in breast cancer. *Nature Med* 2005;12(1):114.
20. Yu Q, Sicinska E, Geng Y, et al. Requirement for CDK4 kinase function in breast cancer. *Cancer Cell* 2006;9(1):23.
21. Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. *Nature* 2000;406(6797):747.
22. Sørlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. *Proc Natl Acad Sci U S A* 2001;98(19):10869.
23. Gruberger S, Ringnér M, Chen Y, et al. Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. *Cancer Res* 2001;61(16):5979.
24. van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. *Nature* 2002;415(6871):530.
25. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. *N Engl J Med* 2002;347(25):1999.
26. Piccart MJ, Loi S, Van't Veer L, et al. Multi-center external validation study of the Amsterdam 70-gene prognostic signature in node negative untreated breast cancer: are the results still outperforming the clinical-pathological criteria? *Breast Cancer Res Treat* 2004;88(S17):(abst 38).
27. Goldhirsch A, Wood WC, Gelber RD, et al. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. *J Clin Oncol* 2003;21(17):3357.
28. Sotiriou C, Wirapati P, Loi S, et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. *J Natl Cancer Inst* 2006;98(4):262.
29. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. *N Engl J Med* 2004;351(27):2817.
30. Albain KS, Barlow WE, Shak S, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. *Lancet Oncol* 2010;11(1):55.
31. Mamounas E, Tang G, Fisher B, et al. Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. *J Clin Oncol* 2010;28(10):1677.
32. Ma XJ, Hilsenbeck SG, Wang W, et al. The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer. *J Clin Oncol* 2006;24(28):4611.
33. Ma XJ, Wang Z, Ryan PD, et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. *Cancer Cell* 2004;5(6):607.
34. Ayers M, Symmans WF, Stec J, et al. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. *J Clin Oncol* 2004;22(12):2284.
35. Acharya CR, Hsu DS, Anders CK, et al. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer. *JAMA* 2008;299(13):1574.
36. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. *J Clin Oncol* 2007;25(33):5287.
37. Barski A, Cuddapah S, Cui K, et al. High-resolution profiling of histone methylations in the human genome. *Cell* 2007;129(4):823.
38. Veeck J, Esteller M. Breast cancer epigenetics: from DNA methylation to microRNAs. *J Mammary Gland Biol Neoplasia* 2010;15(1):5.
39. Fiskus W, Ren Y, Mohapatra A, et al. Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-alpha levels and transcriptional activity: a result of hyperacetylation and inhibition of chaperone function of heat shock protein 90. *Clin Cancer Res* 2007;13(16):4882.
40. Zhou Q, Shaw PG, Davidson NE. Inhibition of histone deacetylase suppresses EGF signaling pathways by destabilizing EGFR mRNA in ER-negative human breast cancer cells. *Breast Cancer Res Treat* 2009;117(2):443.
41. Lee Y, Ahn C, Han J, et al. The nuclear RNase III Drosha initiates microRNA processing. *Nature* 2003;425(6956):415.
42. Reinhart B, Slack FJ, Basson M, et al. The 21 nucleotide let-7 RNA regulates *C. elegans* developmental timing. *Nature* 2000;403:901.
43. Camps C, Buffa FM, Colella S, et al. hsa-miR-210 is induced by hypoxia and is an independent prognostic factor in breast cancer. *Clin Cancer Res* 2008;14(5):1340.

44. Foekens JA, Sieuwerts AM, Smid M, et al. Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer. *Proc Natl Acad Sci U S A* 2008;105(35):13021.
45. Iorio MV, Casalini P, Tagliabue E, et al. microRNA profiling as a tool to understand prognosis, therapy response and resistance in breast cancer. *Eur J Cancer* 2008;44(18):2753.
46. Kovalchuk O, Filkowski J, Meservy J, et al. Involvement of microRNA-451 in resistance of the MDF-7 breast cancer cells to chemotherapeutic drug doxorubicin. *Mol Cancer Ther* 2008;7:2152.
47. Miller T, Ghoshal K, Ramaswamy B, et al. microRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. *J Biol Chem* 2008;283:29897.
48. Hanahan D, Weinberg RA. The hallmarks of cancer. *Cell* 2000;100(1):57.
49. Massarweh S, Schiff R. Unraveling the mechanisms of endocrine resistance in breast cancer: new therapeutic opportunities. *Clin Cancer Res* 2007;13(7):1950.
50. Yarden Y, Sliwkowski MX. Untangling the ErbB signaling network. *Nat Rev Mol Cell Biol* 2001;2(2):127.
51. Hudis CA. Trastuzumab—mechanism of action and use in clinical practice. *N Engl J Med* 2007;357(1):39.
52. Hynes NE, Dey JH. PI3K inhibition overcomes trastuzumab resistance: blockade of ErbB2/ErbB3 is not always enough. *Cancer Cell* 2009;15(5):353.
53. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. *Nat Rev Cancer* 2008;8(8):579.

Chapter 25 – References

1. Wermer P. Genetic aspects of adenomatosis of endocrine glands. *Am J Med* 1954;16:363.
2. Chandrasekharappa SC, Guru SC, Manickam P, et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. *Science* 1997;276:404.
3. Manickam P, Vogel AM, Agarwal SK, et al. Isolation, characterization, expression and functional analysis of the zebrafish ortholog of MEN1. *Mamm Genome* 2000;11:448.
4. Agarwal SK, Debelenko LV, Kester MB, et al. Analysis of recurrent germline mutations in the MEN1 gene encountered in apparently unrelated families. *Hum Mutat* 1998;12:75.
5. Owens M, Ellard S, Vaidya B. Analysis of gross deletions in the MEN1 gene in patients with multiple endocrine neoplasia type 1. *Clin Endocrinol (Oxf)* 2008;68:350.
6. Schussheim DH, Skarulis MC, Agarwal SK, et al. Multiple endocrine neoplasia type 1: new clinical and basic findings. *Trends Endocrinol Metab* 2001;12:173.
7. Brown EM, Gamba G, Riccardi D, et al. Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid. *Nature* 1993;366:575.
8. Pollak MR, Brown EM, Chou YH, et al. Mutations in the human Ca(2+)-sensing receptor cause familial hypocalcaemic hypercalcaemia and neonatal severe hyperparathyroidism. *Cell* 1993;75:1297.
9. Pollak MR, Brown EM, Estep HL, et al. Autosomal dominant hypocalcaemia caused by a Ca(2+)-sensing receptor gene mutation. *Nat Genet* 1994;8:303.
10. Jackson CE, Norum RA, Boyd SB, et al. Hereditary hyperparathyroidism and multiple ossifying jaw fibromas: a clinically and genetically distinct syndrome. *Surgery* 1990;108:1006; discussion 1012.
11. Cavaco BM, Guerra L, Bradley KJ, et al. Hyperparathyroidism-jaw tumor syndrome in Roma families from Portugal is due to a founder mutation of the HRPT2 gene. *J Clin Endocrinol Metab* 2004;89:1747.
12. Guarneri V, Scillitani A, Muscarella LA, et al. Diagnosis of parathyroid tumors in familial isolated hyperparathyroidism with HRPT2 mutation: implications for cancer surveillance. *J Clin Endocrinol Metab* 2006;91:2827.
13. Bradley KJ, Cavaco BM, Bowl MR, et al. Parafibromin mutations in hereditary hyperparathyroidism syndromes and parathyroid tumours. *Clin Endocrinol (Oxf)* 2006;64:299.
14. Carpten JD, Robbins CM, Villablanca A, et al. HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. *Nat Genet* 2002;32:676.
15. Lin L, Czapiga M, Nini L, Zhang JH, Simonds WF. Nuclear localization of the parafibromin tumor suppressor protein implicated in the hyperparathyroidism-jaw tumor syndrome enhances its proapoptotic function. *Mol Cancer Res* 2007;5:183.
16. Howell VM, Haven CJ, Kahnoski K, et al. HRPT2 mutations are associated with malignancy in sporadic parathyroid tumours. *J Med Genet* 2003;40:657.
17. Shattuck TM, Valimaki S, Obara T, et al. Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. *N Engl J Med* 2003;349:1722.
18. Krebs LJ, Shattuck TM, Arnold A. HRPT2 mutational analysis of typical sporadic parathyroid adenomas. *J Clin Endocrinol Metab* 2005;90:5015.
19. Warner J, Epstein M, Sweet A, et al. Genetic testing in familial isolated hyperparathyroidism: unexpected results and their implications. *J Med Genet* 2004;41:155.
20. Warner JV, Nyholt DR, Busfield F, et al. Familial isolated hyperparathyroidism is linked to a 1.7 Mb region on chromosome 2p13.3–14. *J Med Genet* 2006;43:e12.
21. Carney JA, Gordon H, Carpenter PC, Shenoy BV, Go VL. The complex of myxomas, spotty pigmentation, and endocrine overactivity. *Medicine (Baltimore)* 1985;64:270.
22. Daly AF, Jaffrain-Rea ML, Ciccarelli A, et al. Clinical characterization of familial isolated pituitary adenomas. *J Clin Endocrinol Metab* 2006;91:3316.
23. Vierimaa O, Georgitsi M, Lehtonen R, et al. Pituitary adenoma predisposition caused by germline mutations in the AIP gene. *Science* 2006;312:1228.
24. Daly AF, Vanbellinghen JF, Khoo SK, et al. Aryl hydrocarbon receptor interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families. *J Clin Endocrinol Metab* 2007;92(5):1891.
25. Steiner AL, Goodman AD, Powers SR. Study of a kindred with pheochromocytoma, medullary thyroid carcinoma, hyperparathyroidism and Cushing's disease: multiple endocrine neoplasia, type 2. *Medicine (Baltimore)* 1968;47:371.
26. Takahashi M, Ritz J, Cooper GM. Activation of a novel human transforming gene, ret, by DNA rearrangement. *Cell* 1985;42:581.
27. Tahira T, Ishizaka Y, Itoh F, Sugimura T, Nagao M. Characterization of ret proto-oncogene mRNAs encoding two isoforms of the protein product in a human neuroblastoma cell line. *Oncogene* 1990;5:97.
28. Myers SM, Eng C, Ponder BA, Mulligan LM. Characterization of RET proto-oncogene 3' splicing variants and polyadenylation sites: a novel C-terminus for RET. *Oncogene* 1995;11:2039.
29. de Graaff E, Srinivas S, Kilkenny C, et al. Differential activities of the RET tyrosine kinase receptor isoforms during mammalian embryogenesis. *Genes Dev* 2001;15:2433.
30. Baloh RH, Tansey MG, Lampe PA, et al. Artemin, a novel member of the GDNF ligand family, supports peripheral and central neurons and signals through the GFRalpha3-RET receptor complex. *Neuron* 1998;21:1291.
31. Creedon DJ, Tansey MG, Baloh RH, et al. Neurturin shares receptors and signal transduction pathways with glial cell line-derived neurotrophic factor in sympathetic neurons. *Proc Natl Acad Sci U S A* 1997;94:7018.
32. Sanicola M, Hession C, Worley D, et al. Glial cell line-derived neurotrophic factor-dependent RET activation can be mediated by two different cell-surface accessory proteins. *Proc Natl Acad Sci U S A* 1997;94:6238.
33. Ichihara M, Murakumo Y, Takahashi M. RET and neuroendocrine tumors. *Cancer Lett* 2004;204:197.
34. Wells SA Jr, Santoro M. Targeting the RET pathway in thyroid cancer. *Clin Cancer Res* 2009;15:7119.
35. Knowles PP, Murray-Rust J, Kjaer S, et al. Structure and chemical inhibition of the RET tyrosine kinase domain. *J Biol Chem* 2006;281:33577.
36. Donis-Keller H, Dou S, Chi D, et al. Mutations in the RET proto-oncogene are associated with MEN2A and FMTC. *Hum Mol Genet* 1993;2:851.
37. Mulligan LM, Kwok JB, Healey CS, et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. *Nature* 1993;363:458.
38. Miyauchi A, Futami H, Hai N, et al. Two germline missense mutations at codons 804 and 806 of the RET proto-oncogene in the same allele in a patient with multiple endocrine neoplasia type 2B without codon 918 mutation. *Jpn J Cancer Res* 1999;90:1.
39. Carlson KM, Bracamontes J, Jackson CE, et al. Parent-of-origin effects in multiple endocrine neoplasia type 2B. *Am J Hum Genet* 1994;55:1076.
40. Brandi ML, Gagel RF, Angeli A, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. *J Clin Endocrinol Metab* 2001;86:5658.
41. Eng C, Clayton D, Schuffenecker I, et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. *JAMA* 1996;276:1575.

42. Mulligan LM, Eng C, Healey CS, et al. Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. *Nat Genet* 1994;6:70.
43. Machens A, Brauckhoff M, Holzhausen HJ, et al. Codon-specific development of pheochromocytoma in multiple endocrine neoplasia type 2. *J Clin Endocrinol Metab* 2005;90:3999.
44. Kloos RT, Eng C, Evans DB, et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. *Thyroid* 2009;19:565.
45. Eng C, Mulligan LM, Smith DP, et al. Mutation of the RET protooncogene in sporadic medullary thyroid carcinoma. *Genes Chromosomes Cancer* 1995;12:209.
46. Iwashita T, Kato M, Murakami H, et al. Biological and biochemical properties of Ret with kinase domain mutations identified in multiple endocrine neoplasia type 2B and familial medullary thyroid carcinoma. *Oncogene* 1999;18:3919.
47. Mise N, Drostén M, Racek T, Tannapfel A, Putzer BM. Evaluation of potential mechanisms underlying genotype-phenotype correlations in multiple endocrine neoplasia type 2. *Oncogene* 2006;25:6637.
48. Myers SM, Mulligan LM. The RET receptor is linked to stress response pathways. *Cancer Res* 2004;64:4453.
49. Jaattela M. Heat shock proteins as cellular lifeguards. *Ann Med* 1999;31:261.
50. Jain S, Watson MA, DeBenedetti MK, et al. Expression profiles provide insights into early malignant potential and skeletal abnormalities in multiple endocrine neoplasia type 2B syndrome tumors. *Cancer Res* 2004;64:3907.
51. Marsh DJ, Theodosopoulos G, Martin-Schulte K, et al. Genome-wide copy number imbalances identified in familial and sporadic medullary thyroid carcinoma. *J Clin Endocrinol Metab* 2003;88:1866.
52. Hemmer S, Wasenius VM, Knuutila S, Franssila K, Joensuu H. DNA copy number changes in thyroid carcinoma. *Am J Pathol* 1999;154:1539.
53. Frisk T, Zedenius J, Lundberg J, et al. CGH alterations in medullary thyroid carcinomas in relation to the RET M918T mutation and clinical outcome. *Int J Oncol* 2001;18:1219.
54. Elisei R, Romei C, Cosci B, et al. RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center. *J Clin Endocrinol Metab* 2007;92:4725.
55. Skinner MA, Moley JA, Dille WG, et al. Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. *N Engl J Med* 2005;353:1105.
56. Sherman SI, Angelos P, Ball DW, et al. Thyroid carcinoma. *J Natl Compr Canc Netw* 2007;5:568.
57. Kendall-Taylor P. Guidelines for the management of thyroid cancer. *Clin Endocrinol (Oxf)* 2003;58:400.
58. Lombardo F, Baudin E, Chieffari E, et al. Familial medullary thyroid carcinoma: clinical variability and low aggressiveness associated with RET mutation at codon 804. *J Clin Endocrinol Metab* 2002;87:1674.
59. Fusco A, Grieco M, Santoro M, et al. A new oncogene in human thyroid papillary carcinomas and their lymph-nodal metastases. *Nature* 1987;328:170.
60. Klugbauer S, Lengfelder E, Demidchik EP, Rabes HM. High prevalence of RET rearrangement in thyroid tumors of children from Belarus after the Chernobyl reactor accident. *Oncogene* 1995;11:2459.
61. Nikiforov YE, Rowland JM, Bove KE, Monforte-Munoz H, Fagin JA. Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. *Cancer Res* 1997;57:1690.
62. Williams GH, Rooney S, Thomas GA, Cummins G, Williams ED. RET activation in adult and childhood papillary thyroid carcinoma using a reverse transcriptase-N-polymerase chain reaction approach on archival-nested material. *Br J Cancer* 1996;74:585.
63. Nikiforova MN, Stringer JR, Blough R, et al. Proximity of chromosomal loci that participate in radiation-induced rearrangements in human cells. *Science* 2000;290:138.
64. Pierotti MA, Greco A. Oncogenic rearrangements of the NTRK1/NGF receptor. *Cancer Lett* 2006;232:90.
65. Kimura ET, Nikiforova MN, Zhu Z, et al. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. *Cancer Res* 2003;63:1454.
66. Kroll TG, Sarraf P, Pecciarini L, et al. PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]. *Science* 2000;289:1357.
67. Nikiforova MN, Lynch RA, Biddinger PW, et al. RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. *J Clin Endocrinol Metab* 2003;88:2318.
68. Esapa CT, Johnson SJ, Kendall-Taylor P, Lennard TW, Harris PE. Prevalence of Ras mutations in thyroid neoplasia. *Clin Endocrinol (Oxf)* 1999;50:529.
69. Garcia-Rostan G, Zhao H, Camp RL, et al. Ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. *J Clin Oncol* 2003;21:3226.
70. Sorrentino R, Libertini S, Pallante PL, et al. Aurora B overexpression associates with the thyroid carcinoma undifferentiated phenotype and is required for thyroid carcinoma cell proliferation. *J Clin Endocrinol Metab* 2005;90:928.

Chapter 26 – References

1. Limon J, Turc-Carel C, Dal Cin P, Rao U, Sandberg AA. Recurrent chromosome translocations in liposarcoma. *Cancer Genet Cytogenet* 1986;22:93.
2. Crozat A, Aman P, Mandahl N, Ron D. Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma. *Nature* 1993;363:640–644.
3. Sandberg AA. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: liposarcoma. *Cancer Genet Cytogenet* 2004;155:1–24.
4. Xiang H, Wang J, Hisaoka M, Zhu X. Characteristic sequence motifs located at the genomic breakpoints of the translocation t(12;16) and t(12;22) in myxoid liposarcoma. *Pathology* 2008;40:547–552.
5. Schwarzbach MH, Koesters R, Germann A, et al. Comparable transforming capacities and differential gene expression patterns of variant FUS/CHOP fusion transcripts derived from soft tissue liposarcomas. *Oncogene* 2004;23:6798–6805.
6. Engstrom K, Willen H, Kabjorn-Gustafsson C, et al. The myxoid/round cell liposarcoma fusion oncogene FUS-DDIT3 and the normal DDIT3 induce a liposarcoma phenotype in transfected human fibrosarcoma cells. *Am J Pathol* 2006;168:1642–1653.
7. Zinszner H, Albalat R, Ron D. A novel effector domain from the RNA-binding protein TLS or EWS is required for oncogenic transformation by CHOP. *Genes Dev* 1994;8:2513–2526.
8. Barone MV, Crozat A, Tabaee A, Philipson L, Ron D. CHOP (GADD153) and its oncogenic variant, TLS-CHOP, have opposing effects on the induction of G1/S arrest. *Genes Dev* 1994;8:453–464.
9. Kuroda M, Ishida T, Takanashi M, et al. Oncogenic transformation and inhibition of adipocyte conversion of preadipocytes by TLS/FUS-CHOP type II chimeric protein. *Am J Pathol* 1997;151:735–744.
10. Goransson M, Andersson MK, Forni C, et al. The myxoid liposarcoma FUS-DDIT3 fusion oncoprotein deregulates NF-kappaB target genes by interaction with NFKBIZ. *Oncogene* 2009;28:270–278.
11. Forni C, Minuzzo M, Viridis E, et al. Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors. *Mol Cancer Ther* 2009;8:449–457.
12. Tajima T, Morii T, Kikuchi F, et al. Significance of LRP and PPAR-gamma expression in lipomatous soft tissue tumors. *Open Orthop J* 2010;4:48.
13. Cheng H, Dodge J, Mehl E, et al. Validation of immature adipogenic status and identification of prognostic biomarkers in myxoid liposarcoma using tissue microarrays. *Hum Pathol* 2009;40:1244–1251.
14. Lanckohr C, Kasprzyński A, Klein-Hitpass L, et al. [Identification of genes over-expressed in myxoid/round cell liposarcoma. DNA microarray analysis and immunohistochemical correlation]. *Pathologie* 2010;31:60–66.
15. Hisaoka M, Tsuji S, Morimitsu Y, et al. Detection of TLS/FUS-CHOP fusion transcripts in myxoid and round cell liposarcomas by nested reverse transcription-polymerase chain reaction using archival paraffin-embedded tissues. *Diagn Mol Pathol* 1998;7:96–101.
16. Willmore-Payne C, Holden J, Turner KC, Proia A, Layfield LJ. Translocations and amplifications of chromosome 12 in liposarcoma demonstrated by the LSI CHOP break-apart rearrangement probe. *Arch Pathol Lab Med* 2008;132:952–957.
17. Fiore M, Grosso F, Lo Vullo S, et al. Myxoid/round cell and pleomorphic liposarcomas: prognostic factors and survival in a series of patients treated at a single institution. *Cancer* 2007;109:2522–2531.
18. Antonescu CR, Tschernyavsky SJ, Decuseara R, et al. Prognostic impact of P53 status, TLS-CHOP fusion transcript structure, and histological grade in myxoid liposarcoma: a molecular and clinicopathologic study of 82 cases. *Clin Cancer Res* 2001;7:3977–3987.
19. Barretina J, Taylor BS, Banerji S, et al. Subtype-specific genomic alterations define new targets for soft tissue sarcoma therapy. *Nature Genetics* 2010;42:715–721.
20. Mentzel T, Brown LE, Dvorak HF, et al. The association between tumour progression and vascularity in myxofibrosarcoma and myxoid/round cell liposarcoma. *Virchows Arch* 2001;438:13–22.
21. de Vreeze RS, de Jong D, Haas RL, Stewart F, van Coevorden F. Effectiveness of radiotherapy in myxoid sarcomas is associated with a dense vascular pattern. *Int J Radiat Oncol Biol Phys* 2008;72:1480–1487.
22. Germano G, Frapolli R, Simone M, et al. Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. *Cancer Res* 2010;70:2235–2244.
23. Burchill SA. Ewing's sarcoma: diagnostic, prognostic, and therapeutic implications of molecular abnormalities. *J Clin Pathol* 2003;56:96–102.
24. Ordóñez JL, Osuna D, Herrero D, de Alava E, Madoz-Gurpide J. Advances in Ewing's sarcoma research: where are we now and what lies ahead? *Cancer Res* 2009;69:7140–7150.
25. Fukuma M, Okita H, Hata J, Umezawa A. Upregulation of Id2, an oncogenic helix-loop-helix protein, is mediated by the chimeric EWS/ets protein in Ewing sarcoma. *Oncogene* 2003;22:1.
26. Abaan OD, Levenson A, Khan O, et al. PTPL1 is a direct transcriptional target of EWS-FLI1 and modulates Ewing's Sarcoma tumorigenesis. *Oncogene* 2005;24:2715–2722.
27. Siligan C, Ban J, Bachmaier R, et al. EWS-FLI1 target genes recovered from Ewing's sarcoma chromatin. *Oncogene* 2005;24:2512–2524.
28. Garcia-Aragoncillo E, Carrillo J, Lalli E, et al. DAX1, a direct target of EWS/FLI1 oncoprotein, is a principal regulator of cell-cycle progression in Ewing's tumor cells. *Oncogene* 2008;27:6034–6043.
29. Nakatani F, Tanaka K, Sakimura R, et al. Identification of p21WAF1/CIP1 as a direct target of EWS-Fl1 oncogenic fusion protein. *J Biol Chem* 2003;278:15105–15115.
30. Hahm KB, Cho K, Lee C, et al. Repression of the gene encoding the TGF-beta type II receptor is a major target of the EWS-FLI1 oncoprotein. *Nat Genet* 1999;23:222–227.
31. Prieur A, Tirode F, Cohen P, Delattre O. EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. *Mol Cell Biol* 2004;24:7275–7283.
32. Owen LA, Kowalewski AA, Lessnick SL. EWS/FLI mediates transcriptional repression via NKX2.2 during oncogenic transformation in Ewing's sarcoma. *PLoS One* 2008;3:e1965.
33. Cironi L, Riggi N, Provero P, et al. IGF1 is a common target gene of Ewing's sarcoma fusion proteins in mesenchymal progenitor cells. *PLoS One* 2008;3:e2634.
34. Kauer M, Ban J, Kofler R, et al. A molecular function map of Ewing's sarcoma. *PLoS One* 2009;4:e5415.
35. Kovar H. Downstream EWS/FLI1 – upstream Ewing's sarcoma. *Genome Med* 2010;2:8.
36. Yamaguchi U, Hasegawa T, Morimoto Y, et al. A practical approach to the clinical diagnosis of Ewing's sarcoma/primitive neuroectodermal tumour and other small round cell tumours sharing EWS rearrangement using new fluorescence in situ hybridisation probes for EWSR1 on formalin fixed, paraffin wax embedded tissue. *J Clin Pathol* 2005;58:1051–1056.
37. de Alava E, Kawai A, Healey JH, et al. EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma. *J Clin Oncol* 1998;16:1248–1255.
38. Kolb EA, Gorlick R. Development of IGF-IR inhibitors in pediatric sarcomas. *Curr Oncol Rep* 2009;11:307–313.

39. Toretsky JA, Gorlick R. IGF-1R targeted treatment of sarcoma. *Lancet Oncol* 2010;11:105.
40. Wachtel M, Schafer BW. Targets for cancer therapy in childhood sarcomas. *Cancer Treat Rev* 2010;36:318–321.
41. Erkizan HV, Kong Y, Merchant M, et al. A small molecule blocking oncogenic protein EWS-FL11 interaction with RNA helicase A inhibits growth of Ewing's sarcoma. *Nat Med* 2009;15:750–756.
42. Ladanyi M, Gerald WL. Fusion of the EWS and WT1 genes in the desmoplastic small round cell tumor. *Cancer Res* 1994;54:2837–2840.
43. Gerald WL, Haber DA. The EWS-WT1 gene fusion in desmoplastic small round cell tumor. *Semin Cancer Biol* 2005;15:197–205.
44. Hartwig S, Ho J, Pandey P, et al. Genomic characterization of Wilms' tumor suppressor 1 targets in nephron progenitor cells during kidney development. *Development* 2010;137:1189–1203.
45. Stuart-Buttle CE, Smart CJ, Pritchard S, Martin D, Welch IM. Desmoplastic small round cell tumour: a review of literature and treatment options. *Surg Oncol* 2008;17:107–112.
46. Lee SB, Kolquist KA, Nichols K, et al. The EWS-WT1 translocation product induces PDGFA in desmoplastic small round-cell tumour. *Nat Genet* 1997;17:309–313.
47. George S, Merriam P, Maki RG, et al. Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. *J Clin Oncol* 2009;27:3154–3160.
48. Wong JC, Lee SB, Bell MD, et al. Induction of the interleukin-2/15 receptor beta-chain by the EWS-WT1 translocation product. *Oncogene* 2002;21:2009–2019.
49. Haldar M, Randall RL, Capecchi MR. Synovial sarcoma: from genetics to genetic-based animal modeling. *Clin Orthop Relat Res* 2008;466:2156–2167.
50. dos Santos NR, Torensma R, de Vries TJ, et al. Heterogeneous expression of the SSX cancer/testis antigens in human melanoma lesions and cell lines. *Cancer Res* 2000;60:1654–1662.
51. Kato H, Tjernberg A, Zhang W, et al. SYT associates with human SNF/SWI complexes and the C-terminal region of its fusion partner SSX1 targets histones. *J Biol Chem* 2002;277:5498–5505.
52. Soulez M, Saurin AJ, Freemont PS, Knight JC. SSX and the synovial-sarcoma-specific chimaeric protein SYT-SSX co-localize with the human Polycomb group complex. *Oncogene* 1999;18:2739–2746.
53. de Bruijn DR, Nap JP, van Kessel AG. The (epi)genetics of human synovial sarcoma. *Genes Chromosomes Cancer* 2007;46:107–117.
54. Cironi L, Provero P, Riggi N, et al. Epigenetic features of human mesenchymal stem cells determine their permissiveness for induction of relevant transcriptional changes by SYT-SSX1. *PLoS One* 2009;4:e7904.
55. Haldar M, Hedberg ML, Hockin MF, Capecchi MR. A CreER-based random induction strategy for modeling translocation-associated sarcomas in mice. *Cancer Res* 2009;69:3657–3664.
56. Ishida M, Miyamoto M, Naitoh S, et al. The SYT-SSX fusion protein down-regulates the cell proliferation regulator COM1 in t(x;18) synovial sarcoma. *Mol Cell Biol* 2007;27:1348–1355.
57. Lubieniecka JM, de Bruijn DR, Su L, et al. Histone deacetylase inhibitors reverse SS18-SSX-mediated polycomb silencing of the tumor suppressor early growth response 1 in synovial sarcoma. *Cancer Res* 2008;68:4303–4310.
58. Siddiqui S, Mills J, Matushansky I. Epigenetic remodeling of chromatin architecture: exploring tumor differentiation therapies in mesenchymal stem cells and sarcomas. *Curr Stem Cell Res Ther* 2010;5:63–73.
59. Nielsen TO, West RB. Translating gene expression into clinical care: sarcomas as a paradigm. *J Clin Oncol* 2010;28:1796–1805.
60. Saito T, Nagai M, Ladanyi M. SYT-SSX1 and SYT-SSX2 interfere with repression of E-cadherin by snail and slug: a potential mechanism for aberrant mesenchymal to epithelial transition in human synovial sarcoma. *Cancer Res* 2006;66:6919–6927.
61. Canter RJ, Qin LX, Maki RG, et al. A synovial sarcoma-specific preoperative nomogram supports a survival benefit to ifosfamide-based chemotherapy and improves risk stratification for patients. *Clin Cancer Res* 2008;14:8191–8197.
62. Takenaka S, Ueda T, Naka N, et al. Prognostic implication of SYT-SSX fusion type in synovial sarcoma: a multi-institutional retrospective analysis in Japan. *Oncol Rep* 2008;19:467–476.
63. Sekiya T, Zaret KS. Repression by Groucho/TLE/Grg proteins: genomic site recruitment generates compacted chromatin in vitro and impairs activator binding in vivo. *Mol Cell* 2007;28:291–303.
64. Jagdis A, Rubin BP, Tubbs RR, Pacheco M, Nielsen TO. Prospective evaluation of TLE1 as a diagnostic immunohistochemical marker in synovial sarcoma. *Am J Surg Pathol* 2009;33:1743–1751.
65. Sun Y, Gao D, Liu Y, et al. IGF2 is critical for tumorigenesis by synovial sarcoma oncoprotein SYT-SSX1. *Oncogene* 2006;25:1042–1052.
66. de Bruijn DR, Allander SV, van Dijk AH, et al. The synovial-sarcoma-associated SS18-SSX2 fusion protein induces epigenetic gene (de)regulation. *Cancer Res* 2006;66:9474.
67. Galili N, Davis RJ, Fredericks WJ, et al. Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma. *Nat Genet* 1993;5:230–235.
68. Davis RJ, D'Cruz CM, Lovell MA, Biegel JA, Barr FG. Fusion of PAX7 to FKHR by the variant t(1;13)(p36;q14) translocation in alveolar rhabdomyosarcoma. *Cancer Res* 1994;54:2869–2872.
69. Williamson D, Missiaglia E, de Reynies A, et al. Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma. *J Clin Oncol* 2010.
70. Sorensen PH, Lynch JC, Qualman SJ, et al. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group. *J Clin Oncol* 2002;20:2672–2679.
71. Wexler LH, Ladanyi M. Diagnosing alveolar rhabdomyosarcoma: morphology must be coupled with fusion confirmation. *J Clin Oncol* 2010;28:2126–2128.
72. Davicioni E, Anderson MJ, Finkenstein FG, et al. Molecular classification of rhabdomyosarcoma—genotypic and phenotypic determinants of diagnosis: a report from the Children's Oncology Group. *Am J Pathol* 2009;174:550–564.
73. Taniguchi E, Nishijo K, McCleish AT, et al. PDGFR-A is a therapeutic target in alveolar rhabdomyosarcoma. *Oncogene* 2008;27:6550–6560.
74. Nishijo K, Chen QR, Zhang L, et al. Credentialing a pre-clinical mouse model of alveolar rhabdomyosarcoma. *Cancer Res* 2009;69:2902–2911.
75. Fisher C. Soft tissue sarcomas with non-EWS translocations: molecular genetic features and pathologic and clinical correlations. *Virchows Arch* 2010;456:153–166.
76. Ladanyi M, Lui MY, Antonescu CR, et al. The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25. *Oncogene* 2001;20:48–57.
77. Armah HB, Parwani AV. Xp11.2 translocation renal cell carcinoma. *Arch Pathol Lab Med* 2010;134:124–129.
78. Argani P, Lal P, Hutchinson B, et al. Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions: a sensitive and specific immunohistochemical assay. *Am J Surg Pathol* 2003;27:750–761.
79. Pang LJ, Chang B, Zou H, et al. Alveolar soft part sarcoma: a biomarker diagnostic strategy using TFE3 immunoassay and ASPL-TFE3 fusion transcripts in paraffin-embedded tumor tissues. *Diagn Mol Pathol* 2008;17:245–252.

80. Lazar AJ, Das P, Tuvin D, et al. Angiogenesis-promoting gene patterns in alveolar soft part sarcoma. *Clin Cancer Res* 2007;13:7314.
81. Lazar AJ, Lahat G, Myers SE, et al. Validation of potential therapeutic targets in alveolar soft part sarcoma: an immunohistochemical study utilizing tissue microarray. *Histopathology* 2009;55:750–755.
82. Stockwin LH, Vistica DT, Kenney S, et al. Gene expression profiling of alveolar soft-part sarcoma (ASPS). *BMC Cancer* 2009;9:22.
83. Vistica DT, Hollingshead M, Borgel SD, et al. Therapeutic vulnerability of an in vivo model of alveolar soft part sarcoma (ASPS) to antiangiogenic therapy. *J Pediatr Hematol Oncol* 2009;31:561–570.
84. Stacchiotti S, Tamborini E, Marrari A, et al. Response to sunitinib malate in advanced alveolar soft part sarcoma. *Clin Cancer Res* 2009;15:1096–1104.
85. McArthur GA, Demetri GD, van Oosterom A, et al. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. *J Clin Oncol* 2005;23:866–873.
86. Pedeutour F, Coindre JM, Sozzi G, et al. Supernumerary ring chromosomes containing chromosome 17 sequences. A specific feature of dermatofibrosarcoma protuberans? *Cancer Genet Cytogenet* 1994;76:1–9.
87. O'Brien KP, Seroussi E, Dal Cin P, et al. Various regions within the alpha-helical domain of the COL1A1 gene are fused to the second exon of the PDGFB gene in dermatofibrosarcomas and giant-cell fibroblastomas. *Genes Chromosomes Cancer* 1998;23:187–193.
88. Simon MP, Pedeutour F, Sirvent N, et al. Deregulation of the platelet-derived growth factor B-chain gene via fusion with collagen gene COL1A1 in dermatofibrosarcoma protuberans and giant-cell fibroblastoma. *Nat Genet* 1997;15:95–98.
89. Patel KU, Szabo SS, Hernandez VS, et al. Dermatofibrosarcoma protuberans COL1A1-PDGFB fusion is identified in virtually all dermatofibrosarcoma protuberans cases when investigated by newly developed multiplex reverse transcription polymerase chain reaction and fluorescence in situ hybridization assays. *Hum Pathol* 2008;39:184–193.
90. Kiuru-Kuhlefelt S, El-Rifai W, Fanburg-Smith J, et al. Concomitant DNA copy number amplification at 17q and 22q in dermatofibrosarcoma protuberans. *Cytogenet Cell Genet* 2001;92:192–195.
91. Abbott JJ, Erickson-Johnson M, Wang X, Nascimento AG, Oliveira AM. Gains of COL1A1-PDGFB genomic copies occur in fibrosarcomatous transformation of dermatofibrosarcoma protuberans. *Mod Pathol* 2006;19:1512–1518.
92. Shimizu A, O'Brien KP, Sjoblom T, et al. The dermatofibrosarcoma protuberans-associated collagen type Ialpha1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB. *Cancer Res* 1999;59:3719.
93. Maki RG, Awan RA, Dixon RH, Jhanwar S, Antonescu CR. Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans. *Int J Cancer* 2002;100:623–626.
94. Sirvent N, Maire G, Pedeutour F. Genetics of dermatofibrosarcoma protuberans family of tumors: from ring chromosomes to tyrosine kinase inhibitor treatment. *Genes Chromosomes Cancer* 2003;37:1–19.
95. Panagopoulos I, Mertens F, Isaksson M, et al. Molecular genetic characterization of the EWS/CHN and RBP56/CHN fusion genes in extraskelletal myxoid chondrosarcoma. *Genes Chromosomes Cancer* 2002;35:340–352.
96. Sjogren H, Meis-Kindblom JM, Orndal C, et al. Studies on the molecular pathogenesis of extraskelletal myxoid chondrosarcoma-cytogenetic, molecular genetic, and cDNA microarray analyses. *Am J Pathol* 2003;162:781–792.
97. Hisaoka M, Hashimoto H. Extraskelletal myxoid chondrosarcoma: updated clinicopathological and molecular genetic characteristics. *Pathol Int* 2005;55:453–463.
98. Sandberg AA. Genetics of chondrosarcoma and related tumors. *Curr Opin Oncol* 2004;16:342–354.
99. Ohkura N, Yaguchi H, Tsukada T, Yamaguchi K. The EWS/NOR1 fusion gene product gains a novel activity affecting pre-mRNA splicing. *J Biol Chem* 2002;277:535–543.
100. Bertolotti A, Lutz Y, Heard DJ, Chambon P, Tora L. hTAF(II)68, a novel RNA/ssDNA-binding protein with homology to the pro-oncoproteins TLS/FUS and EWS is associated with both TFIID and RNA polymerase II. *EMBO J* 1996;15:5022–5031.
101. Arvand A, Denny CT. Biology of EWS/ETS fusions in Ewing's family tumors. *Oncogene* 2001;20:5747–5754.
102. Subramanian S, West RB, Marinelli RJ, et al. The gene expression profile of extraskelletal myxoid chondrosarcoma. *J Pathol* 2005;206:433–444.
103. Sen-Gupta S, Van Der Luijt RB, Bowles LV, Meera Khan P, Delhanty JD. Somatic mutation of APC gene in desmoid tumour in familial adenomatous polyposis. *Lancet* 1993;342:552–553.
104. Okamoto M, Sato C, Kohno Y, et al. Molecular nature of chromosome 5q loss in colorectal tumors and desmoids from patients with familial adenomatous polyposis. *Hum Genet* 1990;85:595–599.
105. Tejpar S, Nollet F, Li C, et al. Predominance of beta-catenin mutations and beta-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor). *Oncogene* 1999;18:6615.
106. Lazar AJ, Tuvin D, Hajibashi S, et al. Specific mutations in the beta-catenin gene (CTNBN1) correlate with local recurrence in sporadic desmoid tumors. *Am J Pathol* 2008;173:1518–1527.
107. Kong Y, Poon R, Nadesan P, et al. Matrix metalloproteinase activity modulates tumor size, cell motility, and cell invasiveness in murine aggressive fibromatosis. *Cancer Res* 2004;64:5795–5803.
108. Heinrich MC, McArthur GA, Demetri GD, et al. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). *J Clin Oncol* 2006;24:1195–1203.
109. Horvai AE, DeVries S, Roy R, O'Donnell RJ, Waldman F. Similarity in genetic alterations between paired well-differentiated and dedifferentiated components of dedifferentiated liposarcoma. *Mod Pathol* 2009;22:1477–1488.
110. Rieker RJ, Weitz J, Lehner B, et al. Genomic profiling reveals subsets of dedifferentiated liposarcoma to follow separate molecular pathways. *Virchows Arch* 456:277–285.
111. Mariani O, Brennetot C, Coindre JM, et al. JUN oncogene amplification and overexpression block adipocytic differentiation in highly aggressive sarcomas. *Cancer Cell* 2007;11:361–374.
112. Snyder EL, Sandstrom DJ, Law K, et al. c-Jun amplification and overexpression are oncogenic in liposarcoma but not always sufficient to inhibit the adipocytic differentiation programme. *J Pathol* 2009;218:292–300.
113. Singer S, Socci ND, Ambrosini G, et al. Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma. *Cancer Res* 2007;67:6626–6636.
114. Taylor BS, Barretina J, Socci ND, et al. Functional copy-number alterations in cancer. *PLoS One* 2008;3:e3179.
115. Fletcher CD, Gustafson P, Rydholm A, Willen H, Akerman M. Clinicopathologic re-evaluation of 100 malignant fibrous histiocytomas: prognostic relevance of subclassification. *J Clin Oncol* 2001;19:3045–3050.
116. Fletcher CD, Unni KK, Mertens F. Pathology and genetics of tumors of soft tissue and bone. In: Kleihues P, Sobin LH, eds. *World Health Organization Classification of Tumours*. Lyon, France: IARC Press, 2002.

117. Hollowood K, Fletcher CD. Malignant fibrous histiocytoma: morphologic pattern or pathologic entity? *Semin Diagn Pathol* 1995;12:210–220.
118. Bridge RS Jr, Bridge JA, Neff JR, et al. Recurrent chromosomal imbalances and structurally abnormal breakpoints within complex karyotypes of malignant peripheral nerve sheath tumour and malignant triton tumour: a cytogenetic and molecular cytogenetic study. *J Clin Pathol* 2004;57:1172.
119. Mertens F, Fletcher CD, Dal Cin P, et al. Cytogenetic analysis of 46 pleomorphic soft tissue sarcomas and correlation with morphologic and clinical features: a report of the CHAMP Study Group. *Chromosomes and Morphology. Genes Chromosomes Cancer* 1998;22:16–25.
120. Willems SM, Debiec-Rychter M, Szuhai K, Hogendoorn PC, Sciot R. Local recurrence of myxofibrosarcoma is associated with increase in tumour grade and cytogenetic aberrations, suggesting a multistep tumour progression model. *Mod Pathol* 2006;19:407–416.
121. Weiss SW. Malignant fibrous histiocytoma. A reaffirmation. *Am J Surg Pathol* 1982;6:773–784.
122. Weiss SW, Enzinger FM. Malignant fibrous histiocytoma: an analysis of 200 cases. *Cancer* 1978;41:2250–2266.
123. Fletcher CD. Pleomorphic malignant fibrous histiocytoma: fact or fiction? A critical reappraisal based on 159 tumors diagnosed as pleomorphic sarcoma. *Am J Surg Pathol* 1992;16:213–228.
124. Aspberg F, Mertens F, Bauer HC, et al. Near-haploidy in two malignant fibrous histiocytomas. *Cancer Genet Cytogenet* 1995;79:119–122.
125. Mandahl N, Heim S, Willen H, et al. Characteristic karyotypic anomalies identify subtypes of malignant fibrous histiocytoma. *Genes Chromosomes Cancer* 1989;1:9–14.
126. Schmidt H, Korber S, Hinze R, et al. Cytogenetic characterization of ten malignant fibrous histiocytomas. *Cancer Genet Cytogenet* 1998;100:134–142.
127. Szymanska J, Tarkkanen M, Wiklund T, et al. A cytogenetic study of malignant fibrous histiocytoma. *Cancer Genet Cytogenet* 1995;85:91–96.
128. Walter TA, Weh HJ, Schlag PM, Zornig C, Hossfeld DK. Cytogenetic studies in malignant fibrous histiocytoma. *Cancer Genet Cytogenet* 1997;94:131–134.
129. Larramendy ML, Tarkkanen M, Blomqvist C, et al. Comparative genomic hybridization of malignant fibrous histiocytoma reveals a novel prognostic marker. *Am J Pathol* 1997;151:1153–1161.
130. Mairal A, Terrier P, Chibon F, et al. Loss of chromosome 13 is the most frequent genomic imbalance in malignant fibrous histiocytomas. A comparative genomic hybridization analysis of a series of 30 cases. *Cancer Genet Cytogenet* 1999;111:134–138.
131. Simons A, Schepens M, Jeuken J, et al. Frequent loss of 9p21 (p16(INK4A)) and other genomic imbalances in human malignant fibrous histiocytoma. *Cancer Genet Cytogenet* 2000;118:89.
132. Weng WH, Ahlen J, Lui WO, et al. Gain of 17q in malignant fibrous histiocytoma is associated with a longer disease-free survival and a low risk of developing distant metastasis. *Br J Cancer* 2003;89:720–726.
133. Chibon F, Mairal A, Freneau P, et al. The RB1 gene is the target of chromosome 13 deletions in malignant fibrous histiocytoma. *Cancer Res* 2000;60:6339–6345.
134. Derre J, Lagace R, Nicolas A, et al. Leiomyosarcomas and most malignant fibrous histiocytomas share very similar comparative genomic hybridization imbalances: an analysis of a series of 27 leiomyosarcomas. *Lab Invest* 2001;81:211–215.
135. Parente F, Grosgeorge J, Coindre JM, et al. Comparative genomic hybridization reveals novel chromosome deletions in 90 primary soft tissue tumors. *Cancer Genet Cytogenet* 1999;115:89–95.
136. Chibon F, Mariani O, Derre J, et al. ASK1 (MAP3K5) as a potential therapeutic target in malignant fibrous histiocytomas with 12q14–q15 and 6q23 amplifications. *Genes Chromosomes Cancer* 2004;40:32–37.
137. Chibon F, Mariani O, Derre J, et al. A subgroup of malignant fibrous histiocytomas is associated with genetic changes similar to those of well-differentiated liposarcomas. *Cancer Genet Cytogenet* 2002;139:24–29.
138. Chibon F, Mariani O, Mairal A, et al. The use of clustering software for the classification of comparative genomic hybridization data. an analysis of 109 malignant fibrous histiocytomas. *Cancer Genet Cytogenet* 2003;141:75–78.
139. Reid AH, Tsai MM, Venzon DJ, et al. MDM2 amplification, P53 mutation, and accumulation of the P53 gene product in malignant fibrous histiocytoma. *Diagn Mol Pathol* 1996;5:65–73.
140. Taubert H, Wurl P, Meye A, et al. Molecular and immunohistochemical p53 status in liposarcoma and malignant fibrous histiocytoma: identification of seven new mutations for soft tissue sarcomas. *Cancer* 1995;76:1187–1196.
141. Yoo J, Lee HK, Kang CS, et al. p53 gene mutations and p53 protein expression in human soft tissue sarcomas. *Arch Pathol Lab Med* 1997;121:395–399.
142. Mandahl N, Fletcher CD, Dal Cin P, et al. Comparative cytogenetic study of spindle cell and pleomorphic leiomyosarcomas of soft tissues: a report from the CHAMP Study Group. *Cancer Genet Cytogenet* 2000;116:66–73.
143. Sandberg AA. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: leiomyosarcoma. *Cancer Genet Cytogenet* 2005;161:1–19.
144. Yang J, Du X, Chen K, et al. Genetic aberrations in soft tissue leiomyosarcoma. *Cancer Lett* 2009;275:1.
145. Wang R, Tittley JC, Lu YJ, et al. Loss of 13q14–q21 and gain of 5p14–pter in the progression of leiomyosarcoma. *Mod Pathol* 2003;16:778–785.
146. Hu J, Rao UN, Jasani S, et al. Loss of DNA copy number of 10q is associated with aggressive behavior of leiomyosarcomas: a comparative genomic hybridization study. *Cancer Genet Cytogenet* 2005;161:20–27.
147. Hernandez E, Charytonowicz E, Dudas ME, et al. The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas. *Nat Med* 2007;13:748–753.
148. Mita MM, Tolcher AW. The role of mTOR inhibitors for treatment of sarcomas. *Curr Oncol Rep* 2007;9:316–322.
149. Kleinerman RA, Tucker MA, Abramson DH, et al. Risk of soft tissue sarcomas by individual subtype in survivors of hereditary retinoblastoma. *J Natl Cancer Inst* 2007;99:24–31.
150. Evans DG, Baser ME, McGaughan J, et al. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. *J Med Genet* 2002;39:311–314.
151. Mantripragada KK, Spurlock G, Kluwe L, et al. High-resolution DNA copy number profiling of malignant peripheral nerve sheath tumors using targeted microarray-based comparative genomic hybridization. *Clin Cancer Res* 2008;14:1015–1024.
152. Cichowski K, Jacks T. NF1 tumor suppressor gene function: narrowing the GAP. *Cell* 2001;104:593–604.
153. Carroll SL, Ratner N. How does the Schwann cell lineage form tumors in NF1? *Glia* 2008;56:1590–1605.
154. Mantripragada KK, de Stahl TD, Patridge C, et al. Genome-wide high-resolution analysis of DNA copy number alterations in NF1-associated malignant peripheral nerve sheath tumors using 32K BAC array. *Genes Chromosomes Cancer* 2009;48:897–907.
155. Upadhyaya M, Kluwe L, Spurlock G, et al. Germline and somatic NF1 gene mutation spectrum in NF1-associated malignant peripheral nerve sheath tumors (MPNSTs). *Hum Mutat* 2008;29:74–82.
156. Fletcher CD, Dal Cin P, de Wever I, et al. Correlation between clinicopathological features and karyotype in spindle cell sarcomas. A report of 130 cases from the CHAMP study group. *Am J Pathol* 1999;154:1841–1847.

157. Mertens F, Dal Cin P, De Wever I, et al. Cytogenetic characterization of peripheral nerve sheath tumours: a report of the CHAMP study group. *J Pathol* 2000;190:31–38.
158. Kresse SH, Skarn M, Ohnstad HO, et al. DNA copy number changes in high-grade malignant peripheral nerve sheath tumors by array CGH. *Mol Cancer* 2008;7:48.
159. Skotheim RI, Kallioniemi A, Bjerkhagen B, et al. Topoisomerase-II alpha is upregulated in malignant peripheral nerve sheath tumors and associated with clinical outcome. *J Clin Oncol* 2003;21:4586.
160. Storlazzi CT, Brekke HR, Mandahl N, et al. Identification of a novel amplicon at distal 17q containing the BIRC5/SURVIVIN gene in malignant peripheral nerve sheath tumours. *J Pathol* 2006;209:492–500.
161. Birindelli S, Perrone F, Oggionni M, et al. Rb and TP53 pathway alterations in sporadic and NF1-related malignant peripheral nerve sheath tumors. *Lab Invest* 2001;81:833–844.
162. Agesen TH, Florenes VA, Molenaar WM, et al. Expression patterns of cell cycle components in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumors. *J Neuropathol Exp Neurol* 2005;64:74–81.
163. Keizman D, Issakov J, Meller I, et al. Expression and significance of EGFR in malignant peripheral nerve sheath tumor. *J Neurooncol* 2009;94:383–388.
164. Ling BC, Wu J, Miller SJ, et al. Role for the epidermal growth factor receptor in neurofibromatosis-related peripheral nerve tumorigenesis. *Cancer Cell* 2005;7:65–75.
165. Johannessen CM, Reczek EE, James MF, et al. The NF1 tumor suppressor critically regulates TSC2 and mTOR. *Proc Natl Acad Sci U S A* 2005;102:8573–8578.
166. Ambrosini G, Cheema HS, Seelman S, et al. Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells. *Mol Cancer Ther* 2008;7:890–896.
167. Maki RG, D'Adamo DR, Keohan ML, et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. *J Clin Oncol* 2009;27:3133–3140.
168. Antonescu CR, Yoshida A, Guo T, et al. KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors. *Cancer Res* 2009;69:7175–7179.
169. Manner J, Radlwimmer B, Hohenberger P, et al. MYC high level gene amplification is a distinctive feature of angiosarcomas after irradiation or chronic lymphedema. *Am J Pathol* 2010;176:34–39.
170. Debiec-Rychter M, de Wever I, Hagemeijer A, Sciort R. Is 4q13 a recurring breakpoint in solitary fibrous tumors? *Cancer Genet Cytogenet* 2001;131:69–73.
171. Mandahl N, Orndal C, Heim S, et al. Aberrations of chromosome segment 12q13–15 characterize a subgroup of hemangiopericytomas. *Cancer* 1993;71:3009–3013.
172. Hadju M, Singer S, Maki RG, et al. IGF2 over-expression in solitary fibrous tumours is independent of anatomical location and is related to loss of imprinting. *J Pathol* 2010;221:300–307.
173. Li Y, Chang Q, Rubin BP, et al. Insulin receptor activation in solitary fibrous tumours. *J Pathol* 2007;211:550–554.
174. Zafar H, Takimoto CH, Weiss G. Doege-Potter syndrome: hypoglycemia associated with malignant solitary fibrous tumor. *Med Oncol* 2003;20:403.
175. Rossi G, Schirosi L, Giovanardi F, et al. Pleural malignant solitary fibrous tumor with sarcomatous overgrowth showing PDGFRbeta mutation. *Chest* 2006;130:581–583.
176. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. *CA Cancer J Clin* 2009;59:225–249.
177. Metzker ML. Sequencing technologies—the next generation. *Nat Rev Genet* 2010;11:31–46.
178. Wang Z, Gerstein M, Snyder M. RNA-Seq: a revolutionary tool for transcriptomics. *Nat Rev Genet* 2009;10:57–63.
179. Wold B, Myers RM. Sequence census methods for functional genomics. *Nat Methods* 2008;5:19–21.
180. Mortazavi A, Williams BA, McCue K, Schaeffer L, Wold B. Mapping and quantifying mammalian transcriptomes by RNA-Seq. *Nat Methods* 2008;5:621–628.
181. Pepke S, Wold B, Mortazavi A. Computation for ChIP-seq and RNA-seq studies. *Nat Methods* 2009;6:S22–S32.
182. Strebhardt K, Ullrich A. Paul Ehrlich's magic bullet concept: 100 years of progress. *Nat Rev Cancer* 2008;8:473–480.
183. Delucas LJ, Hamrick D, Cosenza L, et al. Protein crystallization: virtual screening and optimization. *Prog Biophys Mol Biol* 2005;88:285–309.
184. Sharp SY, Prodromou C, Boxall K, et al. Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinolic pyrazole/isoxazole amide analogues. *Mol Cancer Ther* 2007;6:1198–1211.
185. Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. *Nature* 2005;435:677–681.
186. Schneider G, Fechner U. Computer-based de novo design of drug-like molecules. *Nat Rev Drug Discov* 2005;4:649–663.
187. Sugita S, Seki K, Yokozawa K, et al. Analysis of CHOP rearrangement in pleomorphic liposarcomas using fluorescence in situ hybridization. *Cancer Sci* 2009;100:82–87.
188. Terry J, Barry TS, Horsman DE, et al. Fluorescence in situ hybridization for the detection of t(X;18)(p11.2;q11.2) in a synovial sarcoma tissue microarray using a breakapart-style probe. *Diagn Mol Pathol* 2005;14:77–82.
189. Meier VS, Kuhne T, Jundt G, Gudat F. Molecular diagnosis of Ewing tumors: improved detection of EWS-FLI-1 and EWS-ERG chimeric transcripts and rapid determination of exon combinations. *Diagn Mol Pathol* 1998;7:29–35.
190. Barr FG, Smith LM, Lynch JC, et al. Examination of gene fusion status in archival samples of alveolar rhabdomyosarcoma entered on the Intergroup Rhabdomyosarcoma Study-III trial: a report from the Children's Oncology Group. *J Mol Diagn* 2006;8:202.
191. Mandahl N, Heim S, Willen H, Rydholm A, Mitelman F. Supernumerary ring chromosome as the sole cytogenetic abnormality in a dermatofibrosarcoma protuberans. *Cancer Genet Cytogenet* 1990;49:273–275.
192. Hisaoka M, Ishida T, Kuo TT, et al. Clear cell sarcoma of soft tissue: a clinicopathologic, immunohistochemical, and molecular analysis of 33 cases. *Am J Surg Pathol* 2008;32:452–460.
193. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. *Science* 1998;279:577–580.
194. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. *Science* 2003;299:708–710.
195. Tanas MR, Goldblum Jr. Fluorescence in situ hybridization in the diagnosis of soft tissue neoplasms: a review. *Adv Anat Pathol* 2009;16:383–391.

Chapter 27 – References

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. *CA Cancer J Clin* 2010;60(5):277.
2. Michaloglou C, Vredeveld LC, Soengas MS, et al. BRAF600-associated senescence-like cell cycle arrest of human naevi. *Nature* 2005;436(7051):720.
3. Stark M, Hayward N. Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays. *Cancer Res* 2007;67(6):2632.
4. Lin WM, Baker AC, Beroukhim R, et al. Modeling genomic diversity and tumor dependency in malignant melanoma. *Cancer Res* 2008;68(3):664.
5. Hussussian CJ, Struewing JP, Goldstein AM, et al. Germline p16 mutations in familial melanoma. *Nat Gen* 1994;8(1):15.
6. Chin L, Pomerantz J, Polsky D, et al. Cooperative effects of INK4a and ras in melanoma susceptibility in vivo. *Genes Devel* 1997;11(21):2822.
7. FitzGerald MG, Harkin DP, Silva-Arrieta S, et al. Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population. *Proc Natl Acad Sci U S A* 1996;93(16):8541.
8. Sharpless NE, Kannan K, Xu J, Bosenberg MW, Chin L. Both products of the mouse *Ink4a/Arf* locus suppress melanoma formation in vivo. *Oncogene* 2003;22(32):5055.
9. Molven A, Grimstvedt MB, Steine SJ, et al. A large Norwegian family with inherited malignant melanoma, multiple atypical nevi, and CDK4 mutation. *Genes Chromosomes Cancer* 2005;44(1):10.
10. Muthusamy V, Hobbs C, Nogueira C, et al. Amplification of CDK4 and MDM2 in malignant melanoma. *Genes Chromosomes Cancer* 2006;45(5):447.
11. Sotillo R, García JF, Ortega S, et al. Invasive melanoma in *Cdk4*-targeted mice. *Proc Natl Acad Sci U S A* 2001;98(23):13312.
12. Fletcher O, Easton D, Anderson K, et al. Lifetime risks of common cancers among retinoblastoma survivors. *J Natl Cancer Inst* 2004;96(5):357.
13. Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. *N Engl J Med* 2005;353(20):2135.
14. Berger MF, Levin JZ, Vijayendran K, et al. Integrative analysis of the melanoma transcriptome. *Genome Res* 2010;20(4):413.
15. Chin L. The genetics of malignant melanoma: lessons from mouse and man. *Nat Rev Cancer* 2003;3(8):559.
16. Bardeesy N, Bastian BC, Hezel A, et al. Dual inactivation of RB and p53 pathways in RAS-induced melanomas. *Mol Cell Biol* 2001;21(6):2144.
17. Chin L, Garraway LA, Fisher DE. Malignant melanoma: genetics and therapeutics in the genomic era. *Genes Dev* 2006;20(16):2149.
18. O'Hagan RC, Brennan CW, Strahs A, et al. Array comparative genome hybridization for tumor classification and gene discovery in mouse models of malignant melanoma. *Cancer Res* 2003;63(17):5352.
19. Demunter A, Stas M, Degreef H, De Wolf-Peeters C, van den Oord JJ. Analysis of N- and K-ras mutations in the distinctive tumor progression phases of melanoma. *J Invest Dermatol* 2001;117(6):1483.
20. Bastian BC, LeBoit PE, Pinkel D. Mutations and copy number increase of HRAS in Spitz nevi with distinctive histopathological features. *Am J Pathol* 2000;157(3):967.
21. Shukla VK, Hughes DC, Hughes LE, McCormick F, Padua RA. ras mutations in human melanotic lesions: K-ras activation is a frequent and early event in melanoma development. *Oncogene Res* 1989;5(2):121.
22. Thomas RK, Baker AC, Debiasi RM, et al. High-throughput oncogene mutation profiling in human cancer. *Nat Genet* 2007;39(3):347.
23. Papp T, Pemsel H, Zimmermann R, et al. Mutational analysis of the N-ras, p53, p16INK4a, CDK4, and MC1R genes in human congenital melanocytic naevi. *J Med Genet* 1999;36(8):610.
24. Ackermann J, Fruttschi M, Kaloulis K, et al. Metastasizing melanoma formation caused by expression of activated N-RasQ61K on an INK4a-deficient background. *Cancer Res* 2005;65(10):4005.
25. Eskandarpour M, Kiaii S, Zhu C, et al. Suppression of oncogenic NRAS by RNA interference induces apoptosis of human melanoma cells. *Int J Cancer* 2005;115(1):65.
26. Chin L, Tam A, Pomerantz J, et al. Essential role for oncogenic Ras in tumour maintenance. *Nature* 1999;400(6743):468.
27. Kabbarah O, Chin L. Revealing the genomic heterogeneity of melanoma. *Cancer Cell* 2005;8(6):439.
28. Kumar R, Angelini S, Snellman E, Hemminki K. BRAF mutations are common somatic events in melanocytic nevi. *J Invest Dermatol* 2004;122(2):342.
29. Patton EE, Widlund HR, Kutok JL, et al. BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma. *Curr Biol* 2005;15(3):249.
30. Dhomen N, Reis-Filho JS, da Rocha Dias S, et al. Oncogenic Braf induces melanocyte senescence and melanoma in mice. *Cancer Cell* 2009;15(4):294.
31. Hingorani SR, Jacobetz MA, Robertson GP, Herlyn M, Tuveson DA. Suppression of BRAF(V599E) in human melanoma abrogates transformation. *Cancer Res* 2003;63(17):5198.
32. Wellbrock C, Ogilvie L, Hedley D, et al. V599EB-RAF is an oncogene in melanocytes. *Cancer Res* 2004;64(7):2338.
33. Karasarides M, Chioleches A, Hayward R, et al. B-RAF is a therapeutic target in melanoma. *Oncogene* 2004;23(37):6292.
34. Hoeflich KP, Gray DC, Eby MT, et al. Oncogenic BRAF is required for tumor growth and maintenance in melanoma models. *Cancer Res* 2006;66(2):999.
35. Cartledge RA, Thomas GR, Cagnol S, et al. Oncogenic BRAF(V600E) inhibits BIM expression to promote melanoma cell survival. *Pigment Cell Melanoma Res* 2008;21(5):534.
36. VanBrocklin MW, Verhaegen M, Soengas MS, Holmen SL. Mitogen-activated protein kinase inhibition induces translocation of Bmf to promote apoptosis in melanoma. *Cancer Res* 2009;69(5):1985.
37. Zheng B, Jeong JH, Asara JM, et al. Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation. *Mol Cell* 2009;33(2):237.
38. Sala E, Luca Mologni, Silvia Truffa, et al. BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells. *Mol Cancer Res* 2008;6(5):751.
39. Sondergaard JN, Nazarian R, Wang Q, et al. Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific raf inhibitor PLX4032. *J Transl Med* 2010;8(1):39.
40. Tsai J, Lee JT, Wang W, et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. *Proc Natl Acad Sci U S A* 2008;105(8):3041.
41. Flaherty K, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. *N Engl J Med* 2010;36(9):809–815.
42. Heidorn SJ, Milagre C, Whittaker S, et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. *Cell* 2010;140(2):209.
43. Poulidakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF. *Nature* 2010;464(7287):427.

44. Hatzivassiliou G, Song K, Yen I, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. *Nature* 2010;464(7287):431.
45. Murugan AK, Dong J, Xie J, Xing M. MEK1 mutations, but not ERK2 mutations, occur in melanomas and colon carcinomas, but none in thyroid carcinomas. *Cell Cycle* 2009;8(13):2122.
46. Solit DB, Garraway LA, Pratils CA, et al. BRAF mutation predicts sensitivity to MEK inhibition. *Nature* 2006;439(7074):358.
47. Infante JR, Fecher LA, Nallapareddy S, et al. Safety and efficacy results from the first-in-human study of the oral MEK 1/2 inhibitor GSK1120212. *J Clin Oncol* 2010;28(15S):(abst 2503).
48. Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. *Proc Natl Acad Sci U S A* 2009;106(48):20411.
49. Chudnovsky Y, Adams AE, Robbins PB, Lin Q, Khavari PA. Use of human tissue to assess the oncogenic activity of melanoma-associated mutations. *Nat Genet* 2005;37(7):745.
50. Robertson GP. Functional and therapeutic significance of Akt deregulation in malignant melanoma. *Cancer Metastasis Rev* 2005;24(2):273.
51. Dankort D, Curley DP, Cartledge RA, et al. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. *Nat Genet* 2009;41(5):544.
52. Mishra PJ, Ha L, Rieker J, et al. Dissection of RAS downstream pathways in melanomagenesis: a role for Ral in transformation. *Oncogene* 2010;29(16):2449.
53. Goel VK, Lazar AJ, Warneke CL, Redston MS, Haluska FG. Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma. *J Invest Dermatol* 2006;126(1):154.
54. You MJ, Castrillon DH, Bastian BC, et al. Genetic analysis of Pten and Ink4a/Arf interactions in the suppression of tumorigenesis in mice. *Proc Natl Acad Sci U S A* 2002;99(3):1455.
55. Nogueira C, Kim KH, Sung H, et al. Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis. *Oncogene* 2010;29(47):6222.
56. Dai DL, Martinka M, Li G. Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases. *J Clin Oncol* 2005;23(7):1473.
57. Davies MA, Stemke-Hale K, Lin E, et al. Integrated molecular and clinical analysis of AKT activation in metastatic melanoma. *Clin Cancer Res* 2009;15(24):7538.
58. Davies MA, Stemke-Hale K, Tellez C, et al. A novel AKT3 mutation in melanoma tumours and cell lines. *Br J Cancer* 2008;99(8):1265.
59. Stahl JM, Sharma A, Cheung M, et al. Deregulated Akt3 activity promotes development of malignant melanoma. *Cancer Res* 2004;64(19):7002.
60. Yoeli-Lerner M, Yiu GK, Rabinovitz I, et al. Akt blocks breast cancer cell motility and invasion through the transcription factor NFAT. *Mol Cell* 2005;20(4):539.
61. Nishimura EK, Jordan SA, Oshima H, et al. Dominant role of the niche in melanocyte stem-cell fate determination. *Nature* 2002;416(6883):854.
62. Isabel Zhu Y, Fitzpatrick JE. Expression of c-kit (CD117) in Spitz nevus and malignant melanoma. *J Cutan Pathol* 2006;33(1):33.
63. Montone KT, van Belle P, Elenitsas R, Elder DE. Proto-oncogene c-kit expression in malignant melanoma: protein loss with tumor progression. *Mod Pathol* 1997;10(9):939.
64. Shen SS, Zhang PS, Eton O, Prieto VG. Analysis of protein tyrosine kinase expression in melanocytic lesions by tissue array. *J Cutan Pathol* 2003;30(9):539.
65. Willmore-Payne C, Holden JA, Hirschowitz S, Layfield LJ. BRAF and c-kit gene copy number in mutation-positive malignant melanoma. *Human Pathology* 2006;37(5):520.
66. Conca E, Negri T, Gronchi A, et al. Activate and resist: L576P-KIT in GIST. *Mol Cancer Ther* 2009;8(9):2491.
67. Hodi FS, Friedlander P, Corless CL, et al. Major response to imatinib mesylate in KIT-mutated melanoma. *J Clin Oncol* 2008;26(12):2046.
68. Udart M, Utikal J, Krahn GM, Peter RU. Chromosome 7 aneusomy. A marker for metastatic melanoma? Expression of the epidermal growth factor receptor gene and chromosome 7 aneusomy in nevi, primary malignant melanomas and metastases. *Neoplasia* 2001;3(3):245.
69. Huang TS, Rauth S, Das Gupta TK. Overexpression of EGF receptor is associated with spontaneous metastases of a human melanoma cell line in nude mice. *Anticancer Res* 1996;16(6B):3557.
70. Bardeesy N, Kim M, Xu J, et al. Role of epidermal growth factor receptor signaling in RAS-driven melanoma. *Mol Cell Biol* 2005;25(10):4176.
71. Sibilina M, Fleischmann A, Behrens A, et al. The EGF receptor provides an essential survival signal for SOS-dependent skin tumor development. *Cell* 2000;102(2):211.
72. Prickett TD, Neena SA, Xiaomu Wei, et al. Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. *Nat Genet* 2009;41(10):1127.
73. Bastian BC, LeBoit PE, Hamm H, Brocker E-B, Pincel D. Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization. *Cancer Res* 1998;58(10):2170.
74. Recio JA, Noonan FP, Takayama H, et al. Ink4a/arf deficiency promotes ultraviolet radiation-induced melanomagenesis. *Cancer Res* 2002;62(22):6724.
75. Garraway LA, Widlund HR, Rubin MA, et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. *Nature* 2005;436(7047):117.
76. Garraway LA, Sellers WR. From integrated genomics to tumor lineage dependency. *Cancer Res* 2006;66(5):2506.
77. Garraway LA, Sellers WR. Lineage dependency and lineage-survival oncogenes in human cancer. *Nat Rev Cancer* 2006;6(8):593.
78. Price ER, Ding HF, Badalian T, et al. Lineage-specific signaling in melanocytes. C-kit stimulation recruits p300/CBP to microphthalmia. *J Biol Chem* 1998; 273(29):17983.
79. Jané-Valbuena J, Widlund HR, Perner S, et al. An oncogenic role for ETV1 in melanoma. *Cancer Res* 2010;70(5):2075.
80. McGill GG, Horstmann M, Widlund HR, et al. Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability. *Cell* 2002;109(6):707.
81. Dorsky RI, Moon RT, Raible DW. Control of neural crest cell fate by the Wnt signalling pathway. *Nature* 1998;396(6709):370.
82. Yasumoto K, Kazuhisa T, Hideo S, et al. Microphthalmia-associated transcription factor interacts with LEF-1, a mediator of Wnt signaling. *EMBO J* 2002;21(11):2703.
83. Widlund HR, Horstmann MA, Price ER, et al. Beta-catenin-induced melanoma growth requires the downstream target Microphthalmia-associated transcription factor. *J Cell Biol* 2002;158(6):1079.
84. Rubinfeld B, Robbins P, El-Gamil M, et al. Stabilization of beta-catenin by genetic defects in melanoma cell lines. *Science* 1997;275(5307):1790.
85. Rimm DL, Caca K, Hu G, Harrison FB, Fearon ER. Frequent nuclear/cytoplasmic localization of beta-catenin without exon 3 mutations in malignant melanoma. *Am J Pathol* 1999;154(2):325.
86. Weeraratna AT, Jiang Y, Hostetter G, et al. Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. *Cancer Cell* 2002;1(3):279.
87. Bastiaens M, Jeanette ter H, Nelleke GS, et al. The melanocortin-1-receptor gene is the major freckle gene. *Hum Mol Genet* 2001;10(16):1701.
88. Healy E, Siobhán A. Jordan, Peter S, et al. Functional variation of MC1R alleles from red-haired individuals. *Hum Mol Genet* 2001;10(21):2397.

89. Khaled M, Larribere L, Bille K, et al. Microphthalmia associated transcription factor is a target of the phosphatidylinositol-3-kinase pathway. *J Invest Dermatol* 2003;121(4):831.
90. D'Orazio JA, Nobuhisa T, Cui R, et al. Topical drug rescue strategy and skin protection based on the role of Mc1r in UV-induced tanning. *Nature* 2006;443(7109):340.
91. Cui R, Widlund HR, Feige E, et al. Central role of p53 in the suntan response and pathologic hyperpigmentation. *Cell* 2007;128(5):853.
92. Kim M, Gans JD, Nogueira C, et al. Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. *Cell* 2006;125(7):1269.
93. Schatton T, Murphy GE, Frank NY, et al. Identification of cells initiating human melanomas. *Nature* 2008;451(7176):345.
94. Frank NY, Margaryan A, Huang Y, et al. ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. *Cancer Res* 2005;65(10):4320.
95. Quintana E, Shackleton M, Sabel MS, et al. Efficient tumour formation by single human melanoma cells. *Nature* 2008;456(7222):593.
96. Pleasance ED, Cheetham RK, Stephens PJ, et al. A comprehensive catalogue of somatic mutations from a human cancer genome. *Nature* 2010;463(7278):191.
97. Du J, Widlund HR, Horstmann MA, et al. Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. *Cancer Cell* 2004;6(6):565.
98. International network of cancer genome projects. *Nature* 2010;464(7291):993.
99. Chin L, Gray JW. Translating insights from the cancer genome into clinical practice. *Nature* 2008;452(7187):553.
100. Scott KL, Kabbarah O, Liang MC, et al. GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancer. *Nature* 2009;459(7250):1085.
101. Wajapeyee N, Serra RW, Zhu X, Mahalingam M, Green MR. Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. *Cell* 2008;132(3):363.
102. Gobeil S, Zhu X, Doillon CJ, Green MR. A genome-wide shRNA screen identifies GAS1 as a novel melanoma metastasis suppressor gene. *Genes Dev* 2008;22(21):2932.

Chapter 28 – References

1. Louis DN, Pomeroy SL, Cairncross JG. Focus on CNS neoplasia. *Cancer Cell* 2002;1:125.
2. Czernicki T, Zegarska J, Paczek L, et al. Gene expression profile as a prognostic factor in high-grade gliomas. *Int J Oncol* 2005;30:55.
3. Freije WA, Castro-Vargas FE, Fang Z, et al. Gene expression profiling of gliomas strongly predicts survival. *Cancer Res* 2004;64: 6503.
4. Nutt CL, Mani DR, Betensky RA, et al. Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. *Cancer Res* 2003;63:1602.
5. Roerig P, Nessling M, Radlwimmer B, et al. Molecular classification of human gliomas using matrix-based comparative genomic hybridization. *Int J Cancer* 2005; 117:95.
6. Schmidt MC, Antweiler S, Urban N, et al. Impact of genotype and morphology on the prognosis of glioblastoma. *J Neuropathol Exp Neurol* 2002;61:321.
7. Wiltshire RN, Herndon JE 2nd, Lloyd A, et al. Comparative genomic hybridization analysis of astrocytomas: prognostic and diagnostic implications. *J Mol Diagn* 2004;6:166.
8. McCabe MG, Ichimura K, Liu L, et al. High-resolution array-based comparative genomic hybridization of medulloblastomas and supratentorial primitive neuroectodermal tumors. *J Neuropathol Exp Neurol* 2006;65:549.
9. Pomeroy SL, Tamayo P, Gaasenbeek M, et al. Prediction of central nervous system embryonal tumour outcome based on gene expression. *Nature* 2002;415:436.
10. Gabeau-Lacet D, Engler D, Gupta S, et al. Genomic profiling of atypical meningiomas associates gain of 1q with poor clinical outcome. *J Neuropathol Exp Neurol* 2009;68:1155.
11. Gutmann DH, Maher EA, Van Dyke T. Mouse models of human cancers consortium workshop on nervous system tumors. *Cancer Res* 2006;66:10.
12. de Vries NA, Beijnen JH, van Tellingen O. High-grade glioma mouse models and their applicability for preclinical testing. *Cancer Treat Rev* 2009;35:714.
13. Huse JT, Holland EC. Genetically engineered mouse models of brain cancer and the promise of preclinical testing. *Brain Pathol* 2009;19:132.
14. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, eds. *World Health Organization Histological Classification of Tumours of the Central Nervous System*. Lyon: IARC Press, 2007.
15. Robertson GP, Huang HJ, Cavenee WK. Identification and validation of tumor suppressor genes. *Mol Cell Bi Commun* 1999;2:1.
16. Shete S, Hosking FJ, Robertson LB, et al. Genome-wide association study identifies five susceptibility loci for glioma. *Nat Genet* 2009;41:899.
17. Wrensch M, Jenkins RB, Chang JS, et al. Variants in the CDKN2B and TEL1 regions are associated with high-grade glioma susceptibility. *Nat Genet* 2009;41:905.
18. Maher EA, Furnari FB, Bachoo RM, et al. Malignant glioma: genetics and biology of a grave matter. *Genes Dev* 2001;15:1311.
19. Louis DN, von Deimling A, Chung RY, et al. Comparative study of p53 gene and protein alterations in human astrocytic tumors. *J Neuropathol Exp Neurol* 1993;52:31.
20. von Deimling A, Eibl RH, Ohgaki H, et al. p53 mutations are associated with 17p allelic loss in grade II and grade III astrocytoma. *Cancer Res* 1992;52:2987.
21. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. *Nature* 2008;455:1061.
22. Bogler O, Huang H-JS, Cavenee WK. Loss of wild-type p53 bestows a growth advantage on primary cortical astrocytes and facilitates their in vitro transformation. *Cancer Res* 1995;55:2746.
23. Reilly KM, Loisel DA, Bronson RT, McLaughlin ME, Jacks T. Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects. *Nat Genet* 2000;26:109.
24. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. *N Engl J Med* 2009;360:765.
25. Camelo-Piragua S, Jansen M, Ganguly A, Kim JCM, Louis DN, Nutt CL. Mutant IDH1-specific immunohistochemistry distinguishes diffuse astrocytoma from astrocytosis. *Acta Neuropathol* 2010;119:509.
26. Nakamura M, Watanabe T, Yonekawa Y, Kleihues P, Ohgaki H. Promoter methylation of the DNA repair gene MGMT in astrocytomas is frequently associated with G:C → A:T mutations of the TP53 tumor suppressor gene. *Carcinogenesis* 2001;22:1715.
27. Weller M, Felsberg J, Hartmann C, et al. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. *J Clin Oncol* 2009;27:5743.
28. Ichimura K, Schmidt EE, Goike HM, and Collins VP. Human glioblastomas with no alterations of the CDKN2A (p16INK4A, MTS1) and CDK4 genes have frequent mutations of the retinoblastoma gene. *Oncogene* 1996;13:1065.
29. Ueki K, Ono Y, Henson JW, Efrid JT, von Deimling A, Louis DN. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. *Cancer Res* 1996;56:150.
30. Xiao A, Wu H, Pandolfi PP, Louis DN, Van Dyke T. Astrocyte inactivation of the pRb pathway predisposes mice to malignant astrocytoma development that is accelerated by PTEN mutation. *Cancer Cell* 2002;1:157.
31. Backlund LM, Nilsson BR, Liu L, Ichimura K, and Collins VP. Mutations in Rb1 pathway-related genes are associated with poor prognosis in anaplastic astrocytomas. *Br J Cancer* 2005;93:124.
32. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. *Science* 2008;321:1807.
33. Liu W, James CD, Frederick L, Alderete BE, Jenkins RB. PTEN/MMAC1 mutations and EGFR amplification in glioblastomas. *Cancer Res* 1997;57:5254.
34. Furnari FB, Lin H, Huang HS, and Cavenee WK. Growth suppression of glioma cells by PTEN requires a functional phosphatase catalytic domain. *Proc Natl Acad Sci U S A* 1997;94:12479.
35. Kwon CH, Zhao D, Chen J, et al. Pten haploinsufficiency accelerates formation of high-grade astrocytomas. *Cancer Res* 2008;68:3286.
36. Ekstrand AJ, James CD, Cavenee WK, Seliger B, Pettersson RF, Collins VP. Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. *Cancer Res* 1991;51:2164.
37. Hayashi Y, Ueki K, Waha A, Wiestler OD, Louis DN, von Deimling A. Association of EGFR gene amplification and CDKN2 (p16/MTS1) gene deletion in glioblastoma multiforme. *Brain Pathol* 1997;7:871.
38. Ekstrand AJ, Sugawa N, James CD, Collins VP. Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. *Proc Natl Acad Sci U S A* 1992;89:4309.
39. Ekstrand AJ, Longo N, Hamid ML, et al. Functional characterization of an EGF receptor with a truncated extracellular domain expressed in glioblastomas with EGFR gene amplification. *Oncogene* 1994;9:2313.
40. Nishikawa R, Ji XD, Harmon RC, et al. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. *Proc Natl Acad Sci U S A* 1994;91:7727.

41. Holland EC, Hively WP, DePinho RA, Varmus HE. A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice. *Genes Dev* 1998; 12:3675.
42. Zhao S, Lin Y, Xu W, et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1 α . *Science* 2009;324:261.
43. Jensen RL. Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target. *J Neurooncol* 2009;92:317.
44. Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. *Nature* 2009;462:739.
45. Verhaak RG, Hoadley KA, Purdom E, et al; Cancer Genome Atlas Research Network. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. *Cancer Cell* 2010;17:98.
46. von Deimling A, von Ammon K, Schoenfeld D, Westler OD, Seizinger BR, Louis DN. Subsets of glioblastoma multiforme defined by molecular genetic analysis. *Brain Pathol* 1993;3:19.
47. Nigro JM, Misra A, Zhang L, et al. Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma. *Cancer Res* 2005;65:1678.
48. Pelloski CE, Mahajan A, Maor M, et al. YKL-40 expression is associated with poorer response to radiation and shorter overall survival in glioblastoma. *Clin Cancer Res* 2005;11:3326.
49. Phillips HS, Kharbanda S, Chen R, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. *Cancer Cell* 2006;9:157.
50. Maher EA, Brennan C, Wen PY, et al. Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities. *Cancer Res* 2006;66:11502.
51. Sharma MK, Mansur DB, Reifenberger G, et al. Distinct genetic signatures among pilocytic astrocytomas relate to their brain region origin. *Cancer Res* 2007;67:890.
52. Jones DT, Kocialkowski S, Liu L, et al. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. *Cancer Res* 2008;68:8673.
53. Jones DT, Kocialkowski S, Liu L, Pearson DM, Ichimura K, Collins VP. Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma. *Oncogene* 2009;28:2119.
54. Pollack IF, Finkelstein SD, Burnham J, et al; Children's Cancer Group. Age and TP53 mutation frequency in childhood malignant gliomas: results in a multi-institutional cohort. *Cancer Res* 2001;61:7404.
55. Pollack IF, Hamilton RL, James CD, et al; Children's Oncology Group. Rarity of PTEN deletions and EGFR amplification in malignant gliomas of childhood: results from the Children's Cancer Group 945 cohort. *J Neurosurg* 2006;105:418.
56. Schiffman JD, Hodgson JG, VandenBerg SR, Flaherty P, Polley MY, Yu M, Fisher PG, Rowitch DH, Ford JM, Berger MS, Ji H, Gutmann DH, James CD. Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. *Cancer Res* 2006;66:11502.
57. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. *Nature* 2002;417:949.
58. Reifenberger G, Louis DN. Oligodendroglioma: toward molecular definitions in diagnostic neuro-oncology. *J Neuropathol Exp Neurol* 2003;62:111.
59. Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. *Cancer Res* 2006;66:9852.
60. Laird PW. Principles and challenges of genome-wide DNA methylation analysis. *Nat Rev Genet* 2010;11:191.
61. Cairncross JG, Ueki K, Zlatescu MC, et al. Specific chromosomal losses predict chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. *J Natl Cancer Inst* 1998;90:1473.
62. Kouwenhoven MC, Kros JM, French PJ, et al. 1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment. *Eur J Cancer* 2006;42:2499.
63. Snuderl M, Eichler AF, Ligon KL, et al. Polysomy for chromosomes 1 and 19 predicts earlier recurrence in anaplastic oligodendrogliomas with concurrent 1p/19q loss. *Clin Cancer Res* 2009;15:6430.
64. Ino Y, Betensky RA, Zlatescu MC, et al. Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. *Clin Cancer Res* 2001;7:839.
65. Yip S, Iafrate AJ, Louis DN. Molecular diagnostic testing in malignant gliomas: a practical update on predictive markers. *J Neuropathol Exp Neurol* 2008;67:1.
66. Ebert C, von Haken M, Meyer-Puttitz B, et al. Molecular genetic analysis of ependymal tumors. NF2 mutations and chromosome 22q loss occur preferentially in intramedullary spinal ependymomas. *Am J Pathol* 1999;155:627.
67. Carter M, Nicholson J, Ross F, et al. Gain of 1q and loss of 22 are the most common changes detected by comparative genomic hybridisation in paediatric ependymoma. *Br J Cancer* 2002;86:929.
68. Reardon DA, Entrekun RE, Sublett J, et al. Chromosome arm 6q loss is the most common recurrent autosomal alteration detected in primary pediatric ependymoma. *Genes Chromosomes Cancer* 1999;24:230.
69. Puget S, Grill J, Valent A, et al. Candidate genes on chromosome 9q33–34 involved in the progression of childhood ependymomas. *J Clin Oncol* 2009;27:1884.
70. Suarez-Merino B, Hubank M, Revesz T, et al. Microarray analysis of pediatric ependymoma identifies a cluster of 112 candidate genes including four transcripts at 22q12.1-q13.3. *Neuro-Oncology* 2005;7:20.
71. Korshunov A, Neben K, Wrobel G, et al. Gene expression patterns in ependymomas correlate with tumor location, grade, and patient age. *Am J Pathol* 2003;163:1721.
72. Lukashova-v Zangen I, Kneitz S, Monoranu CM, Rutkowski S, Hinkes B, Vince GH, Huang B, Roggendorf W. Ependymoma gene expression profiles associated with histological subtype, proliferation, and patient survival. *Acta Neuropathol* 2007;113(3):325.
73. Tabori U, Baskin B, Shago M, et al. Universal poor survival in children with medulloblastoma harboring somatic TP53 mutations. *J Clin Oncol* 2010;28:1345.
74. Aldosari N, Bigner SH, Burger PC, et al. MYCC and MYCN oncogene amplification in medulloblastoma. A fluorescence in situ hybridization study on paraffin sections from the Children's Oncology Group. *Arch Pathol Lab Med* 2002;126:540.
75. Di C, Liao S, Adamson DC, Parrett TJ, et al. Identification of OTX2 as a medulloblastoma oncogene whose product can be targeted by all-trans retinoic acid. *Cancer Res* 2005;65:919.
76. Adamson DC, Shi Q, Wortham M, et al. OTX2 is critical for the maintenance and progression of Shh-independent medulloblastomas. *Cancer Res* 2010;70:181.
77. Raffel C. Medulloblastoma: molecular genetics and animal models. *Neoplasia* 2004;6:3102004.
78. Taylor MD, Liu L, Raffel C, et al. Mutations in SUFU predispose to medulloblastoma. *Nat Genet* 2002;31:306.
79. de Haas T, Hasselt N, Troost D, et al. Molecular risk stratification of medulloblastoma patients based on immunohistochemical analysis of MYC, LDHB, and CCNB1 expression. *Clin Cancer Res* 2008;14:4154.

80. Wellenreuther R, Kraus JA, Lenartz D, et al. Analysis of the neurofibromatosis 2 gene reveals molecular variants of meningioma. *Am J Pathol* 1995;146:827.
81. Mihaila D, Jankowski M, Gutierrez JA, et al; NABTT CNS Consortium. Meningiomas: loss of heterozygosity on chromosome 10 and marker-specific correlations with grade, recurrence, and survival. *Clin Cancer Res* 2003;9:4443.
82. Watson MA, Gutmann DH, Peterson K, et al. Molecular characterization of human meningiomas by gene expression profiling using high-density oligonucleotide microarrays. *Am J Pathol* 2002;161:665.
83. Wrobel G, Roerig P, Kokocinski F, et al. Microarray-based gene expression profiling of benign, atypical and anaplastic meningiomas identifies novel genes associated with meningioma progression. *Int J Cancer* 2005;114:249.
84. Lusa EA, Watson MA, Chicoine MR, et al. Integrative genomic analysis identifies NDRG2 as a candidate tumor suppressor gene frequently inactivated in clinically aggressive meningioma. *Cancer Res* 2005;65:7121.
85. Singh SK, Hawkins C, Clarke ID, S et al. Identification of human brain tumour initiating cells. *Nature* 2004;432:396.
86. Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. *Nature* 2006;444:756.
87. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. *N Engl J Med* 2005;352:997.
88. Cahill DP, Levine KK, Betensky RA, et al. Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. *Clin Cancer Res* 2007;13:2038.
89. Yip S, Miao J, Cahill DP, et al. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance. *Clin Cancer Res* 2009;15:4622.
90. Mellinghoff IK, Wang MY, Vivanco I, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. *N Engl J Med* 2005;353:2012.
91. Haas-Kogan DA, Prados MD, Tihan T, et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. *J Natl Cancer Inst* 2005;97:880.
92. Huang PH, Mukasa A, Bonavia R, et al. Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma. *Proc Natl Acad Sci U S A* 2007;104:12867.
93. Stommel JM, Kimmelman AC, Ying H, et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. *Science* 2007;318:287.

Chapter 29 – References

1. Knudson AG Jr. Hereditary cancers disclose a class of cancer genes. *Cancer* 1989;63:1888.
2. Ylisaukko-oja SK, Kiuru M, Lehtonen HJ, et al. Analysis of fumarate hydratase mutations in a population-based series of early onset uterine leiomyosarcoma patients. *Int J Cancer* 2006;119(2):283.
3. Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. *Proc Natl Acad Sci U S A* 1971;68:820.
4. Comings DE. A general theory of carcinogenesis. *Proc Natl Acad Sci U S A* 1973;70:3324.
5. Devesa SS. The incidence of retinoblastoma. *Am J Ophthalmol* 1975;80:263.
6. Knudson AG Jr, Hethcote HW, Brown BW. Mutation and childhood cancer: a probabilistic model for the incidence of retinoblastoma. *Proc Natl Acad Sci U S A* 1975;72:5116.
7. Smith LM, Donaldson SS, Egbert PR, et al. Aggressive management of second primary tumors in survivors of hereditary retinoblastoma. *Int J Radiat Oncol Biol Phys* 1989;17:499.
8. Cavenee WK, Dryja TP, Phillips RA, et al. Expression of recessive alleles by chromosomal mechanisms in retinoblastoma. *Nature* 1983;305:779.
9. Squire J, Dryja TP, Dunn J, et al. Cloning of the esterase D gene: a polymorphic gene probe closely linked to the retinoblastoma locus on chromosome 13. *Proc Natl Acad Sci U S A* 1986;83:6573.
10. Friend SH, Bernard R, Rogelj S, et al. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. *Nature* 1986;323:643.
11. Bookstein R, Shew JY, Chen PL, et al. Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene. *Science* 1990;247:712.
12. Gonzalez-Fernandez F, Lopes MB, Garcia-Fernandez JM, et al. Expression of developmentally defined retinal phenotypes in the histogenesis of retinoblastoma. *Am J Pathol* 1992;141:363.
13. Laurie NA, Donovan SL, Shih CS, et al. Inactivation of the p53 pathway in retinoblastoma. *Nature* 2006;444(7115):61.
14. Reed D, Shen Y, Shelat A, et al. Identification and characterization of the first small molecule inhibitor of MDMX. *J Biol Chem* 2010;285:10786.
15. Marine JC, Dyer MA, Jochemsen AG. MDMX: from bench to bedside. *J Cell Science* 2007;120(Pt 3):371.
16. Matsunaga E. Hereditary retinoblastoma: penetrance, expressivity and age of onset. *Hum Genet* 1976;33:1.
17. Schubert EL, Strong LC, Hansen MF. A splicing mutation in RB1 in low penetrance retinoblastoma. *Br J Cancer* 1986;53:661.
18. Beckwith JB, Kiviat NB, Bonadio JF. Nephrogenic rests, nephroblastomatosis, and the pathogenesis of Wilms' tumor. *Pediatr Pathol* 1990;10:1.
19. Mueller RF. The Denys-Drash syndrome. *J Med Genet* 1994;31:471.
20. Sotelo-Avila C, Gonzalez-Crussi F, Fowler JW. Complete and incomplete forms of Beckwith-Wiedemann syndrome: their oncogenic potential. *J Pediatr* 1980;96:47.
21. Riccardi VM, Sujansky E, Smith AC, et al. Chromosomal imbalance in the Aniridia-Wilms' tumor association: 11p interstitial deletion. *Pediatrics* 1978;61:604.
22. Ton CC, Hirvonen H, Miwa H, et al. Positional cloning and characterization of a paired box- and homeobox-containing gene from the aniridia region. *Cell* 1991;67:1059.
23. Call KM, Glaser T, Ito CY, et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. *Cell* 1990;60:509.
24. Gessler M, Poustka A, Cavenee W, et al. Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping. *Nature* 1990;343:774.
25. Bonetta L, Kuehn SE, Huang A, et al. Wilms tumor locus on 11p13 defined by multiple CpG island-associated transcripts. *Science* 1990;250:994.
26. Drash A, Sherman F, Hartmann WH, et al. A syndrome of pseudohermaphroditism, Wilms' tumor, hypertension, and degenerative renal disease. *J Pediatr* 1970;76:585.
27. Jadresic L, Leake J, Gordon I, et al. Clinicopathologic review of twelve children with nephropathy, Wilms tumor, and genital abnormalities (Drash syndrome). *J Pediatr* 1990;117:717.
28. Coppes MJ, Liefers GJ, Higuchi M, et al. Inherited WT1 mutation in Denys-Drash syndrome. *Cancer Res* 1992;52:6125.
29. Koufos A, Grundy P, Morgan K, et al. Familial Wiedemann-Beckwith syndrome and a second Wilms tumor locus both map to 11p15.5. *Am J Hum Genet* 1989;44:711.
30. Matsuoka S, Edwards MC, Bai C, et al. p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene. *Genes Dev* 1995;9:650.
31. Hartmann W, Waha A, Koch A, et al. p57(KIP2) is not mutated in hepatoblastoma but shows increased transcriptional activity in a comparative analysis of the three imprinted genes p57(KIP2), IGF2, and H19. *Am J Pathol* 2000;157:1393.
32. Rivera MN, Kim WJ, Driscoll DR, et al. An X chromosome gene, WTX, is commonly inactivated in Wilms tumor. *Science* 2007;315:642.
33. Huff V. Wilms tumor genetics: a new, UnX-pected twist to the story. *Cancer Cell* 2007;11(2):105.
34. Maw MA, Grundy PE, Millow LJ, et al. A third Wilms' tumor locus on chromosome 16q. *Cancer Res* 1992;52:3094.
35. Huff V, Reeve AE, Leppert M, et al. Nonlinkage of 16q markers to familial predisposition to Wilms' tumor. *Cancer Res* 1992;52:6117.
36. Huson SM, Compston DA, Harper PS. A genetic study of von Recklinghausen neurofibromatosis in south east Wales. II. Guidelines for genetic counseling. *J Med Genet* 1989;26:712.
37. Lynch TM, Gutmann DH. Neurofibromatosis 1. *Neurol Clin* 2002;20:841.
38. Miettinen M, Fetsch JF, Sobin LH, Lasota J. Gastrointestinal stromal tumors in patients with neurofibromatosis 1: a clinicopathologic and molecular genetic study of 45 cases. *Am J Surg Pathol* 2006;30:90.
39. Marchuk DA, Saulino AM, Tavakkol R, et al. cDNA cloning of the type 1 neurofibromatosis gene: complete sequence of the NF1 gene product. *Genomics* 1991;11:931.
40. Viskochil D, Buchberg AM, Xu G, et al. Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus. *Cell* 1990;62:187.
41. Tidyman WE, Rauen KA. The RASopathies: developmental syndromes of Ras/MAKP pathway dysregulation. *Curr Opin Genet Dev* 2009;19:230.
42. Dasgupta B, Yi Y, Chen DY, et al. Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors. *Cancer Res* 2005;65(7):2755.
43. Martuza RL, Eldridge R. Neurofibromatosis 2 (bilateral acoustic neurofibromatosis). *N Engl J Med* 1988;318:684.
44. Trofatter JA, MacCollin MM, Rutter JL, et al. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. *Cell* 1993;72:791.
45. Rouleau GA, Merel P, Lutchman M, et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. *Nature* 1993;363:515.

46. Sun CX, Robb VA, Gutmann DH. Protein 4.1 tumor suppressors: getting a FERM grip on growth regulation. *J Cell Sci* 2002;115:3991.
47. Khanna C, Wan X, Bose S, et al. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. *Nat Med* 2004;10:182.
48. Lallemand D, Curto M, Saotome I, et al. NF2 deficiency promotes tumorigenesis and metastasis by destabilizing adherens junctions. *Genes Dev* 2003;17:1090.
49. Ammoun S, Cunliffe CH, Allen JC, et al. ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma. *Neuro Oncol* 2010;12:834.
50. Brodeur GM, Sekhon G, Goldstein MN. Chromosomal aberrations in human neuroblastomas. *Cancer* 1977;40:2256.
51. Caron H, van Sluis P, de Kraker J, et al. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. *N Engl J Med* 1996;334:225.
52. Lau L, Hansford LM, Cheng LS, et al. Cyclooxygenase inhibitors modulate the p53/HDM2 pathway and enhance chemotherapy-induced apoptosis in neuroblastoma. *Oncogene* 2007;26:1920.
53. Irwin MS, Kaelin WG. p53 family update: p73 and p63 develop their own identities. *Cell Growth Differ* 2001;12:337.
54. Melino G, De Laurenzi V, Vousden KH. p73: Friend or foe in tumorigenesis. *Nat Rev Cancer* 2002;2:605.
55. Casciano I, Mazzocco K, Boni L, et al. Expression of DeltaNp73 is a molecular marker for adverse outcome in neuroblastoma patients. *Cell Death Differ* 2002;9:246.
56. Douc-Rasy S, Barrois M, Echeyne M, et al. DeltaN-p73alpha accumulates in human neuroblastic tumors. *Am J Pathol* 2002;160:631.
57. Biedler JL, Ross R, Sharske S, et al. Human neuroblastoma cytogenetics: search for significance of homogeneously staining regions in double minute chromosomes. In: Evans AE, ed. *Advances in Neuroblastoma Research*. New York: Raven, 1980:81.
58. Schwab M, Alitalo K, Klempnauer KH, et al. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. *Nature* 1983;305:245.
59. Thiele CJ, Reynolds CP, Israel MA. Decreased expression of N-myc precedes retinoic acid-induced morphological differentiation of human neuroblastoma. *Nature* 1985;313:404.
60. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. *N Engl J Med* 1999;341:1165.
61. Schwab M, Ellison J, Busch M, et al. Enhanced expression of the human gene N-myc consequent to amplification of DNA may contribute to malignant progression of neuroblastoma. *Proc Natl Acad Sci U S A* 1984;81:4940.
62. Nakagawara A, Arima-Nakagawara M, Scavarda NJ, et al. Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. *N Engl J Med* 1993;328:847.
63. Ho R, Eggert A, Hishiki T, et al. Resistance to chemotherapy mediated by TrkB in neuroblastomas. *Cancer Res* 2002;62:6462.
64. Jaboin J, Kim CJ, Kaplan DR, et al. Brain-derived neurotrophic factor activation of TrkB protects neuroblastoma cells from chemotherapy-induced apoptosis via phosphatidylinositol 3'-kinase pathway. *Cancer Res* 2002;62:6756.
65. Norris MD, Bordow SB, Marshall GM, et al. Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma. *N Engl J Med* 1996;334:231.
66. Bown N, Cotterill S, Lastowska M, et al. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. *N Engl J Med* 1999;340:1954.
67. Trochet D, Bourdeaut F, Janoueix-Lerosey I, et al. Germline mutations of the paired-like homeobox 2B (PHOX2B) gene in neuroblastoma. *Am J Hum Genet* 2004;74:761.
68. Mosse YP, Laduenslager M, Longo L, et al. Identification of ALK as a major familial neuroblastoma predisposition gene. *Nature* 2008;455:967.
69. Janoueix-Larosey I, Lequin D, Bruggieres L, et al. Somatic and germline activation mutations in the ALK kinase receptor in neuroblastoma. *Nature* 2008;455:967.
70. George RE, Sanda T, Hanna M, et al. Alkylating mutations in ALK provide a therapeutic target in neuroblastoma. *Nature* 2008;455:975.
71. Chen Y, Takita J, Choi YL, et al. Oncogenic mutations of ALK kinase in neuroblastoma. *Nature* 2008;477:971.
72. Attiyeh EF, London WB, Mosse YP, et al. Chromosome 1p and 11q deletions and outcome in neuroblastoma. *N Engl J Med* 2005;353(21):2243.
73. Binz N, Shalaby T, Rivera P, et al. Telomerase inhibition, telomere shortening, cell growth suppression and induction of apoptosis by telomestatin in childhood neuroblastoma cells. *Eur J Cancer* 2005;41:2873.
74. Ohali A, Avigad S, Ash S, et al. Telomere length is a prognostic factor in neuroblastoma. *Cancer* 2006;107:1391.
75. Ewing J. Classics in oncology. Diffuse endothelioma of bone: proceedings of the New York Pathological Society, 1921. *CA Cancer J Clin* 1972;22:95.
76. Turc-Carel C, Philip I, Berger MP, et al. Chromosomal translocation (11;22) in cell lines of Ewing's sarcoma. *C R Seances Acad Sci III* 1983;296:1101.
77. Whang-Peng J, Triche T, Knutsen T, et al. Chromosome translocation in peripheral neuroepithelioma. *N Engl J Med* 1984;311:584.
78. Delattre O, Zucman J, Ploustage B, et al. Gene fusion with an ETS DNA binding domain caused by chromosome translocation in human cancers. *Nature* 1992;359:162.
79. Zucman J, Delattre O, Desmaziere C, et al. Cloning and characterization of the Ewing's sarcoma and peripheral neuroepithelioma t(11;22) translocation breakpoints. *Genes Chromosomes Cancer* 1992;5:271.
80. May WA, Gishizky ML, Lessnick SL, et al. Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation. *Proc Natl Acad Sci U S A* 1993;90:5752.
81. Sorensen PH, Lessnick SL, Lopez-Terrada D, et al. A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG. *Nat Genet* 1994;6:146.
82. Jeon IS, Davis JN, Braun BS, et al. A variant Ewing's sarcoma translocation (7;22) fuses the EWS gene to the ETS gene ETV1. *Oncogene* 1995;10:1229.
83. Kaneko Y, Yoshida K, Handa M, et al. Fusion of an ETS-family gene, EIAF, to EWS by t(17;22) (q12;q12) chromosome translocation in an undifferentiated sarcoma of infancy. *Genes Chromosomes Cancer* 1996;15(2):115.
84. Peter M, Couturier J, Pacquement H, et al. A new member of the ETS family fused to EWS in Ewing tumors. *Oncogene* 1997;14(10):1159.
85. deAlava E, Kawai A, Healey J, et al. EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma. *J Clin Oncol* 1998;16:1.
86. Le Deley MC, Delattre O, Schaefer KL, et al. Impact of EWS-ETS fusion type on disease progression in Ewing's sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro-E.W.I.N.G. 99 trial. *J Clin Oncol* 2010;28:1982.
87. van Doorninck JA, Ji L, Schaub B, et al. Current treatment protocols have eliminated the prognostic advantage of type 1 fusions in Ewing sarcoma: a report from the Children's Oncology Group. *J Clin Oncol* 2010;28:1989.
88. Hahm KB, Cho K, Lee C, et al. Repression of the gene encoding the TGF-beta type II receptor is a major target of the EWS-FLI1 oncoprotein. *Nat Genet* 1999;23:222.

89. Lessnick SL, Dacwag CS, Golub TR. The Ewing's sarcoma oncoprotein EWS/FLI induces a p53-dependent growth arrest in primary human fibroblasts. *Cancer Cell* 2002;1:393.
90. Deneen B, Denny CT. Loss of p16 pathways stabilizes EWS/FLI1 expression and complements EWS/FLI1 mediated transformation. *Oncogene* 2001;20:6731.
91. Smith R, Owen LA, Trem DJ, et al. Expression profiling of EWS/FLI identifies NKX2.2 as a critical target gene in Ewing's sarcoma. *Cancer Cell* 2006;9(5):405.
92. Kinsey M, Smith R, Lessnick SL. NR0B1 is required for the oncogenic phenotype mediated by EWS/FLI in Ewing's sarcoma. *Mol Cancer Res* 2006;4:851.
93. Gangwal K, Sankar S, Hollenhorst PC, et al. Microsatellites as EWS/FLI response elements in Ewing's sarcoma. *Proc Natl Acad Sci U S A* 2008;105:10149.
94. Parham DM, Webber B, Holt H, et al. Immunohistochemical study of childhood rhabdomyosarcomas and related neoplasms: results of an Intergroup Rhabdomyosarcoma Study Project. *Cancer* 1991;67:3072.
95. Dias P, Parham DM, Shapiro DN, et al. Myogenic regulatory protein (MyoD1) expression in childhood solid tumors: diagnostic utility in rhabdomyosarcoma. *Am J Pathol* 1990;137:1283.
96. Minniti CP, Tsokos M, Newton WA Jr, et al. Specific expression of insulin-like growth factor-II in rhabdomyosarcoma tumor cells. *Am J Clin Pathol* 1994;101:198.
97. Scoble H, Witte D, Shimada H, et al. Molecular differential pathology of rhabdomyosarcoma. *Genes Chromosomes Cancer* 1989;1:23.
98. Scoble H, Cavenee W, Ghavimi F, et al. A model for embryonal rhabdomyosarcoma tumorigenesis that involves genome imprinting. *Proc Natl Acad Sci U S A* 1989;86:7480.
99. Rainier S, Johnson LA, Dobry CJ, et al. Relaxation of imprinted genes in human cancer. *Nature* 1993;362:747.
100. Zhan S, Shapiro DN, Helman LJ. Activation of an imprinted allele of the insulin-like growth factor II gene implicated in rhabdomyosarcoma. *J Clin Invest* 1994;94:445.
101. Gripp KW. Tumor predisposition in Costello syndrome. *Am J Med Genet C Semin Med Genet* 2005;137C:72.
102. Kratz CP, Steinemann D, Niemyer CM, et al. Uniparental disomy at chromosome 11p15.5 followed by HRAS mutations in embryonal rhabdomyosarcoma: lessons from Costello syndrome. *Hum Mol Genet* 2007;16:374.
103. Douglass EC, Valentine M, Etcubanas E, et al. A specific chromosomal abnormality in rhabdomyosarcoma. *Cytogenet Cell Genet* 1987;45:148 (published erratum appears in *Cytogenet Cell Genet* 1988;47:following 232).
104. Barr FG, Galili N, Holick J, et al. Rearrangement of the PAX3 paired box gene in the paediatric solid tumour alveolar rhabdomyosarcoma. *Nat Genet* 1993;3:113.
105. Davis RJ, D'Cruz CM, Lovell MA, et al. Fusion of PAX7 to FKHR by the variant t(1;13) (p36;q14) translocation in alveolar rhabdomyosarcoma. *Cancer Res* 1994;54:2869.
106. Sorensen PH, Lynch JC, Qualman SJ, et al. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the Children's Oncology Group. *J Clin Oncol* 2002;20(11):2672.
107. Williamson D, Missiaglia E, de Reyniès A, et al. Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma. *J Clin Oncol* 2010;28:2151.
108. Kelly KM, Womer RB, Sorensen PH, et al. Common and variant gene fusions predict distinct clinical phenotypes in rhabdomyosarcoma. *J Clin Oncol* 1997;15:1831.
109. Keller C, Arenkiel BR, Coffin CM, El-Bardeesy N, DePinho RA, Capocchi MR. Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: cooperativity of Ink4a/ARF and Trp53 loss of function. *Genes Dev* 2004;18:2614.
110. Lagutina I, Conway SJ, Sublett J, et al. Pax3-FKHR knock-in mice show developmental aberrations but do not develop tumors. *Mol Cell Biol* 2002;22:7204.
111. Ginsberg JP, Davis RJ, Benniselli JL, et al. Up-regulation of MET but not neural cell adhesion molecule expression by the PAX3-FKHR fusion protein in alveolar rhabdomyosarcoma. *Cancer Res* 1998;58:3542.
112. Ferracini R, Olivero M, Di Renzo MF, et al. Retrogenic expression of the MET proto-oncogene correlates with the invasive phenotype of human rhabdomyosarcomas. *Oncogene* 1996;12:1697.
113. Sharp R, Recio JA, Jhappan C, et al. Synergism between Ink4a/ARF inactivation and aberrant HGF/SF signaling in rhabdomyosarcomagenesis. *Nat Med* 2002;8:1276.
114. Tiffin N, Williams RD, Shipley J, et al. PAX7 expression in embryonal rhabdomyosarcoma suggests an origin in muscle satellite cells. *Br J Cancer* 2003;89:327.
115. Stratton MR, Fisher C, Gusterson BA, et al. Detection of point mutations in N-ras and K-ras genes of human embryonal rhabdomyosarcomas using oligonucleotide probes and the polymerase chain reaction. *Cancer Res* 1989;49:6324.
116. Merlino G, Helman LJ. Rhabdomyosarcoma—working out the pathways. *Oncogene* 1999;18:5340.
117. Taylor JG 6th, Cheuk AT, Tsang PS, et al. Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models. *J Clin Invest* 2009;119:3395.
118. Li FP, Fraumeni JF Jr. Rhabdomyosarcoma in children: epidemiologic study and identification of a familial cancer syndrome. *J Natl Cancer Inst* 1969;43:1365.
119. Li FP, Fraumeni JF Jr, Mulvihill JJ, et al. A cancer family syndrome in twenty-four kindreds. *Cancer Res* 1988;48:5358.
120. Nichols KE, Malkin D, Garber JE, et al. Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. *Cancer Epidemiol Biomarkers Prev* 2001;10:83.
121. Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. *Science* 1990;250:1233.
122. Srivastava S, Zou ZQ, Pirolo K, et al. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. *Nature* 1990;348:747.
123. Varley JM, Thorncroft M, McGown G, et al. A detailed study of loss of heterozygosity on chromosome 17 in tumours from Li-Fraumeni patients carrying a mutation to the TP53 gene. *Oncogene* 1997;14:865.
124. Olivier M, Eeles R, Hollstein M, et al. The IARC TP53 database: new online mutation analysis and recommendations to users. *Hum Mutat* 2002;19:607.
125. Bell DW, Varley JM, Szyllo TE, et al. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. *Science* 1999;286:2528.
126. Bougeard G, Limacher JM, Martin C, et al. Detection of 11 germline inactivating TP53 mutations and absence of TP63 and HCHK2 mutations in 17 French families with Li-Fraumeni or Li-Fraumeni-like syndrome. *J Med Genet* 2001;38:253.
127. Diller L, Sexsmith E, Gottlieb A, et al. Germline p53 mutations are frequently detected in young children with rhabdomyosarcoma. *J Clin Invest* 1995;95:1606.
128. McIntyre JF, Smith-Sorensen B, Friend SH, et al. Germline mutations of the p53 tumor suppressor gene in children with osteosarcoma. *J Clin Oncol* 1994;12:925.
129. Wagner J, Portwine C, Rabin K, et al. High frequency of germline p53 mutations in childhood adrenocortical cancer. *J Natl Cancer Inst* 1994;86:1707.
130. Varley JM, McGown G, Thorncroft M, et al. Are there low-penetrance TP53 alleles? Evidence from childhood adrenocortical tumors. *Am J Hum Genet* 1999;65:995.
131. Chompret A, Brugieres L, Ronsin M, et al. P53 germline mutations in childhood cancers and cancer risk for carrier individuals. *Brit J Cancer* 2001;82:1932.

132. Tinat J, Bougeard G, Baert-Desurmont S, et al. 2009 version of the Chompret criteria for Li-Fraumeni syndrome. *J Clin Oncol* 2009;27(26):e108.
133. Ribeiro RC, Sandrini F, Figueiredo B, et al. An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. *Proc Natl Acad Sci U S A* 2001;98:9330.
134. DiGiammarino EL, Lee AS, Cadwell C, et al. A novel mechanism of tumorigenesis involving pH-dependent destabilization of a mutant p53 tetramer. *Nat Struct Biol* 2002;9:12.
135. Olivier M, Goldgar DE, Sodha N, et al. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. *Cancer Res* 2003;63:6643.
136. Tabori U, Nanda S, Druker H, et al. Younger age of cancer initiation is associated with shorter telomere length in Li-Fraumeni syndrome. *Cancer Res* 2007;67:1415.
137. Marcel V, Palmero EI, Falagan-Lotsch P, et al. TP53 PIN 3 and MDM2 SNP309 polymorphisms as genetic modifiers in the Li-Fraumeni syndrome: impact on age at first diagnosis. *J Med Genet* 2009;46:766.
138. Shlien A, Tabori U, Marshall CR, et al. Excessive genomic DNA copy number variation in the Li-Fraumeni cancer predisposition syndrome. *Proc Natl Acad Sci U S A* 2008;105:11264.
139. Clericuzio CL, Johnson C. Screening for Wilms tumor in high-risk individuals. *Hematol Oncol Clin North Am* 1995;9:1253.
140. Mannens M, Hoovers JM, Redeker E, et al. Parental imprinting of human chromosome region 11p15.3-pter involved in the Beckwith-Wiedemann syndrome and various human neoplasia. *Eur J Hum Genet* 1994;2:3.
141. Engel JR, Smallwood A, Harper A, et al. Epigenetic-phenotype correlations in Beckwith-Wiedemann syndrome. *J Med Genet* 2000;37:921.
142. Henry I, Bonaiti-Pellie C, Chehensse V, et al. Uniparental paternal disomy in a genetic cancer-predisposing syndrome. *Nature* 1991;351:665.
143. Reik W, Brown KW, Schneid H, et al. Imprinting mutations in the Beckwith-Wiedemann syndrome suggested by altered imprinting pattern in the IGF2-H19 domain. *Hum Mol Genet* 1995;4:2379.
144. Li M, Squire J, Shuman C, et al. Imprinting status of 11p15 genes in Beckwith-Wiedemann syndrome patients with CDKN1C mutations. *Genomics* 2001;74:370.
145. Feinberg AP. Genomic imprinting and gene activation in cancer. *Nat Genet* 1993;4:110.
146. Gorlin RJ. Nevoid basal-cell carcinoma syndrome. *Medicine (Baltimore)* 1987;66:98.
147. Gailani MR, Stahle-Backdahl M, Leffell DJ, et al. The role of the human homologue of Drosophila patched in sporadic basal cell carcinomas. *Nat Genet* 1996;14:78.
148. Hahn H, Wicking C, Zaphiropoulos PG, et al. Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. *Cell* 1996;85:841.
149. Cowan R, Hoban P, Kelsey A, et al. The gene for the nevoid basal cell carcinoma syndrome acts as a tumour-suppressor gene in medulloblastoma. *Br J Cancer* 1997;76:141.
150. Taylor MD, Liu L, Raffel C, et al. Mutations in SUFU predispose to medulloblastoma. *Nat Genet* 2002;31:306.
151. Hahn H, Wojnowski L, Zimmer AM, et al. Rhabdomyosarcomas and radiation hypersensitivity in a mouse model of Gorlin syndrome. *Nat Med* 1998;4:619.
152. Zhan S, Helman LJ. Glimpsing the cause of rhabdomyosarcoma. *Nat Med* 1998;4:559.
153. Parham DM, Weeks DA, Beckwith JB. The clinicopathologic spectrum of putative extrarenal rhabdoid tumors. An analysis of 42 cases studied with immunohistochemistry or electron microscopy. *Am J Surg Pathol* 1994;18:1010.
154. Versteeg I, Sevenet N, Lange J, et al. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. *Nature* 1998;394:203.
155. Grand F, Kulkarni S, Chase A, et al. Frequent deletion of hSNF5/INI1, a component of the SWI/SNF complex, in chronic myeloid leukemia. *Cancer Res* 1999;59:3870.
156. Sevenet N, Sheridan E, Amram D, et al. Constitutional mutations of the hSNF5/INI1 gene predispose to a variety of cancers. *Am J Hum Genet* 1999;65:1342.
157. Biegel JA, Zhou JY, Rorke LB, et al. Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. *Cancer Res* 1999;59:74.
158. Field M, Shanley S, Kirk J. Inherited cancer susceptibility syndromes in pediatric practice. *J Paediatr Child Health* 2007;43:219.
159. Moore SW, Appfelstaedt J, Zaahl MG. Familial medullary carcinoma prevention, risk evaluation, and RET in children of families with MEN2A. *J Pediatr Surg* 2007;42:326.
160. Grosfeld FJ, Beemer FA, Lips CJ, et al. Parents' responses to disclosure of genetic test results of their children. *Am J Med Genet* 2000;94:316.
161. Michie S, Bobrow M, Marteau TM. Predictive genetic testing in children and adults: a study of emotional impact. *J Med Genet* 2001;38:519.
162. Lammens C, Bleiker Aaronson N, Aaronson N, et al. Attitudes towards pre-implantation genetic diagnosis for hereditary cancer. *Fam Cancer* 2009;8(4):457.
163. Malkin D. Prenatal diagnosis, preimplantation genetic diagnosis and cancer: was Hamlet wrong? *J Clin Oncol* 2009;27(27):4446.
164. Roth MT, Painter RB. Genetic discrimination in health insurance: an overview and analysis of the issues. *Nurs Clin North Am* 2000;35:731.

Chapter 30 – References

- Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. *Blood* 1994;84:1361.
- Swerdlow SH, Campo E, Harris NL, et al. *WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues*. Lyon, France: IARC, 2008.
- Burrows PD, Cooper MD. B cell development and differentiation. *Curr Opin Immunol* 1997;9:239.
- Jung D, Giallourakis C, Mostoslavsky R, Alt FW. Mechanism and control of V(D)J recombination at the immunoglobulin heavy chain locus. *Annu Rev Immunol* 2006;24:541–570.
- Rajewsky K. Clonal selection and learning in the antibody system. *Nature* 1996;381:751–758.
- Klein U, Dalla-Favera R. Germinal centres: role in B-cell physiology and malignancy. *Nat Rev Immunol* 2008;8:22–33.
- MacLennan IC. Germinal centers. *Annu Rev Immunol* 1994;12:117–139.
- Neuberger MS. Antibody diversification by somatic mutation: from Burnet onwards. *Immunol Cell Biol* 2008;86:124–132.
- Goossens T, Klein U, Küppers R. Frequent occurrence of deletions and duplications during somatic hypermutation: implications for oncogene translocations and heavy chain disease. *Proc Natl Acad Sci U S A* 1998;95:2463–2468.
- Küppers R, Zhao M, Hansmann ML, Rajewsky K. Tracing B cell development in human germinal centres by molecular analysis of single cells picked from histological sections. *EMBO J* 1993;12:4955.
- Klein U, Tu Y, Stolovitzky GA, et al. Transcriptional analysis of the B cell germinal center reaction. *Proc Natl Acad Sci U S A* 2003;100:2639.
- Cattoretti G, Chang CC, Cechova K, et al. BCL-6 protein is expressed in germinal-center B cells. *Blood* 1995;86:45.
- Chang CC, Ye BH, Chaganti RS, Dalla-Favera R. BCL-6, a POZ/zinc-finger protein, is a sequence-specific transcriptional repressor. *Proc Natl Acad Sci U S A* 1996;93:6947–6952.
- Basso K, Saito M, Sumazin P, et al. Integrated biochemical and computational approach identifies BCL6 direct target genes controlling multiple pathways in normal germinal center B cells. *Blood* 2010;115:975–984.
- Niu H, Cattoretti G, Dalla-Favera R. BCL6 controls the expression of the B7-1/CD80 costimulatory receptor in germinal center B cells. *J Exp Med* 2003;198:211–221.
- Ci W, Polo JM, Cerchetti L, et al. The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL. *Blood* 2009;113:5536–5548.
- Phan RT, Dalla-Favera R. The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells. *Nature* 2004;432:635–639.
- Phan RT, Saito M, Basso K, Niu H, Dalla-Favera R. BCL6 interacts with the transcription factor Miz-1 to suppress the cyclin-dependent kinase inhibitor p21 and cell cycle arrest in germinal center B cells. *Nat Immunol* 2005;6:1054–1060.
- Ranuncolo SM, Polo JM, Dierov J, et al. Bcl-6 mediates the germinal center B cell phenotype and lymphomagenesis through transcriptional repression of the DNA-damage sensor ATR. *Nat Immunol* 2007;8:705.
- Ranuncolo SM, Polo JM, Melnick A. BCL6 represses CHEK1 and suppresses DNA damage pathways in normal and malignant B-cells. *Blood Cells Mol Dis* 2008;41:95.
- Keller AD, Maniatis T. Identification and characterization of a novel repressor of beta-interferon gene expression. *Genes Dev* 1991;5:868.
- Turner CA Jr, Mack DH, Davis MM. Blimp-1, a novel zinc finger-containing protein that can drive the maturation of B lymphocytes into immunoglobulin-secreting cells. *Cell* 1994;77:297–306.
- Shaffer AL, Yu X, He Y, et al. BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. *Immunity* 2000;13:199–212.
- Tunyaplin C, Shaffer AL, Angelin-Duclos CD, et al. Direct repression of *prdm1* by Bcl-6 inhibits plasmacytic differentiation. *J Immunol* 2004;173:1158–1165.
- Saito M, Novak U, Piovani E, et al. BCL6 suppression of BCL2 via Miz1 and its disruption in diffuse large B cell lymphoma. *Proc Natl Acad Sci U S A* 2009;106:11294–11299.
- Liu YJ, Arpin C, de Bouteiller O, et al. Sequential triggering of apoptosis, somatic mutation and isotype switch during germinal center development. *Semin Immunol* 1996;8:169–177.
- Longerich S, Basu U, Alt F, Storb U. AID in somatic hypermutation and class switch recombination. *Curr Opin Immunol* 2006;18:164–174.
- Muramatsu M, Kinoshita K, Fagarasan S, et al. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. *Cell* 2000;102:553–563.
- Revy P, Muto T, Levy Y, et al. Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2). *Cell* 2000;102:565–575.
- Küppers R, Klein U, Hansmann ML, Rajewsky K. Cellular origin of human B-cell lymphomas. *N Engl J Med* 1999;341:1520.
- von Boehmer H, Aifantis I, Gounari F, et al. Thymic selection revisited: how essential is it? *Immunol Rev* 2003;219:62–78.
- Küppers R, Dalla-Favera R. Mechanisms of chromosomal translocations in B cell lymphomas. *Oncogene* 2001;20:5580–5594.
- Tsujimoto Y, Gorham J, Cossman J, Jaffe E, Croce CM. The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining. *Science* 1985;229:1390–1393.
- Tsujimoto Y, Louie E, Bashir MM, Croce CM. The reciprocal partners of both the t(14; 18) and the t(11; 14) translocations involved in B-cell neoplasms are rearranged by the same mechanism. *Oncogene* 1988;2:347–351.
- Ramiro AR, Jankovic M, Eisenreich T, et al. AID is required for c-myc/IgH chromosome translocations in vivo. *Cell* 2004;118:431–438.
- Robbiani DF, Jankovic M, Eisenreich T, et al. AID is required for the chromosomal breaks in c-myc that lead to c-myc/IgH translocations. *Cell* 2008;135:1028–1038.
- Pasqualucci L, Bhagat G, Jankovic M, et al. AID is required for germinal center-derived lymphomagenesis. *Nat Genet* 2008;40:108–112.
- Takizawa M, Tolarová H, Li Z, et al. AID expression levels determine the extent of cMyc oncogenic translocations and the incidence of B cell tumor development. *J Exp Med* 2008;205:1949–1957.
- Akasaka H, Akasaka T, Kurata M, et al. Molecular anatomy of BCL6 translocations revealed by long-distance polymerase chain reaction-based assays. *Cancer Res* 2000;60:2335–2341.
- Chen W, Iida S, Louie DC, Dalla-Favera R, Chaganti RS. Heterologous promoters fused to BCL6 by chromosomal translocations affecting band 3q27 cause its deregulated expression during B-cell differentiation. *Blood* 1998;91:603.
- Ye BH, Lista F, Lo Coco F, et al. Alterations of a zinc finger-encoding gene, BCL-6, in diffuse large-cell lymphoma. *Science* 1993;262:747–750.

42. Ye BH, Rao PH, Chaganti RS, Dalla-Favera R. Cloning of bcl-6, the locus involved in chromosome translocations affecting band 3q27 in B-cell lymphoma. *Cancer Res* 1993;53:2732–2735.
43. Yoshida S, Kaneita Y, Aoki Y, et al. Identification of heterologous translocation partner genes fused to the BCL6 gene in diffuse large B-cell lymphomas: 5'-RACE and LA-PCR analyses of biopsy samples. *Oncogene* 1999;18:7994–7999.
44. Baron BW, Nucifora G, McCabe N, et al. Identification of the gene associated with the recurring chromosomal translocations t(3;14)(q27;q32) and t(3;22)(q27;q11) in B-cell lymphomas. *Proc Natl Acad Sci U S A* 1993;90:5262–5266.
45. Kerckaert JP, Deweindt C, Tilly H, et al. LAZ3, a novel zinc-finger encoding gene, is disrupted by recurring chromosome 3q27 translocations in human lymphomas. *Nat Genet* 1993;5:66–70.
46. Miki T, Kawamata N, Arai A, et al. Molecular cloning of the breakpoint for 3q27 translocation in B-cell lymphomas and leukemias. *Blood* 1994;83:217–222.
47. Pasqualucci L, Neumeister P, Goossens T, et al. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. *Nature* 2001;412:341–346.
48. Pasqualucci L, Migliazza A, Fracchiolla N, et al. BCL-6 mutations in normal germinal center B cells: evidence of somatic hypermutation acting outside Ig loci. *Proc Natl Acad Sci U S A* 1998;95:11816–11821.
49. Shen HM, Peters A, Baron B, Zhu X, Storb U. Mutation of BCL-6 gene in normal B cells by the process of somatic hypermutation of Ig genes. *Science* 1998;280:1750–1752.
50. Müschen M, Re D, Jungnickel B, Diehl V, Rajewsky K, Küppers R. Somatic mutation of the CD95 gene in human B cells as a side-effect of the germinal center reaction. *J Exp Med* 2000;192:1833.
51. Gordon MS, Kanegai CM, Doerr JR, Wall R. Somatic hypermutation of the B cell receptor genes B29 (Igbeta, CD79b) and mb1 (Igalpha, CD79a). *Proc Natl Acad Sci U S A* 2003;100:4126–4131.
52. Peng HZ, Du MQ, Koulis A, et al. Nonimmunoglobulin gene hypermutation in germinal center B cells. *Blood* 1993;93:2167–2172.
53. Vakiani E, Basso K, Klein U, et al. Genetic and phenotypic analysis of B-cell post-transplant lymphoproliferative disorders provides insights into disease biology. *Hematol Oncol* 2008;26:199–211.
54. Montesinos-Rongen M, Van Roost D, Schaller C, Wiestler OD, Decker M. Primary diffuse large B-cell lymphomas of the central nervous system are targeted by aberrant somatic hypermutation. *Blood* 2004;103:1869–1875.
55. Gaidano G, Pasqualucci L, Capello D, et al. Aberrant somatic hypermutation in multiple subtypes of AIDS-associated non-Hodgkin lymphoma. *Blood* 2003;102:1833–1841.
56. Deutsch AJ, Agelsreiter A, Staber PB, et al. MALT lymphoma and extranodal diffuse large B-cell lymphoma are targeted by aberrant somatic hypermutation. *Blood* 2007;109:3500–3504.
57. Cerri M, Capello D, Muti G, et al. Aberrant somatic hypermutation in post-transplant lymphoproliferative disorders. *Br J Haematol* 2004;127:362–364.
58. Storb U, Peters A, Klotz E, et al. Cis-acting sequences that affect somatic hypermutation of Ig genes. *Immunol Rev* 1998;162:153–160.
59. Houldsworth J, Mathew S, Rao PH, et al. REL proto-oncogene is frequently amplified in extranodal diffuse large cell lymphoma. *Blood* 1996;87:25.
60. Houldsworth J, Olshen AB, Cattoretto G, et al. Relationship between REL amplification, REL function, and clinical and biologic features in diffuse large B-cell lymphomas. *Blood* 2004;103:1862–1868.
61. Rao PH, Houldsworth J, Dyomina K, et al. Chromosomal and gene amplification in diffuse large B-cell lymphoma. *Blood* 1998;92:234–240.
62. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. *N Engl J Med* 2002;346:1937–1947.
63. Green MR, Monti S, Rodig SJ, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. *Blood* 2010;116:3268.
64. Bhatia K, Huppi K, Spangler G, et al. Point mutations in the c-Myc transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas. *Nat Genet* 1993;5:56–61.
65. Bhatia K, Spangler G, Gaidano G, et al. Mutations in the coding region of c-myc occur frequently in acquired immunodeficiency syndrome-associated lymphomas. *Blood* 1994;84:883–888.
66. Tanaka S, Louie DC, Kant JA, Reed JC. Frequent incidence of somatic mutations in translocated BCL2 oncogenes of non-Hodgkin's lymphomas. *Blood* 1992;79:229–237.
67. Compagno M, Lim WK, Grunn A, et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. *Nature* 2009;459:717–721.
68. Lenz G, Davis RE, Ngo VN, et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. *Science* 2008;319:1676–1679.
69. Neri A, Knowles DM, Greco A, McCormick F, Dalla-Favera R. Analysis of RAS oncogene mutations in human lymphoid malignancies. *Proc Natl Acad Sci U S A* 1988;85:9268–9272.
70. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. *Science* 1991;253:49.
71. Ballerini P, Gaidano G, Gong JZ, et al. Multiple genetic lesions in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. *Blood* 1993;81:166–176.
72. Gaidano G, Ballerini P, Gong JZ, et al. p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. *Proc Natl Acad Sci U S A* 1991;88:5413–5417.
73. Lo Coco F, Gaidano G, Louie DC, et al. p53 mutations are associated with histologic transformation of follicular lymphoma. *Blood* 1993;82:2289–2295.
74. Gaidano G, Hauptschein RS, Parsa NZ, et al. Deletions involving two distinct regions of 6q in B-cell non-Hodgkin lymphoma. *Blood* 1992;80:1781–1787.
75. Offit K, Wong G, Filippa DA, Tao Y, Chaganti RS. Cytogenetic analysis of 434 consecutively ascertained specimens of non-Hodgkin's lymphoma: clinical correlations. *Blood* 1991;77:1508–1515.
76. Mandelbaum J, Bhagat G, Tang H, et al. BLIMP1 is a tumor suppressor gene frequently disrupted in activated B-cell like diffuse large B-cell lymphoma. *Cancer Cell* 2010;18(6):568.
77. Pasqualucci L, Compagno M, Houldsworth J, et al. Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma. *J Exp Med* 2006;203:311–317.
78. Tam W, Gomez M, Chadburn A, et al. Mutational analysis of PRDM1 indicates a tumor-suppressor role in diffuse large B-cell lymphomas. *Blood* 2006;107:4090–4100.
79. Kato M, Sanada M, Kato I, et al. Frequent inactivation of A20 in B-cell lymphomas. *Nature* 2009;459:712–716.
80. Novak U, Rinaldi A, Kwee I, et al. The NF- κ B negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas. *Blood* 2009;113:4918–4921.
81. Schmitz R, Hansmann ML, Bohle V, et al. TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma. *J Exp Med* 2009;206:981.
82. Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. *N Engl J Med* 2000;343:1910–1916.

83. Dohner H, Stilgenbauer S, Dohner K, Bentz M, Lichter P. Chromosome aberrations in B-cell chronic lymphocytic leukemia: reassessment based on molecular cytogenetic analysis. *J Mol Med* 1999;77:266–281.
84. Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. *Proc Natl Acad Sci U S A* 2002;99:15524–15529.
85. Kalachikov S, Migliazza A, Cayanis E, et al. Cloning and gene mapping of the chromosome 13q14 region deleted in chronic lymphocytic leukemia. *Genomics* 1997;42:369–377.
86. Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T. Identification of novel genes coding for small expressed RNAs. *Science* 2001;294:853–858.
87. Migliazza A, Bosch F, Komatsu H, et al. Nucleotide sequence, transcription map, and mutation analysis of the 13q14 chromosomal region deleted in B-cell chronic lymphocytic leukemia. *Blood* 2001;97:2098–2104.
88. Klein U, Lia M, Crespo M, et al. The DLEU2/miR-15-a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. *Cancer Cell* 2010;17:28–40.
89. Jares P, Colomer D, Campo E. Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. *Nat Rev Cancer* 2007;7:750–762.
90. Thome M. CARMA1, BCL-10 and MALT1 in lymphocyte development and activation. *Nat Rev Immunol* 2004;4:348.
91. Pasqualucci L. *Blood* 2010.
92. zur Hausen H, Schulte-Holthausen H, Klein G, et al. EBV DNA in biopsies of Burkitt tumours and anaplastic carcinomas of the nasopharynx. *Nature* 1970;228:1056–1058.
93. Magrath IT. African Burkitt's lymphoma. History, biology, clinical features, and treatment. *Am J Pediatr Hematol Oncol* 1991;13:222–246.
94. Neri A, Barriga F, Inghirami G, et al. Epstein-Barr virus infection precedes clonal expansion in Burkitt's and acquired immunodeficiency syndrome-associated lymphoma. *Blood* 1991;77:1092–1095.
95. Carbone A, Ghoghini A, Gaidano G, et al. Expression status of BCL-6 and syndecan-1 identifies distinct histogenetic subtypes of Hodgkin's disease. *Blood* 1998;92:2220–2228.
96. Hamilton-Dutoit SJ, Pallesen G. A survey of Epstein-Barr virus gene expression in sporadic non-Hodgkin's lymphomas. Detection of Epstein-Barr virus in a subset of peripheral T-cell lymphomas. *Am J Pathol* 1992;140:1315–1325.
97. Horenstein MG, Nador RG, Chadburn A, et al. Epstein-Barr virus latent gene expression in primary effusion lymphomas containing Kaposi's sarcoma-associated herpesvirus/human herpesvirus-8. *Blood* 1997;90:1186–1191.
98. Cingolani A, Gastaldi R, Fassone L, et al. Epstein-Barr virus infection is predictive of CNS involvement in systemic AIDS-related non-Hodgkin's lymphomas. *J Clin Oncol* 2000;18:3325–3330.
99. Fassone L, Bhatia K, Gotierrez M, et al. Molecular profile of Epstein-Barr virus infection in HHV-8-positive primary effusion lymphoma. *Leukemia* 2000;14:271–277.
100. Larocca LM, Capello D, Rinelli A, et al. The molecular and phenotypic profile of primary central nervous system lymphoma identifies distinct categories of the disease and is consistent with histogenetic derivation from germinal center-related B cells. *Blood* 1998;92:1011–1019.
101. Kieff E, Leibowitz D. Oncogenesis by herpesvirus. In: Weinberg RA, ed. *Oncogenes and the Molecular Origin of Cancer*. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1989:259.
102. Raab-Traub N, Flynn K. The structure of the termini of the Epstein-Barr virus as a marker of clonal cellular proliferation. *Cell* 1986;47:883–889.
103. Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. *Science* 1994;266:1865–1869.
104. Soulier J, Grollet L, Oksenhendler E, et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castlemann's disease. *Blood* 1995;86:1276–1280.
105. Carbone A, Gaidano G. HHV-8-positive body-cavity-based lymphoma: a novel lymphoma entity. *Br J Haematol* 1997;97:515–522.
106. Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. *N Engl J Med* 1995;332:1186–1191.
107. Gaidano G, Pastore C, Ghoghini A, et al. Distribution of human herpesvirus-8 sequences throughout the spectrum of AIDS-related neoplasia. *AIDS* 1996;10:941–949.
108. Moore PS, Gao SJ, Dominguez G, et al. Primary characterization of a herpesvirus agent associated with Kaposi's sarcoma. *J Virol* 1996;70:549–558.
109. Poesz BJ, Ruscetti FW, Gazdar AF, et al. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. *Proc Natl Acad Sci U S A* 1980;77:7415–7419.
110. Ferreira OC Jr, Planellas V, Rosenblatt JD. Human T-cell leukemia viruses: epidemiology, biology, and pathogenesis. *Blood Rev* 1997;11:91–104.
111. Uchiyama T. Human T cell leukemia virus type I (HTLV-I) and human diseases. *Annu Rev Immunol* 1997;15:15.
112. Yoshida M. Howard Temin Memorial Lectureship. Molecular biology of HTLV-1: deregulation of host cell gene expression and cell cycle. *Leukemia* 1997;11(Suppl 3):1–2.
113. Cross SL, Feinberg MB, Wolf JB, et al. Regulation of the human interleukin-2 receptor alpha chain promoter: activation of a nonfunctional promoter by the transactivator gene of HTLV-I. *Cell* 1987;49:47–56.
114. Fujii M, Sassone-Corsi P, Verma IM. c-fos promoter transactivation by the tax1 protein of human T-cell leukemia virus type I. *Proc Natl Acad Sci U S A* 1988;85:8526–8530.
115. Inoue J, Seiki M, Taniguchi T, Tsuru S, Yoshida M. Induction of interleukin 2 receptor gene expression by p40x encoded by human T-cell leukemia virus type 1. *Embo J* 1986;5:2883–2888.
116. Nimer SD, Coles LS, Katsikeros R, et al. Activation of the GM-CSF promoter by HTLV-I and -II tax proteins. *Oncogene* 1989;4:671–676.
117. Wano Y, Feinberg M, Hosking JB, Bogerd H, Greene WC. Stable expression of the tax gene of type I human T-cell leukemia virus in human T cells activates specific cellular genes involved in growth. *Proc Natl Acad Sci U S A* 1988;85:9733–9737.
118. Jeang KT, Widen SG, Semmes OJt, Wilson SH. HTLV-I trans-activator protein, tax, is a trans-repressor of the human beta-polymerase gene. *Science* 1990;247:1082–1084.
119. Jin DY, Spencer F, Jeang KT. Human T cell leukemia virus type 1 oncoprotein Tax targets the human mitotic checkpoint protein MAD1. *Cell* 1998;93:81–91.
120. Marcucci F, Mele A. Hepatitis viruses and non-Hodgkin lymphoma: epidemiology, mechanisms of tumorigenesis and therapeutic opportunities. *Blood* 2010.
121. Wotherspoon AC, Ortiz-Hidalgo C, Falzon MR, Isaacson PG. *Helicobacter pylori*-associated gastritis and primary B-cell gastric lymphoma. *Lancet* 1991;338:1175.
122. Dogliani C, Wotherspoon AC, Moschini A, de Boni M, Isaacson PG. High incidence of primary gastric lymphoma in northeastern Italy. *Lancet* 1992;339:834–835.
123. Parsonnet J, Hansen S, Rodriguez L, et al. *Helicobacter pylori* infection and gastric lymphoma. *N Engl J Med* 1994;330:1267–1271.
124. Wotherspoon AC, Dogliani C, Diss TC, et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of *Helicobacter pylori*. *Lancet* 1993;342:575–577.

125. Liu H, Ruskon-Fourmestraux A, Lavergne-Slove A, et al. Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to *Helicobacter pylori* eradication therapy. *Lancet* 2001;357:39–40.
126. Ferreri AJ, Dolcetti R, Magnino S, Doglioni C, Ponzoni M. Chlamydial infection: the link with ocular adnexal lymphomas. *Nat Rev Clin Oncol* 2009;6:658–669.
127. Stefanovic A, Lossos IS. Extranodal marginal zone lymphoma of the ocular adnexa. *Blood* 2009;114:501–510.
128. Ferreri AJ, Ponzoni M, Guidoboni M, et al. Regression of ocular adnexal lymphoma after Chlamydia psittaci-eradicating antibiotic therapy. *J Clin Oncol* 2005;23:5067–5073.
129. Tsujimoto Y, Jaffe E, Cossman J, et al. Clustering of breakpoints on chromosome 11 in human B-cell neoplasms with the t(11;14) chromosome translocation. *Nature* 1985;315:340–343.
130. Tsujimoto Y, Yunis J, Onorato-Showe L, et al. Molecular cloning of the chromosomal breakpoint of B-cell lymphomas and leukemias with the t(11;14) chromosome translocation. *Science* 1984;224:1403–1406.
131. Erikson J, Finan J, Tsujimoto Y, Nowell PC, Croce CM. The chromosome 14 breakpoint in neoplastic B cells with the t(11;14) translocation involves the immunoglobulin heavy chain locus. *Proc Natl Acad Sci U S A* 1984;81:4144.
132. Motokura T, Bloom T, Kim HG, et al. A novel cyclin encoded by a bcl1-linked candidate oncogene. *Nature* 1991;350:512–515.
133. Rosenberg CL, Wong E, Petty EM, et al. PRAD1, a candidate BCL1 oncogene: mapping and expression in centrocytic lymphoma. *Proc Natl Acad Sci U S A* 1991;88:9638–9642.
134. Withers DA, Harvey RC, Faust JB, et al. Characterization of a candidate bcl-1 gene. *Mol Cell Biol* 1991;11:4846–4853.
135. Seto M, Yamamoto K, Iida S, et al. Gene rearrangement and overexpression of PRAD1 in lymphoid malignancy with t(11;14)(q13;q32) translocation. *Oncogene* 1992;7:1401–1406.
136. Komatsu H, Iida S, Yamamoto K, et al. A variant chromosome translocation at 11q13 identifying PRAD1/cyclin D1 as the BCL-1 gene. *Blood* 1994;84:1226–1231.
137. Wiestner A, Tehrani M, Chiorazzi M, et al. Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival. *Blood* 2007;109:4599–4606.
138. Bea S, Salaverria I, Armengol L, et al. Uniparental disomies, homozygous deletions, amplifications, and target genes in mantle cell lymphoma revealed by integrative high-resolution whole-genome profiling. *Blood* 2009;113:3059–3069.
139. Jiang W, Kahn SM, Zhou P, et al. Overexpression of cyclin D1 in rat fibroblasts causes abnormalities in growth control, cell cycle progression and gene expression. *Oncogene* 1993;8:3447–3457.
140. Bodrug SE, Warner BJ, Bath ML, et al. Cyclin D1 transgene impedes lymphocyte maturation and collaborates in lymphomagenesis with the myc gene. *Embo J* 1994;13:2124–2130.
141. Lovec H, Grzeschiczek A, Kowalski MB, Moroy T. Cyclin D1/bcl-1 cooperates with myc genes in the generation of B-cell lymphoma in transgenic mice. *Embo J* 1994;13:3487.
142. Schaffner C, Idler I, Stilgenbauer S, Dohner H, Lichter P. Mantle cell lymphoma is characterized by inactivation of the ATM gene. *Proc Natl Acad Sci U S A* 2000;97:2773–2778.
143. Louie DC, Offit K, Jaslow R, et al. p53 overexpression as a marker of poor prognosis in mantle cell lymphomas with t(11;14)(q13;q32). *Blood* 1995;86:2892–2899.
144. Pinyol M, Hernandez L, Cazorla M, et al. Deletions and loss of expression of p16INK4a and p21Waf1 genes are associated with aggressive variants of mantle cell lymphomas. *Blood* 1997;89:272–280.
145. Bea S, Tort F, Pinyol M, et al. BMI-1 gene amplification and overexpression in hematological malignancies occur mainly in mantle cell lymphomas. *Cancer Res* 2001;61:2409–2412.
146. Chapman CJ, Mockridge CI, Rowe M, Rickinson AB, Stevenson FK. Analysis of VH genes used by neoplastic B cells in endemic Burkitt's lymphoma shows somatic hypermutation and intraclonal heterogeneity. *Blood* 1995;85:2176–2181.
147. Chapman CJ, Zhou JX, Gregory C, Rickinson AB, Stevenson FK. VH and VL gene analysis in sporadic Burkitt's lymphoma shows somatic hypermutation, intraclonal heterogeneity, and a role for antigen selection. *Blood* 1996;88:3562–3568.
148. Jain R, Roncella S, Hashimoto S, et al. A potential role for antigen selection in the clonal evolution of Burkitt's lymphoma. *J Immunol* 1994;153:45–52.
149. Tamaru J, Hummel M, Marafioti T, et al. Burkitt's lymphomas express VH genes with a moderate number of antigen-selected somatic mutations. *Am J Pathol* 1995;147:1398–1407.
150. Dave SS, Fu K, Wright GW, et al. Molecular diagnosis of Burkitt's lymphoma. *N Engl J Med* 2006;354:2431–2442.
151. Hummel M, Bentink S, Berger H, et al. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. *N Engl J Med* 2006;354:2419.
152. Dalla-Favera R, Bregni M, Erikson J, et al. Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. *Proc Natl Acad Sci U S A* 1982;79:7824–7827.
153. Dalla-Favera R, Martinotti S, Gallo RC, Erikson J, Croce CM. Translocation and rearrangements of the c-myc oncogene locus in human undifferentiated B-cell lymphomas. *Science* 1983;219:963–967.
154. Dalla-Favera R. Chromosomal translocations involving the c-myc oncogene in lymphoid neoplasia. In: Kirsch IR, ed. *The Causes and Consequences of Chromosomal Aberrations*. Boca Raton: CRC Press, 1993:312.
155. Taub R, Kirsch I, Morton C, et al. Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. *Proc Natl Acad Sci U S A* 1982;79:7837–7841.
156. Davis M, Malcolm S, Rabbitts TH. Chromosome translocation can occur on either side of the c-myc oncogene in Burkitt lymphoma cells. *Nature* 1984;308:286–288.
157. Neri A, Barriga F, Knowles DM, Magrath IT, Dalla-Favera R. Different regions of the immunoglobulin heavy-chain locus are involved in chromosomal translocations in distinct pathogenetic forms of Burkitt lymphoma. *Proc Natl Acad Sci U S A* 1988;85:2748–2752.
158. Pelicci PG, Knowles DM II, Magrath I, Dalla-Favera R. Chromosomal breakpoints and structural alterations of the c-myc locus differ in endemic and sporadic forms of Burkitt lymphoma. *Proc Natl Acad Sci U S A* 1986; 83:2984–2988.
159. ar-Rushdi A, Nishikura K, Erikson J, et al. Differential expression of the translocated and the untranslocated c-myc oncogene in Burkitt lymphoma. *Science* 1983; 222:390–393.
160. Hayday AC, Gillies SD, Saito H, et al. Activation of a translocated human c-myc gene by an enhancer in the immunoglobulin heavy-chain locus. *Nature* 1984;307:334.
161. Rabbitts TH, Forster A, Baer R, Hamlyn PH. Transcription enhancer identified near the human C mu immunoglobulin heavy chain gene is unavailable to the translocated c-myc gene in a Burkitt lymphoma. *Nature* 1983;306:806–809.
162. Cesarman E, Dalla-Favera R, Bentley D, Groudine M. Mutations in the first exon are associated with altered transcription of c-myc in Burkitt lymphoma. *Science* 1987;238:1272–1275.

163. Gu W, Bhatia K, Magrath IT, Dang CV, Dalla-Favera R. Binding and suppression of the Myc transcriptional activation domain by p107. *Science* 1994;264:251–254.
164. Gregory MA, Hann SR. c-Myc proteolysis by the ubiquitin-proteasome pathway: stabilization of c-Myc in Burkitt's lymphoma cells. *Mol Cell Biol* 2000;20:2423–2435.
165. Hemann MT, Bric A, Teruya-Feldstein J, et al. Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. *Nature* 2005;436:807–811.
166. Adhikary S, Eilers M. Transcriptional regulation and transformation by Myc proteins. *Nat Rev Mol Cell Biol* 2005;6:635–645.
167. Meyer N, Penn LZ. Reflecting on 25 years with MYC. *Nat Rev Cancer* 2008;8:976–990.
168. Dominguez-Sola D, Ying CY, Grandori C, et al. Non-transcriptional control of DNA replication by c-Myc. *Nature* 2007;448:445–451.
169. Eilers M, Eisenman RN. Myc's broad reach. *Genes Dev* 2008;22:2755–2766.
170. Amati B, Brooks MW, Levy N, et al. Oncogenic activity of the c-Myc protein requires dimerization with Max. *Cell* 1993;72:233–245.
171. Amati B, Dalton S, Brooks MW, et al. Transcriptional activation by the human c-Myc oncoprotein in yeast requires interaction with Max. *Nature* 1992;359:423–426.
172. Blackwood EM, Eisenman RN. Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. *Science* 1991;251:1211.
173. Blackwood EM, Luscher B, Eisenman RN. Myc and Max associate in vivo. *Genes Dev* 1992;6:71–80.
174. Gu W, Cechova K, Tassi V, Dalla-Favera R. Opposite regulation of gene transcription and cell proliferation by c-Myc and Max. *Proc Natl Acad Sci U S A* 1993;90:2935–2939.
175. Kretzner L, Blackwood EM, Eisenman RN. Myc and Max proteins possess distinct transcriptional activities. *Nature* 1992;359:426–429.
176. Grandori C, Cowley SM, James LP, Eisenman RN. The Myc/Max/Mad network and the transcriptional control of cell behavior. *Annu Rev Cell Dev Biol* 2000;16:653–699.
177. Dang CV, O'Donnell KA, Zeller KL, et al. The c-Myc target gene network. *Semin Cancer Biol* 2006;16:253–264.
178. Felsher DW, Bishop JM. Transient excess of MYC activity can elicit genomic instability and tumorigenesis. *Proc Natl Acad Sci U S A* 1999;96:3940–3944.
179. Adams JM, Harris AW, Pinkert CA, et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. *Nature* 1985;318:533–538.
180. Kovalchuk AL, Qi CF, Torrey TA, et al. Burkitt lymphoma in the mouse. *J Exp Med* 2000;192:1183–1190.
181. Martinez-Delgado B, Robledo M, Arranz E, et al. Hypermethylation of p15/ink4b/MTS2 gene is differentially implicated among non-Hodgkin's lymphomas. *Leukemia* 1998;12:937–941.
182. Lombardi L, Newcomb EW, Dalla-Favera R. Pathogenesis of Burkitt lymphoma: expression of an activated c-myc oncogene causes the tumorigenic conversion of EBV-infected human B lymphoblasts. *Cell* 1987;49:161–170.
183. Prevot S, Hamilton-Dutoit S, Audouin J, et al. Analysis of African Burkitt's and high-grade B cell non-Burkitt's lymphoma for Epstein-Barr virus genomes using in situ hybridization. *Br J Haematol* 1992;80:27–32.
184. Bornkamm GW. Epstein-Barr virus and its role in the pathogenesis of Burkitt's lymphoma: an unresolved issue. *Semin Cancer Biol* 2009;19:351.
185. Thorley-Lawson DA, Allday MJ. The curious case of the tumour virus: 50 years of Burkitt's lymphoma. *Nat Rev Microbiol* 2008;6:913–924.
186. Bakhshi A, Jensen JP, Goldman P, et al. Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18. *Cell* 1985;41:899–906.
187. Cleary ML, Sklar J. Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18. *Proc Natl Acad Sci U S A* 1985;82:7439–7443.
188. Cleary ML, Smith SD, Sklar J. Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation. *Cell* 1986;47:19–28.
189. Ott G, Katzenberger T, Lohr A, et al. Cytomorphologic, immunohistochemical, and cytogenetic profiles of follicular lymphoma: 2 types of follicular lymphoma grade 3. *Blood* 2002;99:3806–3812.
190. Tsujimoto Y, Finger LR, Yunis J, Nowell PC, Croce CM. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. *Science* 1984;226:1097–1099.
191. Cleary ML, Galili N, Sklar J. Detection of a second t(14;18) breakpoint cluster region in human follicular lymphomas. *J Exp Med* 1986;164:315–320.
192. Graninger WB, Seto M, Boutain B, Goldman P, Korsmeyer SJ. Expression of Bcl-2 and Bcl-2-Ig fusion transcripts in normal and neoplastic cells. *J Clin Invest* 1987;80:1512–1515.
193. Ngan BY, Chen-Levy Z, Weiss LM, Warnke RA, Cleary ML. Expression in non-Hodgkin's lymphoma of the bcl-2 protein associated with the t(14;18) chromosomal translocation. *N Engl J Med* 1988;318:1638.
194. Petrovic AS, Young RL, Hilgarth B, et al. The Ig heavy chain 3' end confers a posttranscriptional processing advantage to Bcl-2-IgH fusion RNA in t(14;18) lymphoma. *Blood* 1998;91:3952–3961.
195. Buchonnet G, Jardin F, Jean N, et al. Distribution of BCL2 breakpoints in follicular lymphoma and correlation with clinical features: specific subtypes or same disease? *Leukemia* 2002;16:1852–1856.
196. Hockenbery D, Nunez G, Millman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. *Nature* 1990;348:334–336.
197. Korsmeyer SJ. Bcl-2 initiates a new category of oncogenes: regulators of cell death. *Blood* 1992;80:879–886.
198. Nunez G, Seto M, Seremetis S, et al. Growth- and tumor-promoting effects of deregulated BCL2 in human B-lymphoblastoid cells. *Proc Natl Acad Sci U S A* 1989;86:4589–4593.
199. Vaux DL, Cory S, Adams JM. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. *Nature* 1988;335:440–442.
200. Cleary ML, Meeker TC, Levy S, et al. Clustering of extensive somatic mutations in the variable region of an immunoglobulin heavy chain gene from a human B cell lymphoma. *Cell* 1986;44:97–106.
201. Bahler DW, Levy R. Clonal evolution of a follicular lymphoma: evidence for antigen selection. *Proc Natl Acad Sci U S A* 1992;89:6770–6774.
202. Zelenetz AD, Chen TT, Levy R. Clonal expansion in follicular lymphoma occurs subsequent to antigenic selection. *J Exp Med* 1992;176:1137–1148.
203. Morin RD, Johnson NA, Severson TM, et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. *Nat Genet* 2010;42:181.
204. Bastard C, Deweindt C, Kerckaert JP, et al. LAZ3 rearrangements in non-Hodgkin's lymphoma: correlation with histology, immunophenotype, karyotype, and clinical outcome in 217 patients. *Blood* 1994;83:2423–2427.
205. Lo Coco F, Ye BH, Lista F, et al. Rearrangements of the BCL6 gene in diffuse large cell non-Hodgkin's lymphoma. *Blood* 1994;83:1757–1759.
206. Otsuki T, Yano T, Clark HM, et al. Analysis of LAZ3 (BCL-6) status in B-cell non-Hodgkin's lymphomas: results of rearrangement and gene expression studies and a mutational analysis of coding region sequences. *Blood* 1995;85:2877–2884.

207. Akasaka T, Lossos IS, Levy R. BCL6 gene translocation in follicular lymphoma: a harbinger of eventual transformation to diffuse aggressive lymphoma. *Blood* 2003;102:1443–1448.
208. Ichikawa A, Hotta T, Takagi N, et al. Mutations of p53 gene and their relation to disease progression in B-cell lymphoma. *Blood* 1992;79:2701–2707.
209. O'Shea D, O'Riain C, Taylor C, et al. The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival. *Blood* 2008;112:3126–3129.
210. Sander CA, Yano T, Clark HM, et al. p53 mutation is associated with progression in follicular lymphomas. *Blood* 1993;82:1994–2004.
211. Elenitoba-Johnson KS, Gascoyne RD, Lim MS, et al. Homozygous deletions at chromosome 9p21 involving p16 and p15 are associated with histologic progression in follicle center lymphoma. *Blood* 1998;91:4677–4685.
212. Yano T, Jaffe ES, Longo DL, Raffeld M. MYC rearrangements in histologically progressed follicular lymphomas. *Blood* 1992;80:758.
213. Martinez-Climent JA, Alizadeh AA, Segraves R, et al. Transformation of follicular lymphoma to diffuse large cell lymphoma is associated with a heterogeneous set of DNA copy number and gene expression alterations. *Blood* 2003;101:3109–3117.
214. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. *Blood* 1997;89:3909–3918.
215. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. *Nature* 2000;403:503–511.
216. Wright G, Tan B, Rosenwald A, et al. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. *Proc Natl Acad Sci U S A* 2003;100:9991–9996.
217. Savage KJ, Monti S, Kutok JL, et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. *Blood* 2003;102:3871–3879.
218. Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. *J Exp Med* 2003;198:851–862.
219. Choi WW, Weisenburger DD, Greiner TC, et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. *Clin Cancer Res* 2009;15:5494–5502.
220. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. *Blood* 2004;103:275–282.
221. Monti S, Savage KJ, Kutok JL, et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. *Blood* 2005;105:1851–1861.
222. Dalla-Favera R, Pasqualucci L. Molecular genetics of lymphomas. In: Mauch PM, Armitage JO, Coiffier B, Dalla-Favera R, Harris NL, eds. *Non-Hodgkin's Lymphoma*. Philadelphia, PA: Lippincott Williams & Wilkins, 2010:825.
223. Lenz G, Staudt LM. Aggressive lymphomas. *N Engl J Med* 2010;362:1417–1429.
224. Lenz G, Wright GW, Emre NC, et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. *Proc Natl Acad Sci U S A* 2008;105:13520–13525.
225. Iqbal J, Campo J, Delabie RD, et al. BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma. *Am J Pathol* 2004;165:159–166.
226. Kawasaki C, Ohshim K, Suzumiya J, et al. Rearrangements of bcl-1, bcl-2, bcl-6, and c-myc in diffuse large B-cell lymphomas. *Leuk Lymphoma* 2001;42:1099–1106.
227. Ladanyi M, Offit K, Jhanwar SC, Filippa DA, Chaganti RS. MYC rearrangement and translocations involving band 8q24 in diffuse large cell lymphomas. *Blood* 1991;77:1057–1063.
228. Iqbal J, Greiner TC, Patel K, et al. Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma. *Leukemia* 2007;21:2332–2343.
229. Pasqualucci L, Migliazza A, Fracchiolla N, et al. Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma. *Blood* 2003;101:2914–2923.
230. Wang X, Li Z, Naganuma A, Ye BH. Negative autoregulation of BCL-6 is bypassed by genetic alterations in diffuse large B cell lymphomas. *Proc Natl Acad Sci U S A* 2002;99:15018–15023.
231. Pello D, Vitolo U, Pasqualucci L, et al. Distribution and pattern of BCL-6 mutations throughout the spectrum of B-cell neoplasia. *Blood* 2000;95:651.
232. Migliazza A, Martinotti S, Chen W, et al. Frequent somatic hypermutation of the 5' noncoding region of the BCL6 gene in B-cell lymphoma. *Proc Natl Acad Sci U S A* 1995;92:12520–12524.
233. Saito M, Gao J, Basso K, et al. A signaling pathway mediating downregulation of BCL6 in germinal center B cells is blocked by BCL6 gene alterations in B cell lymphoma. *Cancer Cell* 2007;12:280–292.
234. Iqbal J, Neppalli VT, Wright G, et al. BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. *J Clin Oncol* 2006;24:961–968.
235. Monni O, Joensuu H, Franssila K, et al. BCL2 overexpression associated with chromosomal amplification in diffuse large B-cell lymphoma. *Blood* 1997;90:1168–1174.
236. Davis RE, Ngo VN, Lenz G, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. *Nature* 2010;463:88–92.
237. Gronbaek K, Worm J, Ralfkiaer E, et al. ATM mutations are associated with inactivation of the ARF-TP53 tumor suppressor pathway in diffuse large B-cell lymphoma. *Blood* 2002;100:1430–1437.
238. Bai M, Vlachonikolis J, Agnantis NJ, et al. Low expression of p27 protein combined with altered p53 and Rb/p16 expression status is associated with increased expression of cyclin A and cyclin B1 in diffuse large B-cell lymphomas. *Mod Pathol* 2001;14:1105–1113.
239. Offit K, Jhanwar S, Ebrahim SA, et al. t(3;22)(q27;q11): a novel translocation associated with diffuse non-Hodgkin's lymphoma. *Blood* 1989;74:1876–1879.
240. Ye BH, Chaganti S, Chang CC, et al. Chromosomal translocations cause deregulated BCL6 expression by promoter substitution in B cell lymphoma. *Embo J* 1995;14:6209–6217.
241. Cattoretti G, Pasqualucci L, Ballon G, et al. Deregulated BCL6 expression recapitulates the pathogenesis of human diffuse large B cell lymphomas in mice. *Cancer Cell* 2005;7:445.
242. Angelin-Duclos C, Cattoretti G, Lin KI, Calame K. Commitment of B lymphocytes to a plasma cell fate is associated with Blimp-1 expression in vivo. *J Immunol* 2000;165:5462–5471.
243. Cattoretti G, Angelin-Duclos C, Shaknovich R, et al. PRDM1/Blimp-1 is expressed in human B-lymphocytes committed to the plasma cell lineage. *J Pathol* 2005;206:76–86.
244. Shapiro-Shelef M, Lin KI, McHeyzer-Williams LJ, et al. Blimp-1 is required for the formation of immunoglobulin secreting plasma cells and pre-plasma memory B cells. *Immunity* 2003;19:607–620.
245. Joos S, Küpper M, Ohl S, et al. Genomic imbalances including amplification of the tyrosine kinase gene JAK2 in CD30+ Hodgkin cells. *Cancer Res* 2000;60:549–552.

246. Mestre C, Rubio-Moscardo F, Rosenwald A, et al. Homozygous deletion of SOCS1 in primary mediastinal B-cell lymphoma detected by CGH to BAC microarrays. *Leukemia* 2005;19:1082–1084.
247. Melzner I, Bucur AJ, Brüderlein S, et al. Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line. *Blood* 2005;105:2535–2542.
248. Weniger MA, Bucur AJ, Brüderlein S, et al. Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation. *Oncogene* 2006;25:2679–2684.
249. Muller AM, Ihorst G, Mertelsmann R, Engelhardt M. Epidemiology of non-Hodgkin's lymphoma (NHL): trends, geographic distribution, and etiology. *Ann Hematol* 2005;84:1–12.
250. Bertoni F, Cazzaniga G, Bosshard G, et al. Immunoglobulin heavy chain diversity genes rearrangement pattern indicates that MALT-type gastric lymphoma B cells have undergone an antigen selection process. *Br J Haematol* 1997;97:830–836.
251. Wotherspoon AC. Gastric lymphoma of mucosa-associated lymphoid tissue and *Helicobacter pylori*. *Annu Rev Med* 1998;49:289.
252. Bende RJ, Aarts WM, Riedl RG, et al. Among B cell non-Hodgkin's lymphomas, MALT lymphomas express a unique antibody repertoire with frequent rheumatoid factor reactivity. *J Exp Med* 2005;201:1229–1241.
253. Hussell T, Isaacson PG, Crabtree JE, Dogan A, Spencer J. Immunoglobulin specificity of low grade B cell gastrointestinal lymphoma of mucosa-associated lymphoid tissue (MALT) type. *Am J Pathol* 1993;142:285–292.
254. Akagi T, Motegi M, Tamura A, et al. A novel gene, MALT1 at 18q21, is involved in t(11;18) (q21;q21) found in low-grade B-cell lymphoma of mucosa-associated lymphoid tissue. *Oncogene* 1999;18:5785–5794.
255. Dierlamm J, Baens M, Wlodarska I, et al. The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21) associated with mucosa-associated lymphoid tissue lymphomas. *Blood* 1999;93:3601–3609.
256. Remstein ED, James CD, Kurtin PJ. Incidence and subtype specificity of API2-MALT1 fusion translocations in extranodal, nodal, and splenic marginal zone lymphomas. *Am J Pathol* 2000;156:1183–1188.
257. Baens M, Maes B, Steyls A, et al. The product of the t(11;18), an API2-MLT fusion, marks nearly half of gastric MALT type lymphomas without large cell proliferation. *Am J Pathol* 2000;156:1433–1439.
258. Motegi M, Yonezumi M, Suzuki H, et al. API2-MALT1 chimeric transcripts involved in mucosa-associated lymphoid tissue type lymphoma predict heterogeneous products. *Am J Pathol* 2000;156:807–812.
259. Lucas PC, Kuffa P, Gu S, et al. A dual role for the API2 moiety in API2-MALT1-dependent NF-kappaB activation: heterotypic oligomerization and TRAF2 recruitment. *Oncogene* 2007;26:5643.
260. Sanchez-Izquierdo D, Buchonnet G, Siebert R, et al. MALT1 is deregulated by both chromosomal translocation and amplification in B-cell non-Hodgkin lymphoma. *Blood* 2003;101:4539–4546.
261. Streubel B, Lamprecht A, Dierlamm J, et al. T(14;18) (q32;q21) involving IGH and MALT1 is a frequent chromosomal aberration in MALT lymphoma. *Blood* 2003;101:2335–2339.
262. Willis TG, Jadayel DM, Du MQ, et al. Bcl10 is involved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types. *Cell* 1999;96:35–45.
263. Zhang Q, Siebert R, Yan M, et al. Inactivating mutations and overexpression of BCL10, a caspase recruitment domain-containing gene, in MALT lymphoma with t(1;14)(p22;q32). *Nat Genet* 1999;22:63–68.
264. Ruland J, Duncan GS, Elia A, et al. Bcl10 is a positive regulator of antigen receptor-induced activation of NF-kappaB and neural tube closure. *Cell* 2001;104:33–42.
265. Xue L, Morris SW, Orihuela C, et al. Defective development and function of Bcl10-deficient follicular, marginal zone and B1 B cells. *Nat Immunol* 2003;4:857–865.
266. Wotherspoon AC, Finn TM, Isaacson PG. Trisomy 3 in low-grade B-cell lymphomas of mucosa-associated lymphoid tissue. *Blood* 1995;85:2000–2004.
267. Ott G, Kalla J, Steinhoff A, et al. Trisomy 3 is not a common feature in malignant lymphomas of mucosa-associated lymphoid tissue type. *Am J Pathol* 1998;153:689–694.
268. Wlodarska I, Veyt E, De Paep P, et al. FOXP1, a gene highly expressed in a subset of diffuse large B-cell lymphoma, is recurrently targeted by genomic aberrations. *Leukemia* 2005;19:1299–1305.
269. Streubel B, Vinatzer U, Lamprecht A, Raderer M, Chott A. T(3;14)(p14.1;q32) involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphoma. *Leukemia* 2005;19:652–658.
270. Hu H, Wang B, Borde M, et al. Foxp1 is an essential transcriptional regulator of B cell development. *Nat Immunol* 2006;7:819.
271. Du M, Peng H, Singh N, Isaacson PG, Pan L. The accumulation of p53 abnormalities is associated with progression of mucosa-associated lymphoid tissue lymphoma. *Blood* 1995;86:4587–4593.
272. Gaidano G, D Capello A, Gloghini, et al. Frequent mutation of bcl-6 proto-oncogene in high grade, but not low grade, MALT lymphomas of the gastrointestinal tract. *Haematologica* 1999;84:582–588.
273. Gaidano G, Volpe G, Pastore C, et al. Detection of BCL-6 rearrangements and p53 mutations in Malt-lymphomas. *Am J Hematol* 1997;56:206–213.
274. Caligaris-Cappio E, Hamblin TJ. B-cell chronic lymphocytic leukemia: a bird of a different feather. *J Clin Oncol* 1999;17:399–408.
275. Stevenson F, Sahota S, Zhu D, et al. Insight into the origin and clonal history of B-cell tumors as revealed by analysis of immunoglobulin variable region genes. *Immunol Rev* 1998;162:247–259.
276. Fais F, Ghiotto F, Hashimoto S, et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. *J Clin Invest* 1998;102:1515–1525.
277. Oscier DG, Thompsett A, Zhu D, Stevenson FK. Differential rates of somatic hypermutation in V(H) genes among subsets of chronic lymphocytic leukemia defined by chromosomal abnormalities. *Blood* 1997;89:4153–4160.
278. Klein U, Tu Y, Stolovitzky GA, et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. *J Exp Med* 2001;194:1625–1638.
279. Rosenwald A, Alizadeh AA, Widhopf G, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. *J Exp Med* 2001;194:1639–1647.
280. Widhopf GF II, Rassenti LZ, Toy TL, et al. Chronic lymphocytic leukemia B cells of more than 1% of patients express virtually identical immunoglobulins. *Blood* 2004;104:2499.
281. Messmer BT, Albesiano E, Efremov DG, et al. Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia. *J Exp Med* 2004;200:519–525.
282. Tobin G, Thunberg U, Karlsson K, et al. Subsets with restricted immunoglobulin gene rearrangement features indicate a role for antigen selection in the development of chronic lymphocytic leukemia. *Blood* 2004;104:2879–2885.
283. Murray F, Darzentas N, Hadzidimitriou A, et al. Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: implications for the role of antigen selection in leukemogenesis. *Blood* 2008;111:1524–1533.

284. Stamatopoulos K, Belessi C, Moreno C, et al. Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: Pathogenetic implications and clinical correlations. *Blood* 2007;109:259–270.
285. Tobin G, Thunberg U, Johnson A, et al. Chronic lymphocytic leukemias utilizing the VH3–21 gene display highly restricted Vlambda2–14 gene use and homologous CDR3s: implicating recognition of a common antigen epitope. *Blood* 2003;101:4952–4957.
286. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. *Blood* 1999;94:1840–1847.
287. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. *Blood* 1999;94:1848–1854.
288. Rawstron AC, Bennett FL, O'Connor SJ, et al. Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. *N Engl J Med* 2008;359:575.
289. Anastasi J, Le Beau MM, Vardiman JW, et al. Detection of trisomy 12 in chronic lymphocytic leukemia by fluorescence in situ hybridization to interphase cells: a simple and sensitive method. *Blood* 1992;79:1796–1801.
290. Hjalmar V, Kimby E, Matutes E, et al. Trisomy 12 and lymphoplasmacytoid lymphocytes in chronic leukemic B-cell disorders. *Haematologica* 1998;83:602–609.
291. Julliusson G, Oscier DG, Fitchett M, et al. Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. *N Engl J Med* 1990;323:720–724.
292. Bullrich F, Rasio D, Kitada S, et al. ATM mutations in B-cell chronic lymphocytic leukemia. *Cancer Res* 1999;59:24–27.
293. Stankovic T, Weber P, Stewart G, et al. Inactivation of ataxia telangiectasia mutated gene in B-cell chronic lymphocytic leukemia. *Lancet* 1999;353:26–29.
294. Starostik P, Kazmierczak B, Napolitano R, et al. Deficiency of the ATM protein expression defines an aggressive subgroup of B-cell chronic lymphocytic leukemia. *Cancer Res* 1998;58:4552–4557.
295. Gaidano G, Newcomb EW, Gong JZ, et al. Analysis of alterations of oncogenes and tumor suppressor genes in chronic lymphocytic leukemia. *Am J Pathol* 1994;144:1312–1319.
296. Carbone A, Ghoghini A. AIDS-related lymphomas: from pathogenesis to pathology. *Br J Haematol* 2005;130:662–670.
297. Knowles DM. Etiology and pathogenesis of AIDS-related non-Hodgkin's lymphoma. *Hematol Oncol Clin North Am* 2003;17:785–820.
298. Gaidano G, Capello D, Carbone A. The molecular basis of acquired immunodeficiency syndrome-related lymphomagenesis. *Semin Oncol* 2000;27:431–441.
299. Gaidano G, Carbone A. Primary effusion lymphoma: a liquid phase lymphoma of fluid-filled body cavities. *Adv Cancer Res* 2001;80:115.
300. Gaidano G, Ghoghini A, Gattei V, et al. Association of Kaposi's sarcoma-associated herpesvirus-positive primary effusion lymphoma with expression of the CD138/syndecan-1 antigen. *Blood* 1997;90:4894–4900.
301. Gaidano G, Lo Coco F, Ye BH, et al. Rearrangements of the BCL-6 gene in acquired immunodeficiency syndrome-associated non-Hodgkin's lymphoma: association with diffuse large-cell subtype. *Blood* 1994;84:397–402.
302. Carbone A, Gaidano G, Ghoghini A, et al. BCL-6 protein expression in AIDS-related non-Hodgkin's lymphomas: inverse relationship with Epstein-Barr virus-encoded latent membrane protein-1 expression. *Am J Pathol* 1997;150:155–165.
303. Carbone A, Gaidano G, Ghoghini A, et al. Differential expression of BCL-6, CD138/syndecan-1, and Epstein-Barr virus-encoded latent membrane protein-1 identifies distinct histogenetic subsets of acquired immunodeficiency syndrome-related non-Hodgkin's lymphomas. *Blood* 1998;91:747–755.
304. Riboldi P, Gaidano G, Schettino EW, et al. Two acquired immunodeficiency syndrome-associated Burkitt's lymphomas produce specific anti-IgM cold agglutinins using somatically mutated VH4–21 segments. *Blood* 1994;83:2952–2961.
305. Gaidano G, Carbone A, Pastore C, et al. Frequent mutation of the 5' noncoding region of the BCL-6 gene in acquired immunodeficiency syndrome-related non-Hodgkin's lymphomas. *Blood* 1997;89:3755–3762.
306. MacMahon EM, Glass JD, Hayward SD, et al. Epstein-Barr virus in AIDS-related primary central nervous system lymphoma. *Lancet* 1991;338:969–973.
307. Montesinos-Rongen M, Schmitz R, Brunn A, et al. Mutations of CARD11 but not TNFAIP3 may activate the NF-kappaB pathway in primary CNS lymphoma. *Acta Neuropathol* 2010;120:529–535.
308. Antinori A, Larocca LM, Fassone L, et al. HHV-8/KSHV is not associated with AIDS-related primary central nervous system lymphoma. *Brain Pathol* 1999;9:199.
309. Gaidano G, Capello D, Pastore C, et al. Analysis of human herpesvirus type 8 infection in AIDS-related and AIDS-unrelated primary central nervous system lymphoma. *J Infect Dis* 1997;175:1193–1197.
310. de Leval L, Bisig B, Thielen C, Boniver J, Gaulard P. Molecular classification of T-cell lymphomas. *Crit Rev Oncol Hematol* 2009;72:125–143.
311. Taylor GP. The epidemiology of HTLV-I in Europe. *J Acquir Immune Defic Syndr Hum Retrovirol* 1996;13(Suppl 1):S8–S14.
312. Tsukasaki K, Tsushima H, Yamamura M, et al. Integration patterns of HTLV-I provirus in relation to the clinical course of ATL: frequent clonal change at crisis from indolent disease. *Blood* 1997;89:948–956.
313. Takatsuki K, Matsuoka M, Yamaguchi K. Adult T-cell leukemia in Japan. *J Acquir Immune Defic Syndr Hum Retrovirol* 1996;13(Suppl 1):S15–S19.
314. Uittenbogaard MN, Giebler HA, Reisman D, Nyborg JK. Transcriptional repression of p53 by human T-cell leukemia virus type I Tax protein. *J Biol Chem* 1995;270:28503–28506.
315. Cesarman E, Chadburn A, Inghirami G, Gaidano G, Knowles DM. Structural and functional analysis of oncogenes and tumor suppressor genes in adult T-cell leukemia/lymphoma shows frequent p53 mutations. *Blood* 1992;80:3205–3216.
316. Sakashita A, Hattori T, Miller CW, et al. Mutations of the p53 gene in adult T-cell leukemia. *Blood* 1992;79:477–480.
317. Gaulard P, Bourquelot P, Kanavaros P, et al. Expression of the alpha/beta and gamma/delta T-cell receptors in 57 cases of peripheral T-cell lymphomas. Identification of a subset of gamma/delta T-cell lymphomas. *Am J Pathol* 1990;137:617–628.
318. de Leval L, Rickman DS, Thielen C, et al. The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. *Blood* 2007;109:4952.
319. Martin-Subero JI, Wlodarska I, Bastard C, et al. Chromosomal rearrangements involving the BCL3 locus are recurrent in classical Hodgkin and peripheral T-cell lymphoma. *Blood* 2006;108:401–402; author reply 402–403.
320. Almire C, Bertrand P, Ruminy P, et al. PVRL2 is translocated to the TRA0 locus in t(14;19)(q11;q13)-positive peripheral T-cell lymphomas. *Genes Chromosomes Cancer* 2007;46:1011–1018.
321. Feldman AL, Law M, Remstein ED, et al. Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomas. *Leukemia* 2009;23:574–580.
322. Panwalkar AW, Armitage JO. T-cell/NK-cell lymphomas: a review. *Cancer Lett* 2007;253:1–13.
323. Piccaluga PP, Agostinelli C, Califano A, et al. Gene expression analysis of angioimmunoblastic lymphoma indicates derivation from T follicular helper cells and vascular endothelial growth factor deregulation. *Cancer Res* 2007;67:10703–10710.

324. Grogg KL, Attygalle AD, Macon WR, et al. Angioimmunoblastic T-cell lymphoma: a neoplasm of germinal-center T-helper cells? *Blood* 2005;106:1501–1502.
325. Neri A, Fracchiolla NS, Roscetti E, et al. Molecular analysis of cutaneous B- and T-cell lymphomas. *Blood* 1995;86:3160–3172.
326. Neri A, Chang CC, Lombardi L, et al. B cell lymphoma-associated chromosomal translocation involves candidate oncogene *lyt-10*, homologous to NF-kappa B p50. *Cell* 1991;67:1075–1087.
327. Fornari A, Piva R, Chiarle R, Novero D, Inghirami G. Anaplastic large cell lymphoma: one or more entities among T-cell lymphoma? *Hematol Oncol* 2009;27:161–170.
328. Lamant L, de Reyniès A, Duplantier MM, et al. Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes. *Blood* 2007;109:2156.
329. Gascoyne RD, Aoun P, Wu D, et al. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. *Blood* 1999;93:3913–3921.
330. Savage KJ, Harris NL, Vose JM, et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. *Blood* 2008;111:5496–5504.
331. Shiota M, Nakamura S, Ichinohasama R, et al. Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: a distinct clinicopathologic entity. *Blood* 1995;86:1954–1960.
332. Piva R, Agnelli L, Pellegrino E, et al. Gene expression profiling uncovers molecular classifiers for the recognition of anaplastic large-cell lymphoma within peripheral T-cell neoplasms. *J Clin Oncol* 2010;28:1583–1590.
333. Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G. The anaplastic lymphoma kinase in the pathogenesis of cancer. *Nat Rev Cancer* 2008;8:11–23.
334. Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, *ALK*, to a nucleolar protein gene, *NPM*, in non-Hodgkin's lymphoma. *Science* 1994;263:1281–1284.
335. Kasprzycka M, Marzec M, Liu X, Zhang Q, Wasik MA. Nucleophosmin/anaplastic lymphoma kinase (NPM/ALK) oncoprotein induces the T regulatory cell phenotype by activating STAT3. *Proc Natl Acad Sci U S A* 2006;103:9964–9969.
336. Marzec M, Zhang Q, Goradia A, et al. Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). *Proc Natl Acad Sci U S A* 2008;105:20852–20857.
337. Zhang Q, Wang HY, Liu X, Wasik MA. STAT5A is epigenetically silenced by the tyrosine kinase NPM1-ALK and acts as a tumor suppressor by reciprocally inhibiting NPM1-ALK expression. *Nat Med* 2007;13:1341.
338. Bai RY, Ouyang T, Miething C, et al. Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway. *Blood* 2000;96:4319–4327.
339. Chiarle R, Gong JZ, Guasparri I, et al. NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors. *Blood* 2003;101:1919–1927.
340. Kuefer MU, Look AT, Pulford K, et al. Retrovirus-mediated gene transfer of NPM-ALK causes lymphoid malignancy in mice. *Blood* 1997;90:2901–3010.
341. Lange K, Uckert W, Blankenstein T, et al. Overexpression of NPM-ALK induces different types of malignant lymphomas in IL-9 transgenic mice. *Oncogene* 2003;22:517–527.
342. Hernandez L, Beà S, Bellosillo B, et al. Diversity of genomic breakpoints in TFG-ALK translocations in anaplastic large cell lymphomas: identification of a new TFG-ALK(XL) chimeric gene with transforming activity. *Am J Pathol* 2002;160:1487–1494.
343. Colleoni GW, Bridge JA, Garicochea B, et al. ATIC-ALK: A novel variant ALK gene fusion in anaplastic large cell lymphoma resulting from the recurrent cryptic chromosomal inversion, *inv(2)(p23q35)*. *Am J Pathol* 2000;156:781–789.
344. Ma Z, Cools J, Marynen P, et al. *Inv(2)(p23q35)* in anaplastic large-cell lymphoma induces constitutive anaplastic lymphoma kinase (ALK) tyrosine kinase activation by fusion to ATIC, an enzyme involved in purine nucleotide biosynthesis. *Blood* 2000;95:2144–2149.
345. Kuppers R. The biology of Hodgkin's lymphoma. *Nat Rev Cancer* 2009;9:15–27.
346. Schwering I, Bräuninger A, Klein U, et al. Loss of the B-lineage-specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. *Blood* 2003;101:1505.
347. Re D, Müschen M, Ahmadi T, et al. Oct-2 and Bob-1 deficiency in Hodgkin and Reed Sternberg cells. *Cancer Res* 2001;61:2080–2084.
348. Stein H, Marafioti T, Foss HD, et al. Down-regulation of BOB.1/OBF.1 and Oct2 in classical Hodgkin disease but not in lymphocyte predominant Hodgkin disease correlates with immunoglobulin transcription. *Blood* 2001;97:496–501.
349. Küppers R, Rajewsky K, Zhao M, et al. Hodgkin disease: Hodgkin and Reed-Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development. *Proc Natl Acad Sci U S A* 1994;91:10962–10966.
350. Kanzler H, Kuppers R, Hansmann ML, Rajewsky K. Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. *J Exp Med* 1996;184:1495–1505.
351. Martin-Subero JI, Gesk S, Harder L, et al. Recurrent involvement of the REL and BCL11A loci in classical Hodgkin lymphoma. *Blood* 2002;99:1474–1477.
352. Barth TF, Martin-Subero JI, Joos S, et al. Gains of 2p involving the REL locus correlate with nuclear c-Rel protein accumulation in neoplastic cells of classical Hodgkin lymphoma. *Blood* 2003;101:3681–3686.
353. Jungnickel B, Staratschek-Jox A, Bräuninger A, et al. Clonal deleterious mutations in the *IkappaBalpha* gene in the malignant cells in Hodgkin's lymphoma. *J Exp Med* 2000;191:395–402.
354. Emmerich F, Meiser M, Hummel M, et al. Overexpression of I kappa B alpha without inhibition of NF-kappaB activity and mutations in the I kappa B alpha gene in Reed-Sternberg cells. *Blood* 1999;94:3129–3134.
355. Schmitz R, Stanelle J, Hansmann ML, Kuppers R. Pathogenesis of classical and lymphocyte-predominant Hodgkin lymphoma. *Annu Rev Pathol* 2009;4:151.
356. Wlodarska I, Nooyen P, Maes B, et al. Frequent occurrence of BCL6 rearrangements in nodular lymphocyte predominance Hodgkin lymphoma but not in classical Hodgkin lymphoma. *Blood* 2003;101:706–710.
357. Martin-Subero JI, Klapper W, Sotnikova A, et al. Chromosomal breakpoints affecting immunoglobulin loci are recurrent in Hodgkin and Reed-Sternberg cells of classical Hodgkin lymphoma. *Cancer Res* 2006;66:10332–10338.

Chapter 31 – References

1. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. *Nat Med* 1997;3:730.
2. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. *Blood* 2000;96:3343.
3. Saito Y, Kitamura H, Hijikata A, et al. Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells. *Sci Transl Med* 2007;2(17):17.
4. Taussig DC, Miraki-Moud F, Anjos-Afonso F, et al. Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells. *Blood* 2008;112:568–575.
5. Cozzio A, Passegue E, Ayton PM, Karsunky H, Cleary ML, Weissman IL. Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors. *Genes Dev* 2003;17:3029–3035.
6. Huntly BJ, Shigematsu H, Deguchi K, et al. MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. *Cancer Cell* 2004;6:587–596.
7. Somervaille TCP, Cleary ML. Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia. *Cancer Cell* 2006;10:257–268.
8. Kelly PN, Dakic A, Adams JM, Nutt SL, Strasser A. Tumor Growth Need Not Be Driven by Rare Cancer Stem Cells. *Science* 2007;317:337.
9. Huntly BJ, Gilliland DG. Leukaemia stem cells and the evolution of cancer-stem-cell research. *Nat Rev Cancer* 2005;5:311–321.
10. Jamieson CH, Ailles LE, Dylla SJ, et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. *N Engl J Med* 2004;351:657–667.
11. Speicher MR, Carter NP. The new cytogenetics: blurring the boundaries with molecular biology. *Nat Rev Genet* 2005;6:782–792.
12. Feuk L, Carson AR, Scherer SW. Structural variation in the human genome. *Nat Rev Genet* 2006;7:85.
13. Ley TJ, Mardis ER, Ding L, et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. *Nature* 2008;456:66.
14. Loriaux MM, Levine RL, Tyner JW, et al. High-throughput sequence analysis of the tyrosine kinase in acute myeloid leukemia. *Blood* 2008;111:4788.
15. Yamashita Y, Yuan J, Suetake I, et al. Array-based genomic resequencing of human leukemia. *Oncogene* 2010;29(25):3723.
16. International Cancer Genome Consortium. International network of cancer genome projects. *Nature* 2010;464:993–998.
17. Rowley JD. The role of chromosome translocations in leukemogenesis. *Semin Hematol* 1999;36:59–72.
18. Koschmieder S, Halmos B, Levantini E, Tenen DG. Dysregulation of the C/EBP{alpha} differentiation pathway in human cancer. *J Clin Oncol* 2009;27:619–628.
19. Speck NA, Gilliland DG. Core-binding factors in haematopoiesis and leukaemia. *Nat Rev Cancer* 2002;2:502–513.
20. Wang Q, Stacy T, Binder M, Marin-Padilla M, Sharpe AH, Speck NA. Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. *Proc Natl Acad Sci U S A* 1996;93:3444–3449.
21. Okuda T, van Deursen J, Hiebert SW, Grosveld G, Downing JR. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. *Cell* 1996;84:321–330.
22. Lutterbach B, Westendorf JJ, Linggi B, et al. ETO, a target of t(8;21) in acute leukemia, interacts with the N-CoR and mSin3 corepressors. *Mol Cell Biol* 1998;18:7176–7184.
23. He LZ, Guidez F, Tribioli C, et al. Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL. *Nat Genet* 1998;18:126–135.
24. Pandolfi PP. Histone deacetylases and transcriptional therapy with their inhibitors. *Cancer Chemother Pharmacol* 2001;48 Suppl 1:S17–19.
25. Yan M, Kanbe E, Peterson LF, et al. A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis. *Nat Med* 2006;12:945–949.
26. Jiao B, Wu CF, Liang Y, et al. AML1-ETO9a is correlated with C-KIT overexpression/mutations and indicates poor disease outcome in t(8;21) acute myeloid leukemia-M2. *Leukemia* 2009;23:1598.
27. Castilla LH, Garrett L, Adya N, et al. The fusion gene Cbfb-MYH11 blocks myeloid differentiation and predisposes mice to acute myelomonocytic leukaemia. *Nat Genet* 1999;23:144.
28. Goddard AD, Borrow J, Freemont PS, Solomon E. Characterization of a zinc finger gene disrupted by the t(15;17) in acute promyelocytic leukemia. *Science* 1991;254:1371.
29. Kakizuka A, Miller WH, Jr., Umesono K, et al. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. *Cell* 1991;66:663–674.
30. de Thé H, Lavau C, Marchio A, Chomienne C, Degos L, Dejean A. The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. *Cell* 1991;66:675–684.
31. Zelent A, Guidez F, Melnick A, Waxman S, Licht JD. Translocations of the RARalpha gene in acute promyelocytic leukemia. *Oncogene* 2001;20:7186–7203.
32. Salomoni P, Pandolfi PP. The role of PML in tumor suppression. *Cell* 2002;108:165–170.
33. Scaglioni PP, Pandolfi PP. The theory of APL revisited. *Curr Top Microbiol Immunol* 2007;313:85–100.
34. Grisolan JL, Wesselschmidt RL, Pelicci PG, Ley TJ. Altered myeloid development and acute leukemia in transgenic mice expressing PML-RAR alpha under control of cathepsin G regulatory sequences. *Blood* 1997;89:376–387.
35. He LZ, Tribioli C, Rivi R, et al. Acute leukemia with promyelocytic features in PML/RARalpha transgenic mice. *Proc Natl Acad Sci U S A* 1997;94:5302–5307.
36. Brown D, Kogan S, Lagasse E, et al. A PMLRARalpha transgene initiates murine acute promyelocytic leukemia. *Proc Natl Acad Sci U S A* 1997;94:2551–2556.
37. Tallman MS, Nabhan C, Feusner JH, Rowe JM. Acute promyelocytic leukemia: evolving therapeutic strategies. *Blood* 2002;99:759–767.
38. Abramovich C, Humphries RK. Hox regulation of normal and leukemic hematopoietic stem cells. *Curr Opin Hematol* 2005;12:210–216.
39. Borrow J, Shearman AM, Stanton VP Jr, et al. The t(7;11)(p15;p15) translocation in acute myeloid leukaemia fuses the genes for nucleoporin NUP98 and class I homeoprotein HOXA9. *Nat Genet* 1996;12:159.
40. Nakamura T, Largaespada DA, Lee MP, et al. Fusion of the nucleoporin gene NUP98 to HOXA9 by the chromosome translocation t(7;11)(p15;p15) in human myeloid leukaemia. *Nat Genet* 1996;12:154.
41. Kasper LH, Brindle PK, Schnabel CA, Pritchard CE, Cleary ML, van Deursen JM. CREB binding protein interacts with nucleoporin-specific FG repeats that activate transcription and mediate NUP98-HOXA9 oncogenicity. *Mol Cell Biol* 1999;19:764.
42. Rawat VP, Cusan M, Deshpande A, et al. Ectopic expression of the homeobox gene Cdx2 is the transforming event in a mouse model of t(12;13)(p13;q12) acute myeloid leukemia. *Proc Natl Acad Sci U S A* 2004;101:817–822.

43. Bansal D, Scholl C, Frahling S, et al. Cdx4 dysregulates Hox gene expression and generates acute myeloid leukemia alone and in cooperation with Meis1a in a murine model. *Proceedings of the National Academy of Sciences* 2006;103:16924–16929.
44. Davidson AJ, Ernst P, Wang Y, et al. cdx4 mutants fail to specify blood progenitors and can be rescued by multiple hox genes. *Nature*. 2003;425:300–306.
45. Eguchi M, Eguchi-Ishimae M, Greaves M. Molecular pathogenesis of MLL-associated leukemias. *Int J Hematol* 2005;82:9–20.
46. Slany RK. The molecular biology of mixed lineage leukemia. *Haematologica* 2009;94:984–993.
47. Yu BD, Hanson RD, Hess JL, Horning SE, Korsmeyer SJ. MLL, a mammalian trithorax-group gene, functions as a transcriptional maintenance factor in morphogenesis. *Proc Natl Acad Sci U S A* 1998;95:10632–10636.
48. Whitman SP, Strout MP, Marcucci G, et al. The partial nonandent duplication of the MLL (ALL1) gene is a novel rearrangement that generates three distinct fusion transcripts in B-cell acute lymphoblastic leukemia. *Cancer Res* 2001;61:59–63.
49. Hsieh JJ, Cheng EH, Korsmeyer SJ. Taspase1: a threonine aspartase required for cleavage of MLL and proper HOX gene expression. *Cell* 2003;115:293–303.
50. Hsieh JJ, Ernst P, Erdjument-Bromage H, Tempst P, Korsmeyer SJ. Proteolytic cleavage of MLL generates a complex of N- and C-terminal fragments that confers protein stability and subnuclear localization. *Mol Cell Biol* 2003;23:186.
51. Wei J, Wunderlich M, Fox C, et al. Microenvironment determines lineage fate in a human model of MLL-AF9 leukemia. *Cancer Cell* 2008;13:483.
52. Taki T, Sako M, Tsuchida M, Hayashi Y. The t(11;16)(q23;p13) translocation in myelodysplastic syndrome fuses the MLL gene to the CBP gene. *Blood* 1997; 89:3945.
53. Carapeti M, Aguiar RC, Goldman JM, Cross NC. A novel fusion between MOZ and the nuclear receptor coactivator TIF2 in acute myeloid leukemia. *Blood* 1998;91: 3127–3133.
54. Deguchi K, Ayton PM, Carapeti M, et al. MOZ-TIF2-induced acute myeloid leukemia requires the MOZ nucleosome binding motif and TIF2-mediated recruitment of CBP. *Cancer Cell*. 2003;3:259–271.
55. Lavau C, Luo RT, Du C, Thirman MJ. Retrovirus-mediated gene transfer of MLL-ELL transforms primary myeloid progenitors and causes acute myeloid leukemias in mice. *Proc Natl Acad Sci U S A* 2000;97:10984–10989.
56. Kung AL, Rebel VI, Bronson RT, et al. Gene dose-dependent control of hematopoiesis and hematologic tumor suppression by CBP. *Genes Dev* 2000;14:272–277.
57. Ma Z, Morris SW, Valentine V, et al. Fusion of two novel genes, RBM15 and MKL1, in the t(1;22)(p13;q13) of acute megakaryoblastic leukemia. *Nat Genet* 2001;28:220–221.
58. Mercher T, Busson-Le Coniat M, Khac FN, et al. Recurrence of OTT-MAL fusion in t(1;22) of infant AML-M7. *Genes Chromosomes Cancer* 2002;33:22–28.
59. Raffel GD, Mercher T, Shigematsu H, et al. Ott1(Rbm15) has pleiotropic roles in hematopoietic development. *Proc Natl Acad Sci U S A* 2007;104:6001–6006.
60. Miralles F, Posern G, Zaromytidou AI, Treisman R. Actin dynamics control SRF activity by regulation of its coactivator MAL. *Cell*. 2003;113:329–342.
61. Cheng EC, Luo Q, Bruscia EM, et al. Role for MKL1 in megakaryocytic maturation. *Blood* 2009;113:2826–2834.
62. Mercher T, Raffel GD, Moore SA, et al. The OTT-MAL fusion oncogene activates RBPJ-mediated transcription and induces acute megakaryoblastic leukemia in a knockin mouse model. *J Clin Invest* 2009;119:852–864.
63. Hirai H. Molecular mechanisms of myelodysplastic syndrome. *Jpn J Clin Oncol* 2003;33:153.
64. Sweetser DA, Chen CS, Blomberg AA, et al. Loss of heterozygosity in childhood de novo acute myelogenous leukemia. *Blood* 2001;98:1188.
65. Ebert BL, Pretz J, Bosco J, et al. Identification of RPS14 as a 5q(-) syndrome gene by RNA interference screen. *Nature* 2008;451:335.
66. Liu TX, Becker MW, Jelinek J, et al. Chromosome 5q deletion and epigenetic suppression of the gene encoding [alpha]-catenin (CTNNA1) in myeloid cell transformation. *Nat Med* 2007;13:78–83.
67. Joslin JM, Fernald AA, Tennant TR, et al. Haploinsufficiency of EGR1, a candidate gene in the del(5q), leads to the development of myeloid disorders. *Blood* 2007;110:719–726.
68. Fodde R, Smits R. CANCER BIOLOGY: Enhanced: A Matter of Dosage. *Science* 2002;298:761–763.
69. Song WJ, Sullivan MG, Legare RD, et al. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. *Nat Genet* 1999;23:166–175.
70. Seidman JG, Seidman C. Transcription factor haploinsufficiency: when half a loaf is not enough. *J Clin Invest*. 2002;109:451–455.
71. Armstrong SA, Look AT. Molecular genetics of acute lymphoblastic leukemia. *J Clin Oncol* 2005;23:6306–6315.
72. O'Neil J, Look AT. Mechanisms of transcription factor deregulation in lymphoid cell transformation. *Oncogene* 2007;26:6838–6849.
73. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. *Nature* 2009;458:719–724.
74. Beaupre DM, Kurzrock R. RAS and leukemia: from basic mechanisms to gene-directed therapy. *J Clin Oncol*. 1999;17:1071–1079.
75. Lancel JE, Karp JE. Farnesyltransferase inhibitors in hematologic malignancies: new horizons in therapy. *Blood* 2003;102:3880–3889.
76. Braun BS, Shannon K. Targeting Ras in myeloid leukemias. *Clin Cancer Res* 2008;14:2249–2252.
77. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. *Blood*. 2005;105:2640–2653.
78. Stirewalt DL, Radich JP. The role of FLT3 in hematopoietic malignancies. *Nat Rev Cancer* 2003;3:650.
79. Griffith J, Black J, Faerman C, et al. The structural basis for autoinhibition of FLT3 by the juxtamembrane domain. *Mol Cell* 2004;13:169.
80. Griffin JD. Point mutations in the FLT3 gene in AML. *Blood*. 2001;97:2193A–2193.
81. Abu-Duhier FM, Goodeve AC, Wilson GA, et al. FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group. *Br J Haematol* 2000;111:190.
82. Kiyoi H, Naoe T, Nakano Y, et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. *Blood*. 1999;93:3074–3080.
83. Meshinchi S, Woods WG, Stirewalt DL, et al. Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. *Blood*. 2001;97:89–94.
84. Frohling S, Scholl C, Levine RL, et al. Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. *Cancer Cell* 2007;12:501–513.
85. Pardanani AD, Levine RL, Lasho T, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. *Blood* 2006;108:3472–3476.
86. Hussein K, Bock O, Theophile K, et al. MPLW515L mutation in acute megakaryoblastic leukaemia. *Leukemia* 2009;23:852–855.
87. Malinge S, Ragu C, Della-Valle V, et al. Activating mutations in human acute megakaryoblastic leukemia. *Blood*. 2008;112:4220–4226.
88. Baker SJ, Rane SG, Reddy EP. Hematopoietic cytokine receptor signaling. *Oncogene* 2007;26:6724–6737.

89. Frohling S, Lipka DB, Kayser S, et al. Rare occurrence of the JAK2 V617F mutation in AML subtypes M5, M6, and M7. *Blood*. 2006;107:1242–1243.
90. Mercher T, Wernig G, Moore SA, et al. JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model. *Blood* 2006;108:2770–2779.
91. Walters DK, Mercher T, Gu TL, et al. Activating alleles of JAK3 in acute megakaryoblastic leukemia. *Cancer Cell* 2006;10:65–75.
92. Mullighan CG, Downing JR. Genome-wide profiling of genetic alterations in acute lymphoblastic leukemia: recent insights and future directions. *Leukemia* 2009;23:1209.
93. Haber DA, Buckler AJ, Glaser T, et al. An internal deletion within an 11p13 zinc finger gene contributes to the development of Wilms' tumor. *Cell* 1990;61:1257.
94. Hohenstein P, Hastie ND. The many facets of the Wilms' tumour gene, WT1. *Hum Mol Genet* 2006;15:R196.
95. Baird PN, Simmons PJ. Expression of the Wilms' tumor gene (WT1) in normal hemopoiesis. *Exp Hematol* 1997;25:312–320.
96. Yang L, Han Y, Saurez Saiz F, Minden MD. A tumor suppressor and oncogene: the WT1 story. *Leukemia* 2007;21:868–876.
97. Miyagi T, Ahuja H, Kubota T, et al. Expression of the candidate Wilms' tumor gene, WT1, in human leukemia cells. *Leukemia* 1993;7:970–977.
98. Miwa H, Beran M, Saunders GF. Expression of the Wilms' tumor gene (WT1) in human leukemias. *Leukemia* 1992;6:405–409.
99. Smith SI, Down M, Boyd AW, Li CL. Expression of the Wilms' Tumor Suppressor Gene, WT1, Reduces the Tumorigenicity of the Leukemic Cell Line M1 in C.B-17 scid/scid Mice. *Cancer Res* 2000;60:808–814.
100. King-Underwood L, Renshaw J, Pritchard-Jones K. Mutations in the Wilms' tumor gene WT1 in leukemias. *Blood*. 1996;87:2171–2179.
101. Summers K, Stevens J, Kakkas I, et al. Wilms' tumour 1 mutations are associated with FLT3-ITD and failure of standard induction chemotherapy in patients with normal karyotype AML. *Leukemia* 2007;21:550–551.
102. Virappane P, Gale R, Hills R, et al. Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party. *J Clin Oncol* 2008;26:5429–5435.
103. Paschka P, Marcucci G, Ruppert AS, et al. Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study. *J Clin Oncol* 2008;26:4595–4602.
104. Gaidzik VI, Schlenk RF, Moschny S, et al. Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group. *Blood* 2009;113:4505.
105. Vousden KH, Lu X. Live or let die: the cell's response to p53. *Nat Rev Cancer* 2002;2:594.
106. Hiroyuki N, Shinichi M, Masafumi T, et al. Prognostic significance of loss of a chromosome 17p and p53 gene mutations in blast crisis of chronic myelogenous leukaemia. *Br J Haematol* 1994;87:425.
107. Dohner H, Fischer K, Bentz M, et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. *Blood*. 1995;85:1580–1589.
108. Sander CA, Yano T, Clark HM, et al. p53 mutation is associated with progression in follicular lymphomas. *Blood*. 1993;82:1994–2004.
109. Venkatachalam S, Shi Y-P, Jones SN, et al. Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation. *EMBO J* 1998;17:4657–4667.
110. Haferlach C, Dicker F, Herholz H, et al. Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype. *Leukemia* 2008;22:1539–1541.
111. Fenaux P, Jonveaux P, Quiquandon I, et al. P53 gene mutations in acute myeloid leukemia with 17p monosomy. *Blood*. 1991;78:1652–1657.
112. Watanabe T, Hotta T, Ichikawa A, et al. The MDM2 oncogene overexpression in chronic lymphocytic leukemia and low-grade lymphoma of B-cell origin. *Blood* 1994;84:3158–3165.
113. Claudia S, Wolfgang K, Alexander K, Wolfgang H, Susanne S, Torsten H. Acute myeloid leukemia with a complex aberrant karyotype is a distinct biological entity characterized by genomic imbalances and a specific gene expression profile. *Genes, Chromosomes and Cancer*. 2005;43:227–238.
114. Bronno van der H, Dimitri AB, Beverloo HB, et al. Various distinctive cytogenetic abnormalities in patients with acute myeloid leukaemia aged 60 years and older express adverse prognostic value: results from a prospective clinical trial. *British Journal of Haematology*. 2007;136:96–105.
115. Seifert H, Mohr B, Thiede C, et al. The prognostic impact of 17p (p53) deletion in 2272 adults with acute myeloid leukemia. *Leukemia* 2009;23:656.
116. Fenaux P, Preudhomme C, Quiquandon I, et al. Mutations of the P53 gene in acute myeloid leukaemia. *Br J Haematol* 1992;80:178.
117. Lai JL, Preudhomme C, Zandecki M, et al. Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion: an entity characterized by specific dysgranulopoiesis and a high incidence of P53 mutations. *Leukemia* 1995;9:370.
118. Claudia S, Torsten H, Sabina B, et al. Loss of genetic material is more common than gain in acute myeloid leukemia with complex aberrant karyotype: A detailed analysis of 125 cases using conventional chromosome analysis and fluorescence in situ hybridization including 24-color FISH. *Genes, Chromosomes and Cancer* 2002;35:20–29.
119. Nahi H, Lehmann Sr, Bengtzen S, et al. Chromosomal aberrations in 17p predict in vitro drug resistance and short overall survival in acute myeloid leukemia. *Leukemia & Lymphoma*. 2008;49:508–516.
120. Markus S, Silke S, Christian T, Gerhard E, Thomas I. *MDR1* and *MRP1* gene expression are independent predictors for treatment outcome in adult acute myeloid leukaemia. *British Journal of Haematology*. 2005;128:324–332.
121. Geraldo Barroso C, Jr, Flavia da Cunha V, Giselle Pinto de F, et al. Coexpression of p53 protein and MDR functional phenotype in leukemias: The predominant association in chronic myeloid leukemia. *Cytometry Part B: Clinical Cytometry*. 2004;61B:1–8.
122. Radtke F, Wilson A, MacDonald HR. Notch signaling in hematopoiesis and lymphopoiesis: lessons from *Drosophila*. *Bioessays* 2005;27:1117–1128.
123. Weng AP, Ferrando AA, Lee W, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. *Science* 2004;306:269–271.
124. Grabher C, von Boehmer H, Look AT. Notch 1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukaemia. *Nat Rev Cancer* 2006;6:347–359.
125. DeAngelo DJ, Stone JR, Silverman LB, et al. A phase I clinical trial of the Notch inhibitor MK-0752 in patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) and other leukemias. *ASCO Meeting Abstracts* 2006:6585.
126. Real PJ, Tosello V, Palomero T, et al. Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. *Nat Med* 2009;15:50–58.
127. Falini B, Mecucci C, Tiacci E, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. *N Engl J Med* 2005;352:254.

128. Falini B, Nicoletti I, Martelli MF, Mecucci C. Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features. *Blood* 2007;109:874.
129. Michaud J, Wu F, Osato M, et al. In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: implications for mechanisms of pathogenesis. *Blood* 2002;99:1364.
130. Osato M, Asou N, Abdalla E, et al. Biallelic and heterozygous point mutations in the runt domain of the AML1/PEBP2alphaB gene associated with myeloblastic leukemias. *Blood* 1999;93:1817–1824.
131. Mueller BU, Pabst T. C/EBPalpha and the pathophysiology of acute myeloid leukemia. *Curr Opin Hematol* 2006;13:7–14.
132. Leroy H, Roumier C, Huyghe P, Biggio V, Fenaux P, Preudhomme C. CEBPA point mutations in hematological malignancies. *Leukemia*. 2005;19:329–334.
133. Wechsler J, Greene M, McDevitt MA, et al. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. *Nat Genet* 2002;32:148–152.
134. Malinge S, Izraeli S, Crispino JD. Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome. *Blood* 2009;113:2619–2628.
135. Mullighan CG, Goorha S, Radtke I, et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. *Nature* 2007;446:758–764.
136. Golub TR, Barker GF, Lovett M, Gilliland DG. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. *Cell* 1994;77:307–316.
137. Higuchi M, O'Brien D, Kumaravelu P, Lenny N, Yeoh EJ, Downing JR. Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia. *Cancer Cell* 2002;1:63–74.
138. Wiemels JL, Cazzaniga G, Daniotti M, et al. Prenatal origin of acute lymphoblastic leukaemia in children. *Lancet* 1999;354:1499–1503.
139. Gilliland DG. Molecular genetics of human leukemias: new insights into therapy. *Semin Hematol*. 2002;39:6–11.
140. Kelly LM, Liu Q, Kutok JL, Williams IR, Boulton CL, Gilliland DG. FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model. *Blood* 2002;99:310.
141. Chan IT, Kutok JL, Williams IR, et al. Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease. *J Clin Invest* 2004;113:528.
142. Dash AB, Williams IR, Kutok JL, et al. A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9. *Proc Natl Acad Sci U S A* 2002;99:7622.
143. Grisolan J, O'Neal J, Cain J, Tomasson MH. An activated receptor tyrosine kinase, TEL/PDGFbetaR, cooperates with AML1/ETO to induce acute myeloid leukemia in mice. *Proc Natl Acad Sci U S A* 2003;100:9506.
144. Kelly LM, Kutok JL, Williams IR, et al. PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model. *Proc Natl Acad Sci U S A* 2002;99:8283.

Chapter 32 – References

1. Deininger MW. Chronic myeloid leukemia: an historical perspective. *American Society of Hematology Education Program Book*, 50th Anniversary Review. 2008:418.
2. Nowell PC, Hungerford DA. Chromosome studies on normal and leukemic human leukocytes. *J Natl Cancer Inst* 1960;25:85.
3. Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. *Nature* 1973;243:290.
4. Bartram CR, de Klein A, Hagemeijer A, et al. Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. *Nature*. 1983;306:277–280.
5. Groffen J, Stephenson JR, Heisterkamp N, et al. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. *Cell* 1984;36:93–99.
6. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. *Science* 1990;247:824–830.
7. Melo JV. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. *Blood* 1996;88:2375–2384.
8. Roman J, Parziale A, Gottardi E, et al. Novel type of BCR-ABL transcript in a chronic myelogenous leukaemia patient relapsed after bone marrow transplantation. *Br J Haematol*. 2000;111:644–646.
9. Huntly BJ, Guilhot F, Reid AG, et al. Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions. *Blood* 2003;102:2205.
10. Quintas-Cardama A, Kantarjian H, Talpaz M, et al. Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia. *Blood* 2005;105:2281.
11. Albano F, Anelli L, Zagaria A, et al. Downregulated expression of genes mapping on chromosome 9 in chronic myeloid leukemia cases bearing genomic deletions on der(9). *Leukemia* 2009;23:813.
12. Melo JV, Gordon DE, Cross NC, et al. The ABL-BCR fusion gene is expressed in chronic myeloid leukemia. *Blood* 1993;81:158–165.
13. Hantschel O, Superti-Furga G. Regulation of the c-Abl and Bcr-Abl tyrosine kinases. *Nat Rev Mol Cell Biol*. 2004;5:33–44.
14. Quintas-Cardama A, Cortes J. Molecular biology of bcr-abl1-positive chronic myeloid leukemia. *Blood*. 2009;113:1619–1630.
15. Chu S, Li L, Singh H, Bhatia R. BCR-tyrosine 177 plays an essential role in Ras and Akt activation and in human hematopoietic progenitor transformation in chronic myelogenous leukemia. *Cancer Res*. 2007;67:7045–7053.
16. Sattler M, Mohi MG, Pride YB, et al. Critical role for Gab2 in transformation by BCR/ABL. *Cancer Cell* 2002;1:479–492.
17. Gaston I, Johnson KJ, Oda T, et al. Coexistence of phosphotyrosine-dependent and -independent interactions between Cbl and Bcr-Abl. *Exp Hematol*. 2004;32:113–121.
18. Naka K, Hoshii T, Muraguchi T, et al. TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia. *Nature* 2010;463:676.
19. Kikuchi S, Nagai T, Kunitama M, Kiritto K, Ozawa K, Komatsu N. Active FKHL1 overcomes imatinib resistance in chronic myelogenous leukemia-derived cell lines via the production of tumor necrosis factor-related apoptosis-inducing ligand. *Cancer Sci* 2007;98:1949.
20. Agarwal A, Bumm TG, Corbin AS, et al. Absence of SKP2 expression attenuates BCR-ABL-induced myeloproliferative disease. *Blood* 2008;112:1960.
21. Markova B, Albers C, Breitenbuecher F, et al. Novel pathway in Bcr-Abl signal transduction involves Akt-independent, PLC-gamma1-driven activation of mTOR/p70S6-kinase pathway. *Oncogene*; 29:739–751.
22. Ly C, Arechiga AF, Melo JV, Walsh CM, Ong ST. Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin. *Cancer Res*. 2003;63:5716–5722.
23. Kardinal C, Konkol B, Lin H, et al. Chronic myelogenous leukemia blast cell proliferation is inhibited by peptides that disrupt Grb2-SoS complexes. *Blood* 2001;98:1773–1781.
24. Marais R, Light Y, Paterson HF, Marshall CJ. Ras recruits Raf-1 to the plasma membrane for activation by tyrosine phosphorylation. *Embo J*. 1995;14:3136–3145.
25. Salomoni P, Wasik MA, Riedel RF, et al. Expression of constitutively active Raf-1 in the mitochondria restores antiapoptotic and leukemogenic potential of a transformation-deficient BCR/ABL mutant. *J Exp Med*. 1998;187:1995–2007.
26. Thomas EK, Cancelas JA, Zheng Y, Williams DA. Rac GTPases as key regulators of p210-BCR-ABL-dependent leukemogenesis. *Leukemia*. 2008;22:898–904.
27. Thomas EK, Cancelas JA, Chae HD, et al. Rac guanosine triphosphatases represent integrative molecular therapeutic targets for BCR-ABL-induced myeloproliferative disease. *Cancer Cell* 2007;12:467.
28. Frank DA, Varticovski L. BCR/ABL leads to the constitutive activation of Stat proteins, and shares an epitope with tyrosine phosphorylated Stats. *Leukemia* 1996;10:1724.
29. Ilaria RL, Jr., Van Etten RA. P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. *J Biol Chem* 1996;271:31704.
30. Klejman A, Schreiner SJ, Nieborowska-Skorska M, et al. The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells. *Embo J*. 2002;21:5766–5774.
31. Sexl V, Piekorz R, Moriggl R, et al. Stat5a/b contribute to interleukin 7-induced B-cell precursor expansion, but abl- and bcr/abl-induced transformation are independent of stat5. *Blood*. 2000;96:2277–2283.
32. Hoelbl A, Schuster C, Kovacic B, et al. Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia. *EMBO Mol Med* 2010;2:98–110.
33. Verfaillie CM, Hurley R, Zhao RC, et al. Pathophysiology of CML: do defects in integrin function contribute to the premature circulation and massive expansion of the BCR/ABL positive clone? *J Lab Clin Med*. 1997;129:584–591.
34. Ramaraj P, Singh H, Niu N, et al. Effect of mutational inactivation of tyrosine kinase activity on BCR/ABL-induced abnormalities in cell growth and adhesion in human hematopoietic progenitors. *Cancer Res* 2004;64:5322–5331.
35. Melo JV, Barnes DJ. Chronic myeloid leukaemia as a model of disease evolution in human cancer. *Nat Rev Cancer* 2007;7:441–453.
36. Risch HA, McLaughlin JR, Cole DE, et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. *J Natl Cancer Inst* 2006;98:1694.
37. Koptyra M, Falinski R, Nowicki MO, et al. BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance. *Blood* 2006;108:319.
38. Brehme M, Hantschel O, Colinge J, et al. Charting the molecular network of the drug target Bcr-Abl. *Proc Natl Acad Sci U S A* 2009;106:7414.

39. Pear WS, Miller JP, Xu L, et al. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. *Blood* 1998;92:3780–3792.
40. Koschmieder S, Gottgens B, Zhang P, et al. Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis. *Blood* 2005;105:324–334.
41. Agliano A, Martin-Padura I, Mancuso P, et al. Human acute leukemia cells injected in NOD/LtSz-scid/IL-2Rgamma null mice generate a faster and more efficient disease compared to other NOD/scid-related strains. *Int J Cancer* 2008;123:2222–2227.
42. Abrahamsson AE, Geron I, Gotlib J, et al. Glycogen synthase kinase 3beta missplicing contributes to leukemia stem cell generation. *Proc Natl Acad Sci U S A* 2009;106:3925–3929.
43. Fialkow PJ, Jacobson RJ, Papayannopoulou T. Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. *Am J Med* 1977;63:125–130.
44. Huntly BJ, Shigematsu H, Deguchi K, et al. MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. *Cancer Cell* 2004;6:587–596.
45. Petzer AL, Eaves CJ, Barnett MJ, Eaves AC. Selective expansion of primitive normal hematopoietic cells in cytokine-supplemented cultures of purified cells from patients with chronic myeloid leukemia. *Blood* 1997;90:64.
46. Ito K, Bernardi R, Morotti A, et al. PML targeting eradicates quiescent leukaemia-initiating cells. *Nature* 2008;453:1072.
47. Sengupta A, Arnett J, Dunn S, Williams DA, Cancelas JA. Rac2 GTPase deficiency depletes BCR-ABL+ leukemic stem cells and progenitors in vivo. *Blood* 2010; 116(1):81.
48. Zhao C, Chen A, Jamieson CH, et al. Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. *Nature* 2009;458:776–779.
49. Barnes DJ, Schultheis B, Adedeji S, Melo JV. Dose-dependent effects of Bcr-Abl in cell line models of different stages of chronic myeloid leukemia. *Oncogene* 2005;24:6432–6440.
50. Perrotti D, Neviani P. reSETting PP2A tumour suppressor activity in blast crisis and imatinib-resistant chronic myelogenous leukaemia. *Br J Cancer* 2006;95:775–781.
51. Dash AB, Williams IR, Kutok JL, et al. A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9. *Proc Natl Acad Sci U S A* 2002;99:7622–7627.
52. Nucifora G, Birn DJ, Espinosa R, 3rd, et al. Involvement of the AML1 gene in the t(3;21) in therapy-related leukemia and in chronic myeloid leukemia in blast crisis. *Blood* 1993;81:2728–2734.
53. Wu M, Kwon HY, Rattis F, et al. Imaging hematopoietic precursor division in real time. *Cell Stem Cell* 2007;1:541–554.
54. Chang JS, Santhanam R, Trotta R, et al. High levels of the BCR/ABL oncoprotein are required for the MAPK-hnRNP-E2 dependent suppression of C/EBPalpha-driven myeloid differentiation. *Blood* 2007;110:994.
55. Pabst T, Mueller BU, Zhang P, et al. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. *Nat Genet* 2001;27:263.
56. Pabst T, Stillner E, Neuberg D, et al. Mutations of the myeloid transcription factor CEBPA are not associated with the blast crisis of chronic myeloid leukaemia. *Br J Haematol* 2006;133:400.
57. Jamieson CH, Ailles LE, Dylla SJ, et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. *N Engl J Med* 2004;351:657–667.
58. McWeeney SK, Pemberton LC, LoWWriaux MM, et al. A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib. *Blood* 2010;115:315–325.
59. Radich JP, Dai H, Mao M, et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. *Proc Natl Acad Sci U S A* 2006;103:2794–2799.
60. Matutes E, Wotherspoon A, Catovsky D. Differential diagnosis in chronic lymphocytic leukaemia. *Best Pract Res Clin Haematol* 2007;20:367–384.
61. Montserrat E, Gomis F, Vallespi T, et al. Presenting features and prognosis of chronic lymphocytic leukemia in younger adults. *Blood* 1991;78:1545–1551.
62. Eichhorst B, Goede V, Hallek M. Treatment of elderly patients with chronic lymphocytic leukemia. *Leuk Lymphoma* 2009;50:171–178.
63. Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. *J Clin Oncol* 2005;23:4079–4088.
64. Wierda W, O'Brien S, Wen S, et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. *J Clin Oncol* 2005;23:4070.
65. Wierda W, O'Brien S, Faderl S, et al. A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens. *Cancer* 2006;106:337.
66. Ghia P, Scielzo C, Frenquelli M, Muzio M, Caligaris-Cappio F. From normal to clonal B cells: Chronic lymphocytic leukemia (CLL) at the crossroad between neoplasia and autoimmunity. *Autoimmun Rev* 2007;7:127.
67. Caligaris-Cappio F, Ghia P. The normal counterpart to the chronic lymphocytic leukemia B cell. *Best Pract Res Clin Haematol* 2007;20:385–397.
68. Oppezzo P, Magnac C, Bianchi S, et al. Do CLL B cells correspond to naive or memory B-lymphocytes? Evidence for an active Ig switch unrelated to phenotype expression and Ig mutational pattern in B-CLL cells. *Leukemia* 2002;16:2438–2446.
69. Hamblin TJ, Davis Z, Gardiner A, et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. *Blood* 1999;94:1848–1854.
70. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. *Blood* 1999;94:1840–1847.
71. Klein U, Tu Y, Stolovitzky GA, et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. *J Exp Med* 2001;194:1625–1638.
72. Rosenwald A, Alizadeh AA, Widhopf G, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. *J Exp Med* 2001;194:1639.
73. Orchard JA, Ibbotson RE, Davis Z, et al. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. *Lancet* 2004;363:105.
74. Wiestner A, Rosenwald A, Barry TS, et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. *Blood* 2003;101:4944.
75. Rassenti LZ, Huynh L, Toy TL, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. *N Engl J Med* 2004;351:893–901.
76. Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. *N Engl J Med* 2003;348:1764–1775.

77. Chen L, Apgar J, Huynh L, et al. ZAP-70 directly enhances IgM signaling in chronic lymphocytic leukemia. *Blood* 2005;105:2036–2041.
78. Gobessi S, Laurenti L, Longo PG, Sica S, Leone G, Efremov DG. ZAP-70 enhances B-cell-receptor signaling despite absent or inefficient tyrosine kinase activation in chronic lymphocytic leukemia and lymphoma B cells. *Blood*. 2007;109:2032–2039.
79. Chen L, Huynh L, Apgar J, et al. ZAP-70 enhances IgM signaling independent of its kinase activity in chronic lymphocytic leukemia. *Blood*. 2008;111:2685–2692.
80. Juliusson G, Gahrton G. Chromosome aberrations in B-cell chronic lymphocytic leukemia. Pathogenetic and clinical implications. *Cancer Genet Cytogenet*. 1990;45:143–160.
81. Juliusson G, Merup M. Cytogenetics in chronic lymphocytic leukemia. *Semin Oncol* 1998;25:19.
82. Oscier DG, Stevens J, Hamblin TJ, Pickering RM, Lambert R, Fitchett M. Correlation of chromosome abnormalities with laboratory features and clinical course in B-cell chronic lymphocytic leukaemia. *Br J Haematol* 1990;76:352.
83. Oscier DG, Stevens J, Hamblin TJ, Pickering RM, Fitchett M. Prognostic factors in stage AO B-cell chronic lymphocytic leukaemia. *Br J Haematol* 1990;76:348.
84. Juliusson G, Oscier DG, Fitchett M, et al. Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. *N Engl J Med*. 1990;323:720–724.
85. Mayr C, Speicher MR, Kofler DM, et al. Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia. *Blood* 2006;107:742–751.
86. Kujawski L, Ouillette P, Erba H, et al. Genomic complexity identifies patients with aggressive chronic lymphocytic leukemia. *Blood*. 2008;112:1993–2003.
87. Pfeifer D, Pantic M, Skatulla I, et al. Genome-wide analysis of DNA copy number changes and LOH in CLL using high-density SNP arrays. *Blood*. 2007;109:1202–1210.
88. Schwaenen C, Nessling M, Wessendorf S, et al. Automated array-based genomic profiling in chronic lymphocytic leukemia: development of a clinical tool and discovery of recurrent genomic alterations. *Proc Natl Acad Sci U S A*. 2004;101:1039–1044.
89. Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. *N Engl J Med* 2000;343:1910–1916.
90. Krober A, Seiler T, Benner A, et al. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. *Blood*. 2002;100:1410–1416.
91. Shanafelt TD, Witzig TE, Fink SR, et al. Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. *J Clin Oncol* 2006;24:4634.
92. Grever MR, Lucas DM, Dewald GW, et al. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. *J Clin Oncol* 2007;25:799.
93. Austen B, Powell JE, Alvi A, et al. Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL. *Blood* 2005;106:3175.
94. Oscier DG, Gardiner AC, Mould SJ, et al. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. *Blood*. 2002;100:1177–1184.
95. Lin K, Sherrington PD, Dennis M, Matrai Z, Cawley JC, Pettitt AR. Relationship between p53 dysfunction, CD38 expression, and IgV(H) mutation in chronic lymphocytic leukemia. *Blood*. 2002;100:1404–1409.
96. Zenz T, Habe S, Denzel T, et al. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. *Blood*. 2009;114:2589–2597.
97. Zenz T, Krober A, Scherer K, et al. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. *Blood*. 2008;112:3322–3329.
98. Austen B, Skowronska A, Baker C, et al. Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion. *J Clin Oncol* 2007;25:5448.
99. Pettitt AR, Sherrington PD, Stewart G, Cawley JC, Taylor AM, Stankovic T. p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation. *Blood* 2001;98:814.
100. Schaffner C, Stilgenbauer S, Rappold GA, Dohner H, Lichter P. Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic lymphocytic leukemia. *Blood* 1999;94:748.
101. Brown JR, Levine RL, Thompson C, et al. Systematic genomic screen for tyrosine kinase mutations in CLL. *Leukemia* 2008;22:1966–1969.
102. Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. *Proc Natl Acad Sci U S A* 2002;99:15524–15529.
103. Calin GA, Ferracin M, Cimmino A, et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. *N Engl J Med* 2005;353:1793–1801.
104. Raveche ES, Salerno E, Scaglione BJ, et al. Abnormal microRNA-16 locus with synteny to human 13q14 linked to CLL in NZB mice. *Blood* 2007;109:5079–5086.
105. Klein U, Lia M, Crespo M, et al. The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. *Cancer Cell* 2010;17:28–40.
106. Cimmino A, Calin GA, Fabbri M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. *Proc Natl Acad Sci U S A*. 2005;102:13944–13949.
107. Rush LJ, Raval A, Funchain P, et al. Epigenetic profiling in chronic lymphocytic leukemia reveals novel methylation targets. *Cancer Res* 2004;64:2424.
108. Kanduri M, Cahill N, Goransson H, et al. Differential genome-wide array-based methylation profiles in prognostic subsets of chronic lymphocytic leukemia. *Blood* 2010;115:296.
109. Tong WG, Wierda WG, Lin E, et al. Genome-wide DNA methylation profiling of chronic lymphocytic leukemia allows identification of epigenetically repressed molecular pathways with clinical impact [published online ahead of print August 27, 2010]. *Epigenetics*. doi:10.4161/epi.5.6.12179.
110. Rahmatpanah FB, Carstens S, Hooshmand SI, et al. Large-scale analysis of DNA methylation in chronic lymphocytic leukemia. *Epigenomics*. 2009;1:39–61.
111. Yuille MR, Condie A, Stone EM, et al. TCL1 is activated by chromosomal rearrangement or by hypomethylation. *Genes Chromosomes Cancer*. 2001;30:336–341.
112. Hanada M, Delia D, Aiello A, Stadtmayer E, Reed JC. bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. *Blood*. 1993;82:1820–1828.
113. Corcoran M, Parker A, Orchard J, et al. ZAP-70 methylation status is associated with ZAP-70 expression status in chronic lymphocytic leukemia. *Haematologica*. 2005;90:1078–1088.
114. Liu TH, Raval A, Chen SS, Matkovic JJ, Byrd JC, Plass C. CpG island methylation and expression of the secreted frizzled-related protein gene family in chronic lymphocytic leukemia. *Cancer Res*. 2006;66:653–658.
115. Motiwala T, Majumder S, Kutay H, et al. Methylation and silencing of protein tyrosine phosphatase receptor type O in chronic lymphocytic leukemia. *Clin Cancer Res*. 2007;13:3174–3181.

116. Raval A, Tanner SM, Byrd JC, et al. Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia. *Cell* 2007;129:879.
117. Yu L, Liu C, Vandeusen J, et al. Global assessment of promoter methylation in a mouse model of cancer identifies ID4 as a putative tumor-suppressor gene in human leukemia. *Nat Genet* 2005;37:265.
118. Chen SS, Sherman MH, Hertlein E, et al. Epigenetic alterations in a murine model for chronic lymphocytic leukemia. *Cell Cycle* 2009;8:3663.
119. Chen SS, Raval A, Johnson AJ, et al. Epigenetic changes during disease progression in a murine model of human chronic lymphocytic leukemia. *Proc Natl Acad Sci U S A* 2009;106:13433–13438.
120. Gine E, Martinez A, Villamor N, et al. Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia (“accelerated” chronic lymphocytic leukemia) with aggressive clinical behavior. *Haematologica*.
121. Bonato M, Pittaluga S, Tierens A, et al. Lymph node histology in typical and atypical chronic lymphocytic leukemia. *Am J Surg Pathol*. 1998;22:49–56.
122. Hayes GM, Busch R, Voegt J, et al. Isolation of malignant B cells from patients with chronic lymphocytic leukemia (CLL) for analysis of cell proliferation: Validation of a simplified method suitable for multi-center clinical studies. *Leuk Res*. 2009.
123. Calissano C, Damle RN, Hayes G, et al. In vivo intraclonal and interclonal kinetic heterogeneity in B-cell chronic lymphocytic leukemia. *Blood*. 2009;114:4832–4842.
124. Messmer BT, Messmer D, Allen SL, et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. *J Clin Invest* 2005;115:755–764.
125. Dancescu M, Rubio-Trujillo M, Biron G, Bron D, Delespesse G, Sarfati M. Interleukin 4 protects chronic lymphocytic leukemic B cells from death by apoptosis and upregulates Bcl-2 expression. *J Exp Med* 1992;176:1319.
126. McConkey DJ, Chandra J, Wright S, et al. Apoptosis sensitivity in chronic lymphocytic leukemia is determined by endogenous endonuclease content and relative expression of BCL-2 and BAX. *J Immunol* 1996;156:2624.
127. Pepper C, Bentley P, Hoy T. Regulation of clinical chemoresistance by bcl-2 and bax oncoproteins in B-cell chronic lymphocytic leukaemia. *Br J Haematol* 1996;95:513.
128. Robertson LE, Plunkett W, McConnell K, Keating MJ, McDonnell TJ. Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome. *Leukemia*. 1996;10:456–459.
129. Vogler M, Butterworth M, Majid A, et al. Concurrent upregulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia. *Blood*. 2009;113:4403–4413.
130. Smit LA, Hallaert DY, Spijker R, et al. Differential Noxa/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlates with survival capacity. *Blood*. 2007;109:1660–1668.
131. Pedersen IM, Kitada S, Leoni LM, et al. Protection of CLL B cells by a follicular dendritic cell line is dependent on induction of Mcl-1. *Blood*. 2002;100:1795–1801.
132. Furman RR, Asgary Z, Mascarenhas JO, et al. Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells. *J Immunol* 2000;164:2200–2206.
133. Lu D, Zhao Y, Tawatao R, et al. Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. *Proc Natl Acad Sci U S A*. 2004;101:3118–3123.
134. Hegde GV, Peterson KJ, Emanuel K, et al. Hedgehog-induced survival of B-cell chronic lymphocytic leukemia cells in a stromal cell microenvironment: a potential new therapeutic target. *Mol Cancer Res* 2008;6:1928.
135. Frank DA, Mahajan S, Ritz J. B lymphocytes from patients with chronic lymphocytic leukemia contain signal transducer and activator of transcription (STAT) 1 and STAT3 constitutively phosphorylated on serine residues. *J Clin Invest* 1997;100:3140.
136. Pekarsky Y, Palamarchuk A, Maximov V, et al. Tcl1 functions as a transcriptional regulator and is directly involved in the pathogenesis of CLL. *Proc Natl Acad Sci U S A* 2008;105:19643.
137. Nishio M, Endo T, Tsukada N, et al. Nurse-like cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1alpha. *Blood*. 2005;106:1012–1020.
138. Munzert G, Kirchner D, Stobbe H, et al. Tumor necrosis factor receptor-associated factor 1 gene overexpression in B-cell chronic lymphocytic leukemia: analysis of NF-kappa B/Rel-regulated inhibitors of apoptosis. *Blood*. 2002;100:3749–3756.
139. Bernal A, Pastore RD, Asgary Z, et al. Survival of leukemic B cells promoted by engagement of the antigen receptor. *Blood*. 2001;98:3050–3057.
140. Hewamana S, Lin TT, Rowntree C, et al. Rel a is an independent biomarker of clinical outcome in chronic lymphocytic leukemia. *J Clin Oncol*. 2009;27:763–769.
141. Hewamana S, Lin TT, Jenkins C, et al. The novel nuclear factor-kappaB inhibitor LC-1 is equipotent in poor prognostic subsets of chronic lymphocytic leukemia and shows strong synergy with fludarabine. *Clin Cancer Res*. 2008;14:8102–8111.
142. Hewamana S, Alghazal S, Lin TT, et al. The NF-kappaB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target. *Blood* 2008;111:4681.
143. Chen L, Widhopf G, Huynh L, et al. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. *Blood* 2002;100:4609.
144. Buchner M, Fuchs S, Prinz G, et al. Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia. *Cancer Res* 2009;69:5424.
145. Trentin L, Frasson M, Donella-Deana A, et al. Geldanamycin-induced Lyn dissociation from aberrant Hsp90-stabilized cytosolic complex is an early event in apoptotic mechanisms in B-chronic lymphocytic leukemia. *Blood*. 2008;112:4665–4674.
146. Quiroga MP, Balakrishnan K, Kurtova AV, et al. B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406. *Blood*. 2009;114:1029–1037.
147. Cuni S, Perez-Aciego P, Perez-Chacon G, et al. A sustained activation of PI3K/NF-kappaB pathway is critical for the survival of chronic lymphocytic leukemia B cells. *Leukemia*. 2004;18:1391–1400.
148. Ringshausen I, Schneller F, Bogner C, et al. Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase Cdelta. *Blood*. 2002;100:3741–3748.
149. Srinivasan L, Sasaki Y, Calado DP, et al. PI3 kinase signals BCR-dependent mature B cell survival. *Cell*. 2009;139:573–586.
150. Herman SE, Gordon AL, Wagner AJ, et al. The phosphatidylinositol 3-kinase- δ inhibitor CAL-101 demonstrates promising pre-clinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. *Blood* 2010;116:2078–2088.
151. Stilgenbauer S, Sander S, Bullinger L, et al. Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival. *Haematologica* 2007;92:1242.
152. Roos G, Krober A, Grabowski P, et al. Short telomeres are associated with genetic complexity, high-risk genomic aberrations, and short survival in chronic lymphocytic leukemia. *Blood* 2008;111:2246.
153. Ricca I, Rocci A, Drandi D, et al. Telomere length identifies two different prognostic subgroups among VH-unmutated B-cell chronic lymphocytic leukemia patients. *Leukemia* 2007;21:697.